#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Mothers with Substance Addictions Show Reduced Reward Responses When Viewing Their Own Infant’s Face
#Text=Maternal addiction constitutes a major public health problem affecting children, with high rates of abuse, neglect, and foster care placement.
1-1	0-7	Mothers	_	
1-2	8-12	with	_	
1-3	13-22	Substance	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[1]	
1-4	23-33	Addictions	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[1]	
1-5	34-38	Show	_	
1-6	39-46	Reduced	_	
1-7	47-53	Reward	_	
1-8	54-63	Responses	_	
1-9	64-68	When	_	
1-10	69-76	Viewing	_	
1-11	77-82	Their	_	
1-12	83-86	Own	_	
1-13	87-93	Infant	_	
1-14	93-94	’	_	
1-15	94-95	s	_	
1-16	96-100	Face	_	
1-17	101-109	Maternal	_	
1-18	110-119	addiction	_	
1-19	120-131	constitutes	_	
1-20	132-133	a	_	
1-21	134-139	major	_	
1-22	140-146	public	_	
1-23	147-153	health	_	
1-24	154-161	problem	_	
1-25	162-171	affecting	_	
1-26	172-180	children	_	
1-27	180-181	,	_	
1-28	182-186	with	_	
1-29	187-191	high	_	
1-30	192-197	rates	_	
1-31	198-200	of	_	
1-32	201-206	abuse	_	
1-33	206-207	,	_	
1-34	208-215	neglect	_	
1-35	215-216	,	_	
1-36	217-220	and	_	
1-37	221-227	foster	_	
1-38	228-232	care	_	
1-39	233-242	placement	_	
1-40	242-243	.	_	

#Text=However, little is known about the ways in which substance addiction alters brain function related to maternal behavior.
2-1	244-251	However	_	
2-2	251-252	,	_	
2-3	253-259	little	_	
2-4	260-262	is	_	
2-5	263-268	known	_	
2-6	269-274	about	_	
2-7	275-278	the	_	
2-8	279-283	ways	_	
2-9	284-286	in	_	
2-10	287-292	which	_	
2-11	293-302	substance	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[2]	
2-12	303-312	addiction	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[2]	
2-13	313-319	alters	_	
2-14	320-325	brain	_	
2-15	326-334	function	_	
2-16	335-342	related	_	
2-17	343-345	to	_	
2-18	346-354	maternal	_	
2-19	355-363	behavior	_	
2-20	363-364	.	_	

#Text=Prior studies have shown that infant face cues activate similar dopamine-associated brain reward regions to substances of abuse.
3-1	365-370	Prior	_	
3-2	371-378	studies	_	
3-3	379-383	have	_	
3-4	384-389	shown	_	
3-5	390-394	that	_	
3-6	395-401	infant	_	
3-7	402-406	face	_	
3-8	407-411	cues	_	
3-9	412-420	activate	_	
3-10	421-428	similar	_	
3-11	429-448	dopamine-associated	_	
3-12	449-454	brain	_	
3-13	455-461	reward	_	
3-14	462-469	regions	_	
3-15	470-472	to	_	
3-16	473-483	substances	_	
3-17	484-486	of	_	
3-18	487-492	abuse	_	
3-19	492-493	.	_	

#Text=Here, we report on a functional MRI study documenting that mothers with addictions demonstrate reduced activation of reward regions when shown reward-related cues of their own infants.
4-1	494-498	Here	_	
4-2	498-499	,	_	
4-3	500-502	we	_	
4-4	503-509	report	_	
4-5	510-512	on	_	
4-6	513-514	a	_	
4-7	515-525	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[3]	
4-8	526-529	MRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[3]	
4-9	530-535	study	_	
4-10	536-547	documenting	_	
4-11	548-552	that	_	
4-12	553-560	mothers	_	
4-13	561-565	with	_	
4-14	566-576	addictions	_	
4-15	577-588	demonstrate	_	
4-16	589-596	reduced	_	
4-17	597-607	activation	_	
4-18	608-610	of	_	
4-19	611-617	reward	_	
4-20	618-625	regions	_	
4-21	626-630	when	_	
4-22	631-636	shown	_	
4-23	637-651	reward-related	_	
4-24	652-656	cues	_	
4-25	657-659	of	_	
4-26	660-665	their	_	
4-27	666-669	own	_	
4-28	670-677	infants	_	
4-29	677-678	.	_	

#Text=Thirty-six mothers receiving inpatient treatment for substance addiction were scanned at 6 months postpartum, while viewing happy and sad face images of their own infant compared to those of a matched unknown infant.
5-1	679-689	Thirty-six	_	
5-2	690-697	mothers	_	
5-3	698-707	receiving	_	
5-4	708-717	inpatient	_	
5-5	718-727	treatment	_	
5-6	728-731	for	_	
5-7	732-741	substance	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[4]	
5-8	742-751	addiction	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[4]	
5-9	752-756	were	_	
5-10	757-764	scanned	_	
5-11	765-767	at	_	
5-12	768-769	6	_	
5-13	770-776	months	_	
5-14	777-787	postpartum	_	
5-15	787-788	,	_	
5-16	789-794	while	_	
5-17	795-802	viewing	_	
5-18	803-808	happy	_	
5-19	809-812	and	_	
5-20	813-816	sad	_	
5-21	817-821	face	_	
5-22	822-828	images	_	
5-23	829-831	of	_	
5-24	832-837	their	_	
5-25	838-841	own	_	
5-26	842-848	infant	_	
5-27	849-857	compared	_	
5-28	858-860	to	_	
5-29	861-866	those	_	
5-30	867-869	of	_	
5-31	870-871	a	_	
5-32	872-879	matched	_	
5-33	880-887	unknown	_	
5-34	888-894	infant	_	
5-35	894-895	.	_	

#Text=When viewing happy face images of their own infant, mothers with addictions showed a striking pattern of decreased activation in dopamine- and oxytocin-innervated brain regions, including the hypothalamus, ventral striatum, and ventromedial prefrontal cortex—regions in which increased activation has previously been observed in mothers without addictions.
6-1	896-900	When	_	
6-2	901-908	viewing	_	
6-3	909-914	happy	_	
6-4	915-919	face	_	
6-5	920-926	images	_	
6-6	927-929	of	_	
6-7	930-935	their	_	
6-8	936-939	own	_	
6-9	940-946	infant	_	
6-10	946-947	,	_	
6-11	948-955	mothers	_	
6-12	956-960	with	_	
6-13	961-971	addictions	_	
6-14	972-978	showed	_	
6-15	979-980	a	_	
6-16	981-989	striking	_	
6-17	990-997	pattern	_	
6-18	998-1000	of	_	
6-19	1001-1010	decreased	_	
6-20	1011-1021	activation	_	
6-21	1022-1024	in	_	
6-22	1025-1033	dopamine	_	
6-23	1033-1034	-	_	
6-24	1035-1038	and	_	
6-25	1039-1058	oxytocin-innervated	_	
6-26	1059-1064	brain	_	
6-27	1065-1072	regions	_	
6-28	1072-1073	,	_	
6-29	1074-1083	including	_	
6-30	1084-1087	the	_	
6-31	1088-1100	hypothalamus	_	
6-32	1100-1101	,	_	
6-33	1102-1109	ventral	_	
6-34	1110-1118	striatum	_	
6-35	1118-1119	,	_	
6-36	1120-1123	and	_	
6-37	1124-1136	ventromedial	_	
6-38	1137-1147	prefrontal	_	
6-39	1148-1162	cortex—regions	_	
6-40	1163-1165	in	_	
6-41	1166-1171	which	_	
6-42	1172-1181	increased	_	
6-43	1182-1192	activation	_	
6-44	1193-1196	has	_	
6-45	1197-1207	previously	_	
6-46	1208-1212	been	_	
6-47	1213-1221	observed	_	
6-48	1222-1224	in	_	
6-49	1225-1232	mothers	_	
6-50	1233-1240	without	_	
6-51	1241-1251	addictions	_	
6-52	1251-1252	.	_	

#Text=Our results are the first to demonstrate that mothers with addictions show reduced activation in key reward regions of the brain in response to their own infant’s face cues.
7-1	1253-1256	Our	_	
7-2	1257-1264	results	_	
7-3	1265-1268	are	_	
7-4	1269-1272	the	_	
7-5	1273-1278	first	_	
7-6	1279-1281	to	_	
7-7	1282-1293	demonstrate	_	
7-8	1294-1298	that	_	
7-9	1299-1306	mothers	_	
7-10	1307-1311	with	_	
7-11	1312-1322	addictions	_	
7-12	1323-1327	show	_	
7-13	1328-1335	reduced	_	
7-14	1336-1346	activation	_	
7-15	1347-1349	in	_	
7-16	1350-1353	key	_	
7-17	1354-1360	reward	_	
7-18	1361-1368	regions	_	
7-19	1369-1371	of	_	
7-20	1372-1375	the	_	
7-21	1376-1381	brain	_	
7-22	1382-1384	in	_	
7-23	1385-1393	response	_	
7-24	1394-1396	to	_	
7-25	1397-1402	their	_	
7-26	1403-1406	own	_	
7-27	1407-1413	infant	_	
7-28	1413-1414	’	_	
7-29	1414-1415	s	_	
7-30	1416-1420	face	_	
7-31	1421-1425	cues	_	
7-32	1425-1426	.	_	

#Text=Introduction
#Text=Most mothers find engaging with their infants to be a uniquely rewarding and gratifying experience.
8-1	1427-1439	Introduction	_	
8-2	1440-1444	Most	_	
8-3	1445-1452	mothers	_	
8-4	1453-1457	find	_	
8-5	1458-1466	engaging	_	
8-6	1467-1471	with	_	
8-7	1472-1477	their	_	
8-8	1478-1485	infants	_	
8-9	1486-1488	to	_	
8-10	1489-1491	be	_	
8-11	1492-1493	a	_	
8-12	1494-1502	uniquely	_	
8-13	1503-1512	rewarding	_	
8-14	1513-1516	and	_	
8-15	1517-1527	gratifying	_	
8-16	1528-1538	experience	_	
8-17	1538-1539	.	_	

#Text=With the birth of the infant, many facets of a woman’s life that used to take precedence recede, and the infant becomes the center of the mother’s attention and affection.
9-1	1540-1544	With	_	
9-2	1545-1548	the	_	
9-3	1549-1554	birth	_	
9-4	1555-1557	of	_	
9-5	1558-1561	the	_	
9-6	1562-1568	infant	_	
9-7	1568-1569	,	_	
9-8	1570-1574	many	_	
9-9	1575-1581	facets	_	
9-10	1582-1584	of	_	
9-11	1585-1586	a	_	
9-12	1587-1592	woman	_	
9-13	1592-1593	’	_	
9-14	1593-1594	s	_	
9-15	1595-1599	life	_	
9-16	1600-1604	that	_	
9-17	1605-1609	used	_	
9-18	1610-1612	to	_	
9-19	1613-1617	take	_	
9-20	1618-1628	precedence	_	
9-21	1629-1635	recede	_	
9-22	1635-1636	,	_	
9-23	1637-1640	and	_	
9-24	1641-1644	the	_	
9-25	1645-1651	infant	_	
9-26	1652-1659	becomes	_	
9-27	1660-1663	the	_	
9-28	1664-1670	center	_	
9-29	1671-1673	of	_	
9-30	1674-1677	the	_	
9-31	1678-1684	mother	_	
9-32	1684-1685	’	_	
9-33	1685-1686	s	_	
9-34	1687-1696	attention	_	
9-35	1697-1700	and	_	
9-36	1701-1710	affection	_	
9-37	1710-1711	.	_	

#Text=Our previous work has shown that an infant’s face, particularly when smiling, has unique salience and reward value to new mothers.
10-1	1712-1715	Our	_	
10-2	1716-1724	previous	_	
10-3	1725-1729	work	_	
10-4	1730-1733	has	_	
10-5	1734-1739	shown	_	
10-6	1740-1744	that	_	
10-7	1745-1747	an	_	
10-8	1748-1754	infant	_	
10-9	1754-1755	’	_	
10-10	1755-1756	s	_	
10-11	1757-1761	face	_	
10-12	1761-1762	,	_	
10-13	1763-1775	particularly	_	
10-14	1776-1780	when	_	
10-15	1781-1788	smiling	_	
10-16	1788-1789	,	_	
10-17	1790-1793	has	_	
10-18	1794-1800	unique	_	
10-19	1801-1809	salience	_	
10-20	1810-1813	and	_	
10-21	1814-1820	reward	_	
10-22	1821-1826	value	_	
10-23	1827-1829	to	_	
10-24	1830-1833	new	_	
10-25	1834-1841	mothers	_	
10-26	1841-1842	.	_	

#Text=This reward experience may underlie and promote mother-infant attachment, motivating mothers to continue to care for their infants in the face of extreme fatigue or other competing needs.
11-1	1843-1847	This	_	
11-2	1848-1854	reward	_	
11-3	1855-1865	experience	_	
11-4	1866-1869	may	_	
11-5	1870-1878	underlie	_	
11-6	1879-1882	and	_	
11-7	1883-1890	promote	_	
11-8	1891-1904	mother-infant	_	
11-9	1905-1915	attachment	_	
11-10	1915-1916	,	_	
11-11	1917-1927	motivating	_	
11-12	1928-1935	mothers	_	
11-13	1936-1938	to	_	
11-14	1939-1947	continue	_	
11-15	1948-1950	to	_	
11-16	1951-1955	care	_	
11-17	1956-1959	for	_	
11-18	1960-1965	their	_	
11-19	1966-1973	infants	_	
11-20	1974-1976	in	_	
11-21	1977-1980	the	_	
11-22	1981-1985	face	_	
11-23	1986-1988	of	_	
11-24	1989-1996	extreme	_	
11-25	1997-2004	fatigue	_	
11-26	2005-2007	or	_	
11-27	2008-2013	other	_	
11-28	2014-2023	competing	_	
11-29	2024-2029	needs	_	
11-30	2029-2030	.	_	

#Text=However, two decades of animal and human research have shown that this critical bond between the mother and her infant may be compromised as a result of maternal substance-use behaviors, especially substance addictions.
12-1	2031-2038	However	_	
12-2	2038-2039	,	_	
12-3	2040-2043	two	_	
12-4	2044-2051	decades	_	
12-5	2052-2054	of	_	
12-6	2055-2061	animal	_	
12-7	2062-2065	and	_	
12-8	2066-2071	human	_	
12-9	2072-2080	research	_	
12-10	2081-2085	have	_	
12-11	2086-2091	shown	_	
12-12	2092-2096	that	_	
12-13	2097-2101	this	_	
12-14	2102-2110	critical	_	
12-15	2111-2115	bond	_	
12-16	2116-2123	between	_	
12-17	2124-2127	the	_	
12-18	2128-2134	mother	_	
12-19	2135-2138	and	_	
12-20	2139-2142	her	_	
12-21	2143-2149	infant	_	
12-22	2150-2153	may	_	
12-23	2154-2156	be	_	
12-24	2157-2168	compromised	_	
12-25	2169-2171	as	_	
12-26	2172-2173	a	_	
12-27	2174-2180	result	_	
12-28	2181-2183	of	_	
12-29	2184-2192	maternal	_	
12-30	2193-2206	substance-use	_	
12-31	2207-2216	behaviors	_	
12-32	2216-2217	,	_	
12-33	2218-2228	especially	_	
12-34	2229-2238	substance	_	
12-35	2239-2249	addictions	_	
12-36	2249-2250	.	_	

#Text=Even during intermittent periods of sobriety, mothers with addictions are observed to be less attentive and responsive, while more intrusive and hostile, to their infants.
13-1	2251-2255	Even	_	
13-2	2256-2262	during	_	
13-3	2263-2275	intermittent	_	
13-4	2276-2283	periods	_	
13-5	2284-2286	of	_	
13-6	2287-2295	sobriety	_	
13-7	2295-2296	,	_	
13-8	2297-2304	mothers	_	
13-9	2305-2309	with	_	
13-10	2310-2320	addictions	_	
13-11	2321-2324	are	_	
13-12	2325-2333	observed	_	
13-13	2334-2336	to	_	
13-14	2337-2339	be	_	
13-15	2340-2344	less	_	
13-16	2345-2354	attentive	_	
13-17	2355-2358	and	_	
13-18	2359-2369	responsive	_	
13-19	2369-2370	,	_	
13-20	2371-2376	while	_	
13-21	2377-2381	more	_	
13-22	2382-2391	intrusive	_	
13-23	2392-2395	and	_	
13-24	2396-2403	hostile	_	
13-25	2403-2404	,	_	
13-26	2405-2407	to	_	
13-27	2408-2413	their	_	
13-28	2414-2421	infants	_	
13-29	2421-2422	.	_	

#Text=Compared to mothers without addictions, they find infant cues to be less gratifying and more stressful, which places their infants at increased risk for abuse or neglect.
14-1	2423-2431	Compared	_	
14-2	2432-2434	to	_	
14-3	2435-2442	mothers	_	
14-4	2443-2450	without	_	
14-5	2451-2461	addictions	_	
14-6	2461-2462	,	_	
14-7	2463-2467	they	_	
14-8	2468-2472	find	_	
14-9	2473-2479	infant	_	
14-10	2480-2484	cues	_	
14-11	2485-2487	to	_	
14-12	2488-2490	be	_	
14-13	2491-2495	less	_	
14-14	2496-2506	gratifying	_	
14-15	2507-2510	and	_	
14-16	2511-2515	more	_	
14-17	2516-2525	stressful	_	
14-18	2525-2526	,	_	
14-19	2527-2532	which	_	
14-20	2533-2539	places	_	
14-21	2540-2545	their	_	
14-22	2546-2553	infants	_	
14-23	2554-2556	at	_	
14-24	2557-2566	increased	_	
14-25	2567-2571	risk	_	
14-26	2572-2575	for	_	
14-27	2576-2581	abuse	_	
14-28	2582-2584	or	_	
14-29	2585-2592	neglect	_	
14-30	2592-2593	.	_	

#Text=According to the most recent national survey, 24.6 million Americans aged 12 years or older (9.4% of the population) were active illicit substance users.
15-1	2594-2603	According	_	
15-2	2604-2606	to	_	
15-3	2607-2610	the	_	
15-4	2611-2615	most	_	
15-5	2616-2622	recent	_	
15-6	2623-2631	national	_	
15-7	2632-2638	survey	_	
15-8	2638-2639	,	_	
15-9	2640-2644	24.6	_	
15-10	2645-2652	million	_	
15-11	2653-2662	Americans	_	
15-12	2663-2667	aged	_	
15-13	2668-2670	12	_	
15-14	2671-2676	years	_	
15-15	2677-2679	or	_	
15-16	2680-2685	older	_	
15-17	2686-2687	(	_	
15-18	2687-2691	9.4%	_	
15-19	2692-2694	of	_	
15-20	2695-2698	the	_	
15-21	2699-2709	population	_	
15-22	2709-2710	)	_	
15-23	2711-2715	were	_	
15-24	2716-2722	active	_	
15-25	2723-2730	illicit	_	
15-26	2731-2740	substance	_	
15-27	2741-2746	users	_	
15-28	2746-2747	.	_	

#Text=Binge alcohol use was reported by 60.1 million (22.9%) and 21.6 million (8.2%) qualified for a substance-use disorder as defined by the fourth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR).
16-1	2748-2753	Binge	_	
16-2	2754-2761	alcohol	_	
16-3	2762-2765	use	_	
16-4	2766-2769	was	_	
16-5	2770-2778	reported	_	
16-6	2779-2781	by	_	
16-7	2782-2786	60.1	_	
16-8	2787-2794	million	_	
16-9	2795-2796	(	_	
16-10	2796-2801	22.9%	_	
16-11	2801-2802	)	_	
16-12	2803-2806	and	_	
16-13	2807-2811	21.6	_	
16-14	2812-2819	million	_	
16-15	2820-2821	(	_	
16-16	2821-2825	8.2%	_	
16-17	2825-2826	)	_	
16-18	2827-2836	qualified	_	
16-19	2837-2840	for	_	
16-20	2841-2842	a	_	
16-21	2843-2856	substance-use	_	
16-22	2857-2865	disorder	_	
16-23	2866-2868	as	_	
16-24	2869-2876	defined	_	
16-25	2877-2879	by	_	
16-26	2880-2883	the	_	
16-27	2884-2890	fourth	_	
16-28	2891-2898	edition	_	
16-29	2899-2901	of	_	
16-30	2902-2905	the	_	
16-31	2906-2916	Diagnostic	_	
16-32	2917-2920	and	_	
16-33	2921-2932	Statistical	_	
16-34	2933-2939	Manual	_	
16-35	2940-2942	of	_	
16-36	2943-2949	Mental	_	
16-37	2950-2959	Disorders	_	
16-38	2960-2961	(	_	
16-39	2961-2970	DSM-IV-TR	_	
16-40	2970-2971	)	_	
16-41	2971-2972	.	_	

#Text=Among women who are substance users, approximately 90% are of reproductive age.
17-1	2973-2978	Among	_	
17-2	2979-2984	women	_	
17-3	2985-2988	who	_	
17-4	2989-2992	are	_	
17-5	2993-3002	substance	_	
17-6	3003-3008	users	_	
17-7	3008-3009	,	_	
17-8	3010-3023	approximately	_	
17-9	3024-3027	90%	_	
17-10	3028-3031	are	_	
17-11	3032-3034	of	_	
17-12	3035-3047	reproductive	_	
17-13	3048-3051	age	_	
17-14	3051-3052	.	_	

#Text=Annually, an estimated 212,000 pregnancies involve illicit drugs, 370,000 involve alcohol, and 606,000 involve tobacco.
18-1	3053-3061	Annually	_	
18-2	3061-3062	,	_	
18-3	3063-3065	an	_	
18-4	3066-3075	estimated	_	
18-5	3076-3083	212,000	_	
18-6	3084-3095	pregnancies	_	
18-7	3096-3103	involve	_	
18-8	3104-3111	illicit	_	
18-9	3112-3117	drugs	_	
18-10	3117-3118	,	_	
18-11	3119-3126	370,000	_	
18-12	3127-3134	involve	_	
18-13	3135-3142	alcohol	_	
18-14	3142-3143	,	_	
18-15	3144-3147	and	_	
18-16	3148-3155	606,000	_	
18-17	3156-3163	involve	_	
18-18	3164-3171	tobacco	_	
18-19	3171-3172	.	_	

#Text=While many women abstain from substance use during pregnancy, substance use is often rapidly resumed after child birth, with 30% of mothers drinking, 20% smoking, and 10% binge-drinking within 3 months of their child’s birth.
19-1	3173-3178	While	_	
19-2	3179-3183	many	_	
19-3	3184-3189	women	_	
19-4	3190-3197	abstain	_	
19-5	3198-3202	from	_	
19-6	3203-3212	substance	_	
19-7	3213-3216	use	_	
19-8	3217-3223	during	_	
19-9	3224-3233	pregnancy	_	
19-10	3233-3234	,	_	
19-11	3235-3244	substance	_	
19-12	3245-3248	use	_	
19-13	3249-3251	is	_	
19-14	3252-3257	often	_	
19-15	3258-3265	rapidly	_	
19-16	3266-3273	resumed	_	
19-17	3274-3279	after	_	
19-18	3280-3285	child	_	
19-19	3286-3291	birth	_	
19-20	3291-3292	,	_	
19-21	3293-3297	with	_	
19-22	3298-3301	30%	_	
19-23	3302-3304	of	_	
19-24	3305-3312	mothers	_	
19-25	3313-3321	drinking	_	
19-26	3321-3322	,	_	
19-27	3323-3326	20%	_	
19-28	3327-3334	smoking	_	
19-29	3334-3335	,	_	
19-30	3336-3339	and	_	
19-31	3340-3343	10%	_	
19-32	3344-3358	binge-drinking	_	
19-33	3359-3365	within	_	
19-34	3366-3367	3	_	
19-35	3368-3374	months	_	
19-36	3375-3377	of	_	
19-37	3378-3383	their	_	
19-38	3384-3389	child	_	
19-39	3389-3390	’	_	
19-40	3390-3391	s	_	
19-41	3392-3397	birth	_	
19-42	3397-3398	.	_	

#Text=Substance use increases the odds of child neglect fourfold and is involved in up to 80% of child maltreatment cases and 60% of infant out-of-home placements.
20-1	3399-3408	Substance	_	
20-2	3409-3412	use	_	
20-3	3413-3422	increases	_	
20-4	3423-3426	the	_	
20-5	3427-3431	odds	_	
20-6	3432-3434	of	_	
20-7	3435-3440	child	_	
20-8	3441-3448	neglect	_	
20-9	3449-3457	fourfold	_	
20-10	3458-3461	and	_	
20-11	3462-3464	is	_	
20-12	3465-3473	involved	_	
20-13	3474-3476	in	_	
20-14	3477-3479	up	_	
20-15	3480-3482	to	_	
20-16	3483-3486	80%	_	
20-17	3487-3489	of	_	
20-18	3490-3495	child	_	
20-19	3496-3508	maltreatment	_	
20-20	3509-3514	cases	_	
20-21	3515-3518	and	_	
20-22	3519-3522	60%	_	
20-23	3523-3525	of	_	
20-24	3526-3532	infant	_	
20-25	3533-3544	out-of-home	_	
20-26	3545-3555	placements	_	
20-27	3555-3556	.	_	

#Text=The annual public health burden related to substance misuse is estimated to be half a trillion dollars, although adverse consequences associated with maternal substance use extend far beyond this, taking a major toll on the well-being and development of the young children who are affected.
21-1	3557-3560	The	_	
21-2	3561-3567	annual	_	
21-3	3568-3574	public	_	
21-4	3575-3581	health	_	
21-5	3582-3588	burden	_	
21-6	3589-3596	related	_	
21-7	3597-3599	to	_	
21-8	3600-3609	substance	_	
21-9	3610-3616	misuse	_	
21-10	3617-3619	is	_	
21-11	3620-3629	estimated	_	
21-12	3630-3632	to	_	
21-13	3633-3635	be	_	
21-14	3636-3640	half	_	
21-15	3641-3642	a	_	
21-16	3643-3651	trillion	_	
21-17	3652-3659	dollars	_	
21-18	3659-3660	,	_	
21-19	3661-3669	although	_	
21-20	3670-3677	adverse	_	
21-21	3678-3690	consequences	_	
21-22	3691-3701	associated	_	
21-23	3702-3706	with	_	
21-24	3707-3715	maternal	_	
21-25	3716-3725	substance	_	
21-26	3726-3729	use	_	
21-27	3730-3736	extend	_	
21-28	3737-3740	far	_	
21-29	3741-3747	beyond	_	
21-30	3748-3752	this	_	
21-31	3752-3753	,	_	
21-32	3754-3760	taking	_	
21-33	3761-3762	a	_	
21-34	3763-3768	major	_	
21-35	3769-3773	toll	_	
21-36	3774-3776	on	_	
21-37	3777-3780	the	_	
21-38	3781-3791	well-being	_	
21-39	3792-3795	and	_	
21-40	3796-3807	development	_	
21-41	3808-3810	of	_	
21-42	3811-3814	the	_	
21-43	3815-3820	young	_	
21-44	3821-3829	children	_	
21-45	3830-3833	who	_	
21-46	3834-3837	are	_	
21-47	3838-3846	affected	_	
21-48	3846-3847	.	_	

#Text=Ultimately, offspring growth and development hinge on maternal neurobiological adaptation during the pre- and postpartum period (Figure 1).
22-1	3848-3858	Ultimately	_	
22-2	3858-3859	,	_	
22-3	3860-3869	offspring	_	
22-4	3870-3876	growth	_	
22-5	3877-3880	and	_	
22-6	3881-3892	development	_	
22-7	3893-3898	hinge	_	
22-8	3899-3901	on	_	
22-9	3902-3910	maternal	_	
22-10	3911-3926	neurobiological	_	
22-11	3927-3937	adaptation	_	
22-12	3938-3944	during	_	
22-13	3945-3948	the	_	
22-14	3949-3952	pre	_	
22-15	3952-3953	-	_	
22-16	3954-3957	and	_	
22-17	3958-3968	postpartum	_	
22-18	3969-3975	period	_	
22-19	3976-3977	(	_	
22-20	3977-3983	Figure	_	
22-21	3984-3985	1	_	
22-22	3985-3986	)	_	
22-23	3986-3987	.	_	

#Text=Rodent models have been instrumental in this line of work and have elucidated the following.
23-1	3988-3994	Rodent	_	
23-2	3995-4001	models	_	
23-3	4002-4006	have	_	
23-4	4007-4011	been	_	
23-5	4012-4024	instrumental	_	
23-6	4025-4027	in	_	
23-7	4028-4032	this	_	
23-8	4033-4037	line	_	
23-9	4038-4040	of	_	
23-10	4041-4045	work	_	
23-11	4046-4049	and	_	
23-12	4050-4054	have	_	
23-13	4055-4065	elucidated	_	
23-14	4066-4069	the	_	
23-15	4070-4079	following	_	
23-16	4079-4080	.	_	

#Text=Estrogen and progesterone rise steadily during pregnancy until progesterone drops sharply prior to parturition.
24-1	4081-4089	Estrogen	_	
24-2	4090-4093	and	_	
24-3	4094-4106	progesterone	_	
24-4	4107-4111	rise	_	
24-5	4112-4120	steadily	_	
24-6	4121-4127	during	_	
24-7	4128-4137	pregnancy	_	
24-8	4138-4143	until	_	
24-9	4144-4156	progesterone	_	
24-10	4157-4162	drops	_	
24-11	4163-4170	sharply	_	
24-12	4171-4176	prior	_	
24-13	4177-4179	to	_	
24-14	4180-4191	parturition	_	
24-15	4191-4192	.	_	

#Text=As parturition approaches, there is heightened sensitivity to oxytocin (OT) through increased OT receptor production.
25-1	4193-4195	As	_	
25-2	4196-4207	parturition	_	
25-3	4208-4218	approaches	_	
25-4	4218-4219	,	_	
25-5	4220-4225	there	_	
25-6	4226-4228	is	_	
25-7	4229-4239	heightened	_	
25-8	4240-4251	sensitivity	_	
25-9	4252-4254	to	_	
25-10	4255-4263	oxytocin	_	
25-11	4264-4265	(	_	
25-12	4265-4267	OT	_	
25-13	4267-4268	)	_	
25-14	4269-4276	through	_	
25-15	4277-4286	increased	_	
25-16	4287-4289	OT	_	
25-17	4290-4298	receptor	_	
25-18	4299-4309	production	_	
25-19	4309-4310	.	_	

#Text=The medial preoptic area (MPOA) of the hypothalamus, a region rich in OT receptors, is thought to monitor changes in hormonal levels over the course of pregnancy and stimulate the onset of maternal behavior at parturition via interaction with the mesolimbic motivational circuitry.
26-1	4311-4314	The	_	
26-2	4315-4321	medial	_	
26-3	4322-4330	preoptic	_	
26-4	4331-4335	area	_	
26-5	4336-4337	(	_	
26-6	4337-4341	MPOA	_	
26-7	4341-4342	)	_	
26-8	4343-4345	of	_	
26-9	4346-4349	the	_	
26-10	4350-4362	hypothalamus	_	
26-11	4362-4363	,	_	
26-12	4364-4365	a	_	
26-13	4366-4372	region	_	
26-14	4373-4377	rich	_	
26-15	4378-4380	in	_	
26-16	4381-4383	OT	_	
26-17	4384-4393	receptors	_	
26-18	4393-4394	,	_	
26-19	4395-4397	is	_	
26-20	4398-4405	thought	_	
26-21	4406-4408	to	_	
26-22	4409-4416	monitor	_	
26-23	4417-4424	changes	_	
26-24	4425-4427	in	_	
26-25	4428-4436	hormonal	_	
26-26	4437-4443	levels	_	
26-27	4444-4448	over	_	
26-28	4449-4452	the	_	
26-29	4453-4459	course	_	
26-30	4460-4462	of	_	
26-31	4463-4472	pregnancy	_	
26-32	4473-4476	and	_	
26-33	4477-4486	stimulate	_	
26-34	4487-4490	the	_	
26-35	4491-4496	onset	_	
26-36	4497-4499	of	_	
26-37	4500-4508	maternal	_	
26-38	4509-4517	behavior	_	
26-39	4518-4520	at	_	
26-40	4521-4532	parturition	_	
26-41	4533-4536	via	_	
26-42	4537-4548	interaction	_	
26-43	4549-4553	with	_	
26-44	4554-4557	the	_	
26-45	4558-4568	mesolimbic	_	
26-46	4569-4581	motivational	_	
26-47	4582-4591	circuitry	_	
26-48	4591-4592	.	_	

#Text=The MPOA directly projects to the ventral tegmental area (VTA), ventral striatum (VS), and medial prefrontal cortex (mPFC) and induces dopamine (DA) release into the mesocorticolimbic DA pathway.
27-1	4593-4596	The	_	
27-2	4597-4601	MPOA	_	
27-3	4602-4610	directly	_	
27-4	4611-4619	projects	_	
27-5	4620-4622	to	_	
27-6	4623-4626	the	_	
27-7	4627-4634	ventral	_	
27-8	4635-4644	tegmental	_	
27-9	4645-4649	area	_	
27-10	4650-4651	(	_	
27-11	4651-4654	VTA	_	
27-12	4654-4655	)	_	
27-13	4655-4656	,	_	
27-14	4657-4664	ventral	_	
27-15	4665-4673	striatum	_	
27-16	4674-4675	(	_	
27-17	4675-4677	VS	_	
27-18	4677-4678	)	_	
27-19	4678-4679	,	_	
27-20	4680-4683	and	_	
27-21	4684-4690	medial	_	
27-22	4691-4701	prefrontal	_	
27-23	4702-4708	cortex	_	
27-24	4709-4710	(	_	
27-25	4710-4714	mPFC	_	
27-26	4714-4715	)	_	
27-27	4716-4719	and	_	
27-28	4720-4727	induces	_	
27-29	4728-4736	dopamine	_	
27-30	4737-4738	(	_	
27-31	4738-4740	DA	_	
27-32	4740-4741	)	_	
27-33	4742-4749	release	_	
27-34	4750-4754	into	_	
27-35	4755-4758	the	_	
27-36	4759-4776	mesocorticolimbic	_	
27-37	4777-4779	DA	_	
27-38	4780-4787	pathway	_	
27-39	4787-4788	.	_	

#Text=As a key modulatory site of maternal circuitry, the VS integrates corticolimbic inputs and projects to the ventral pallidum to direct the mother’s responsiveness toward infant cues.
28-1	4789-4791	As	_	
28-2	4792-4793	a	_	
28-3	4794-4797	key	_	
28-4	4798-4808	modulatory	_	
28-5	4809-4813	site	_	
28-6	4814-4816	of	_	
28-7	4817-4825	maternal	_	
28-8	4826-4835	circuitry	_	
28-9	4835-4836	,	_	
28-10	4837-4840	the	_	
28-11	4841-4843	VS	_	
28-12	4844-4854	integrates	_	
28-13	4855-4868	corticolimbic	_	
28-14	4869-4875	inputs	_	
28-15	4876-4879	and	_	
28-16	4880-4888	projects	_	
28-17	4889-4891	to	_	
28-18	4892-4895	the	_	
28-19	4896-4903	ventral	_	
28-20	4904-4912	pallidum	_	
28-21	4913-4915	to	_	
28-22	4916-4922	direct	_	
28-23	4923-4926	the	_	
28-24	4927-4933	mother	_	
28-25	4933-4934	’	_	
28-26	4934-4935	s	_	
28-27	4936-4950	responsiveness	_	
28-28	4951-4957	toward	_	
28-29	4958-4964	infant	_	
28-30	4965-4969	cues	_	
28-31	4969-4970	.	_	

#Text=The mPFC, with its interconnections with the hypothalamic and mesolimbic structures and its established role in attention allocation, organization, and sequencing, is central to the orchestration of a complex array of well-timed and organized maternal behaviors.
29-1	4971-4974	The	_	
29-2	4975-4979	mPFC	_	
29-3	4979-4980	,	_	
29-4	4981-4985	with	_	
29-5	4986-4989	its	_	
29-6	4990-5006	interconnections	_	
29-7	5007-5011	with	_	
29-8	5012-5015	the	_	
29-9	5016-5028	hypothalamic	_	
29-10	5029-5032	and	_	
29-11	5033-5043	mesolimbic	_	
29-12	5044-5054	structures	_	
29-13	5055-5058	and	_	
29-14	5059-5062	its	_	
29-15	5063-5074	established	_	
29-16	5075-5079	role	_	
29-17	5080-5082	in	_	
29-18	5083-5092	attention	_	
29-19	5093-5103	allocation	_	
29-20	5103-5104	,	_	
29-21	5105-5117	organization	_	
29-22	5117-5118	,	_	
29-23	5119-5122	and	_	
29-24	5123-5133	sequencing	_	
29-25	5133-5134	,	_	
29-26	5135-5137	is	_	
29-27	5138-5145	central	_	
29-28	5146-5148	to	_	
29-29	5149-5152	the	_	
29-30	5153-5166	orchestration	_	
29-31	5167-5169	of	_	
29-32	5170-5171	a	_	
29-33	5172-5179	complex	_	
29-34	5180-5185	array	_	
29-35	5186-5188	of	_	
29-36	5189-5199	well-timed	_	
29-37	5200-5203	and	_	
29-38	5204-5213	organized	_	
29-39	5214-5222	maternal	_	
29-40	5223-5232	behaviors	_	
29-41	5232-5233	.	_	

#Text=The involvement of these regions in the expression of maternal behavior has been studied extensively in rodents.
30-1	5234-5237	The	_	
30-2	5238-5249	involvement	_	
30-3	5250-5252	of	_	
30-4	5253-5258	these	_	
30-5	5259-5266	regions	_	
30-6	5267-5269	in	_	
30-7	5270-5273	the	_	
30-8	5274-5284	expression	_	
30-9	5285-5287	of	_	
30-10	5288-5296	maternal	_	
30-11	5297-5305	behavior	_	
30-12	5306-5309	has	_	
30-13	5310-5314	been	_	
30-14	5315-5322	studied	_	
30-15	5323-5334	extensively	_	
30-16	5335-5337	in	_	
30-17	5338-5345	rodents	_	
30-18	5345-5346	.	_	

#Text=Estrogen, OT, or DA release into the MPOA elicits maternal behavior in virgin rats, which are normally aversive toward rat pups, while lesions of the MPOA abolish many aspects of maternal behavior in postpartum mothers.
31-1	5347-5355	Estrogen	_	
31-2	5355-5356	,	_	
31-3	5357-5359	OT	_	
31-4	5359-5360	,	_	
31-5	5361-5363	or	_	
31-6	5364-5366	DA	_	
31-7	5367-5374	release	_	
31-8	5375-5379	into	_	
31-9	5380-5383	the	_	
31-10	5384-5388	MPOA	_	
31-11	5389-5396	elicits	_	
31-12	5397-5405	maternal	_	
31-13	5406-5414	behavior	_	
31-14	5415-5417	in	_	
31-15	5418-5424	virgin	_	
31-16	5425-5429	rats	_	
31-17	5429-5430	,	_	
31-18	5431-5436	which	_	
31-19	5437-5440	are	_	
31-20	5441-5449	normally	_	
31-21	5450-5458	aversive	_	
31-22	5459-5465	toward	_	
31-23	5466-5469	rat	_	
31-24	5470-5474	pups	_	
31-25	5474-5475	,	_	
31-26	5476-5481	while	_	
31-27	5482-5489	lesions	_	
31-28	5490-5492	of	_	
31-29	5493-5496	the	_	
31-30	5497-5501	MPOA	_	
31-31	5502-5509	abolish	_	
31-32	5510-5514	many	_	
31-33	5515-5522	aspects	_	
31-34	5523-5525	of	_	
31-35	5526-5534	maternal	_	
31-36	5535-5543	behavior	_	
31-37	5544-5546	in	_	
31-38	5547-5557	postpartum	_	
31-39	5558-5565	mothers	_	
31-40	5565-5566	.	_	

#Text=VS neurons show increased Fos expression during mother-pup interactions, and the magnitude of DA release in the VS measured in vivo corresponds with immediately observed levels of maternal behavior.
32-1	5567-5569	VS	_	
32-2	5570-5577	neurons	_	
32-3	5578-5582	show	_	
32-4	5583-5592	increased	_	
32-5	5593-5596	Fos	_	
32-6	5597-5607	expression	_	
32-7	5608-5614	during	_	
32-8	5615-5625	mother-pup	_	
32-9	5626-5638	interactions	_	
32-10	5638-5639	,	_	
32-11	5640-5643	and	_	
32-12	5644-5647	the	_	
32-13	5648-5657	magnitude	_	
32-14	5658-5660	of	_	
32-15	5661-5663	DA	_	
32-16	5664-5671	release	_	
32-17	5672-5674	in	_	
32-18	5675-5678	the	_	
32-19	5679-5681	VS	_	
32-20	5682-5690	measured	_	
32-21	5691-5693	in	_	
32-22	5694-5698	vivo	_	
32-23	5699-5710	corresponds	_	
32-24	5711-5715	with	_	
32-25	5716-5727	immediately	_	
32-26	5728-5736	observed	_	
32-27	5737-5743	levels	_	
32-28	5744-5746	of	_	
32-29	5747-5755	maternal	_	
32-30	5756-5764	behavior	_	
32-31	5764-5765	.	_	

#Text=Increased DA input into the VS facilitates maternal responses, whereas depletion of DA in the VS or lesions of the VS lead to impaired maternal behavior.
33-1	5766-5775	Increased	_	
33-2	5776-5778	DA	_	
33-3	5779-5784	input	_	
33-4	5785-5789	into	_	
33-5	5790-5793	the	_	
33-6	5794-5796	VS	_	
33-7	5797-5808	facilitates	_	
33-8	5809-5817	maternal	_	
33-9	5818-5827	responses	_	
33-10	5827-5828	,	_	
33-11	5829-5836	whereas	_	
33-12	5837-5846	depletion	_	
33-13	5847-5849	of	_	
33-14	5850-5852	DA	_	
33-15	5853-5855	in	_	
33-16	5856-5859	the	_	
33-17	5860-5862	VS	_	
33-18	5863-5865	or	_	
33-19	5866-5873	lesions	_	
33-20	5874-5876	of	_	
33-21	5877-5880	the	_	
33-22	5881-5883	VS	_	
33-23	5884-5888	lead	_	
33-24	5889-5891	to	_	
33-25	5892-5900	impaired	_	
33-26	5901-5909	maternal	_	
33-27	5910-5918	behavior	_	
33-28	5918-5919	.	_	

#Text=The role of cortical systems has garnered relatively little attention in rodent models of maternal behavior.
34-1	5920-5923	The	_	
34-2	5924-5928	role	_	
34-3	5929-5931	of	_	
34-4	5932-5940	cortical	_	
34-5	5941-5948	systems	_	
34-6	5949-5952	has	_	
34-7	5953-5961	garnered	_	
34-8	5962-5972	relatively	_	
34-9	5973-5979	little	_	
34-10	5980-5989	attention	_	
34-11	5990-5992	in	_	
34-12	5993-5999	rodent	_	
34-13	6000-6006	models	_	
34-14	6007-6009	of	_	
34-15	6010-6018	maternal	_	
34-16	6019-6027	behavior	_	
34-17	6027-6028	.	_	

#Text=However, lesions or localized inhibitions of the medial aspects of the cortex, including the mPFC, or blockade of OT receptors within the mPFC have been shown to disrupt the organization and sequential execution of maternal behavior.
35-1	6029-6036	However	_	
35-2	6036-6037	,	_	
35-3	6038-6045	lesions	_	
35-4	6046-6048	or	_	
35-5	6049-6058	localized	_	
35-6	6059-6070	inhibitions	_	
35-7	6071-6073	of	_	
35-8	6074-6077	the	_	
35-9	6078-6084	medial	_	
35-10	6085-6092	aspects	_	
35-11	6093-6095	of	_	
35-12	6096-6099	the	_	
35-13	6100-6106	cortex	_	
35-14	6106-6107	,	_	
35-15	6108-6117	including	_	
35-16	6118-6121	the	_	
35-17	6122-6126	mPFC	_	
35-18	6126-6127	,	_	
35-19	6128-6130	or	_	
35-20	6131-6139	blockade	_	
35-21	6140-6142	of	_	
35-22	6143-6145	OT	_	
35-23	6146-6155	receptors	_	
35-24	6156-6162	within	_	
35-25	6163-6166	the	_	
35-26	6167-6171	mPFC	_	
35-27	6172-6176	have	_	
35-28	6177-6181	been	_	
35-29	6182-6187	shown	_	
35-30	6188-6190	to	_	
35-31	6191-6198	disrupt	_	
35-32	6199-6202	the	_	
35-33	6203-6215	organization	_	
35-34	6216-6219	and	_	
35-35	6220-6230	sequential	_	
35-36	6231-6240	execution	_	
35-37	6241-6243	of	_	
35-38	6244-6252	maternal	_	
35-39	6253-6261	behavior	_	
35-40	6261-6262	.	_	

#Text=Although our understanding of the corresponding neurobiology in humans is limited to broad conclusions drawn from neuroimaging data and may lack the specificity and sophistication of rodent models, recent data suggest that maternal behavior is similarly regulated by a core set of neural circuits and physiological processes across mammals, from rodents to humans.
36-1	6263-6271	Although	_	
36-2	6272-6275	our	_	
36-3	6276-6289	understanding	_	
36-4	6290-6292	of	_	
36-5	6293-6296	the	_	
36-6	6297-6310	corresponding	_	
36-7	6311-6323	neurobiology	_	
36-8	6324-6326	in	_	
36-9	6327-6333	humans	_	
36-10	6334-6336	is	_	
36-11	6337-6344	limited	_	
36-12	6345-6347	to	_	
36-13	6348-6353	broad	_	
36-14	6354-6365	conclusions	_	
36-15	6366-6371	drawn	_	
36-16	6372-6376	from	_	
36-17	6377-6389	neuroimaging	_	
36-18	6390-6394	data	_	
36-19	6395-6398	and	_	
36-20	6399-6402	may	_	
36-21	6403-6407	lack	_	
36-22	6408-6411	the	_	
36-23	6412-6423	specificity	_	
36-24	6424-6427	and	_	
36-25	6428-6442	sophistication	_	
36-26	6443-6445	of	_	
36-27	6446-6452	rodent	_	
36-28	6453-6459	models	_	
36-29	6459-6460	,	_	
36-30	6461-6467	recent	_	
36-31	6468-6472	data	_	
36-32	6473-6480	suggest	_	
36-33	6481-6485	that	_	
36-34	6486-6494	maternal	_	
36-35	6495-6503	behavior	_	
36-36	6504-6506	is	_	
36-37	6507-6516	similarly	_	
36-38	6517-6526	regulated	_	
36-39	6527-6529	by	_	
36-40	6530-6531	a	_	
36-41	6532-6536	core	_	
36-42	6537-6540	set	_	
36-43	6541-6543	of	_	
36-44	6544-6550	neural	_	
36-45	6551-6559	circuits	_	
36-46	6560-6563	and	_	
36-47	6564-6577	physiological	_	
36-48	6578-6587	processes	_	
36-49	6588-6594	across	_	
36-50	6595-6602	mammals	_	
36-51	6602-6603	,	_	
36-52	6604-6608	from	_	
36-53	6609-6616	rodents	_	
36-54	6617-6619	to	_	
36-55	6620-6626	humans	_	
36-56	6626-6627	.	_	

#Text=A steadily growing body of human neuroimaging studies converges with decades of rodent research pointing to the hypothalamic, mesolimbic, and cortical contributions to maternal behavior.
37-1	6628-6629	A	_	
37-2	6630-6638	steadily	_	
37-3	6639-6646	growing	_	
37-4	6647-6651	body	_	
37-5	6652-6654	of	_	
37-6	6655-6660	human	_	
37-7	6661-6673	neuroimaging	_	
37-8	6674-6681	studies	_	
37-9	6682-6691	converges	_	
37-10	6692-6696	with	_	
37-11	6697-6704	decades	_	
37-12	6705-6707	of	_	
37-13	6708-6714	rodent	_	
37-14	6715-6723	research	_	
37-15	6724-6732	pointing	_	
37-16	6733-6735	to	_	
37-17	6736-6739	the	_	
37-18	6740-6752	hypothalamic	_	
37-19	6752-6753	,	_	
37-20	6754-6764	mesolimbic	_	
37-21	6764-6765	,	_	
37-22	6766-6769	and	_	
37-23	6770-6778	cortical	_	
37-24	6779-6792	contributions	_	
37-25	6793-6795	to	_	
37-26	6796-6804	maternal	_	
37-27	6805-6813	behavior	_	
37-28	6813-6814	.	_	

#Text=Our previous work has demonstrated activations of OT- and DA-innervated brain regions, including the hypothalamus, VS, and mPFC, in first-time mothers when they viewed face images, particularly smiling images, of their own infant compared to those of a demographically matched unknown infant.
38-1	6815-6818	Our	_	
38-2	6819-6827	previous	_	
38-3	6828-6832	work	_	
38-4	6833-6836	has	_	
38-5	6837-6849	demonstrated	_	
38-6	6850-6861	activations	_	
38-7	6862-6864	of	_	
38-8	6865-6867	OT	_	
38-9	6867-6868	-	_	
38-10	6869-6872	and	_	
38-11	6873-6886	DA-innervated	_	
38-12	6887-6892	brain	_	
38-13	6893-6900	regions	_	
38-14	6900-6901	,	_	
38-15	6902-6911	including	_	
38-16	6912-6915	the	_	
38-17	6916-6928	hypothalamus	_	
38-18	6928-6929	,	_	
38-19	6930-6932	VS	_	
38-20	6932-6933	,	_	
38-21	6934-6937	and	_	
38-22	6938-6942	mPFC	_	
38-23	6942-6943	,	_	
38-24	6944-6946	in	_	
38-25	6947-6957	first-time	_	
38-26	6958-6965	mothers	_	
38-27	6966-6970	when	_	
38-28	6971-6975	they	_	
38-29	6976-6982	viewed	_	
38-30	6983-6987	face	_	
38-31	6988-6994	images	_	
38-32	6994-6995	,	_	
38-33	6996-7008	particularly	_	
38-34	7009-7016	smiling	_	
38-35	7017-7023	images	_	
38-36	7023-7024	,	_	
38-37	7025-7027	of	_	
38-38	7028-7033	their	_	
38-39	7034-7037	own	_	
38-40	7038-7044	infant	_	
38-41	7045-7053	compared	_	
38-42	7054-7056	to	_	
38-43	7057-7062	those	_	
38-44	7063-7065	of	_	
38-45	7066-7067	a	_	
38-46	7068-7083	demographically	_	
38-47	7084-7091	matched	_	
38-48	7092-7099	unknown	_	
38-49	7100-7106	infant	_	
38-50	7106-7107	.	_	

#Text=Differential activations of these regions reflected individual differences in maternal attachment and corresponded with the magnitude of maternal peripheral OT response during periods of mother-infant contact.
39-1	7108-7120	Differential	_	
39-2	7121-7132	activations	_	
39-3	7133-7135	of	_	
39-4	7136-7141	these	_	
39-5	7142-7149	regions	_	
39-6	7150-7159	reflected	_	
39-7	7160-7170	individual	_	
39-8	7171-7182	differences	_	
39-9	7183-7185	in	_	
39-10	7186-7194	maternal	_	
39-11	7195-7205	attachment	_	
39-12	7206-7209	and	_	
39-13	7210-7222	corresponded	_	
39-14	7223-7227	with	_	
39-15	7228-7231	the	_	
39-16	7232-7241	magnitude	_	
39-17	7242-7244	of	_	
39-18	7245-7253	maternal	_	
39-19	7254-7264	peripheral	_	
39-20	7265-7267	OT	_	
39-21	7268-7276	response	_	
39-22	7277-7283	during	_	
39-23	7284-7291	periods	_	
39-24	7292-7294	of	_	
39-25	7295-7308	mother-infant	_	
39-26	7309-7316	contact	_	
39-27	7316-7317	.	_	

#Text=Although infant cues, particularly smiling cues from one’s own infant, are powerful stimuli evoking widespread activation of the maternal brain, accumulating evidence demonstrates that maternal care is most importantly implicated in two key neural networks in humans: the limbic circuits regulating motivation/salience (e.g., hypothalamus, VTA, VS, amygdala, anterior cingulate cortex) and the cortical circuits subserving social cognition/empathy (e.g., mPFC, insula, orbitofrontal cortex, superior temporal gyrus [STG], inferior parietal lobule [IPL], inferior frontal gyrus).
40-1	7318-7326	Although	_	
40-2	7327-7333	infant	_	
40-3	7334-7338	cues	_	
40-4	7338-7339	,	_	
40-5	7340-7352	particularly	_	
40-6	7353-7360	smiling	_	
40-7	7361-7365	cues	_	
40-8	7366-7370	from	_	
40-9	7371-7374	one	_	
40-10	7374-7375	’	_	
40-11	7375-7376	s	_	
40-12	7377-7380	own	_	
40-13	7381-7387	infant	_	
40-14	7387-7388	,	_	
40-15	7389-7392	are	_	
40-16	7393-7401	powerful	_	
40-17	7402-7409	stimuli	_	
40-18	7410-7417	evoking	_	
40-19	7418-7428	widespread	_	
40-20	7429-7439	activation	_	
40-21	7440-7442	of	_	
40-22	7443-7446	the	_	
40-23	7447-7455	maternal	_	
40-24	7456-7461	brain	_	
40-25	7461-7462	,	_	
40-26	7463-7475	accumulating	_	
40-27	7476-7484	evidence	_	
40-28	7485-7497	demonstrates	_	
40-29	7498-7502	that	_	
40-30	7503-7511	maternal	_	
40-31	7512-7516	care	_	
40-32	7517-7519	is	_	
40-33	7520-7524	most	_	
40-34	7525-7536	importantly	_	
40-35	7537-7547	implicated	_	
40-36	7548-7550	in	_	
40-37	7551-7554	two	_	
40-38	7555-7558	key	_	
40-39	7559-7565	neural	_	
40-40	7566-7574	networks	_	
40-41	7575-7577	in	_	
40-42	7578-7584	humans	_	
40-43	7584-7585	:	_	
40-44	7586-7589	the	_	
40-45	7590-7596	limbic	_	
40-46	7597-7605	circuits	_	
40-47	7606-7616	regulating	_	
40-48	7617-7627	motivation	_	
40-49	7627-7628	/	_	
40-50	7628-7636	salience	_	
40-51	7637-7638	(	_	
40-52	7638-7641	e.g	_	
40-53	7641-7642	.	_	
40-54	7642-7643	,	_	
40-55	7644-7656	hypothalamus	_	
40-56	7656-7657	,	_	
40-57	7658-7661	VTA	_	
40-58	7661-7662	,	_	
40-59	7663-7665	VS	_	
40-60	7665-7666	,	_	
40-61	7667-7675	amygdala	_	
40-62	7675-7676	,	_	
40-63	7677-7685	anterior	_	
40-64	7686-7695	cingulate	_	
40-65	7696-7702	cortex	_	
40-66	7702-7703	)	_	
40-67	7704-7707	and	_	
40-68	7708-7711	the	_	
40-69	7712-7720	cortical	_	
40-70	7721-7729	circuits	_	
40-71	7730-7740	subserving	_	
40-72	7741-7747	social	_	
40-73	7748-7757	cognition	_	
40-74	7757-7758	/	_	
40-75	7758-7765	empathy	_	
40-76	7766-7767	(	_	
40-77	7767-7770	e.g	_	
40-78	7770-7771	.	_	
40-79	7771-7772	,	_	
40-80	7773-7777	mPFC	_	
40-81	7777-7778	,	_	
40-82	7779-7785	insula	_	
40-83	7785-7786	,	_	
40-84	7787-7800	orbitofrontal	_	
40-85	7801-7807	cortex	_	
40-86	7807-7808	,	_	
40-87	7809-7817	superior	_	
40-88	7818-7826	temporal	_	
40-89	7827-7832	gyrus	_	
40-90	7833-7834	[	_	
40-91	7834-7837	STG	_	
40-92	7837-7838	]	_	
40-93	7838-7839	,	_	
40-94	7840-7848	inferior	_	
40-95	7849-7857	parietal	_	
40-96	7858-7864	lobule	_	
40-97	7865-7866	[	_	
40-98	7866-7869	IPL	_	
40-99	7869-7870	]	_	
40-100	7870-7871	,	_	
40-101	7872-7880	inferior	_	
40-102	7881-7888	frontal	_	
40-103	7889-7894	gyrus	_	
40-104	7894-7895	)	_	
40-105	7895-7896	.	_	

#Text=Increasing attention has been directed to how central components of the maternal circuitry go awry in at-risk mothering and what prevention and intervention efforts may help reverse these abnormalities.
41-1	7897-7907	Increasing	_	
41-2	7908-7917	attention	_	
41-3	7918-7921	has	_	
41-4	7922-7926	been	_	
41-5	7927-7935	directed	_	
41-6	7936-7938	to	_	
41-7	7939-7942	how	_	
41-8	7943-7950	central	_	
41-9	7951-7961	components	_	
41-10	7962-7964	of	_	
41-11	7965-7968	the	_	
41-12	7969-7977	maternal	_	
41-13	7978-7987	circuitry	_	
41-14	7988-7990	go	_	
41-15	7991-7995	awry	_	
41-16	7996-7998	in	_	
41-17	7999-8006	at-risk	_	
41-18	8007-8016	mothering	_	
41-19	8017-8020	and	_	
41-20	8021-8025	what	_	
41-21	8026-8036	prevention	_	
41-22	8037-8040	and	_	
41-23	8041-8053	intervention	_	
41-24	8054-8061	efforts	_	
41-25	8062-8065	may	_	
41-26	8066-8070	help	_	
41-27	8071-8078	reverse	_	
41-28	8079-8084	these	_	
41-29	8085-8098	abnormalities	_	
41-30	8098-8099	.	_	

#Text=With maternal substance misuse, the DA mesocorticolimbic pathway, which is integral to the establishment of maternal behavior, may be co-opted by addictive behaviors.
42-1	8100-8104	With	_	
42-2	8105-8113	maternal	_	
42-3	8114-8123	substance	_	
42-4	8124-8130	misuse	_	
42-5	8130-8131	,	_	
42-6	8132-8135	the	_	
42-7	8136-8138	DA	_	
42-8	8139-8156	mesocorticolimbic	_	
42-9	8157-8164	pathway	_	
42-10	8164-8165	,	_	
42-11	8166-8171	which	_	
42-12	8172-8174	is	_	
42-13	8175-8183	integral	_	
42-14	8184-8186	to	_	
42-15	8187-8190	the	_	
42-16	8191-8204	establishment	_	
42-17	8205-8207	of	_	
42-18	8208-8216	maternal	_	
42-19	8217-8225	behavior	_	
42-20	8225-8226	,	_	
42-21	8227-8230	may	_	
42-22	8231-8233	be	_	
42-23	8234-8242	co-opted	_	
42-24	8243-8245	by	_	
42-25	8246-8255	addictive	_	
42-26	8256-8265	behaviors	_	
42-27	8265-8266	.	_	

#Text=DA-regulated reward pathways that are involved in addiction overlap with those that are key to maternal caregiving, including the hypothalamus, VTA, VS, and mPFC.
43-1	8267-8279	DA-regulated	_	
43-2	8280-8286	reward	_	
43-3	8287-8295	pathways	_	
43-4	8296-8300	that	_	
43-5	8301-8304	are	_	
43-6	8305-8313	involved	_	
43-7	8314-8316	in	_	
43-8	8317-8326	addiction	_	
43-9	8327-8334	overlap	_	
43-10	8335-8339	with	_	
43-11	8340-8345	those	_	
43-12	8346-8350	that	_	
43-13	8351-8354	are	_	
43-14	8355-8358	key	_	
43-15	8359-8361	to	_	
43-16	8362-8370	maternal	_	
43-17	8371-8381	caregiving	_	
43-18	8381-8382	,	_	
43-19	8383-8392	including	_	
43-20	8393-8396	the	_	
43-21	8397-8409	hypothalamus	_	
43-22	8409-8410	,	_	
43-23	8411-8414	VTA	_	
43-24	8414-8415	,	_	
43-25	8416-8418	VS	_	
43-26	8418-8419	,	_	
43-27	8420-8423	and	_	
43-28	8424-8428	mPFC	_	
43-29	8428-8429	.	_	

#Text=Addictive substances, such as cocaine and amphetamine, induce a surge of DA in the VTA and VS, which may positively reinforce subsequent substance use, and over time may result in multiple neuroadaptations in the mesolimbic DA system.
44-1	8430-8439	Addictive	_	
44-2	8440-8450	substances	_	
44-3	8450-8451	,	_	
44-4	8452-8456	such	_	
44-5	8457-8459	as	_	
44-6	8460-8467	cocaine	_	
44-7	8468-8471	and	_	
44-8	8472-8483	amphetamine	_	
44-9	8483-8484	,	_	
44-10	8485-8491	induce	_	
44-11	8492-8493	a	_	
44-12	8494-8499	surge	_	
44-13	8500-8502	of	_	
44-14	8503-8505	DA	_	
44-15	8506-8508	in	_	
44-16	8509-8512	the	_	
44-17	8513-8516	VTA	_	
44-18	8517-8520	and	_	
44-19	8521-8523	VS	_	
44-20	8523-8524	,	_	
44-21	8525-8530	which	_	
44-22	8531-8534	may	_	
44-23	8535-8545	positively	_	
44-24	8546-8555	reinforce	_	
44-25	8556-8566	subsequent	_	
44-26	8567-8576	substance	_	
44-27	8577-8580	use	_	
44-28	8580-8581	,	_	
44-29	8582-8585	and	_	
44-30	8586-8590	over	_	
44-31	8591-8595	time	_	
44-32	8596-8599	may	_	
44-33	8600-8606	result	_	
44-34	8607-8609	in	_	
44-35	8610-8618	multiple	_	
44-36	8619-8635	neuroadaptations	_	
44-37	8636-8638	in	_	
44-38	8639-8642	the	_	
44-39	8643-8653	mesolimbic	_	
44-40	8654-8656	DA	_	
44-41	8657-8663	system	_	
44-42	8663-8664	.	_	

#Text=With extended substance use, the DA reward threshold may be recalibrated to a level achieved through use of addictive substances, and a shift is made within the reward system.
45-1	8665-8669	With	_	
45-2	8670-8678	extended	_	
45-3	8679-8688	substance	_	
45-4	8689-8692	use	_	
45-5	8692-8693	,	_	
45-6	8694-8697	the	_	
45-7	8698-8700	DA	_	
45-8	8701-8707	reward	_	
45-9	8708-8717	threshold	_	
45-10	8718-8721	may	_	
45-11	8722-8724	be	_	
45-12	8725-8737	recalibrated	_	
45-13	8738-8740	to	_	
45-14	8741-8742	a	_	
45-15	8743-8748	level	_	
45-16	8749-8757	achieved	_	
45-17	8758-8765	through	_	
45-18	8766-8769	use	_	
45-19	8770-8772	of	_	
45-20	8773-8782	addictive	_	
45-21	8783-8793	substances	_	
45-22	8793-8794	,	_	
45-23	8795-8798	and	_	
45-24	8799-8800	a	_	
45-25	8801-8806	shift	_	
45-26	8807-8809	is	_	
45-27	8810-8814	made	_	
45-28	8815-8821	within	_	
45-29	8822-8825	the	_	
45-30	8826-8832	reward	_	
45-31	8833-8839	system	_	
45-32	8839-8840	.	_	

#Text=When such a shift occurs, the reward system may then function to modulate gratification and relief associated with addictive substances rather than to orient the individual to salient natural rewards.
46-1	8841-8845	When	_	
46-2	8846-8850	such	_	
46-3	8851-8852	a	_	
46-4	8853-8858	shift	_	
46-5	8859-8865	occurs	_	
46-6	8865-8866	,	_	
46-7	8867-8870	the	_	
46-8	8871-8877	reward	_	
46-9	8878-8884	system	_	
46-10	8885-8888	may	_	
46-11	8889-8893	then	_	
46-12	8894-8902	function	_	
46-13	8903-8905	to	_	
46-14	8906-8914	modulate	_	
46-15	8915-8928	gratification	_	
46-16	8929-8932	and	_	
46-17	8933-8939	relief	_	
46-18	8940-8950	associated	_	
46-19	8951-8955	with	_	
46-20	8956-8965	addictive	_	
46-21	8966-8976	substances	_	
46-22	8977-8983	rather	_	
46-23	8984-8988	than	_	
46-24	8989-8991	to	_	
46-25	8992-8998	orient	_	
46-26	8999-9002	the	_	
46-27	9003-9013	individual	_	
46-28	9014-9016	to	_	
46-29	9017-9024	salient	_	
46-30	9025-9032	natural	_	
46-31	9033-9040	rewards	_	
46-32	9040-9041	.	_	

#Text=Strides have been made in empirically delineating this co-opting of the DA mesocorticolimbic pathway in rodent models.
47-1	9042-9049	Strides	_	
47-2	9050-9054	have	_	
47-3	9055-9059	been	_	
47-4	9060-9064	made	_	
47-5	9065-9067	in	_	
47-6	9068-9079	empirically	_	
47-7	9080-9091	delineating	_	
47-8	9092-9096	this	_	
47-9	9097-9106	co-opting	_	
47-10	9107-9109	of	_	
47-11	9110-9113	the	_	
47-12	9114-9116	DA	_	
47-13	9117-9134	mesocorticolimbic	_	
47-14	9135-9142	pathway	_	
47-15	9143-9145	in	_	
47-16	9146-9152	rodent	_	
47-17	9153-9159	models	_	
47-18	9159-9160	.	_	

#Text=These studies have primarily relied on cocaine administration and have documented cocaine-induced deficits in maternal behavior (see for review), likely via targeted actions on the MPOA, VS, and mPFC.
48-1	9161-9166	These	_	
48-2	9167-9174	studies	_	
48-3	9175-9179	have	_	
48-4	9180-9189	primarily	_	
48-5	9190-9196	relied	_	
48-6	9197-9199	on	_	
48-7	9200-9207	cocaine	_	
48-8	9208-9222	administration	_	
48-9	9223-9226	and	_	
48-10	9227-9231	have	_	
48-11	9232-9242	documented	_	
48-12	9243-9258	cocaine-induced	_	
48-13	9259-9267	deficits	_	
48-14	9268-9270	in	_	
48-15	9271-9279	maternal	_	
48-16	9280-9288	behavior	_	
48-17	9289-9290	(	_	
48-18	9290-9293	see	_	
48-19	9294-9297	for	_	
48-20	9298-9304	review	_	
48-21	9304-9305	)	_	
48-22	9305-9306	,	_	
48-23	9307-9313	likely	_	
48-24	9314-9317	via	_	
48-25	9318-9326	targeted	_	
48-26	9327-9334	actions	_	
48-27	9335-9337	on	_	
48-28	9338-9341	the	_	
48-29	9342-9346	MPOA	_	
48-30	9346-9347	,	_	
48-31	9348-9350	VS	_	
48-32	9350-9351	,	_	
48-33	9352-9355	and	_	
48-34	9356-9360	mPFC	_	
48-35	9360-9361	.	_	

#Text=These actions may be mediated in part by disruptions in the OT system, as cocaine administration suppresses levels of OT, OT neurons, and OT receptors in these regions, particularly in the MPOA where these actions have been studied most.
49-1	9362-9367	These	_	
49-2	9368-9375	actions	_	
49-3	9376-9379	may	_	
49-4	9380-9382	be	_	
49-5	9383-9391	mediated	_	
49-6	9392-9394	in	_	
49-7	9395-9399	part	_	
49-8	9400-9402	by	_	
49-9	9403-9414	disruptions	_	
49-10	9415-9417	in	_	
49-11	9418-9421	the	_	
49-12	9422-9424	OT	_	
49-13	9425-9431	system	_	
49-14	9431-9432	,	_	
49-15	9433-9435	as	_	
49-16	9436-9443	cocaine	_	
49-17	9444-9458	administration	_	
49-18	9459-9469	suppresses	_	
49-19	9470-9476	levels	_	
49-20	9477-9479	of	_	
49-21	9480-9482	OT	_	
49-22	9482-9483	,	_	
49-23	9484-9486	OT	_	
49-24	9487-9494	neurons	_	
49-25	9494-9495	,	_	
49-26	9496-9499	and	_	
49-27	9500-9502	OT	_	
49-28	9503-9512	receptors	_	
49-29	9513-9515	in	_	
49-30	9516-9521	these	_	
49-31	9522-9529	regions	_	
49-32	9529-9530	,	_	
49-33	9531-9543	particularly	_	
49-34	9544-9546	in	_	
49-35	9547-9550	the	_	
49-36	9551-9555	MPOA	_	
49-37	9556-9561	where	_	
49-38	9562-9567	these	_	
49-39	9568-9575	actions	_	
49-40	9576-9580	have	_	
49-41	9581-9585	been	_	
49-42	9586-9593	studied	_	
49-43	9594-9598	most	_	
49-44	9598-9599	.	_	

#Text=The study of corresponding mechanisms in humans is still in a nascent stage, with only two studies appearing on this topic to date.
50-1	9600-9603	The	_	
50-2	9604-9609	study	_	
50-3	9610-9612	of	_	
50-4	9613-9626	corresponding	_	
50-5	9627-9637	mechanisms	_	
50-6	9638-9640	in	_	
50-7	9641-9647	humans	_	
50-8	9648-9650	is	_	
50-9	9651-9656	still	_	
50-10	9657-9659	in	_	
50-11	9660-9661	a	_	
50-12	9662-9669	nascent	_	
50-13	9670-9675	stage	_	
50-14	9675-9676	,	_	
50-15	9677-9681	with	_	
50-16	9682-9686	only	_	
50-17	9687-9690	two	_	
50-18	9691-9698	studies	_	
50-19	9699-9708	appearing	_	
50-20	9709-9711	on	_	
50-21	9712-9716	this	_	
50-22	9717-9722	topic	_	
50-23	9723-9725	to	_	
50-24	9726-9730	date	_	
50-25	9730-9731	.	_	

#Text=The first demonstrated reduced plasma OT levels in postpartum mothers reporting gestational cocaine use.
51-1	9732-9735	The	_	
51-2	9736-9741	first	_	
51-3	9742-9754	demonstrated	_	
51-4	9755-9762	reduced	_	
51-5	9763-9769	plasma	_	
51-6	9770-9772	OT	_	
51-7	9773-9779	levels	_	
51-8	9780-9782	in	_	
51-9	9783-9793	postpartum	_	
51-10	9794-9801	mothers	_	
51-11	9802-9811	reporting	_	
51-12	9812-9823	gestational	_	
51-13	9824-9831	cocaine	_	
51-14	9832-9835	use	_	
51-15	9835-9836	.	_	

#Text=The other is the only existing functional magnetic resonance imaging (fMRI) study of maternal brain responses in substance-using mothers, documenting reduced prefrontal and limbic activations in response to unfamiliar face images and cries of infants.
52-1	9837-9840	The	_	
52-2	9841-9846	other	_	
52-3	9847-9849	is	_	
52-4	9850-9853	the	_	
52-5	9854-9858	only	_	
52-6	9859-9867	existing	_	
52-7	9868-9878	functional	_	
52-8	9879-9887	magnetic	_	
52-9	9888-9897	resonance	_	
52-10	9898-9905	imaging	_	
52-11	9906-9907	(	_	
52-12	9907-9911	fMRI	_	
52-13	9911-9912	)	_	
52-14	9913-9918	study	_	
52-15	9919-9921	of	_	
52-16	9922-9930	maternal	_	
52-17	9931-9936	brain	_	
52-18	9937-9946	responses	_	
52-19	9947-9949	in	_	
52-20	9950-9965	substance-using	_	
52-21	9966-9973	mothers	_	
52-22	9973-9974	,	_	
52-23	9975-9986	documenting	_	
52-24	9987-9994	reduced	_	
52-25	9995-10005	prefrontal	_	
52-26	10006-10009	and	_	
52-27	10010-10016	limbic	_	
52-28	10017-10028	activations	_	
52-29	10029-10031	in	_	
52-30	10032-10040	response	_	
52-31	10041-10043	to	_	
52-32	10044-10054	unfamiliar	_	
52-33	10055-10059	face	_	
52-34	10060-10066	images	_	
52-35	10067-10070	and	_	
52-36	10071-10076	cries	_	
52-37	10077-10079	of	_	
52-38	10080-10087	infants	_	
52-39	10087-10088	.	_	

#Text=Perhaps due to the use of generic images of infants rather than images of the mothers’ own infants, no findings emerged in this study with respect to the mothers’ hypothalamic-mesolimbic activations.
53-1	10089-10096	Perhaps	_	
53-2	10097-10100	due	_	
53-3	10101-10103	to	_	
53-4	10104-10107	the	_	
53-5	10108-10111	use	_	
53-6	10112-10114	of	_	
53-7	10115-10122	generic	_	
53-8	10123-10129	images	_	
53-9	10130-10132	of	_	
53-10	10133-10140	infants	_	
53-11	10141-10147	rather	_	
53-12	10148-10152	than	_	
53-13	10153-10159	images	_	
53-14	10160-10162	of	_	
53-15	10163-10166	the	_	
53-16	10167-10174	mothers	_	
53-17	10174-10175	’	_	
53-18	10176-10179	own	_	
53-19	10180-10187	infants	_	
53-20	10187-10188	,	_	
53-21	10189-10191	no	_	
53-22	10192-10200	findings	_	
53-23	10201-10208	emerged	_	
53-24	10209-10211	in	_	
53-25	10212-10216	this	_	
53-26	10217-10222	study	_	
53-27	10223-10227	with	_	
53-28	10228-10235	respect	_	
53-29	10236-10238	to	_	
53-30	10239-10242	the	_	
53-31	10243-10250	mothers	_	
53-32	10250-10251	’	_	
53-33	10252-10275	hypothalamic-mesolimbic	_	
53-34	10276-10287	activations	_	
53-35	10287-10288	.	_	

#Text=Here, we report on the first human study examining how the mother’s brain response to her own infant is modified in the presence of substance addiction.
54-1	10289-10293	Here	_	
54-2	10293-10294	,	_	
54-3	10295-10297	we	_	
54-4	10298-10304	report	_	
54-5	10305-10307	on	_	
54-6	10308-10311	the	_	
54-7	10312-10317	first	_	
54-8	10318-10323	human	_	
54-9	10324-10329	study	_	
54-10	10330-10339	examining	_	
54-11	10340-10343	how	_	
54-12	10344-10347	the	_	
54-13	10348-10354	mother	_	
54-14	10354-10355	’	_	
54-15	10355-10356	s	_	
54-16	10357-10362	brain	_	
54-17	10363-10371	response	_	
54-18	10372-10374	to	_	
54-19	10375-10378	her	_	
54-20	10379-10382	own	_	
54-21	10383-10389	infant	_	
54-22	10390-10392	is	_	
54-23	10393-10401	modified	_	
54-24	10402-10404	in	_	
54-25	10405-10408	the	_	
54-26	10409-10417	presence	_	
54-27	10418-10420	of	_	
54-28	10421-10430	substance	_	
54-29	10431-10440	addiction	_	
54-30	10440-10441	.	_	

#Text=We employed a well-validated fMRI paradigm in which mothers with addictions viewed face images of their own infants in the scanner, interspersed with those of unknown infants.
55-1	10442-10444	We	_	
55-2	10445-10453	employed	_	
55-3	10454-10455	a	_	
55-4	10456-10470	well-validated	_	
55-5	10471-10475	fMRI	_	
55-6	10476-10484	paradigm	_	
55-7	10485-10487	in	_	
55-8	10488-10493	which	_	
55-9	10494-10501	mothers	_	
55-10	10502-10506	with	_	
55-11	10507-10517	addictions	_	
55-12	10518-10524	viewed	_	
55-13	10525-10529	face	_	
55-14	10530-10536	images	_	
55-15	10537-10539	of	_	
55-16	10540-10545	their	_	
55-17	10546-10549	own	_	
55-18	10550-10557	infants	_	
55-19	10558-10560	in	_	
55-20	10561-10564	the	_	
55-21	10565-10572	scanner	_	
55-22	10572-10573	,	_	
55-23	10574-10586	interspersed	_	
55-24	10587-10591	with	_	
55-25	10592-10597	those	_	
55-26	10598-10600	of	_	
55-27	10601-10608	unknown	_	
55-28	10609-10616	infants	_	
55-29	10616-10617	.	_	

#Text=While both happy and sad faces were utilized, the aim of the present study was to examine activations of OT- and DA-innervated brain regions in mothers with addictions in response to what is typically a robust rewarding cue from their own infant—the infant’s smiling face.
56-1	10618-10623	While	_	
56-2	10624-10628	both	_	
56-3	10629-10634	happy	_	
56-4	10635-10638	and	_	
56-5	10639-10642	sad	_	
56-6	10643-10648	faces	_	
56-7	10649-10653	were	_	
56-8	10654-10662	utilized	_	
56-9	10662-10663	,	_	
56-10	10664-10667	the	_	
56-11	10668-10671	aim	_	
56-12	10672-10674	of	_	
56-13	10675-10678	the	_	
56-14	10679-10686	present	_	
56-15	10687-10692	study	_	
56-16	10693-10696	was	_	
56-17	10697-10699	to	_	
56-18	10700-10707	examine	_	
56-19	10708-10719	activations	_	
56-20	10720-10722	of	_	
56-21	10723-10725	OT	_	
56-22	10725-10726	-	_	
56-23	10727-10730	and	_	
56-24	10731-10744	DA-innervated	_	
56-25	10745-10750	brain	_	
56-26	10751-10758	regions	_	
56-27	10759-10761	in	_	
56-28	10762-10769	mothers	_	
56-29	10770-10774	with	_	
56-30	10775-10785	addictions	_	
56-31	10786-10788	in	_	
56-32	10789-10797	response	_	
56-33	10798-10800	to	_	
56-34	10801-10805	what	_	
56-35	10806-10808	is	_	
56-36	10809-10818	typically	_	
56-37	10819-10820	a	_	
56-38	10821-10827	robust	_	
56-39	10828-10837	rewarding	_	
56-40	10838-10841	cue	_	
56-41	10842-10846	from	_	
56-42	10847-10852	their	_	
56-43	10853-10856	own	_	
56-44	10857-10867	infant—the	_	
56-45	10868-10874	infant	_	
56-46	10874-10875	’	_	
56-47	10875-10876	s	_	
56-48	10877-10884	smiling	_	
56-49	10885-10889	face	_	
56-50	10889-10890	.	_	

#Text=These cues typically form the basis of mother-infant attachment through the intrinsic reward value they hold for mothers and have previously been shown to evoke robust activations of the hypothalamic and mesocorticolimbic brain regions, in comparison to smiling faces of unknown infants, in mothers without addictions.
57-1	10891-10896	These	_	
57-2	10897-10901	cues	_	
57-3	10902-10911	typically	_	
57-4	10912-10916	form	_	
57-5	10917-10920	the	_	
57-6	10921-10926	basis	_	
57-7	10927-10929	of	_	
57-8	10930-10943	mother-infant	_	
57-9	10944-10954	attachment	_	
57-10	10955-10962	through	_	
57-11	10963-10966	the	_	
57-12	10967-10976	intrinsic	_	
57-13	10977-10983	reward	_	
57-14	10984-10989	value	_	
57-15	10990-10994	they	_	
57-16	10995-10999	hold	_	
57-17	11000-11003	for	_	
57-18	11004-11011	mothers	_	
57-19	11012-11015	and	_	
57-20	11016-11020	have	_	
57-21	11021-11031	previously	_	
57-22	11032-11036	been	_	
57-23	11037-11042	shown	_	
57-24	11043-11045	to	_	
57-25	11046-11051	evoke	_	
57-26	11052-11058	robust	_	
57-27	11059-11070	activations	_	
57-28	11071-11073	of	_	
57-29	11074-11077	the	_	
57-30	11078-11090	hypothalamic	_	
57-31	11091-11094	and	_	
57-32	11095-11112	mesocorticolimbic	_	
57-33	11113-11118	brain	_	
57-34	11119-11126	regions	_	
57-35	11126-11127	,	_	
57-36	11128-11130	in	_	
57-37	11131-11141	comparison	_	
57-38	11142-11144	to	_	
57-39	11145-11152	smiling	_	
57-40	11153-11158	faces	_	
57-41	11159-11161	of	_	
57-42	11162-11169	unknown	_	
57-43	11170-11177	infants	_	
57-44	11177-11178	,	_	
57-45	11179-11181	in	_	
57-46	11182-11189	mothers	_	
57-47	11190-11197	without	_	
57-48	11198-11208	addictions	_	
57-49	11208-11209	.	_	

#Text=We predicted that mothers with addictions will demonstrate compromised brain response to their own infant’s faces, particularly happy faces, and that this will be most prominently reflected in patterns of activations in OT- and DA-innervated brain regions.
58-1	11210-11212	We	_	
58-2	11213-11222	predicted	_	
58-3	11223-11227	that	_	
58-4	11228-11235	mothers	_	
58-5	11236-11240	with	_	
58-6	11241-11251	addictions	_	
58-7	11252-11256	will	_	
58-8	11257-11268	demonstrate	_	
58-9	11269-11280	compromised	_	
58-10	11281-11286	brain	_	
58-11	11287-11295	response	_	
58-12	11296-11298	to	_	
58-13	11299-11304	their	_	
58-14	11305-11308	own	_	
58-15	11309-11315	infant	_	
58-16	11315-11316	’	_	
58-17	11316-11317	s	_	
58-18	11318-11323	faces	_	
58-19	11323-11324	,	_	
58-20	11325-11337	particularly	_	
58-21	11338-11343	happy	_	
58-22	11344-11349	faces	_	
58-23	11349-11350	,	_	
58-24	11351-11354	and	_	
58-25	11355-11359	that	_	
58-26	11360-11364	this	_	
58-27	11365-11369	will	_	
58-28	11370-11372	be	_	
58-29	11373-11377	most	_	
58-30	11378-11389	prominently	_	
58-31	11390-11399	reflected	_	
58-32	11400-11402	in	_	
58-33	11403-11411	patterns	_	
58-34	11412-11414	of	_	
58-35	11415-11426	activations	_	
58-36	11427-11429	in	_	
58-37	11430-11432	OT	_	
58-38	11432-11433	-	_	
58-39	11434-11437	and	_	
58-40	11438-11451	DA-innervated	_	
58-41	11452-11457	brain	_	
58-42	11458-11465	regions	_	
58-43	11465-11466	.	_	

#Text=Materials and Methods
#Text=Participants
#Text=Thirty-six postpartum mothers ranging in age from 21 to 47 (M = 27.8 ± 5.6) years were recruited from an inpatient treatment facility1 for substance-use disorders.
59-1	11467-11476	Materials	http://www.case.edu/ProvCaRe/provcare#StudyMethod[5]	
59-2	11477-11480	and	http://www.case.edu/ProvCaRe/provcare#StudyMethod[5]	
59-3	11481-11488	Methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod[5]	
59-4	11489-11501	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
59-5	11502-11512	Thirty-six	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
59-6	11513-11523	postpartum	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
59-7	11524-11531	mothers	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
59-8	11532-11539	ranging	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
59-9	11540-11542	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
59-10	11543-11546	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
59-11	11547-11551	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
59-12	11552-11554	21	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
59-13	11555-11557	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
59-14	11558-11560	47	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
59-15	11561-11562	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
59-16	11562-11563	M	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
59-17	11564-11565	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
59-18	11566-11570	27.8	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
59-19	11571-11572	±	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
59-20	11573-11576	5.6	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
59-21	11576-11577	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
59-22	11578-11583	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
59-23	11584-11588	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
59-24	11589-11598	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
59-25	11599-11603	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
59-26	11604-11606	an	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
59-27	11607-11616	inpatient	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
59-28	11617-11626	treatment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
59-29	11627-11636	facility1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
59-30	11637-11640	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
59-31	11641-11654	substance-use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[7]	
59-32	11655-11664	disorders	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[7]	
59-33	11664-11665	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	

#Text=All participants were English speaking, met criteria for one or more substance-use disorder within the past year as assessed by the Mini International Neuropsychiatric Interview 6.0 (MINI), and reported a history of substance use during the most recent pregnancy.
60-1	11666-11669	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
60-2	11670-11682	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
60-3	11683-11687	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
60-4	11688-11695	English	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
60-5	11696-11704	speaking	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
60-6	11704-11705	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
60-7	11706-11709	met	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
60-8	11710-11718	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
60-9	11719-11722	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
60-10	11723-11726	one	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
60-11	11727-11729	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
60-12	11730-11734	more	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
60-13	11735-11748	substance-use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[8]	
60-14	11749-11757	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[8]	
60-15	11758-11764	within	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
60-16	11765-11768	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
60-17	11769-11773	past	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
60-18	11774-11778	year	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
60-19	11779-11781	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
60-20	11782-11790	assessed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
60-21	11791-11793	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
60-22	11794-11797	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
60-23	11798-11802	Mini	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
60-24	11803-11816	International	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
60-25	11817-11833	Neuropsychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
60-26	11834-11843	Interview	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
60-27	11844-11847	6.0	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
60-28	11848-11849	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
60-29	11849-11853	MINI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
60-30	11853-11854	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
60-31	11854-11855	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
60-32	11856-11859	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
60-33	11860-11868	reported	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
60-34	11869-11870	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
60-35	11871-11878	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
60-36	11879-11881	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
60-37	11882-11891	substance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
60-38	11892-11895	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
60-39	11896-11902	during	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
60-40	11903-11906	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
60-41	11907-11911	most	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
60-42	11912-11918	recent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
60-43	11919-11928	pregnancy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
60-44	11928-11929	.	_	

#Text=Potential participants were excluded if any of the following criteria were met: (a) severe psychiatric symptoms requiring inpatient hospitalization; (b) past or present diagnosis of schizophrenia or other psychotic disorders; (c) pending legal cases (e.g., outstanding arrest warrants or parental rights hearings); (d) insufficient English fluency precluding interview assessments; (e) contraindications for MRI scanning; (f) out-of-home placement of infant for the past month or > 50% of infant’s life; or (g) premature birth of infants, clinical evidence of in-utero drug effects, or other infant medical complications.
61-1	11930-11939	Potential	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-2	11940-11952	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-3	11953-11957	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-4	11958-11966	excluded	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-5	11967-11969	if	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-6	11970-11973	any	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-7	11974-11976	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-8	11977-11980	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-9	11981-11990	following	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-10	11991-11999	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-11	12000-12004	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-12	12005-12008	met	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-13	12008-12009	:	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-14	12010-12011	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-15	12011-12012	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-16	12012-12013	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-17	12014-12020	severe	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-18	12021-12032	psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-19	12033-12041	symptoms	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-20	12042-12051	requiring	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-21	12052-12061	inpatient	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-22	12062-12077	hospitalization	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-23	12077-12078	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-24	12079-12080	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-25	12080-12081	b	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-26	12081-12082	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-27	12083-12087	past	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-28	12088-12090	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-29	12091-12098	present	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-30	12099-12108	diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-31	12109-12111	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-32	12112-12125	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-33	12126-12128	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-34	12129-12134	other	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-35	12135-12144	psychotic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-36	12145-12154	disorders	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-37	12154-12155	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-38	12156-12157	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-39	12157-12158	c	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-40	12158-12159	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-41	12160-12167	pending	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-42	12168-12173	legal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-43	12174-12179	cases	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-44	12180-12181	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-45	12181-12184	e.g	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-46	12184-12185	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-47	12185-12186	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-48	12187-12198	outstanding	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-49	12199-12205	arrest	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-50	12206-12214	warrants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-51	12215-12217	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-52	12218-12226	parental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-53	12227-12233	rights	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-54	12234-12242	hearings	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-55	12242-12243	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-56	12243-12244	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-57	12245-12246	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-58	12246-12247	d	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-59	12247-12248	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-60	12249-12261	insufficient	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-61	12262-12269	English	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-62	12270-12277	fluency	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-63	12278-12288	precluding	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-64	12289-12298	interview	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-65	12299-12310	assessments	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-66	12310-12311	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-67	12312-12313	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-68	12313-12314	e	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-69	12314-12315	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-70	12316-12333	contraindications	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-71	12334-12337	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-72	12338-12341	MRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-73	12342-12350	scanning	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-74	12350-12351	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-75	12352-12353	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-76	12353-12354	f	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-77	12354-12355	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-78	12356-12367	out-of-home	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-79	12368-12377	placement	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-80	12378-12380	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-81	12381-12387	infant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-82	12388-12391	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-83	12392-12395	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-84	12396-12400	past	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-85	12401-12406	month	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-86	12407-12409	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-87	12410-12411	>	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-88	12412-12415	50%	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-89	12416-12418	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-90	12419-12425	infant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-91	12425-12426	’	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-92	12426-12427	s	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-93	12428-12432	life	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-94	12432-12433	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-95	12434-12436	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-96	12437-12438	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-97	12438-12439	g	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-98	12439-12440	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-99	12441-12450	premature	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-100	12451-12456	birth	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-101	12457-12459	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-102	12460-12467	infants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-103	12467-12468	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-104	12469-12477	clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-105	12478-12486	evidence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-106	12487-12489	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-107	12490-12498	in-utero	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-108	12499-12503	drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-109	12504-12511	effects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-110	12511-12512	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-111	12513-12515	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-112	12516-12521	other	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-113	12522-12528	infant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-114	12529-12536	medical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-115	12537-12550	complications	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
61-116	12550-12551	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	

#Text=Of the 40 participants who completed the scanning visit, one participant was excluded due to the use of a narcotic drug that compromised her alertness during the visit; the scans of three additional participants were discarded due to motion artifacts and technical problems.
62-1	12552-12554	Of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
62-2	12555-12558	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
62-3	12559-12561	40	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
62-4	12562-12574	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
62-5	12575-12578	who	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
62-6	12579-12588	completed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
62-7	12589-12592	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
62-8	12593-12601	scanning	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
62-9	12602-12607	visit	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
62-10	12607-12608	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
62-11	12609-12612	one	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
62-12	12613-12624	participant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
62-13	12625-12628	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
62-14	12629-12637	excluded	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
62-15	12638-12641	due	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
62-16	12642-12644	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
62-17	12645-12648	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
62-18	12649-12652	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
62-19	12653-12655	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
62-20	12656-12657	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
62-21	12658-12666	narcotic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
62-22	12667-12671	drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
62-23	12672-12676	that	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
62-24	12677-12688	compromised	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
62-25	12689-12692	her	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
62-26	12693-12702	alertness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
62-27	12703-12709	during	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
62-28	12710-12713	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
62-29	12714-12719	visit	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
62-30	12719-12720	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
62-31	12721-12724	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
62-32	12725-12730	scans	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
62-33	12731-12733	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
62-34	12734-12739	three	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
62-35	12740-12750	additional	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
62-36	12751-12763	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
62-37	12764-12768	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
62-38	12769-12778	discarded	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
62-39	12779-12782	due	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
62-40	12783-12785	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
62-41	12786-12792	motion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
62-42	12793-12802	artifacts	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
62-43	12803-12806	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
62-44	12807-12816	technical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
62-45	12817-12825	problems	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
62-46	12825-12826	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	

#Text=Ethics approval for this study was granted by the institutional review board at Baylor College of Medicine.
63-1	12827-12833	Ethics	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
63-2	12834-12842	approval	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
63-3	12843-12846	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
63-4	12847-12851	this	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
63-5	12852-12857	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
63-6	12858-12861	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
63-7	12862-12869	granted	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
63-8	12870-12872	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
63-9	12873-12876	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
63-10	12877-12890	institutional	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
63-11	12891-12897	review	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
63-12	12898-12903	board	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
63-13	12904-12906	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
63-14	12907-12913	Baylor	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
63-15	12914-12921	College	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
63-16	12922-12924	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
63-17	12925-12933	Medicine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
63-18	12933-12934	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	

#Text=All participants provided written informed consent in accordance with the Declaration of Helsinki.
64-1	12935-12938	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
64-2	12939-12951	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
64-3	12952-12960	provided	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
64-4	12961-12968	written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
64-5	12969-12977	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
64-6	12978-12985	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
64-7	12986-12988	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
64-8	12989-12999	accordance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
64-9	13000-13004	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
64-10	13005-13008	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
64-11	13009-13020	Declaration	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
64-12	13021-13023	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
64-13	13024-13032	Helsinki	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
64-14	13032-13033	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	

#Text=Study Design
#Text=Mothers were screened for study enrollment by licensed chemical dependency counselors and trained research assistants upon admission to the treatment facility.
65-1	13034-13039	Study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
65-2	13040-13046	Design	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
65-3	13047-13054	Mothers	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
65-4	13055-13059	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
65-5	13060-13068	screened	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
65-6	13069-13072	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
65-7	13073-13078	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
65-8	13079-13089	enrollment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
65-9	13090-13092	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
65-10	13093-13101	licensed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
65-11	13102-13110	chemical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
65-12	13111-13121	dependency	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
65-13	13122-13132	counselors	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
65-14	13133-13136	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
65-15	13137-13144	trained	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
65-16	13145-13153	research	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
65-17	13154-13164	assistants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
65-18	13165-13169	upon	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
65-19	13170-13179	admission	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
65-20	13180-13182	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
65-21	13183-13186	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
65-22	13187-13196	treatment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
65-23	13197-13205	facility	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
65-24	13205-13206	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	

#Text=Eligible and enrolled mothers were transported to the Attachment and Neurodevelopment Laboratory for study visits.
66-1	13207-13215	Eligible	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
66-2	13216-13219	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
66-3	13220-13228	enrolled	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
66-4	13229-13236	mothers	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
66-5	13237-13241	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
66-6	13242-13253	transported	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
66-7	13254-13256	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
66-8	13257-13260	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
66-9	13261-13271	Attachment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
66-10	13272-13275	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
66-11	13276-13292	Neurodevelopment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
66-12	13293-13303	Laboratory	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
66-13	13304-13307	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
66-14	13308-13313	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
66-15	13314-13320	visits	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
66-16	13320-13321	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	

#Text=Infants were approximately 5 months old (M = 5.0 ± 2.9) at the time of the first study visit, at which time infant face images were recorded, and mothers underwent fMRI scanning2 at approximately 6 months (M = 6.0 ± 3.4) postpartum, viewing face images of their own and a matched unknown infant.
67-1	13322-13329	Infants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
67-2	13330-13334	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
67-3	13335-13348	approximately	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
67-4	13349-13350	5	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
67-5	13351-13357	months	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
67-6	13358-13361	old	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
67-7	13362-13363	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
67-8	13363-13364	M	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
67-9	13365-13366	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
67-10	13367-13370	5.0	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
67-11	13371-13372	±	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
67-12	13373-13376	2.9	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
67-13	13376-13377	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
67-14	13378-13380	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
67-15	13381-13384	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
67-16	13385-13389	time	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
67-17	13390-13392	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
67-18	13393-13396	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
67-19	13397-13402	first	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
67-20	13403-13408	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
67-21	13409-13414	visit	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
67-22	13414-13415	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
67-23	13416-13418	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
67-24	13419-13424	which	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
67-25	13425-13429	time	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
67-26	13430-13436	infant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
67-27	13437-13441	face	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
67-28	13442-13448	images	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
67-29	13449-13453	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
67-30	13454-13462	recorded	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
67-31	13462-13463	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
67-32	13464-13467	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
67-33	13468-13475	mothers	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
67-34	13476-13485	underwent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
67-35	13486-13490	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[10]	
67-36	13491-13500	scanning2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
67-37	13501-13503	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
67-38	13504-13517	approximately	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
67-39	13518-13519	6	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
67-40	13520-13526	months	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
67-41	13527-13528	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
67-42	13528-13529	M	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
67-43	13530-13531	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
67-44	13532-13535	6.0	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
67-45	13536-13537	±	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
67-46	13538-13541	3.4	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
67-47	13541-13542	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
67-48	13543-13553	postpartum	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
67-49	13553-13554	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
67-50	13555-13562	viewing	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
67-51	13563-13567	face	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
67-52	13568-13574	images	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
67-53	13575-13577	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
67-54	13578-13583	their	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
67-55	13584-13587	own	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
67-56	13588-13591	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
67-57	13592-13593	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
67-58	13594-13601	matched	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
67-59	13602-13609	unknown	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
67-60	13610-13616	infant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
67-61	13616-13617	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	

#Text=Upon completion of the scan, mothers provided ratings on how they perceived the infant to be feeling in each image (i.e., happy faces: “how happy do you think the baby was feeling?”
68-1	13618-13622	Upon	_	
68-2	13623-13633	completion	_	
68-3	13634-13636	of	_	
68-4	13637-13640	the	_	
68-5	13641-13645	scan	_	
68-6	13645-13646	,	_	
68-7	13647-13654	mothers	_	
68-8	13655-13663	provided	_	
68-9	13664-13671	ratings	_	
68-10	13672-13674	on	_	
68-11	13675-13678	how	_	
68-12	13679-13683	they	_	
68-13	13684-13693	perceived	_	
68-14	13694-13697	the	_	
68-15	13698-13704	infant	_	
68-16	13705-13707	to	_	
68-17	13708-13710	be	_	
68-18	13711-13718	feeling	_	
68-19	13719-13721	in	_	
68-20	13722-13726	each	_	
68-21	13727-13732	image	_	
68-22	13733-13734	(	_	
68-23	13734-13737	i.e	_	
68-24	13737-13738	.	_	
68-25	13738-13739	,	_	
68-26	13740-13745	happy	_	
68-27	13746-13751	faces	_	
68-28	13751-13752	:	_	
68-29	13753-13754	“	_	
68-30	13754-13757	how	_	
68-31	13758-13763	happy	_	
68-32	13764-13766	do	_	
68-33	13767-13770	you	_	
68-34	13771-13776	think	_	
68-35	13777-13780	the	_	
68-36	13781-13785	baby	_	
68-37	13786-13789	was	_	
68-38	13790-13797	feeling	_	
68-39	13797-13798	?	_	
68-40	13798-13799	”	_	

#Text=; sad faces: “how sad do you think the baby was feeling?”
69-1	13799-13800	;	_	
69-2	13801-13804	sad	_	
69-3	13805-13810	faces	_	
69-4	13810-13811	:	_	
69-5	13812-13813	“	_	
69-6	13813-13816	how	_	
69-7	13817-13820	sad	_	
69-8	13821-13823	do	_	
69-9	13824-13827	you	_	
69-10	13828-13833	think	_	
69-11	13834-13837	the	_	
69-12	13838-13842	baby	_	
69-13	13843-13846	was	_	
69-14	13847-13854	feeling	_	
69-15	13854-13855	?	_	
69-16	13855-13856	”	_	

#Text=and “how distressed do you think the baby was feeling?”)
70-1	13857-13860	and	_	
70-2	13861-13862	“	_	
70-3	13862-13865	how	_	
70-4	13866-13876	distressed	_	
70-5	13877-13879	do	_	
70-6	13880-13883	you	_	
70-7	13884-13889	think	_	
70-8	13890-13893	the	_	
70-9	13894-13898	baby	_	
70-10	13899-13902	was	_	
70-11	13903-13910	feeling	_	
70-12	13910-13911	?	_	
70-13	13911-13912	”	_	
70-14	13912-13913	)	_	

#Text=as well as their affective response to viewing each infant face (i.e., happy faces: “how happy did this picture make you feel?”
71-1	13914-13916	as	_	
71-2	13917-13921	well	_	
71-3	13922-13924	as	_	
71-4	13925-13930	their	_	
71-5	13931-13940	affective	_	
71-6	13941-13949	response	_	
71-7	13950-13952	to	_	
71-8	13953-13960	viewing	_	
71-9	13961-13965	each	_	
71-10	13966-13972	infant	_	
71-11	13973-13977	face	_	
71-12	13978-13979	(	_	
71-13	13979-13982	i.e	_	
71-14	13982-13983	.	_	
71-15	13983-13984	,	_	
71-16	13985-13990	happy	_	
71-17	13991-13996	faces	_	
71-18	13996-13997	:	_	
71-19	13998-13999	“	_	
71-20	13999-14002	how	_	
71-21	14003-14008	happy	_	
71-22	14009-14012	did	_	
71-23	14013-14017	this	_	
71-24	14018-14025	picture	_	
71-25	14026-14030	make	_	
71-26	14031-14034	you	_	
71-27	14035-14039	feel	_	
71-28	14039-14040	?	_	
71-29	14040-14041	”	_	

#Text=; sad faces: “how sad did this picture make you feel?”
72-1	14041-14042	;	_	
72-2	14043-14046	sad	_	
72-3	14047-14052	faces	_	
72-4	14052-14053	:	_	
72-5	14054-14055	“	_	
72-6	14055-14058	how	_	
72-7	14059-14062	sad	_	
72-8	14063-14066	did	_	
72-9	14067-14071	this	_	
72-10	14072-14079	picture	_	
72-11	14080-14084	make	_	
72-12	14085-14088	you	_	
72-13	14089-14093	feel	_	
72-14	14093-14094	?	_	
72-15	14094-14095	”	_	

#Text=and “how distressed did this picture make you feel?”).
73-1	14096-14099	and	_	
73-2	14100-14101	“	_	
73-3	14101-14104	how	_	
73-4	14105-14115	distressed	_	
73-5	14116-14119	did	_	
73-6	14120-14124	this	_	
73-7	14125-14132	picture	_	
73-8	14133-14137	make	_	
73-9	14138-14141	you	_	
73-10	14142-14146	feel	_	
73-11	14146-14147	?	_	
73-12	14147-14148	”	_	
73-13	14148-14149	)	_	
73-14	14149-14150	.	_	

#Text=Assessment of Substance Use
#Text=We used the MINI to assess the DSM-IV diagnoses of substance-use disorders and the Addiction Severity Index (ASI-Lite) to evaluate the nature and extent of past and present substance use.
74-1	14151-14161	Assessment	_	
74-2	14162-14164	of	_	
74-3	14165-14174	Substance	_	
74-4	14175-14178	Use	_	
74-5	14179-14181	We	_	
74-6	14182-14186	used	_	
74-7	14187-14190	the	_	
74-8	14191-14195	MINI	_	
74-9	14196-14198	to	_	
74-10	14199-14205	assess	_	
74-11	14206-14209	the	_	
74-12	14210-14216	DSM-IV	_	
74-13	14217-14226	diagnoses	_	
74-14	14227-14229	of	_	
74-15	14230-14243	substance-use	_	
74-16	14244-14253	disorders	_	
74-17	14254-14257	and	_	
74-18	14258-14261	the	_	
74-19	14262-14271	Addiction	_	
74-20	14272-14280	Severity	_	
74-21	14281-14286	Index	_	
74-22	14287-14288	(	_	
74-23	14288-14296	ASI-Lite	_	
74-24	14296-14297	)	_	
74-25	14298-14300	to	_	
74-26	14301-14309	evaluate	_	
74-27	14310-14313	the	_	
74-28	14314-14320	nature	_	
74-29	14321-14324	and	_	
74-30	14325-14331	extent	_	
74-31	14332-14334	of	_	
74-32	14335-14339	past	_	
74-33	14340-14343	and	_	
74-34	14344-14351	present	_	
74-35	14352-14361	substance	_	
74-36	14362-14365	use	_	
74-37	14365-14366	.	_	

#Text=The Alcohol Use Disorders Identification Test (AUDIT; Babor et al., 2001) and the Fagerstrom Test for Nicotine Dependence (FTND; Heatherton et al., 1991) were used to measure the severity of alcohol and tobacco use, respectively.
75-1	14367-14370	The	_	
75-2	14371-14378	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest[11]	
75-3	14379-14382	Use	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest[11]	
75-4	14383-14392	Disorders	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest[11]	
75-5	14393-14407	Identification	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest[11]	
75-6	14408-14412	Test	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest[11]	
75-7	14413-14414	(	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest[11]	
75-8	14414-14419	AUDIT	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest[11]	
75-9	14419-14420	;	_	
75-10	14421-14426	Babor	_	
75-11	14427-14429	et	_	
75-12	14430-14432	al	_	
75-13	14432-14433	.	_	
75-14	14433-14434	,	_	
75-15	14435-14439	2001	_	
75-16	14439-14440	)	_	
75-17	14441-14444	and	_	
75-18	14445-14448	the	_	
75-19	14449-14459	Fagerstrom	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence[12]	
75-20	14460-14464	Test	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence[12]	
75-21	14465-14468	for	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence[12]	
75-22	14469-14477	Nicotine	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence[12]	
75-23	14478-14488	Dependence	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence[12]	
75-24	14489-14490	(	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence[12]	
75-25	14490-14494	FTND	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence[12]	
75-26	14494-14495	;	_	
75-27	14496-14506	Heatherton	_	
75-28	14507-14509	et	_	
75-29	14510-14512	al	_	
75-30	14512-14513	.	_	
75-31	14513-14514	,	_	
75-32	14515-14519	1991	_	
75-33	14519-14520	)	_	
75-34	14521-14525	were	_	
75-35	14526-14530	used	_	
75-36	14531-14533	to	_	
75-37	14534-14541	measure	_	
75-38	14542-14545	the	_	
75-39	14546-14554	severity	_	
75-40	14555-14557	of	_	
75-41	14558-14565	alcohol	_	
75-42	14566-14569	and	_	
75-43	14570-14577	tobacco	_	
75-44	14578-14581	use	_	
75-45	14581-14582	,	_	
75-46	14583-14595	respectively	_	
75-47	14595-14596	.	_	

#Text=Urine toxicology screens and alcohol breathalyzer tests were performed at the outset of each scanning session.
76-1	14597-14602	Urine	_	
76-2	14603-14613	toxicology	_	
76-3	14614-14621	screens	_	
76-4	14622-14625	and	_	
76-5	14626-14633	alcohol	_	
76-6	14634-14646	breathalyzer	_	
76-7	14647-14652	tests	_	
76-8	14653-14657	were	_	
76-9	14658-14667	performed	_	
76-10	14668-14670	at	_	
76-11	14671-14674	the	_	
76-12	14675-14681	outset	_	
76-13	14682-14684	of	_	
76-14	14685-14689	each	_	
76-15	14690-14698	scanning	_	
76-16	14699-14706	session	_	
76-17	14706-14707	.	_	

#Text=Stimuli and fMRI Paradigm
#Text=Experimental stimuli consisted of 40 infant-face images from four experimental conditions: 10 own-happy (OH), 10 unknown-happy (UH), 10 own-sad (OS), and 10 unknown-sad (US) infant faces (Figure 2).
77-1	14708-14715	Stimuli	_	
77-2	14716-14719	and	_	
77-3	14720-14724	fMRI	_	
77-4	14725-14733	Paradigm	_	
77-5	14734-14746	Experimental	_	
77-6	14747-14754	stimuli	_	
77-7	14755-14764	consisted	_	
77-8	14765-14767	of	_	
77-9	14768-14770	40	_	
77-10	14771-14782	infant-face	_	
77-11	14783-14789	images	_	
77-12	14790-14794	from	_	
77-13	14795-14799	four	_	
77-14	14800-14812	experimental	_	
77-15	14813-14823	conditions	_	
77-16	14823-14824	:	_	
77-17	14825-14827	10	_	
77-18	14828-14837	own-happy	_	
77-19	14838-14839	(	_	
77-20	14839-14841	OH	_	
77-21	14841-14842	)	_	
77-22	14842-14843	,	_	
77-23	14844-14846	10	_	
77-24	14847-14860	unknown-happy	_	
77-25	14861-14862	(	_	
77-26	14862-14864	UH	_	
77-27	14864-14865	)	_	
77-28	14865-14866	,	_	
77-29	14867-14869	10	_	
77-30	14870-14877	own-sad	_	
77-31	14878-14879	(	_	
77-32	14879-14881	OS	_	
77-33	14881-14882	)	_	
77-34	14882-14883	,	_	
77-35	14884-14887	and	_	
77-36	14888-14890	10	_	
77-37	14891-14902	unknown-sad	_	
77-38	14903-14904	(	_	
77-39	14904-14906	US	_	
77-40	14906-14907	)	_	
77-41	14908-14914	infant	_	
77-42	14915-14920	faces	_	
77-43	14921-14922	(	_	
77-44	14922-14928	Figure	_	
77-45	14929-14930	2	_	
77-46	14930-14931	)	_	
77-47	14931-14932	.	_	

#Text=For each mother, still face images were captured from the videos recorded of her own infant and of a single unknown infant matched on age, race, and affect intensity (and sex, if distinguishable).
78-1	14933-14936	For	_	
78-2	14937-14941	each	_	
78-3	14942-14948	mother	_	
78-4	14948-14949	,	_	
78-5	14950-14955	still	_	
78-6	14956-14960	face	_	
78-7	14961-14967	images	_	
78-8	14968-14972	were	_	
78-9	14973-14981	captured	_	
78-10	14982-14986	from	_	
78-11	14987-14990	the	_	
78-12	14991-14997	videos	_	
78-13	14998-15006	recorded	_	
78-14	15007-15009	of	_	
78-15	15010-15013	her	_	
78-16	15014-15017	own	_	
78-17	15018-15024	infant	_	
78-18	15025-15028	and	_	
78-19	15029-15031	of	_	
78-20	15032-15033	a	_	
78-21	15034-15040	single	_	
78-22	15041-15048	unknown	_	
78-23	15049-15055	infant	_	
78-24	15056-15063	matched	_	
78-25	15064-15066	on	_	
78-26	15067-15070	age	_	
78-27	15070-15071	,	_	
78-28	15072-15076	race	_	
78-29	15076-15077	,	_	
78-30	15078-15081	and	_	
78-31	15082-15088	affect	_	
78-32	15089-15098	intensity	_	
78-33	15099-15100	(	_	
78-34	15100-15103	and	_	
78-35	15104-15107	sex	_	
78-36	15107-15108	,	_	
78-37	15109-15111	if	_	
78-38	15112-15127	distinguishable	_	
78-39	15127-15128	)	_	
78-40	15128-15129	.	_	

#Text=The video-recording was undertaken at the laboratory approximately 5 months postpartum, while eliciting happy and sad expressions from each infant.
79-1	15130-15133	The	_	
79-2	15134-15149	video-recording	_	
79-3	15150-15153	was	_	
79-4	15154-15164	undertaken	_	
79-5	15165-15167	at	_	
79-6	15168-15171	the	_	
79-7	15172-15182	laboratory	_	
79-8	15183-15196	approximately	_	
79-9	15197-15198	5	_	
79-10	15199-15205	months	_	
79-11	15206-15216	postpartum	_	
79-12	15216-15217	,	_	
79-13	15218-15223	while	_	
79-14	15224-15233	eliciting	_	
79-15	15234-15239	happy	_	
79-16	15240-15243	and	_	
79-17	15244-15247	sad	_	
79-18	15248-15259	expressions	_	
79-19	15260-15264	from	_	
79-20	15265-15269	each	_	
79-21	15270-15276	infant	_	
79-22	15276-15277	.	_	

#Text=Two trained raters with established reliability (kappa = .954, p < .001) classified still face images into one of four affect groups based on valence and intensity (see), which provided the basis for the matching between own and unknown infant faces.
80-1	15278-15281	Two	_	
80-2	15282-15289	trained	_	
80-3	15290-15296	raters	_	
80-4	15297-15301	with	_	
80-5	15302-15313	established	_	
80-6	15314-15325	reliability	_	
80-7	15326-15327	(	_	
80-8	15327-15332	kappa	_	
80-9	15333-15334	=	_	
80-10	15335-15339	.954	_	
80-11	15339-15340	,	_	
80-12	15341-15342	p	_	
80-13	15343-15344	<	_	
80-14	15345-15349	.001	_	
80-15	15349-15350	)	_	
80-16	15351-15361	classified	_	
80-17	15362-15367	still	_	
80-18	15368-15372	face	_	
80-19	15373-15379	images	_	
80-20	15380-15384	into	_	
80-21	15385-15388	one	_	
80-22	15389-15391	of	_	
80-23	15392-15396	four	_	
80-24	15397-15403	affect	_	
80-25	15404-15410	groups	_	
80-26	15411-15416	based	_	
80-27	15417-15419	on	_	
80-28	15420-15427	valence	_	
80-29	15428-15431	and	_	
80-30	15432-15441	intensity	_	
80-31	15442-15443	(	_	
80-32	15443-15446	see	_	
80-33	15446-15447	)	_	
80-34	15447-15448	,	_	
80-35	15449-15454	which	_	
80-36	15455-15463	provided	_	
80-37	15464-15467	the	_	
80-38	15468-15473	basis	_	
80-39	15474-15477	for	_	
80-40	15478-15481	the	_	
80-41	15482-15490	matching	_	
80-42	15491-15498	between	_	
80-43	15499-15502	own	_	
80-44	15503-15506	and	_	
80-45	15507-15514	unknown	_	
80-46	15515-15521	infant	_	
80-47	15522-15527	faces	_	
80-48	15527-15528	.	_	

#Text=The adequacy of classification and matching was confirmed by three independent female raters, who demonstrated that own and unknown infant face images did not differ in terms of affect intensity (MOH = 4.20 ± 0.03, MUH = 4.25 ± 0.02, p = .11; MOS = 1.50 ± 0.04, MUS = 1.55 ± 0.04, p = .48).
81-1	15529-15532	The	_	
81-2	15533-15541	adequacy	_	
81-3	15542-15544	of	_	
81-4	15545-15559	classification	_	
81-5	15560-15563	and	_	
81-6	15564-15572	matching	_	
81-7	15573-15576	was	_	
81-8	15577-15586	confirmed	_	
81-9	15587-15589	by	_	
81-10	15590-15595	three	_	
81-11	15596-15607	independent	_	
81-12	15608-15614	female	_	
81-13	15615-15621	raters	_	
81-14	15621-15622	,	_	
81-15	15623-15626	who	_	
81-16	15627-15639	demonstrated	_	
81-17	15640-15644	that	_	
81-18	15645-15648	own	_	
81-19	15649-15652	and	_	
81-20	15653-15660	unknown	_	
81-21	15661-15667	infant	_	
81-22	15668-15672	face	_	
81-23	15673-15679	images	_	
81-24	15680-15683	did	_	
81-25	15684-15687	not	_	
81-26	15688-15694	differ	_	
81-27	15695-15697	in	_	
81-28	15698-15703	terms	_	
81-29	15704-15706	of	_	
81-30	15707-15713	affect	_	
81-31	15714-15723	intensity	_	
81-32	15724-15725	(	_	
81-33	15725-15728	MOH	_	
81-34	15729-15730	=	_	
81-35	15731-15735	4.20	_	
81-36	15736-15737	±	_	
81-37	15738-15742	0.03	_	
81-38	15742-15743	,	_	
81-39	15744-15747	MUH	_	
81-40	15748-15749	=	_	
81-41	15750-15754	4.25	_	
81-42	15755-15756	±	_	
81-43	15757-15761	0.02	_	
81-44	15761-15762	,	_	
81-45	15763-15764	p	_	
81-46	15765-15766	=	_	
81-47	15767-15770	.11	_	
81-48	15770-15771	;	_	
81-49	15772-15775	MOS	_	
81-50	15776-15777	=	_	
81-51	15778-15782	1.50	_	
81-52	15783-15784	±	_	
81-53	15785-15789	0.04	_	
81-54	15789-15790	,	_	
81-55	15791-15794	MUS	_	
81-56	15795-15796	=	_	
81-57	15797-15801	1.55	_	
81-58	15802-15803	±	_	
81-59	15804-15808	0.04	_	
81-60	15808-15809	,	_	
81-61	15810-15811	p	_	
81-62	15812-15813	=	_	
81-63	15814-15817	.48	_	
81-64	15817-15818	)	_	
81-65	15818-15819	.	_	

#Text=Of the 40 total images, 12 own (i.e., 6 OH and 6 OS) and 12 unknown (i.e., 6 UH and 6 US) infant face images were selected for use in each of the two functional runs.
82-1	15820-15822	Of	_	
82-2	15823-15826	the	_	
82-3	15827-15829	40	_	
82-4	15830-15835	total	_	
82-5	15836-15842	images	_	
82-6	15842-15843	,	_	
82-7	15844-15846	12	_	
82-8	15847-15850	own	_	
82-9	15851-15852	(	_	
82-10	15852-15855	i.e	_	
82-11	15855-15856	.	_	
82-12	15856-15857	,	_	
82-13	15858-15859	6	_	
82-14	15860-15862	OH	_	
82-15	15863-15866	and	_	
82-16	15867-15868	6	_	
82-17	15869-15871	OS	_	
82-18	15871-15872	)	_	
82-19	15873-15876	and	_	
82-20	15877-15879	12	_	
82-21	15880-15887	unknown	_	
82-22	15888-15889	(	_	
82-23	15889-15892	i.e	_	
82-24	15892-15893	.	_	
82-25	15893-15894	,	_	
82-26	15895-15896	6	_	
82-27	15897-15899	UH	_	
82-28	15900-15903	and	_	
82-29	15904-15905	6	_	
82-30	15906-15908	US	_	
82-31	15908-15909	)	_	
82-32	15910-15916	infant	_	
82-33	15917-15921	face	_	
82-34	15922-15928	images	_	
82-35	15929-15933	were	_	
82-36	15934-15942	selected	_	
82-37	15943-15946	for	_	
82-38	15947-15950	use	_	
82-39	15951-15953	in	_	
82-40	15954-15958	each	_	
82-41	15959-15961	of	_	
82-42	15962-15965	the	_	
82-43	15966-15969	two	_	
82-44	15970-15980	functional	_	
82-45	15981-15985	runs	_	
82-46	15985-15986	.	_	

#Text=Cry stimuli were also randomly interspersed with the face images, but were not the subject of the current paper.
83-1	15987-15990	Cry	_	
83-2	15991-15998	stimuli	_	
83-3	15999-16003	were	_	
83-4	16004-16008	also	_	
83-5	16009-16017	randomly	_	
83-6	16018-16030	interspersed	_	
83-7	16031-16035	with	_	
83-8	16036-16039	the	_	
83-9	16040-16044	face	_	
83-10	16045-16051	images	_	
83-11	16051-16052	,	_	
83-12	16053-16056	but	_	
83-13	16057-16061	were	_	
83-14	16062-16065	not	_	
83-15	16066-16069	the	_	
83-16	16070-16077	subject	_	
83-17	16078-16080	of	_	
83-18	16081-16084	the	_	
83-19	16085-16092	current	_	
83-20	16093-16098	paper	_	
83-21	16098-16099	.	_	

#Text=The face images were standardized for size (4.5 inches in height), adjusted for luminosity and contrast, displayed against a gray background, and projected onto an overhead mirror display for presentation to mothers during scanning.
84-1	16100-16103	The	_	
84-2	16104-16108	face	_	
84-3	16109-16115	images	_	
84-4	16116-16120	were	_	
84-5	16121-16133	standardized	_	
84-6	16134-16137	for	_	
84-7	16138-16142	size	_	
84-8	16143-16144	(	_	
84-9	16144-16147	4.5	_	
84-10	16148-16154	inches	_	
84-11	16155-16157	in	_	
84-12	16158-16164	height	_	
84-13	16164-16165	)	_	
84-14	16165-16166	,	_	
84-15	16167-16175	adjusted	_	
84-16	16176-16179	for	_	
84-17	16180-16190	luminosity	_	
84-18	16191-16194	and	_	
84-19	16195-16203	contrast	_	
84-20	16203-16204	,	_	
84-21	16205-16214	displayed	_	
84-22	16215-16222	against	_	
84-23	16223-16224	a	_	
84-24	16225-16229	gray	_	
84-25	16230-16240	background	_	
84-26	16240-16241	,	_	
84-27	16242-16245	and	_	
84-28	16246-16255	projected	_	
84-29	16256-16260	onto	_	
84-30	16261-16263	an	_	
84-31	16264-16272	overhead	_	
84-32	16273-16279	mirror	_	
84-33	16280-16287	display	_	
84-34	16288-16291	for	_	
84-35	16292-16304	presentation	_	
84-36	16305-16307	to	_	
84-37	16308-16315	mothers	_	
84-38	16316-16322	during	_	
84-39	16323-16331	scanning	_	
84-40	16331-16332	.	_	

#Text=All images appeared in a pseudorandom sequence with a stimulus duration of 2 seconds and a random inter-stimulus interval of 2 to 11 seconds.
#Text=fMRI Data Acquisition
#Text=Imaging data were acquired using a 3-Tesla Siemens Trio MRI system (Erlangen, Germany) with a standard 12-channel head coil.
85-1	16333-16336	All	_	
85-2	16337-16343	images	_	
85-3	16344-16352	appeared	_	
85-4	16353-16355	in	_	
85-5	16356-16357	a	_	
85-6	16358-16370	pseudorandom	_	
85-7	16371-16379	sequence	_	
85-8	16380-16384	with	_	
85-9	16385-16386	a	_	
85-10	16387-16395	stimulus	_	
85-11	16396-16404	duration	_	
85-12	16405-16407	of	_	
85-13	16408-16409	2	_	
85-14	16410-16417	seconds	_	
85-15	16418-16421	and	_	
85-16	16422-16423	a	_	
85-17	16424-16430	random	_	
85-18	16431-16445	inter-stimulus	_	
85-19	16446-16454	interval	_	
85-20	16455-16457	of	_	
85-21	16458-16459	2	_	
85-22	16460-16462	to	_	
85-23	16463-16465	11	_	
85-24	16466-16473	seconds	_	
85-25	16473-16474	.	_	
85-26	16475-16479	fMRI	_	
85-27	16480-16484	Data	_	
85-28	16485-16496	Acquisition	_	
85-29	16497-16504	Imaging	_	
85-30	16505-16509	data	_	
85-31	16510-16514	were	_	
85-32	16515-16523	acquired	_	
85-33	16524-16529	using	_	
85-34	16530-16531	a	_	
85-35	16532-16533	3	_	
85-36	16533-16534	-	_	
85-37	16534-16539	Tesla	_	
85-38	16540-16547	Siemens	_	
85-39	16548-16552	Trio	_	
85-40	16553-16556	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging	
85-41	16557-16563	system	_	
85-42	16564-16565	(	_	
85-43	16565-16573	Erlangen	_	
85-44	16573-16574	,	_	
85-45	16575-16582	Germany	_	
85-46	16582-16583	)	_	
85-47	16584-16588	with	_	
85-48	16589-16590	a	_	
85-49	16591-16599	standard	_	
85-50	16600-16602	12	_	
85-51	16602-16603	-	_	
85-52	16603-16610	channel	_	
85-53	16611-16615	head	_	
85-54	16616-16620	coil	_	
85-55	16620-16621	.	_	

#Text=Localizer images were acquired for prescribing the functional image volumes parallel to the intercommissural line.
86-1	16622-16631	Localizer	_	
86-2	16632-16638	images	_	
86-3	16639-16643	were	_	
86-4	16644-16652	acquired	_	
86-5	16653-16656	for	_	
86-6	16657-16668	prescribing	_	
86-7	16669-16672	the	_	
86-8	16673-16683	functional	_	
86-9	16684-16689	image	_	
86-10	16690-16697	volumes	_	
86-11	16698-16706	parallel	_	
86-12	16707-16709	to	_	
86-13	16710-16713	the	_	
86-14	16714-16730	intercommissural	_	
86-15	16731-16735	line	_	
86-16	16735-16736	.	_	

#Text=Functional images were obtained using a gradient-echo echo-planar imaging (EPI) sequence (32 axial-oblique slices; repetition time [TR], 2000 ms; echo time [TE], 30 ms; flip angle [FA], 80°; field of view [FOV], 220 mm x 220 mm; matrix, 64 x 64; in-plane resolution, 3.4 mm x 3.4 mm; slice thickness, 4 mm), resulting in 121 images collected per 4:06 min functional run.
87-1	16737-16747	Functional	_	
87-2	16748-16754	images	_	
87-3	16755-16759	were	_	
87-4	16760-16768	obtained	_	
87-5	16769-16774	using	_	
87-6	16775-16776	a	_	
87-7	16777-16790	gradient-echo	_	
87-8	16791-16802	echo-planar	_	
87-9	16803-16810	imaging	_	
87-10	16811-16812	(	_	
87-11	16812-16815	EPI	_	
87-12	16815-16816	)	_	
87-13	16817-16825	sequence	_	
87-14	16826-16827	(	_	
87-15	16827-16829	32	_	
87-16	16830-16843	axial-oblique	_	
87-17	16844-16850	slices	_	
87-18	16850-16851	;	_	
87-19	16852-16862	repetition	_	
87-20	16863-16867	time	_	
87-21	16868-16869	[	_	
87-22	16869-16871	TR	_	
87-23	16871-16872	]	_	
87-24	16872-16873	,	_	
87-25	16874-16878	2000	_	
87-26	16879-16881	ms	_	
87-27	16881-16882	;	_	
87-28	16883-16887	echo	_	
87-29	16888-16892	time	_	
87-30	16893-16894	[	_	
87-31	16894-16896	TE	_	
87-32	16896-16897	]	_	
87-33	16897-16898	,	_	
87-34	16899-16901	30	_	
87-35	16902-16904	ms	_	
87-36	16904-16905	;	_	
87-37	16906-16910	flip	_	
87-38	16911-16916	angle	_	
87-39	16917-16918	[	_	
87-40	16918-16920	FA	_	
87-41	16920-16921	]	_	
87-42	16921-16922	,	_	
87-43	16923-16925	80	_	
87-44	16925-16926	°	_	
87-45	16926-16927	;	_	
87-46	16928-16933	field	_	
87-47	16934-16936	of	_	
87-48	16937-16941	view	_	
87-49	16942-16943	[	_	
87-50	16943-16946	FOV	_	
87-51	16946-16947	]	_	
87-52	16947-16948	,	_	
87-53	16949-16952	220	_	
87-54	16953-16955	mm	_	
87-55	16956-16957	x	_	
87-56	16958-16961	220	_	
87-57	16962-16964	mm	_	
87-58	16964-16965	;	_	
87-59	16966-16972	matrix	_	
87-60	16972-16973	,	_	
87-61	16974-16976	64	_	
87-62	16977-16978	x	_	
87-63	16979-16981	64	_	
87-64	16981-16982	;	_	
87-65	16983-16991	in-plane	_	
87-66	16992-17002	resolution	_	
87-67	17002-17003	,	_	
87-68	17004-17007	3.4	_	
87-69	17008-17010	mm	_	
87-70	17011-17012	x	_	
87-71	17013-17016	3.4	_	
87-72	17017-17019	mm	_	
87-73	17019-17020	;	_	
87-74	17021-17026	slice	_	
87-75	17027-17036	thickness	_	
87-76	17036-17037	,	_	
87-77	17038-17039	4	_	
87-78	17040-17042	mm	_	
87-79	17042-17043	)	_	
87-80	17043-17044	,	_	
87-81	17045-17054	resulting	_	
87-82	17055-17057	in	_	
87-83	17058-17061	121	_	
87-84	17062-17068	images	_	
87-85	17069-17078	collected	_	
87-86	17079-17082	per	_	
87-87	17083-17084	4	_	
87-88	17084-17085	:	_	
87-89	17085-17087	06	_	
87-90	17088-17091	min	_	
87-91	17092-17102	functional	_	
87-92	17103-17106	run	_	
87-93	17106-17107	.	_	

#Text=Two types of anatomical images were acquired: T1 weighted anatomic scan using a fast low-angle shot (FLASH) sequence (40 sagittal slices; TR, 20 ms; TE, 6.86 ms; FA, 25°; FOV, 240 mm x 240 mm; matrix, 256 x 241; in-plane resolution, 1.0 mm x 0.9 mm; slice thickness, 4 mm) and high-resolution anatomic scan using a magnetization-prepared rapid gradient echo (MPRAGE) sequence (176 sagittal slices; TR, 2530 ms; TE, 2.43 ms; FA, 7°; FOV, 256 mm × 256 mm; matrix, 256 × 246; in-plane resolution, 1.0 mm × 1.0 mm; slice thickness, 1 mm) for 3D reconstruction.
88-1	17108-17111	Two	_	
88-2	17112-17117	types	_	
88-3	17118-17120	of	_	
88-4	17121-17131	anatomical	_	
88-5	17132-17138	images	_	
88-6	17139-17143	were	_	
88-7	17144-17152	acquired	_	
88-8	17152-17153	:	_	
88-9	17154-17156	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[13]	
88-10	17157-17165	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[13]	
88-11	17166-17174	anatomic	_	
88-12	17175-17179	scan	_	
88-13	17180-17185	using	_	
88-14	17186-17187	a	_	
88-15	17188-17192	fast	_	
88-16	17193-17202	low-angle	_	
88-17	17203-17207	shot	_	
88-18	17208-17209	(	_	
88-19	17209-17214	FLASH	_	
88-20	17214-17215	)	_	
88-21	17216-17224	sequence	_	
88-22	17225-17226	(	_	
88-23	17226-17228	40	_	
88-24	17229-17237	sagittal	_	
88-25	17238-17244	slices	_	
88-26	17244-17245	;	_	
88-27	17246-17248	TR	_	
88-28	17248-17249	,	_	
88-29	17250-17252	20	_	
88-30	17253-17255	ms	_	
88-31	17255-17256	;	_	
88-32	17257-17259	TE	_	
88-33	17259-17260	,	_	
88-34	17261-17265	6.86	_	
88-35	17266-17268	ms	_	
88-36	17268-17269	;	_	
88-37	17270-17272	FA	_	
88-38	17272-17273	,	_	
88-39	17274-17276	25	_	
88-40	17276-17277	°	_	
88-41	17277-17278	;	_	
88-42	17279-17282	FOV	_	
88-43	17282-17283	,	_	
88-44	17284-17287	240	_	
88-45	17288-17290	mm	_	
88-46	17291-17292	x	_	
88-47	17293-17296	240	_	
88-48	17297-17299	mm	_	
88-49	17299-17300	;	_	
88-50	17301-17307	matrix	_	
88-51	17307-17308	,	_	
88-52	17309-17312	256	_	
88-53	17313-17314	x	_	
88-54	17315-17318	241	_	
88-55	17318-17319	;	_	
88-56	17320-17328	in-plane	_	
88-57	17329-17339	resolution	_	
88-58	17339-17340	,	_	
88-59	17341-17344	1.0	_	
88-60	17345-17347	mm	_	
88-61	17348-17349	x	_	
88-62	17350-17353	0.9	_	
88-63	17354-17356	mm	_	
88-64	17356-17357	;	_	
88-65	17358-17363	slice	_	
88-66	17364-17373	thickness	_	
88-67	17373-17374	,	_	
88-68	17375-17376	4	_	
88-69	17377-17379	mm	_	
88-70	17379-17380	)	_	
88-71	17381-17384	and	_	
88-72	17385-17400	high-resolution	_	
88-73	17401-17409	anatomic	_	
88-74	17410-17414	scan	_	
88-75	17415-17420	using	_	
88-76	17421-17422	a	_	
88-77	17423-17445	magnetization-prepared	_	
88-78	17446-17451	rapid	_	
88-79	17452-17460	gradient	_	
88-80	17461-17465	echo	_	
88-81	17466-17467	(	_	
88-82	17467-17473	MPRAGE	_	
88-83	17473-17474	)	_	
88-84	17475-17483	sequence	_	
88-85	17484-17485	(	_	
88-86	17485-17488	176	_	
88-87	17489-17497	sagittal	_	
88-88	17498-17504	slices	_	
88-89	17504-17505	;	_	
88-90	17506-17508	TR	_	
88-91	17508-17509	,	_	
88-92	17510-17514	2530	_	
88-93	17515-17517	ms	_	
88-94	17517-17518	;	_	
88-95	17519-17521	TE	_	
88-96	17521-17522	,	_	
88-97	17523-17527	2.43	_	
88-98	17528-17530	ms	_	
88-99	17530-17531	;	_	
88-100	17532-17534	FA	_	
88-101	17534-17535	,	_	
88-102	17536-17537	7	_	
88-103	17537-17538	°	_	
88-104	17538-17539	;	_	
88-105	17540-17543	FOV	_	
88-106	17543-17544	,	_	
88-107	17545-17548	256	_	
88-108	17549-17551	mm	_	
88-109	17552-17553	×	_	
88-110	17554-17557	256	_	
88-111	17558-17560	mm	_	
88-112	17560-17561	;	_	
88-113	17562-17568	matrix	_	
88-114	17568-17569	,	_	
88-115	17570-17573	256	_	
88-116	17574-17575	×	_	
88-117	17576-17579	246	_	
88-118	17579-17580	;	_	
88-119	17581-17589	in-plane	_	
88-120	17590-17600	resolution	_	
88-121	17600-17601	,	_	
88-122	17602-17605	1.0	_	
88-123	17606-17608	mm	_	
88-124	17609-17610	×	_	
88-125	17611-17614	1.0	_	
88-126	17615-17617	mm	_	
88-127	17617-17618	;	_	
88-128	17619-17624	slice	_	
88-129	17625-17634	thickness	_	
88-130	17634-17635	,	_	
88-131	17636-17637	1	_	
88-132	17638-17640	mm	_	
88-133	17640-17641	)	_	
88-134	17642-17645	for	_	
88-135	17646-17648	3D	_	
88-136	17649-17663	reconstruction	_	
88-137	17663-17664	.	_	

#Text=Data Analysis
#Text=fMRI analysis
#Text=Preprocessing and analyses of the fMRI data were performed using BrainVoyager QX, version 2.3.1 (Brain Innovation, Maastricht, The Netherlands).
89-1	17665-17669	Data	_	
89-2	17670-17678	Analysis	_	
89-3	17679-17683	fMRI	_	
89-4	17684-17692	analysis	_	
89-5	17693-17706	Preprocessing	_	
89-6	17707-17710	and	_	
89-7	17711-17719	analyses	_	
89-8	17720-17722	of	_	
89-9	17723-17726	the	_	
89-10	17727-17731	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
89-11	17732-17736	data	_	
89-12	17737-17741	were	_	
89-13	17742-17751	performed	_	
89-14	17752-17757	using	_	
89-15	17758-17770	BrainVoyager	_	
89-16	17771-17773	QX	_	
89-17	17773-17774	,	_	
89-18	17775-17782	version	_	
89-19	17783-17788	2.3.1	_	
89-20	17789-17790	(	_	
89-21	17790-17795	Brain	_	
89-22	17796-17806	Innovation	_	
89-23	17806-17807	,	_	
89-24	17808-17818	Maastricht	_	
89-25	17818-17819	,	_	
89-26	17820-17823	The	_	
89-27	17824-17835	Netherlands	_	
89-28	17835-17836	)	_	
89-29	17836-17837	.	_	

#Text=Prior to analysis, blood oxygenation level-dependent (BOLD) images were corrected for slice timing and realigned to the first volume for head motion correction.
90-1	17838-17843	Prior	_	
90-2	17844-17846	to	_	
90-3	17847-17855	analysis	_	
90-4	17855-17856	,	_	
90-5	17857-17862	blood	_	
90-6	17863-17874	oxygenation	_	
90-7	17875-17890	level-dependent	_	
90-8	17891-17892	(	_	
90-9	17892-17896	BOLD	_	
90-10	17896-17897	)	_	
90-11	17898-17904	images	_	
90-12	17905-17909	were	_	
90-13	17910-17919	corrected	_	
90-14	17920-17923	for	_	
90-15	17924-17929	slice	_	
90-16	17930-17936	timing	_	
90-17	17937-17940	and	_	
90-18	17941-17950	realigned	_	
90-19	17951-17953	to	_	
90-20	17954-17957	the	_	
90-21	17958-17963	first	_	
90-22	17964-17970	volume	_	
90-23	17971-17974	for	_	
90-24	17975-17979	head	_	
90-25	17980-17986	motion	_	
90-26	17987-17997	correction	_	
90-27	17997-17998	.	_	

#Text=Head motion of < 2.0 mm translation or 2.0° rotation was deemed acceptable.
91-1	17999-18003	Head	_	
91-2	18004-18010	motion	_	
91-3	18011-18013	of	_	
91-4	18014-18015	<	_	
91-5	18016-18019	2.0	_	
91-6	18020-18022	mm	_	
91-7	18023-18034	translation	_	
91-8	18035-18037	or	_	
91-9	18038-18041	2.0	_	
91-10	18041-18042	°	_	
91-11	18043-18051	rotation	_	
91-12	18052-18055	was	_	
91-13	18056-18062	deemed	_	
91-14	18063-18073	acceptable	_	
91-15	18073-18074	.	_	

#Text=Spatial smoothing was performed with a 4 mm full width at half maximum (FWHM) Gaussian kernel, followed by high-pass filtering using a Fourier basis set of two cycles per run to remove low frequency drifts.
92-1	18075-18082	Spatial	_	
92-2	18083-18092	smoothing	_	
92-3	18093-18096	was	_	
92-4	18097-18106	performed	_	
92-5	18107-18111	with	_	
92-6	18112-18113	a	_	
92-7	18114-18115	4	_	
92-8	18116-18118	mm	_	
92-9	18119-18123	full	_	
92-10	18124-18129	width	_	
92-11	18130-18132	at	_	
92-12	18133-18137	half	_	
92-13	18138-18145	maximum	_	
92-14	18146-18147	(	_	
92-15	18147-18151	FWHM	_	
92-16	18151-18152	)	_	
92-17	18153-18161	Gaussian	_	
92-18	18162-18168	kernel	_	
92-19	18168-18169	,	_	
92-20	18170-18178	followed	_	
92-21	18179-18181	by	_	
92-22	18182-18191	high-pass	_	
92-23	18192-18201	filtering	_	
92-24	18202-18207	using	_	
92-25	18208-18209	a	_	
92-26	18210-18217	Fourier	_	
92-27	18218-18223	basis	_	
92-28	18224-18227	set	_	
92-29	18228-18230	of	_	
92-30	18231-18234	two	_	
92-31	18235-18241	cycles	_	
92-32	18242-18245	per	_	
92-33	18246-18249	run	_	
92-34	18250-18252	to	_	
92-35	18253-18259	remove	_	
92-36	18260-18263	low	_	
92-37	18264-18273	frequency	_	
92-38	18274-18280	drifts	_	
92-39	18280-18281	.	_	

#Text=Functional data were then co-registered with the anatomical data, transformed into 3 x 3 x 3 mm isotropic voxels, and normalized into the Talairach space.
93-1	18282-18292	Functional	_	
93-2	18293-18297	data	_	
93-3	18298-18302	were	_	
93-4	18303-18307	then	_	
93-5	18308-18321	co-registered	_	
93-6	18322-18326	with	_	
93-7	18327-18330	the	_	
93-8	18331-18341	anatomical	_	
93-9	18342-18346	data	_	
93-10	18346-18347	,	_	
93-11	18348-18359	transformed	_	
93-12	18360-18364	into	_	
93-13	18365-18366	3	_	
93-14	18367-18368	x	_	
93-15	18369-18370	3	_	
93-16	18371-18372	x	_	
93-17	18373-18374	3	_	
93-18	18375-18377	mm	_	
93-19	18378-18387	isotropic	_	
93-20	18388-18394	voxels	_	
93-21	18394-18395	,	_	
93-22	18396-18399	and	_	
93-23	18400-18410	normalized	_	
93-24	18411-18415	into	_	
93-25	18416-18419	the	_	
93-26	18420-18429	Talairach	_	
93-27	18430-18435	space	_	
93-28	18435-18436	.	_	

#Text=For each run of each subject data, a general linear model (GLM) was specified, modeling the BOLD signal change for each experimental condition (OH, UH, OS, and US) using a double-gamma hemodynamic response function.
94-1	18437-18440	For	_	
94-2	18441-18445	each	_	
94-3	18446-18449	run	_	
94-4	18450-18452	of	_	
94-5	18453-18457	each	_	
94-6	18458-18465	subject	_	
94-7	18466-18470	data	_	
94-8	18470-18471	,	_	
94-9	18472-18473	a	_	
94-10	18474-18481	general	_	
94-11	18482-18488	linear	_	
94-12	18489-18494	model	_	
94-13	18495-18496	(	_	
94-14	18496-18499	GLM	_	
94-15	18499-18500	)	_	
94-16	18501-18504	was	_	
94-17	18505-18514	specified	_	
94-18	18514-18515	,	_	
94-19	18516-18524	modeling	_	
94-20	18525-18528	the	_	
94-21	18529-18533	BOLD	_	
94-22	18534-18540	signal	_	
94-23	18541-18547	change	_	
94-24	18548-18551	for	_	
94-25	18552-18556	each	_	
94-26	18557-18569	experimental	_	
94-27	18570-18579	condition	_	
94-28	18580-18581	(	_	
94-29	18581-18583	OH	_	
94-30	18583-18584	,	_	
94-31	18585-18587	UH	_	
94-32	18587-18588	,	_	
94-33	18589-18591	OS	_	
94-34	18591-18592	,	_	
94-35	18593-18596	and	_	
94-36	18597-18599	US	_	
94-37	18599-18600	)	_	
94-38	18601-18606	using	_	
94-39	18607-18608	a	_	
94-40	18609-18621	double-gamma	_	
94-41	18622-18633	hemodynamic	_	
94-42	18634-18642	response	_	
94-43	18643-18651	function	_	
94-44	18651-18652	.	_	

#Text=In order to adjust for signal magnitude variability and facilitate comparisons with other research (e.g.,), the resulting regression weights (β) were then percent normalized to reflect percent signal change and concatenated across the entire group of 36 subjects for second-level random-effects analyses.
95-1	18653-18655	In	_	
95-2	18656-18661	order	_	
95-3	18662-18664	to	_	
95-4	18665-18671	adjust	_	
95-5	18672-18675	for	_	
95-6	18676-18682	signal	_	
95-7	18683-18692	magnitude	_	
95-8	18693-18704	variability	_	
95-9	18705-18708	and	_	
95-10	18709-18719	facilitate	_	
95-11	18720-18731	comparisons	_	
95-12	18732-18736	with	_	
95-13	18737-18742	other	_	
95-14	18743-18751	research	_	
95-15	18752-18753	(	_	
95-16	18753-18756	e.g	_	
95-17	18756-18757	.	_	
95-18	18757-18758	,	_	
95-19	18758-18759	)	_	
95-20	18759-18760	,	_	
95-21	18761-18764	the	_	
95-22	18765-18774	resulting	_	
95-23	18775-18785	regression	_	
95-24	18786-18793	weights	_	
95-25	18794-18795	(	_	
95-26	18795-18796	β	_	
95-27	18796-18797	)	_	
95-28	18798-18802	were	_	
95-29	18803-18807	then	_	
95-30	18808-18815	percent	_	
95-31	18816-18826	normalized	_	
95-32	18827-18829	to	_	
95-33	18830-18837	reflect	_	
95-34	18838-18845	percent	_	
95-35	18846-18852	signal	_	
95-36	18853-18859	change	_	
95-37	18860-18863	and	_	
95-38	18864-18876	concatenated	_	
95-39	18877-18883	across	_	
95-40	18884-18887	the	_	
95-41	18888-18894	entire	_	
95-42	18895-18900	group	_	
95-43	18901-18903	of	_	
95-44	18904-18906	36	_	
95-45	18907-18915	subjects	_	
95-46	18916-18919	for	_	
95-47	18920-18932	second-level	_	
95-48	18933-18947	random-effects	_	
95-49	18948-18956	analyses	_	
95-50	18956-18957	.	_	

#Text=Group t-maps were generated representing percent BOLD contrasts between own and unknown infant conditions: OH vs.
96-1	18958-18963	Group	_	
96-2	18964-18970	t-maps	_	
96-3	18971-18975	were	_	
96-4	18976-18985	generated	_	
96-5	18986-18998	representing	_	
96-6	18999-19006	percent	_	
96-7	19007-19011	BOLD	_	
96-8	19012-19021	contrasts	_	
96-9	19022-19029	between	_	
96-10	19030-19033	own	_	
96-11	19034-19037	and	_	
96-12	19038-19045	unknown	_	
96-13	19046-19052	infant	_	
96-14	19053-19063	conditions	_	
96-15	19063-19064	:	_	
96-16	19065-19067	OH	_	
96-17	19068-19070	vs	_	
96-18	19070-19071	.	_	

#Text=UH and OS vs.
97-1	19072-19074	UH	_	
97-2	19075-19078	and	_	
97-3	19079-19081	OS	_	
97-4	19082-19084	vs	_	
97-5	19084-19085	.	_	

#Text=US.
98-1	19086-19088	US	_	
98-2	19088-19089	.	_	

#Text=Analyses were performed at two levels: first using a whole-brain voxel-wise analysis, followed by a region-of-interest analysis of the bilateral striatum to evaluate within-striatal differences in percent BOLD signals to our contrast of interest.
99-1	19090-19098	Analyses	_	
99-2	19099-19103	were	_	
99-3	19104-19113	performed	_	
99-4	19114-19116	at	_	
99-5	19117-19120	two	_	
99-6	19121-19127	levels	_	
99-7	19127-19128	:	_	
99-8	19129-19134	first	_	
99-9	19135-19140	using	_	
99-10	19141-19142	a	_	
99-11	19143-19154	whole-brain	_	
99-12	19155-19165	voxel-wise	_	
99-13	19166-19174	analysis	_	
99-14	19174-19175	,	_	
99-15	19176-19184	followed	_	
99-16	19185-19187	by	_	
99-17	19188-19189	a	_	
99-18	19190-19208	region-of-interest	_	
99-19	19209-19217	analysis	_	
99-20	19218-19220	of	_	
99-21	19221-19224	the	_	
99-22	19225-19234	bilateral	_	
99-23	19235-19243	striatum	_	
99-24	19244-19246	to	_	
99-25	19247-19255	evaluate	_	
99-26	19256-19271	within-striatal	_	
99-27	19272-19283	differences	_	
99-28	19284-19286	in	_	
99-29	19287-19294	percent	_	
99-30	19295-19299	BOLD	_	
99-31	19300-19307	signals	_	
99-32	19308-19310	to	_	
99-33	19311-19314	our	_	
99-34	19315-19323	contrast	_	
99-35	19324-19326	of	_	
99-36	19327-19335	interest	_	
99-37	19335-19336	.	_	

#Text=The striatum was selected structurally, based on a mask derived from the subcortical atlas of the Brain Tutor HD, version 2.2 (Brain Innovation, Maastricht, The Netherlands), and comprised 289 and 302 voxels for the left and right, respectively.
100-1	19337-19340	The	_	
100-2	19341-19349	striatum	_	
100-3	19350-19353	was	_	
100-4	19354-19362	selected	_	
100-5	19363-19375	structurally	_	
100-6	19375-19376	,	_	
100-7	19377-19382	based	_	
100-8	19383-19385	on	_	
100-9	19386-19387	a	_	
100-10	19388-19392	mask	_	
100-11	19393-19400	derived	_	
100-12	19401-19405	from	_	
100-13	19406-19409	the	_	
100-14	19410-19421	subcortical	_	
100-15	19422-19427	atlas	_	
100-16	19428-19430	of	_	
100-17	19431-19434	the	_	
100-18	19435-19440	Brain	_	
100-19	19441-19446	Tutor	_	
100-20	19447-19449	HD	_	
100-21	19449-19450	,	_	
100-22	19451-19458	version	_	
100-23	19459-19462	2.2	_	
100-24	19463-19464	(	_	
100-25	19464-19469	Brain	_	
100-26	19470-19480	Innovation	_	
100-27	19480-19481	,	_	
100-28	19482-19492	Maastricht	_	
100-29	19492-19493	,	_	
100-30	19494-19497	The	_	
100-31	19498-19509	Netherlands	_	
100-32	19509-19510	)	_	
100-33	19510-19511	,	_	
100-34	19512-19515	and	_	
100-35	19516-19525	comprised	_	
100-36	19526-19529	289	_	
100-37	19530-19533	and	_	
100-38	19534-19537	302	_	
100-39	19538-19544	voxels	_	
100-40	19545-19548	for	_	
100-41	19549-19552	the	_	
100-42	19553-19557	left	_	
100-43	19558-19561	and	_	
100-44	19562-19567	right	_	
100-45	19567-19568	,	_	
100-46	19569-19581	respectively	_	
100-47	19581-19582	.	_	

#Text=Post-hoc examination of whole-brain analysis results was conducted by extracting percent signal change values for OH and UH from cubes centered at local peaks within the cluster of (de)activation and extending up to ± 10 voxels per dimension, unless limited by the spatial extent of (de)activation.
101-1	19583-19591	Post-hoc	_	
101-2	19592-19603	examination	_	
101-3	19604-19606	of	_	
101-4	19607-19618	whole-brain	_	
101-5	19619-19627	analysis	_	
101-6	19628-19635	results	_	
101-7	19636-19639	was	_	
101-8	19640-19649	conducted	_	
101-9	19650-19652	by	_	
101-10	19653-19663	extracting	_	
101-11	19664-19671	percent	_	
101-12	19672-19678	signal	_	
101-13	19679-19685	change	_	
101-14	19686-19692	values	_	
101-15	19693-19696	for	_	
101-16	19697-19699	OH	_	
101-17	19700-19703	and	_	
101-18	19704-19706	UH	_	
101-19	19707-19711	from	_	
101-20	19712-19717	cubes	_	
101-21	19718-19726	centered	_	
101-22	19727-19729	at	_	
101-23	19730-19735	local	_	
101-24	19736-19741	peaks	_	
101-25	19742-19748	within	_	
101-26	19749-19752	the	_	
101-27	19753-19760	cluster	_	
101-28	19761-19763	of	_	
101-29	19764-19765	(	_	
101-30	19765-19767	de	_	
101-31	19767-19768	)	_	
101-32	19768-19778	activation	_	
101-33	19779-19782	and	_	
101-34	19783-19792	extending	_	
101-35	19793-19795	up	_	
101-36	19796-19798	to	_	
101-37	19799-19800	±	_	
101-38	19801-19803	10	_	
101-39	19804-19810	voxels	_	
101-40	19811-19814	per	_	
101-41	19815-19824	dimension	_	
101-42	19824-19825	,	_	
101-43	19826-19832	unless	_	
101-44	19833-19840	limited	_	
101-45	19841-19843	by	_	
101-46	19844-19847	the	_	
101-47	19848-19855	spatial	_	
101-48	19856-19862	extent	_	
101-49	19863-19865	of	_	
101-50	19866-19867	(	_	
101-51	19867-19869	de	_	
101-52	19869-19870	)	_	
101-53	19870-19880	activation	_	
101-54	19880-19881	.	_	

#Text=This allowed us to further contrast and visually display patterns of percent BOLD signals for our contrast of interest in our key hypothesized OT- and DA-innervated regions.
102-1	19882-19886	This	_	
102-2	19887-19894	allowed	_	
102-3	19895-19897	us	_	
102-4	19898-19900	to	_	
102-5	19901-19908	further	_	
102-6	19909-19917	contrast	_	
102-7	19918-19921	and	_	
102-8	19922-19930	visually	_	
102-9	19931-19938	display	_	
102-10	19939-19947	patterns	_	
102-11	19948-19950	of	_	
102-12	19951-19958	percent	_	
102-13	19959-19963	BOLD	_	
102-14	19964-19971	signals	_	
102-15	19972-19975	for	_	
102-16	19976-19979	our	_	
102-17	19980-19988	contrast	_	
102-18	19989-19991	of	_	
102-19	19992-20000	interest	_	
102-20	20001-20003	in	_	
102-21	20004-20007	our	_	
102-22	20008-20011	key	_	
102-23	20012-20024	hypothesized	_	
102-24	20025-20027	OT	_	
102-25	20027-20028	-	_	
102-26	20029-20032	and	_	
102-27	20033-20046	DA-innervated	_	
102-28	20047-20054	regions	_	
102-29	20054-20055	.	_	

#Text=In all analyses, statistical threshold of false discovery rate (FDR) corrected q < .05 and a cluster threshold of ≥ 300 mm3 were used to determine clusters of significant activation.
103-1	20056-20058	In	_	
103-2	20059-20062	all	_	
103-3	20063-20071	analyses	_	
103-4	20071-20072	,	_	
103-5	20073-20084	statistical	_	
103-6	20085-20094	threshold	_	
103-7	20095-20097	of	_	
103-8	20098-20103	false	_	
103-9	20104-20113	discovery	_	
103-10	20114-20118	rate	_	
103-11	20119-20120	(	_	
103-12	20120-20123	FDR	_	
103-13	20123-20124	)	_	
103-14	20125-20134	corrected	_	
103-15	20135-20136	q	_	
103-16	20137-20138	<	_	
103-17	20139-20142	.05	_	
103-18	20143-20146	and	_	
103-19	20147-20148	a	_	
103-20	20149-20156	cluster	_	
103-21	20157-20166	threshold	_	
103-22	20167-20169	of	_	
103-23	20170-20171	≥	_	
103-24	20172-20175	300	_	
103-25	20176-20179	mm3	_	
103-26	20180-20184	were	_	
103-27	20185-20189	used	_	
103-28	20190-20192	to	_	
103-29	20193-20202	determine	_	
103-30	20203-20211	clusters	_	
103-31	20212-20214	of	_	
103-32	20215-20226	significant	_	
103-33	20227-20237	activation	_	
103-34	20237-20238	.	_	

#Text=Supra-threshold clusters of active voxels were labeled using a published atlas of the human brain and the Talairach Client (Research Imaging Center, TX, USA).
104-1	20239-20254	Supra-threshold	_	
104-2	20255-20263	clusters	_	
104-3	20264-20266	of	_	
104-4	20267-20273	active	_	
104-5	20274-20280	voxels	_	
104-6	20281-20285	were	_	
104-7	20286-20293	labeled	_	
104-8	20294-20299	using	_	
104-9	20300-20301	a	_	
104-10	20302-20311	published	_	
104-11	20312-20317	atlas	_	
104-12	20318-20320	of	_	
104-13	20321-20324	the	_	
104-14	20325-20330	human	_	
104-15	20331-20336	brain	_	
104-16	20337-20340	and	_	
104-17	20341-20344	the	_	
104-18	20345-20354	Talairach	_	
104-19	20355-20361	Client	_	
104-20	20362-20363	(	_	
104-21	20363-20371	Research	_	
104-22	20372-20379	Imaging	_	
104-23	20380-20386	Center	_	
104-24	20386-20387	,	_	
104-25	20388-20390	TX	_	
104-26	20390-20391	,	_	
104-27	20392-20395	USA	_	
104-28	20395-20396	)	_	
104-29	20396-20397	.	_	

#Text=Post-scan ratings analysis
#Text=Post-scan ratings were analyzed with the STATA/SE, version 13.1 XTMIXED procedure.
105-1	20398-20407	Post-scan	_	
105-2	20408-20415	ratings	_	
105-3	20416-20424	analysis	_	
105-4	20425-20434	Post-scan	_	
105-5	20435-20442	ratings	_	
105-6	20443-20447	were	_	
105-7	20448-20456	analyzed	_	
105-8	20457-20461	with	_	
105-9	20462-20465	the	_	
105-10	20466-20471	STATA	_	
105-11	20471-20472	/	_	
105-12	20472-20474	SE	_	
105-13	20474-20475	,	_	
105-14	20476-20483	version	_	
105-15	20484-20488	13.1	_	
105-16	20489-20496	XTMIXED	_	
105-17	20497-20506	procedure	_	
105-18	20506-20507	.	_	

#Text=Mothers’ ratings of affect, both how they perceived the infant to be feeling in each image and of their own affective responses to the image, were compared for own and unknown infant faces using mixed-effects linear regression analysis that included a subject-level random intercept.
106-1	20508-20515	Mothers	_	
106-2	20515-20516	’	_	
106-3	20517-20524	ratings	_	
106-4	20525-20527	of	_	
106-5	20528-20534	affect	_	
106-6	20534-20535	,	_	
106-7	20536-20540	both	_	
106-8	20541-20544	how	_	
106-9	20545-20549	they	_	
106-10	20550-20559	perceived	_	
106-11	20560-20563	the	_	
106-12	20564-20570	infant	_	
106-13	20571-20573	to	_	
106-14	20574-20576	be	_	
106-15	20577-20584	feeling	_	
106-16	20585-20587	in	_	
106-17	20588-20592	each	_	
106-18	20593-20598	image	_	
106-19	20599-20602	and	_	
106-20	20603-20605	of	_	
106-21	20606-20611	their	_	
106-22	20612-20615	own	_	
106-23	20616-20625	affective	_	
106-24	20626-20635	responses	_	
106-25	20636-20638	to	_	
106-26	20639-20642	the	_	
106-27	20643-20648	image	_	
106-28	20648-20649	,	_	
106-29	20650-20654	were	_	
106-30	20655-20663	compared	_	
106-31	20664-20667	for	_	
106-32	20668-20671	own	_	
106-33	20672-20675	and	_	
106-34	20676-20683	unknown	_	
106-35	20684-20690	infant	_	
106-36	20691-20696	faces	_	
106-37	20697-20702	using	_	
106-38	20703-20716	mixed-effects	_	
106-39	20717-20723	linear	_	
106-40	20724-20734	regression	_	
106-41	20735-20743	analysis	_	
106-42	20744-20748	that	_	
106-43	20749-20757	included	_	
106-44	20758-20759	a	_	
106-45	20760-20773	subject-level	_	
106-46	20774-20780	random	_	
106-47	20781-20790	intercept	_	
106-48	20790-20791	.	_	

#Text=Mixed-effects models were also used to probe for the association between mothers’ two ratings to examine the degree to which mothers’ own affective responses tracked with how they perceived the infant to be feeling.
107-1	20792-20805	Mixed-effects	_	
107-2	20806-20812	models	_	
107-3	20813-20817	were	_	
107-4	20818-20822	also	_	
107-5	20823-20827	used	_	
107-6	20828-20830	to	_	
107-7	20831-20836	probe	_	
107-8	20837-20840	for	_	
107-9	20841-20844	the	_	
107-10	20845-20856	association	_	
107-11	20857-20864	between	_	
107-12	20865-20872	mothers	_	
107-13	20872-20873	’	_	
107-14	20874-20877	two	_	
107-15	20878-20885	ratings	_	
107-16	20886-20888	to	_	
107-17	20889-20896	examine	_	
107-18	20897-20900	the	_	
107-19	20901-20907	degree	_	
107-20	20908-20910	to	_	
107-21	20911-20916	which	_	
107-22	20917-20924	mothers	_	
107-23	20924-20925	’	_	
107-24	20926-20929	own	_	
107-25	20930-20939	affective	_	
107-26	20940-20949	responses	_	
107-27	20950-20957	tracked	_	
107-28	20958-20962	with	_	
107-29	20963-20966	how	_	
107-30	20967-20971	they	_	
107-31	20972-20981	perceived	_	
107-32	20982-20985	the	_	
107-33	20986-20992	infant	_	
107-34	20993-20995	to	_	
107-35	20996-20998	be	_	
107-36	20999-21006	feeling	_	
107-37	21006-21007	.	_	

#Text=Model building was carried out as follows: (a) the initial model included the fixed main effects of infant identity (i.e., own vs. unknown) and mothers’ perceived ratings of infant’s affect; (b) a subject-level random intercept was added to model systematic inter-individual variability; and (c) interaction terms were added sequentially and retained in the model if they improved model fit.
108-1	21008-21013	Model	_	
108-2	21014-21022	building	_	
108-3	21023-21026	was	_	
108-4	21027-21034	carried	_	
108-5	21035-21038	out	_	
108-6	21039-21041	as	_	
108-7	21042-21049	follows	_	
108-8	21049-21050	:	_	
108-9	21051-21052	(	_	
108-10	21052-21053	a	_	
108-11	21053-21054	)	_	
108-12	21055-21058	the	_	
108-13	21059-21066	initial	_	
108-14	21067-21072	model	_	
108-15	21073-21081	included	_	
108-16	21082-21085	the	_	
108-17	21086-21091	fixed	_	
108-18	21092-21096	main	_	
108-19	21097-21104	effects	_	
108-20	21105-21107	of	_	
108-21	21108-21114	infant	_	
108-22	21115-21123	identity	_	
108-23	21124-21125	(	_	
108-24	21125-21128	i.e	_	
108-25	21128-21129	.	_	
108-26	21129-21130	,	_	
108-27	21131-21134	own	_	
108-28	21135-21137	vs	_	
108-29	21137-21138	.	_	
108-30	21139-21146	unknown	_	
108-31	21146-21147	)	_	
108-32	21148-21151	and	_	
108-33	21152-21159	mothers	_	
108-34	21159-21160	’	_	
108-35	21161-21170	perceived	_	
108-36	21171-21178	ratings	_	
108-37	21179-21181	of	_	
108-38	21182-21188	infant	_	
108-39	21188-21189	’	_	
108-40	21189-21190	s	_	
108-41	21191-21197	affect	_	
108-42	21197-21198	;	_	
108-43	21199-21200	(	_	
108-44	21200-21201	b	_	
108-45	21201-21202	)	_	
108-46	21203-21204	a	_	
108-47	21205-21218	subject-level	_	
108-48	21219-21225	random	_	
108-49	21226-21235	intercept	_	
108-50	21236-21239	was	_	
108-51	21240-21245	added	_	
108-52	21246-21248	to	_	
108-53	21249-21254	model	_	
108-54	21255-21265	systematic	_	
108-55	21266-21282	inter-individual	_	
108-56	21283-21294	variability	_	
108-57	21294-21295	;	_	
108-58	21296-21299	and	_	
108-59	21300-21301	(	_	
108-60	21301-21302	c	_	
108-61	21302-21303	)	_	
108-62	21304-21315	interaction	_	
108-63	21316-21321	terms	_	
108-64	21322-21326	were	_	
108-65	21327-21332	added	_	
108-66	21333-21345	sequentially	_	
108-67	21346-21349	and	_	
108-68	21350-21358	retained	_	
108-69	21359-21361	in	_	
108-70	21362-21365	the	_	
108-71	21366-21371	model	_	
108-72	21372-21374	if	_	
108-73	21375-21379	they	_	
108-74	21380-21388	improved	_	
108-75	21389-21394	model	_	
108-76	21395-21398	fit	_	
108-77	21398-21399	.	_	

#Text=The models were fitted by maximum likelihood estimation, and nested models were contrasted using likelihood-ratio chi-squares.
109-1	21400-21403	The	_	
109-2	21404-21410	models	_	
109-3	21411-21415	were	_	
109-4	21416-21422	fitted	_	
109-5	21423-21425	by	_	
109-6	21426-21433	maximum	_	
109-7	21434-21444	likelihood	_	
109-8	21445-21455	estimation	_	
109-9	21455-21456	,	_	
109-10	21457-21460	and	_	
109-11	21461-21467	nested	_	
109-12	21468-21474	models	_	
109-13	21475-21479	were	_	
109-14	21480-21490	contrasted	_	
109-15	21491-21496	using	_	
109-16	21497-21513	likelihood-ratio	_	
109-17	21514-21525	chi-squares	_	
109-18	21525-21526	.	_	

#Text=Results
#Text=Participant Characteristics
#Text=Participants’ sociodemographic and substance-use characteristics are shown in Tables I and II, respectively.
110-1	21527-21534	Results	_	
110-2	21535-21546	Participant	_	
110-3	21547-21562	Characteristics	_	
110-4	21563-21575	Participants	_	
110-5	21575-21576	’	_	
110-6	21577-21593	sociodemographic	_	
110-7	21594-21597	and	_	
110-8	21598-21611	substance-use	_	
110-9	21612-21627	characteristics	_	
110-10	21628-21631	are	_	
110-11	21632-21637	shown	_	
110-12	21638-21640	in	_	
110-13	21641-21647	Tables	_	
110-14	21648-21649	I	_	
110-15	21650-21653	and	_	
110-16	21654-21656	II	_	
110-17	21656-21657	,	_	
110-18	21658-21670	respectively	_	
110-19	21670-21671	.	_	

#Text=Participants were generally of low socioeconomic status, with only 33 percent completing any education beyond high school and 64 percent reporting an annual family income of less than $15,000.
111-1	21672-21684	Participants	_	
111-2	21685-21689	were	_	
111-3	21690-21699	generally	_	
111-4	21700-21702	of	_	
111-5	21703-21706	low	_	
111-6	21707-21720	socioeconomic	_	
111-7	21721-21727	status	_	
111-8	21727-21728	,	_	
111-9	21729-21733	with	_	
111-10	21734-21738	only	_	
111-11	21739-21741	33	_	
111-12	21742-21749	percent	_	
111-13	21750-21760	completing	_	
111-14	21761-21764	any	_	
111-15	21765-21774	education	_	
111-16	21775-21781	beyond	_	
111-17	21782-21786	high	_	
111-18	21787-21793	school	_	
111-19	21794-21797	and	_	
111-20	21798-21800	64	_	
111-21	21801-21808	percent	_	
111-22	21809-21818	reporting	_	
111-23	21819-21821	an	_	
111-24	21822-21828	annual	_	
111-25	21829-21835	family	_	
111-26	21836-21842	income	_	
111-27	21843-21845	of	_	
111-28	21846-21850	less	_	
111-29	21851-21855	than	_	
111-30	21856-21863	$15,000	_	
111-31	21863-21864	.	_	

#Text=Twenty-two percent of women had been court-mandated to receive substance-use treatment, and 58 percent had child protective services (CPS) involvement.
112-1	21865-21875	Twenty-two	_	
112-2	21876-21883	percent	_	
112-3	21884-21886	of	_	
112-4	21887-21892	women	_	
112-5	21893-21896	had	_	
112-6	21897-21901	been	_	
112-7	21902-21916	court-mandated	_	
112-8	21917-21919	to	_	
112-9	21920-21927	receive	_	
112-10	21928-21941	substance-use	_	
112-11	21942-21951	treatment	_	
112-12	21951-21952	,	_	
112-13	21953-21956	and	_	
112-14	21957-21959	58	_	
112-15	21960-21967	percent	_	
112-16	21968-21971	had	_	
112-17	21972-21977	child	_	
112-18	21978-21988	protective	_	
112-19	21989-21997	services	_	
112-20	21998-21999	(	_	
112-21	21999-22002	CPS	_	
112-22	22002-22003	)	_	
112-23	22004-22015	involvement	_	
112-24	22015-22016	.	_	

#Text=Sixty-seven percent (n = 24) were taking psychotropic medications at the time of the present study, including antipsychotic medications (n = 8), mood stabilizers (n = 2), medications for depression or anxiety (n = 13), and stimulant medication (n = 1).
113-1	22017-22028	Sixty-seven	_	
113-2	22029-22036	percent	_	
113-3	22037-22038	(	_	
113-4	22038-22039	n	_	
113-5	22040-22041	=	_	
113-6	22042-22044	24	_	
113-7	22044-22045	)	_	
113-8	22046-22050	were	_	
113-9	22051-22057	taking	_	
113-10	22058-22070	psychotropic	_	
113-11	22071-22082	medications	_	
113-12	22083-22085	at	_	
113-13	22086-22089	the	_	
113-14	22090-22094	time	_	
113-15	22095-22097	of	_	
113-16	22098-22101	the	_	
113-17	22102-22109	present	_	
113-18	22110-22115	study	_	
113-19	22115-22116	,	_	
113-20	22117-22126	including	_	
113-21	22127-22140	antipsychotic	_	
113-22	22141-22152	medications	_	
113-23	22153-22154	(	_	
113-24	22154-22155	n	_	
113-25	22156-22157	=	_	
113-26	22158-22159	8	_	
113-27	22159-22160	)	_	
113-28	22160-22161	,	_	
113-29	22162-22166	mood	_	
113-30	22167-22178	stabilizers	_	
113-31	22179-22180	(	_	
113-32	22180-22181	n	_	
113-33	22182-22183	=	_	
113-34	22184-22185	2	_	
113-35	22185-22186	)	_	
113-36	22186-22187	,	_	
113-37	22188-22199	medications	_	
113-38	22200-22203	for	_	
113-39	22204-22214	depression	_	
113-40	22215-22217	or	_	
113-41	22218-22225	anxiety	_	
113-42	22226-22227	(	_	
113-43	22227-22228	n	_	
113-44	22229-22230	=	_	
113-45	22231-22233	13	_	
113-46	22233-22234	)	_	
113-47	22234-22235	,	_	
113-48	22236-22239	and	_	
113-49	22240-22249	stimulant	_	
113-50	22250-22260	medication	_	
113-51	22261-22262	(	_	
113-52	22262-22263	n	_	
113-53	22264-22265	=	_	
113-54	22266-22267	1	_	
113-55	22267-22268	)	_	
113-56	22268-22269	.	_	

#Text=Because all women were recruited from an inpatient substance-use treatment facility and the majority remained in treatment at the time of the study, most were not using substances at the time of the scanning visit.
114-1	22270-22277	Because	_	
114-2	22278-22281	all	_	
114-3	22282-22287	women	_	
114-4	22288-22292	were	_	
114-5	22293-22302	recruited	_	
114-6	22303-22307	from	_	
114-7	22308-22310	an	_	
114-8	22311-22320	inpatient	_	
114-9	22321-22334	substance-use	_	
114-10	22335-22344	treatment	_	
114-11	22345-22353	facility	_	
114-12	22354-22357	and	_	
114-13	22358-22361	the	_	
114-14	22362-22370	majority	_	
114-15	22371-22379	remained	_	
114-16	22380-22382	in	_	
114-17	22383-22392	treatment	_	
114-18	22393-22395	at	_	
114-19	22396-22399	the	_	
114-20	22400-22404	time	_	
114-21	22405-22407	of	_	
114-22	22408-22411	the	_	
114-23	22412-22417	study	_	
114-24	22417-22418	,	_	
114-25	22419-22423	most	_	
114-26	22424-22428	were	_	
114-27	22429-22432	not	_	
114-28	22433-22438	using	_	
114-29	22439-22449	substances	_	
114-30	22450-22452	at	_	
114-31	22453-22456	the	_	
114-32	22457-22461	time	_	
114-33	22462-22464	of	_	
114-34	22465-22468	the	_	
114-35	22469-22477	scanning	_	
114-36	22478-22483	visit	_	
114-37	22483-22484	.	_	

#Text=All except four women tested negative on a urine toxicology screen on the day of the scan, and none had a positive alcohol breathalyzer test.
115-1	22485-22488	All	_	
115-2	22489-22495	except	_	
115-3	22496-22500	four	_	
115-4	22501-22506	women	_	
115-5	22507-22513	tested	_	
115-6	22514-22522	negative	_	
115-7	22523-22525	on	_	
115-8	22526-22527	a	_	
115-9	22528-22533	urine	_	
115-10	22534-22544	toxicology	_	
115-11	22545-22551	screen	_	
115-12	22552-22554	on	_	
115-13	22555-22558	the	_	
115-14	22559-22562	day	_	
115-15	22563-22565	of	_	
115-16	22566-22569	the	_	
115-17	22570-22574	scan	_	
115-18	22574-22575	,	_	
115-19	22576-22579	and	_	
115-20	22580-22584	none	_	
115-21	22585-22588	had	_	
115-22	22589-22590	a	_	
115-23	22591-22599	positive	_	
115-24	22600-22607	alcohol	_	
115-25	22608-22620	breathalyzer	_	
115-26	22621-22625	test	_	
115-27	22625-22626	.	_	

#Text=Results remained unchanged when the four subjects were excluded from the analyses; hence, data reported below include all subjects.
#Text=fMRI Findings
#Text=Happy faces
#Text=As compared to viewing unknown happy infant faces, viewing the happy faces of their own infants induced significant activation in multiple brain regions of mothers with addictions, including the amygdala, hippocampus, thalamus, cingulate, and brainstem structures including the VTA and substantia nigra (Table III), overlapping regions previously reported in normative groups of mothers.
116-1	22627-22634	Results	_	
116-2	22635-22643	remained	_	
116-3	22644-22653	unchanged	_	
116-4	22654-22658	when	_	
116-5	22659-22662	the	_	
116-6	22663-22667	four	_	
116-7	22668-22676	subjects	_	
116-8	22677-22681	were	_	
116-9	22682-22690	excluded	_	
116-10	22691-22695	from	_	
116-11	22696-22699	the	_	
116-12	22700-22708	analyses	_	
116-13	22708-22709	;	_	
116-14	22710-22715	hence	_	
116-15	22715-22716	,	_	
116-16	22717-22721	data	_	
116-17	22722-22730	reported	_	
116-18	22731-22736	below	_	
116-19	22737-22744	include	_	
116-20	22745-22748	all	_	
116-21	22749-22757	subjects	_	
116-22	22757-22758	.	_	
116-23	22759-22763	fMRI	_	
116-24	22764-22772	Findings	_	
116-25	22773-22778	Happy	_	
116-26	22779-22784	faces	_	
116-27	22785-22787	As	_	
116-28	22788-22796	compared	_	
116-29	22797-22799	to	_	
116-30	22800-22807	viewing	_	
116-31	22808-22815	unknown	_	
116-32	22816-22821	happy	_	
116-33	22822-22828	infant	_	
116-34	22829-22834	faces	_	
116-35	22834-22835	,	_	
116-36	22836-22843	viewing	_	
116-37	22844-22847	the	_	
116-38	22848-22853	happy	_	
116-39	22854-22859	faces	_	
116-40	22860-22862	of	_	
116-41	22863-22868	their	_	
116-42	22869-22872	own	_	
116-43	22873-22880	infants	_	
116-44	22881-22888	induced	_	
116-45	22889-22900	significant	_	
116-46	22901-22911	activation	_	
116-47	22912-22914	in	_	
116-48	22915-22923	multiple	_	
116-49	22924-22929	brain	_	
116-50	22930-22937	regions	_	
116-51	22938-22940	of	_	
116-52	22941-22948	mothers	_	
116-53	22949-22953	with	_	
116-54	22954-22964	addictions	_	
116-55	22964-22965	,	_	
116-56	22966-22975	including	_	
116-57	22976-22979	the	_	
116-58	22980-22988	amygdala	_	
116-59	22988-22989	,	_	
116-60	22990-23001	hippocampus	_	
116-61	23001-23002	,	_	
116-62	23003-23011	thalamus	_	
116-63	23011-23012	,	_	
116-64	23013-23022	cingulate	_	
116-65	23022-23023	,	_	
116-66	23024-23027	and	_	
116-67	23028-23037	brainstem	_	
116-68	23038-23048	structures	_	
116-69	23049-23058	including	_	
116-70	23059-23062	the	_	
116-71	23063-23066	VTA	_	
116-72	23067-23070	and	_	
116-73	23071-23081	substantia	_	
116-74	23082-23087	nigra	_	
116-75	23088-23089	(	_	
116-76	23089-23094	Table	_	
116-77	23095-23098	III	_	
116-78	23098-23099	)	_	
116-79	23099-23100	,	_	
116-80	23101-23112	overlapping	_	
116-81	23113-23120	regions	_	
116-82	23121-23131	previously	_	
116-83	23132-23140	reported	_	
116-84	23141-23143	in	_	
116-85	23144-23153	normative	_	
116-86	23154-23160	groups	_	
116-87	23161-23163	of	_	
116-88	23164-23171	mothers	_	
116-89	23171-23172	.	_	

#Text=Consistent with the extant literature on maternal brain responses, activations were also seen in the inferior frontal gyrus, ventral premotor cortex, insula, STG, visual association areas, and cerebellum.
117-1	23173-23183	Consistent	_	
117-2	23184-23188	with	_	
117-3	23189-23192	the	_	
117-4	23193-23199	extant	_	
117-5	23200-23210	literature	_	
117-6	23211-23213	on	_	
117-7	23214-23222	maternal	_	
117-8	23223-23228	brain	_	
117-9	23229-23238	responses	_	
117-10	23238-23239	,	_	
117-11	23240-23251	activations	_	
117-12	23252-23256	were	_	
117-13	23257-23261	also	_	
117-14	23262-23266	seen	_	
117-15	23267-23269	in	_	
117-16	23270-23273	the	_	
117-17	23274-23282	inferior	_	
117-18	23283-23290	frontal	_	
117-19	23291-23296	gyrus	_	
117-20	23296-23297	,	_	
117-21	23298-23305	ventral	_	
117-22	23306-23314	premotor	_	
117-23	23315-23321	cortex	_	
117-24	23321-23322	,	_	
117-25	23323-23329	insula	_	
117-26	23329-23330	,	_	
117-27	23331-23334	STG	_	
117-28	23334-23335	,	_	
117-29	23336-23342	visual	_	
117-30	23343-23354	association	_	
117-31	23355-23360	areas	_	
117-32	23360-23361	,	_	
117-33	23362-23365	and	_	
117-34	23366-23376	cerebellum	_	
117-35	23376-23377	.	_	

#Text=However, as hypothesized, maternal brain response was significantly reduced in several key OT- and DA- innervated brain regions in own happy compared to unknown happy infant faces.
118-1	23378-23385	However	_	
118-2	23385-23386	,	_	
118-3	23387-23389	as	_	
118-4	23390-23402	hypothesized	_	
118-5	23402-23403	,	_	
118-6	23404-23412	maternal	_	
118-7	23413-23418	brain	_	
118-8	23419-23427	response	_	
118-9	23428-23431	was	_	
118-10	23432-23445	significantly	_	
118-11	23446-23453	reduced	_	
118-12	23454-23456	in	_	
118-13	23457-23464	several	_	
118-14	23465-23468	key	_	
118-15	23469-23471	OT	_	
118-16	23471-23472	-	_	
118-17	23473-23476	and	_	
118-18	23477-23479	DA	_	
118-19	23479-23480	-	_	
118-20	23481-23491	innervated	_	
118-21	23492-23497	brain	_	
118-22	23498-23505	regions	_	
118-23	23506-23508	in	_	
118-24	23509-23512	own	_	
118-25	23513-23518	happy	_	
118-26	23519-23527	compared	_	
118-27	23528-23530	to	_	
118-28	23531-23538	unknown	_	
118-29	23539-23544	happy	_	
118-30	23545-23551	infant	_	
118-31	23552-23557	faces	_	
118-32	23557-23558	.	_	

#Text=Our whole-brain analysis yielded a single cluster of deactivation amid clusters of highly significant activations (Figure 3).
119-1	23559-23562	Our	_	
119-2	23563-23574	whole-brain	_	
119-3	23575-23583	analysis	_	
119-4	23584-23591	yielded	_	
119-5	23592-23593	a	_	
119-6	23594-23600	single	_	
119-7	23601-23608	cluster	_	
119-8	23609-23611	of	_	
119-9	23612-23624	deactivation	_	
119-10	23625-23629	amid	_	
119-11	23630-23638	clusters	_	
119-12	23639-23641	of	_	
119-13	23642-23648	highly	_	
119-14	23649-23660	significant	_	
119-15	23661-23672	activations	_	
119-16	23673-23674	(	_	
119-17	23674-23680	Figure	_	
119-18	23681-23682	3	_	
119-19	23682-23683	)	_	
119-20	23683-23684	.	_	

#Text=The deactivated cluster encompassed the hypothalamus, bilateral VS, and bilateral ventromedial prefrontal regions spanning 258 voxels (Table IV and Figure 3(a)).
120-1	23685-23688	The	_	
120-2	23689-23700	deactivated	_	
120-3	23701-23708	cluster	_	
120-4	23709-23720	encompassed	_	
120-5	23721-23724	the	_	
120-6	23725-23737	hypothalamus	_	
120-7	23737-23738	,	_	
120-8	23739-23748	bilateral	_	
120-9	23749-23751	VS	_	
120-10	23751-23752	,	_	
120-11	23753-23756	and	_	
120-12	23757-23766	bilateral	_	
120-13	23767-23779	ventromedial	_	
120-14	23780-23790	prefrontal	_	
120-15	23791-23798	regions	_	
120-16	23799-23807	spanning	_	
120-17	23808-23811	258	_	
120-18	23812-23818	voxels	_	
120-19	23819-23820	(	_	
120-20	23820-23825	Table	_	
120-21	23826-23828	IV	_	
120-22	23829-23832	and	_	
120-23	23833-23839	Figure	_	
120-24	23840-23841	3	_	
120-25	23841-23842	(	_	
120-26	23842-23843	a	_	
120-27	23843-23844	)	_	
120-28	23844-23845	)	_	
120-29	23845-23846	.	_	

#Text=Figure 3(b) displays a post-hoc examination of local peaks within the deactivated cluster, depicting a negative percent BOLD signal change observed in key OT- and DA-innervated regions in mothers with addictions while viewing their own infant’s happy faces, in contrast to the positive change in percent BOLD signals seen in response to an unknown infant’s face.
121-1	23847-23853	Figure	_	
121-2	23854-23855	3	_	
121-3	23855-23856	(	_	
121-4	23856-23857	b	_	
121-5	23857-23858	)	_	
121-6	23859-23867	displays	_	
121-7	23868-23869	a	_	
121-8	23870-23878	post-hoc	_	
121-9	23879-23890	examination	_	
121-10	23891-23893	of	_	
121-11	23894-23899	local	_	
121-12	23900-23905	peaks	_	
121-13	23906-23912	within	_	
121-14	23913-23916	the	_	
121-15	23917-23928	deactivated	_	
121-16	23929-23936	cluster	_	
121-17	23936-23937	,	_	
121-18	23938-23947	depicting	_	
121-19	23948-23949	a	_	
121-20	23950-23958	negative	_	
121-21	23959-23966	percent	_	
121-22	23967-23971	BOLD	_	
121-23	23972-23978	signal	_	
121-24	23979-23985	change	_	
121-25	23986-23994	observed	_	
121-26	23995-23997	in	_	
121-27	23998-24001	key	_	
121-28	24002-24004	OT	_	
121-29	24004-24005	-	_	
121-30	24006-24009	and	_	
121-31	24010-24023	DA-innervated	_	
121-32	24024-24031	regions	_	
121-33	24032-24034	in	_	
121-34	24035-24042	mothers	_	
121-35	24043-24047	with	_	
121-36	24048-24058	addictions	_	
121-37	24059-24064	while	_	
121-38	24065-24072	viewing	_	
121-39	24073-24078	their	_	
121-40	24079-24082	own	_	
121-41	24083-24089	infant	_	
121-42	24089-24090	’	_	
121-43	24090-24091	s	_	
121-44	24092-24097	happy	_	
121-45	24098-24103	faces	_	
121-46	24103-24104	,	_	
121-47	24105-24107	in	_	
121-48	24108-24116	contrast	_	
121-49	24117-24119	to	_	
121-50	24120-24123	the	_	
121-51	24124-24132	positive	_	
121-52	24133-24139	change	_	
121-53	24140-24142	in	_	
121-54	24143-24150	percent	_	
121-55	24151-24155	BOLD	_	
121-56	24156-24163	signals	_	
121-57	24164-24168	seen	_	
121-58	24169-24171	in	_	
121-59	24172-24180	response	_	
121-60	24181-24183	to	_	
121-61	24184-24186	an	_	
121-62	24187-24194	unknown	_	
121-63	24195-24201	infant	_	
121-64	24201-24202	’	_	
121-65	24202-24203	s	_	
121-66	24204-24208	face	_	
121-67	24208-24209	.	_	

#Text=Analysis within the striatum region-of-interest revealed that the observed deactivation was specific to the ventral portion of the striatum (Figure 4).
122-1	24210-24218	Analysis	_	
122-2	24219-24225	within	_	
122-3	24226-24229	the	_	
122-4	24230-24238	striatum	_	
122-5	24239-24257	region-of-interest	_	
122-6	24258-24266	revealed	_	
122-7	24267-24271	that	_	
122-8	24272-24275	the	_	
122-9	24276-24284	observed	_	
122-10	24285-24297	deactivation	_	
122-11	24298-24301	was	_	
122-12	24302-24310	specific	_	
122-13	24311-24313	to	_	
122-14	24314-24317	the	_	
122-15	24318-24325	ventral	_	
122-16	24326-24333	portion	_	
122-17	24334-24336	of	_	
122-18	24337-24340	the	_	
122-19	24341-24349	striatum	_	
122-20	24350-24351	(	_	
122-21	24351-24357	Figure	_	
122-22	24358-24359	4	_	
122-23	24359-24360	)	_	
122-24	24360-24361	.	_	

#Text=Sad faces
#Text=In our group of mothers with addictions, viewing the sad faces of their own infants relative to unknown infants evoked significant activation in brain regions that largely overlapped with those seen for the happy faces, including the cingulate, thalamus, substantia nigra, parahippocampal gyrus, inferior frontal gyrus, superior frontal gyrus, and cerebellum (Table V).
123-1	24362-24365	Sad	_	
123-2	24366-24371	faces	_	
123-3	24372-24374	In	_	
123-4	24375-24378	our	_	
123-5	24379-24384	group	_	
123-6	24385-24387	of	_	
123-7	24388-24395	mothers	_	
123-8	24396-24400	with	_	
123-9	24401-24411	addictions	_	
123-10	24411-24412	,	_	
123-11	24413-24420	viewing	_	
123-12	24421-24424	the	_	
123-13	24425-24428	sad	_	
123-14	24429-24434	faces	_	
123-15	24435-24437	of	_	
123-16	24438-24443	their	_	
123-17	24444-24447	own	_	
123-18	24448-24455	infants	_	
123-19	24456-24464	relative	_	
123-20	24465-24467	to	_	
123-21	24468-24475	unknown	_	
123-22	24476-24483	infants	_	
123-23	24484-24490	evoked	_	
123-24	24491-24502	significant	_	
123-25	24503-24513	activation	_	
123-26	24514-24516	in	_	
123-27	24517-24522	brain	_	
123-28	24523-24530	regions	_	
123-29	24531-24535	that	_	
123-30	24536-24543	largely	_	
123-31	24544-24554	overlapped	_	
123-32	24555-24559	with	_	
123-33	24560-24565	those	_	
123-34	24566-24570	seen	_	
123-35	24571-24574	for	_	
123-36	24575-24578	the	_	
123-37	24579-24584	happy	_	
123-38	24585-24590	faces	_	
123-39	24590-24591	,	_	
123-40	24592-24601	including	_	
123-41	24602-24605	the	_	
123-42	24606-24615	cingulate	_	
123-43	24615-24616	,	_	
123-44	24617-24625	thalamus	_	
123-45	24625-24626	,	_	
123-46	24627-24637	substantia	_	
123-47	24638-24643	nigra	_	
123-48	24643-24644	,	_	
123-49	24645-24660	parahippocampal	_	
123-50	24661-24666	gyrus	_	
123-51	24666-24667	,	_	
123-52	24668-24676	inferior	_	
123-53	24677-24684	frontal	_	
123-54	24685-24690	gyrus	_	
123-55	24690-24691	,	_	
123-56	24692-24700	superior	_	
123-57	24701-24708	frontal	_	
123-58	24709-24714	gyrus	_	
123-59	24714-24715	,	_	
123-60	24716-24719	and	_	
123-61	24720-24730	cerebellum	_	
123-62	24731-24732	(	_	
123-63	24732-24737	Table	_	
123-64	24738-24739	V	_	
123-65	24739-24740	)	_	
123-66	24740-24741	.	_	

#Text=Activations were also present, and more widespread than those observed for happy faces, in the dorsomedial prefrontal cortex, the opercular part of the inferior frontal gyrus, and several parietal-occipital regions, including the precuneus/paracentral lobule and occipital gyri.
124-1	24742-24753	Activations	_	
124-2	24754-24758	were	_	
124-3	24759-24763	also	_	
124-4	24764-24771	present	_	
124-5	24771-24772	,	_	
124-6	24773-24776	and	_	
124-7	24777-24781	more	_	
124-8	24782-24792	widespread	_	
124-9	24793-24797	than	_	
124-10	24798-24803	those	_	
124-11	24804-24812	observed	_	
124-12	24813-24816	for	_	
124-13	24817-24822	happy	_	
124-14	24823-24828	faces	_	
124-15	24828-24829	,	_	
124-16	24830-24832	in	_	
124-17	24833-24836	the	_	
124-18	24837-24848	dorsomedial	_	
124-19	24849-24859	prefrontal	_	
124-20	24860-24866	cortex	_	
124-21	24866-24867	,	_	
124-22	24868-24871	the	_	
124-23	24872-24881	opercular	_	
124-24	24882-24886	part	_	
124-25	24887-24889	of	_	
124-26	24890-24893	the	_	
124-27	24894-24902	inferior	_	
124-28	24903-24910	frontal	_	
124-29	24911-24916	gyrus	_	
124-30	24916-24917	,	_	
124-31	24918-24921	and	_	
124-32	24922-24929	several	_	
124-33	24930-24948	parietal-occipital	_	
124-34	24949-24956	regions	_	
124-35	24956-24957	,	_	
124-36	24958-24967	including	_	
124-37	24968-24971	the	_	
124-38	24972-24981	precuneus	_	
124-39	24981-24982	/	_	
124-40	24982-24993	paracentral	_	
124-41	24994-25000	lobule	_	
124-42	25001-25004	and	_	
124-43	25005-25014	occipital	_	
124-44	25015-25019	gyri	_	
124-45	25019-25020	.	_	

#Text=Our analysis yielded a single cluster of deactivation in the right IPL extending to the STG, spanning 12 voxels (peak Talairach coordinates: 50, −59, 36; t = −4.62; p = 0.000051).
125-1	25021-25024	Our	_	
125-2	25025-25033	analysis	_	
125-3	25034-25041	yielded	_	
125-4	25042-25043	a	_	
125-5	25044-25050	single	_	
125-6	25051-25058	cluster	_	
125-7	25059-25061	of	_	
125-8	25062-25074	deactivation	_	
125-9	25075-25077	in	_	
125-10	25078-25081	the	_	
125-11	25082-25087	right	_	
125-12	25088-25091	IPL	_	
125-13	25092-25101	extending	_	
125-14	25102-25104	to	_	
125-15	25105-25108	the	_	
125-16	25109-25112	STG	_	
125-17	25112-25113	,	_	
125-18	25114-25122	spanning	_	
125-19	25123-25125	12	_	
125-20	25126-25132	voxels	_	
125-21	25133-25134	(	_	
125-22	25134-25138	peak	_	
125-23	25139-25148	Talairach	_	
125-24	25149-25160	coordinates	_	
125-25	25160-25161	:	_	
125-26	25162-25164	50	_	
125-27	25164-25165	,	_	
125-28	25166-25167	−	_	
125-29	25167-25169	59	_	
125-30	25169-25170	,	_	
125-31	25171-25173	36	_	
125-32	25173-25174	;	_	
125-33	25175-25176	t	_	
125-34	25177-25178	=	_	
125-35	25179-25180	−	_	
125-36	25180-25184	4.62	_	
125-37	25184-25185	;	_	
125-38	25186-25187	p	_	
125-39	25188-25189	=	_	
125-40	25190-25198	0.000051	_	
125-41	25198-25199	)	_	
125-42	25199-25200	.	_	

#Text=There was no activation or deactivation seen in the hypothalamus, VS, or ventromedial prefrontal regions in either whole-brain or region-of-interest analysis of the striatum.
126-1	25201-25206	There	_	
126-2	25207-25210	was	_	
126-3	25211-25213	no	_	
126-4	25214-25224	activation	_	
126-5	25225-25227	or	_	
126-6	25228-25240	deactivation	_	
126-7	25241-25245	seen	_	
126-8	25246-25248	in	_	
126-9	25249-25252	the	_	
126-10	25253-25265	hypothalamus	_	
126-11	25265-25266	,	_	
126-12	25267-25269	VS	_	
126-13	25269-25270	,	_	
126-14	25271-25273	or	_	
126-15	25274-25286	ventromedial	_	
126-16	25287-25297	prefrontal	_	
126-17	25298-25305	regions	_	
126-18	25306-25308	in	_	
126-19	25309-25315	either	_	
126-20	25316-25327	whole-brain	_	
126-21	25328-25330	or	_	
126-22	25331-25349	region-of-interest	_	
126-23	25350-25358	analysis	_	
126-24	25359-25361	of	_	
126-25	25362-25365	the	_	
126-26	25366-25374	striatum	_	
126-27	25374-25375	.	_	

#Text=Post-Scan Rating Findings
#Text=Happy faces
#Text=Mothers with addictions reported perceiving happy faces of their own infants as happier than those of unknown infants (βidentity = .84, 95% CI = .62 to 1.06, z = 7.39, p < .001; Table VI).
127-1	25376-25385	Post-Scan	_	
127-2	25386-25392	Rating	_	
127-3	25393-25401	Findings	_	
127-4	25402-25407	Happy	_	
127-5	25408-25413	faces	_	
127-6	25414-25421	Mothers	_	
127-7	25422-25426	with	_	
127-8	25427-25437	addictions	_	
127-9	25438-25446	reported	_	
127-10	25447-25457	perceiving	_	
127-11	25458-25463	happy	_	
127-12	25464-25469	faces	_	
127-13	25470-25472	of	_	
127-14	25473-25478	their	_	
127-15	25479-25482	own	_	
127-16	25483-25490	infants	_	
127-17	25491-25493	as	_	
127-18	25494-25501	happier	_	
127-19	25502-25506	than	_	
127-20	25507-25512	those	_	
127-21	25513-25515	of	_	
127-22	25516-25523	unknown	_	
127-23	25524-25531	infants	_	
127-24	25532-25533	(	_	
127-25	25533-25542	βidentity	_	
127-26	25543-25544	=	_	
127-27	25545-25548	.84	_	
127-28	25548-25549	,	_	
127-29	25550-25553	95%	_	
127-30	25554-25556	CI	_	
127-31	25557-25558	=	_	
127-32	25559-25562	.62	_	
127-33	25563-25565	to	_	
127-34	25566-25570	1.06	_	
127-35	25570-25571	,	_	
127-36	25572-25573	z	_	
127-37	25574-25575	=	_	
127-38	25576-25580	7.39	_	
127-39	25580-25581	,	_	
127-40	25582-25583	p	_	
127-41	25584-25585	<	_	
127-42	25586-25590	.001	_	
127-43	25590-25591	;	_	
127-44	25592-25597	Table	_	
127-45	25598-25600	VI	_	
127-46	25600-25601	)	_	
127-47	25601-25602	.	_	

#Text=Mothers’ self-reported affect was also more positive in response to their own infants compared to unknown infants (βidentity = 2.45, 95% CI = 2.21 to 2.69, z = 19.69, p < .001; Table VI).
128-1	25603-25610	Mothers	_	
128-2	25610-25611	’	_	
128-3	25612-25625	self-reported	_	
128-4	25626-25632	affect	_	
128-5	25633-25636	was	_	
128-6	25637-25641	also	_	
128-7	25642-25646	more	_	
128-8	25647-25655	positive	_	
128-9	25656-25658	in	_	
128-10	25659-25667	response	_	
128-11	25668-25670	to	_	
128-12	25671-25676	their	_	
128-13	25677-25680	own	_	
128-14	25681-25688	infants	_	
128-15	25689-25697	compared	_	
128-16	25698-25700	to	_	
128-17	25701-25708	unknown	_	
128-18	25709-25716	infants	_	
128-19	25717-25718	(	_	
128-20	25718-25727	βidentity	_	
128-21	25728-25729	=	_	
128-22	25730-25734	2.45	_	
128-23	25734-25735	,	_	
128-24	25736-25739	95%	_	
128-25	25740-25742	CI	_	
128-26	25743-25744	=	_	
128-27	25745-25749	2.21	_	
128-28	25750-25752	to	_	
128-29	25753-25757	2.69	_	
128-30	25757-25758	,	_	
128-31	25759-25760	z	_	
128-32	25761-25762	=	_	
128-33	25763-25768	19.69	_	
128-34	25768-25769	,	_	
128-35	25770-25771	p	_	
128-36	25772-25773	<	_	
128-37	25774-25778	.001	_	
128-38	25778-25779	;	_	
128-39	25780-25785	Table	_	
128-40	25786-25788	VI	_	
128-41	25788-25789	)	_	
128-42	25789-25790	.	_	

#Text=Mothers’ own report of positive affect correlated significantly with how happy they perceived infants to be feeling (βinfant affect = .61, 95% CI = .51 to .70, z = 12.47, p < .001; Table VII).
129-1	25791-25798	Mothers	_	
129-2	25798-25799	’	_	
129-3	25800-25803	own	_	
129-4	25804-25810	report	_	
129-5	25811-25813	of	_	
129-6	25814-25822	positive	_	
129-7	25823-25829	affect	_	
129-8	25830-25840	correlated	_	
129-9	25841-25854	significantly	_	
129-10	25855-25859	with	_	
129-11	25860-25863	how	_	
129-12	25864-25869	happy	_	
129-13	25870-25874	they	_	
129-14	25875-25884	perceived	_	
129-15	25885-25892	infants	_	
129-16	25893-25895	to	_	
129-17	25896-25898	be	_	
129-18	25899-25906	feeling	_	
129-19	25907-25908	(	_	
129-20	25908-25915	βinfant	_	
129-21	25916-25922	affect	_	
129-22	25923-25924	=	_	
129-23	25925-25928	.61	_	
129-24	25928-25929	,	_	
129-25	25930-25933	95%	_	
129-26	25934-25936	CI	_	
129-27	25937-25938	=	_	
129-28	25939-25942	.51	_	
129-29	25943-25945	to	_	
129-30	25946-25949	.70	_	
129-31	25949-25950	,	_	
129-32	25951-25952	z	_	
129-33	25953-25954	=	_	
129-34	25955-25960	12.47	_	
129-35	25960-25961	,	_	
129-36	25962-25963	p	_	
129-37	25964-25965	<	_	
129-38	25966-25970	.001	_	
129-39	25970-25971	;	_	
129-40	25972-25977	Table	_	
129-41	25978-25981	VII	_	
129-42	25981-25982	)	_	
129-43	25982-25983	.	_	

#Text=However, the strength of this association varied as a function of infant identity (βidentity x infant affect = −.33, 95% CI = −.50 to −.16, z = −3.76, p < .001; Table VII).
130-1	25984-25991	However	_	
130-2	25991-25992	,	_	
130-3	25993-25996	the	_	
130-4	25997-26005	strength	_	
130-5	26006-26008	of	_	
130-6	26009-26013	this	_	
130-7	26014-26025	association	_	
130-8	26026-26032	varied	_	
130-9	26033-26035	as	_	
130-10	26036-26037	a	_	
130-11	26038-26046	function	_	
130-12	26047-26049	of	_	
130-13	26050-26056	infant	_	
130-14	26057-26065	identity	_	
130-15	26066-26067	(	_	
130-16	26067-26076	βidentity	_	
130-17	26077-26078	x	_	
130-18	26079-26085	infant	_	
130-19	26086-26092	affect	_	
130-20	26093-26094	=	_	
130-21	26095-26096	−	_	
130-22	26096-26099	.33	_	
130-23	26099-26100	,	_	
130-24	26101-26104	95%	_	
130-25	26105-26107	CI	_	
130-26	26108-26109	=	_	
130-27	26110-26111	−	_	
130-28	26111-26114	.50	_	
130-29	26115-26117	to	_	
130-30	26118-26119	−	_	
130-31	26119-26122	.16	_	
130-32	26122-26123	,	_	
130-33	26124-26125	z	_	
130-34	26126-26127	=	_	
130-35	26128-26129	−	_	
130-36	26129-26133	3.76	_	
130-37	26133-26134	,	_	
130-38	26135-26136	p	_	
130-39	26137-26138	<	_	
130-40	26139-26143	.001	_	
130-41	26143-26144	;	_	
130-42	26145-26150	Table	_	
130-43	26151-26154	VII	_	
130-44	26154-26155	)	_	
130-45	26155-26156	.	_	

#Text=Post-hoc probing of the moderation revealed that this association was significantly stronger for unknown infants (βunknown = .61, 95% CI = .51 to .70, z = 12.47, p < .001) than for own infants (βown = .28, 95% CI = .13 to .42, z = 3.71, p < .001).
131-1	26157-26165	Post-hoc	_	
131-2	26166-26173	probing	_	
131-3	26174-26176	of	_	
131-4	26177-26180	the	_	
131-5	26181-26191	moderation	_	
131-6	26192-26200	revealed	_	
131-7	26201-26205	that	_	
131-8	26206-26210	this	_	
131-9	26211-26222	association	_	
131-10	26223-26226	was	_	
131-11	26227-26240	significantly	_	
131-12	26241-26249	stronger	_	
131-13	26250-26253	for	_	
131-14	26254-26261	unknown	_	
131-15	26262-26269	infants	_	
131-16	26270-26271	(	_	
131-17	26271-26279	βunknown	_	
131-18	26280-26281	=	_	
131-19	26282-26285	.61	_	
131-20	26285-26286	,	_	
131-21	26287-26290	95%	_	
131-22	26291-26293	CI	_	
131-23	26294-26295	=	_	
131-24	26296-26299	.51	_	
131-25	26300-26302	to	_	
131-26	26303-26306	.70	_	
131-27	26306-26307	,	_	
131-28	26308-26309	z	_	
131-29	26310-26311	=	_	
131-30	26312-26317	12.47	_	
131-31	26317-26318	,	_	
131-32	26319-26320	p	_	
131-33	26321-26322	<	_	
131-34	26323-26327	.001	_	
131-35	26327-26328	)	_	
131-36	26329-26333	than	_	
131-37	26334-26337	for	_	
131-38	26338-26341	own	_	
131-39	26342-26349	infants	_	
131-40	26350-26351	(	_	
131-41	26351-26355	βown	_	
131-42	26356-26357	=	_	
131-43	26358-26361	.28	_	
131-44	26361-26362	,	_	
131-45	26363-26366	95%	_	
131-46	26367-26369	CI	_	
131-47	26370-26371	=	_	
131-48	26372-26375	.13	_	
131-49	26376-26378	to	_	
131-50	26379-26382	.42	_	
131-51	26382-26383	,	_	
131-52	26384-26385	z	_	
131-53	26386-26387	=	_	
131-54	26388-26392	3.71	_	
131-55	26392-26393	,	_	
131-56	26394-26395	p	_	
131-57	26396-26397	<	_	
131-58	26398-26402	.001	_	
131-59	26402-26403	)	_	
131-60	26403-26404	.	_	

#Text=This indicated that mothers’ self-reported positive affect increased more closely in line with their perceived increase in an unknown infant’s positive affect than that of their own infant.
132-1	26405-26409	This	_	
132-2	26410-26419	indicated	_	
132-3	26420-26424	that	_	
132-4	26425-26432	mothers	_	
132-5	26432-26433	’	_	
132-6	26434-26447	self-reported	_	
132-7	26448-26456	positive	_	
132-8	26457-26463	affect	_	
132-9	26464-26473	increased	_	
132-10	26474-26478	more	_	
132-11	26479-26486	closely	_	
132-12	26487-26489	in	_	
132-13	26490-26494	line	_	
132-14	26495-26499	with	_	
132-15	26500-26505	their	_	
132-16	26506-26515	perceived	_	
132-17	26516-26524	increase	_	
132-18	26525-26527	in	_	
132-19	26528-26530	an	_	
132-20	26531-26538	unknown	_	
132-21	26539-26545	infant	_	
132-22	26545-26546	’	_	
132-23	26546-26547	s	_	
132-24	26548-26556	positive	_	
132-25	26557-26563	affect	_	
132-26	26564-26568	than	_	
132-27	26569-26573	that	_	
132-28	26574-26576	of	_	
132-29	26577-26582	their	_	
132-30	26583-26586	own	_	
132-31	26587-26593	infant	_	
132-32	26593-26594	.	_	

#Text=In other words, mothers’ own report of happiness increased to a greater degree when perceiving increased happiness in an unknown infant rather than in their own infant.
133-1	26595-26597	In	_	
133-2	26598-26603	other	_	
133-3	26604-26609	words	_	
133-4	26609-26610	,	_	
133-5	26611-26618	mothers	_	
133-6	26618-26619	’	_	
133-7	26620-26623	own	_	
133-8	26624-26630	report	_	
133-9	26631-26633	of	_	
133-10	26634-26643	happiness	_	
133-11	26644-26653	increased	_	
133-12	26654-26656	to	_	
133-13	26657-26658	a	_	
133-14	26659-26666	greater	_	
133-15	26667-26673	degree	_	
133-16	26674-26678	when	_	
133-17	26679-26689	perceiving	_	
133-18	26690-26699	increased	_	
133-19	26700-26709	happiness	_	
133-20	26710-26712	in	_	
133-21	26713-26715	an	_	
133-22	26716-26723	unknown	_	
133-23	26724-26730	infant	_	
133-24	26731-26737	rather	_	
133-25	26738-26742	than	_	
133-26	26743-26745	in	_	
133-27	26746-26751	their	_	
133-28	26752-26755	own	_	
133-29	26756-26762	infant	_	
133-30	26762-26763	.	_	

#Text=Sad faces
#Text=Consistent with the ratings for happy faces, mothers with addictions reported perceiving their own infants’ sad faces as sadder and more distressed than those of unknown infants (sad: βidentity = .64, 95% CI = .37 to .90, z = 4.72, p < .001; distressed: βidentity = .61, 95% CI = .33 to .89, z = 4.26, p < .001; Table VI).
134-1	26764-26767	Sad	_	
134-2	26768-26773	faces	_	
134-3	26774-26784	Consistent	_	
134-4	26785-26789	with	_	
134-5	26790-26793	the	_	
134-6	26794-26801	ratings	_	
134-7	26802-26805	for	_	
134-8	26806-26811	happy	_	
134-9	26812-26817	faces	_	
134-10	26817-26818	,	_	
134-11	26819-26826	mothers	_	
134-12	26827-26831	with	_	
134-13	26832-26842	addictions	_	
134-14	26843-26851	reported	_	
134-15	26852-26862	perceiving	_	
134-16	26863-26868	their	_	
134-17	26869-26872	own	_	
134-18	26873-26880	infants	_	
134-19	26880-26881	’	_	
134-20	26882-26885	sad	_	
134-21	26886-26891	faces	_	
134-22	26892-26894	as	_	
134-23	26895-26901	sadder	_	
134-24	26902-26905	and	_	
134-25	26906-26910	more	_	
134-26	26911-26921	distressed	_	
134-27	26922-26926	than	_	
134-28	26927-26932	those	_	
134-29	26933-26935	of	_	
134-30	26936-26943	unknown	_	
134-31	26944-26951	infants	_	
134-32	26952-26953	(	_	
134-33	26953-26956	sad	_	
134-34	26956-26957	:	_	
134-35	26958-26967	βidentity	_	
134-36	26968-26969	=	_	
134-37	26970-26973	.64	_	
134-38	26973-26974	,	_	
134-39	26975-26978	95%	_	
134-40	26979-26981	CI	_	
134-41	26982-26983	=	_	
134-42	26984-26987	.37	_	
134-43	26988-26990	to	_	
134-44	26991-26994	.90	_	
134-45	26994-26995	,	_	
134-46	26996-26997	z	_	
134-47	26998-26999	=	_	
134-48	27000-27004	4.72	_	
134-49	27004-27005	,	_	
134-50	27006-27007	p	_	
134-51	27008-27009	<	_	
134-52	27010-27014	.001	_	
134-53	27014-27015	;	_	
134-54	27016-27026	distressed	_	
134-55	27026-27027	:	_	
134-56	27028-27037	βidentity	_	
134-57	27038-27039	=	_	
134-58	27040-27043	.61	_	
134-59	27043-27044	,	_	
134-60	27045-27048	95%	_	
134-61	27049-27051	CI	_	
134-62	27052-27053	=	_	
134-63	27054-27057	.33	_	
134-64	27058-27060	to	_	
134-65	27061-27064	.89	_	
134-66	27064-27065	,	_	
134-67	27066-27067	z	_	
134-68	27068-27069	=	_	
134-69	27070-27074	4.26	_	
134-70	27074-27075	,	_	
134-71	27076-27077	p	_	
134-72	27078-27079	<	_	
134-73	27080-27084	.001	_	
134-74	27084-27085	;	_	
134-75	27086-27091	Table	_	
134-76	27092-27094	VI	_	
134-77	27094-27095	)	_	
134-78	27095-27096	.	_	

#Text=Mothers’ self-reported negative affect was also stronger in response to their own infants compared to unknown infants (sad: βidentity = 2.21, 95% CI = 1.90 to 2.52, z = 13.95, p < .001; distressed: βidentity = 1.99, 95% CI = 1.68 to 2.30, z = 12.59, p < .001; Table VI).
135-1	27097-27104	Mothers	_	
135-2	27104-27105	’	_	
135-3	27106-27119	self-reported	_	
135-4	27120-27128	negative	_	
135-5	27129-27135	affect	_	
135-6	27136-27139	was	_	
135-7	27140-27144	also	_	
135-8	27145-27153	stronger	_	
135-9	27154-27156	in	_	
135-10	27157-27165	response	_	
135-11	27166-27168	to	_	
135-12	27169-27174	their	_	
135-13	27175-27178	own	_	
135-14	27179-27186	infants	_	
135-15	27187-27195	compared	_	
135-16	27196-27198	to	_	
135-17	27199-27206	unknown	_	
135-18	27207-27214	infants	_	
135-19	27215-27216	(	_	
135-20	27216-27219	sad	_	
135-21	27219-27220	:	_	
135-22	27221-27230	βidentity	_	
135-23	27231-27232	=	_	
135-24	27233-27237	2.21	_	
135-25	27237-27238	,	_	
135-26	27239-27242	95%	_	
135-27	27243-27245	CI	_	
135-28	27246-27247	=	_	
135-29	27248-27252	1.90	_	
135-30	27253-27255	to	_	
135-31	27256-27260	2.52	_	
135-32	27260-27261	,	_	
135-33	27262-27263	z	_	
135-34	27264-27265	=	_	
135-35	27266-27271	13.95	_	
135-36	27271-27272	,	_	
135-37	27273-27274	p	_	
135-38	27275-27276	<	_	
135-39	27277-27281	.001	_	
135-40	27281-27282	;	_	
135-41	27283-27293	distressed	_	
135-42	27293-27294	:	_	
135-43	27295-27304	βidentity	_	
135-44	27305-27306	=	_	
135-45	27307-27311	1.99	_	
135-46	27311-27312	,	_	
135-47	27313-27316	95%	_	
135-48	27317-27319	CI	_	
135-49	27320-27321	=	_	
135-50	27322-27326	1.68	_	
135-51	27327-27329	to	_	
135-52	27330-27334	2.30	_	
135-53	27334-27335	,	_	
135-54	27336-27337	z	_	
135-55	27338-27339	=	_	
135-56	27340-27345	12.59	_	
135-57	27345-27346	,	_	
135-58	27347-27348	p	_	
135-59	27349-27350	<	_	
135-60	27351-27355	.001	_	
135-61	27355-27356	;	_	
135-62	27357-27362	Table	_	
135-63	27363-27365	VI	_	
135-64	27365-27366	)	_	
135-65	27366-27367	.	_	

#Text=Mothers’ own report of negative affect correlated significantly with how sad and distressed they perceived infants to be feeling (sad: βinfant affect = .62, 95% CI = .52 to .71, z = 12.69, p < .001; distressed: βinfant affect = .56, 95% CI = .47 to .65, z = 12.04, p < .001; Table VII).
136-1	27368-27375	Mothers	_	
136-2	27375-27376	’	_	
136-3	27377-27380	own	_	
136-4	27381-27387	report	_	
136-5	27388-27390	of	_	
136-6	27391-27399	negative	_	
136-7	27400-27406	affect	_	
136-8	27407-27417	correlated	_	
136-9	27418-27431	significantly	_	
136-10	27432-27436	with	_	
136-11	27437-27440	how	_	
136-12	27441-27444	sad	_	
136-13	27445-27448	and	_	
136-14	27449-27459	distressed	_	
136-15	27460-27464	they	_	
136-16	27465-27474	perceived	_	
136-17	27475-27482	infants	_	
136-18	27483-27485	to	_	
136-19	27486-27488	be	_	
136-20	27489-27496	feeling	_	
136-21	27497-27498	(	_	
136-22	27498-27501	sad	_	
136-23	27501-27502	:	_	
136-24	27503-27510	βinfant	_	
136-25	27511-27517	affect	_	
136-26	27518-27519	=	_	
136-27	27520-27523	.62	_	
136-28	27523-27524	,	_	
136-29	27525-27528	95%	_	
136-30	27529-27531	CI	_	
136-31	27532-27533	=	_	
136-32	27534-27537	.52	_	
136-33	27538-27540	to	_	
136-34	27541-27544	.71	_	
136-35	27544-27545	,	_	
136-36	27546-27547	z	_	
136-37	27548-27549	=	_	
136-38	27550-27555	12.69	_	
136-39	27555-27556	,	_	
136-40	27557-27558	p	_	
136-41	27559-27560	<	_	
136-42	27561-27565	.001	_	
136-43	27565-27566	;	_	
136-44	27567-27577	distressed	_	
136-45	27577-27578	:	_	
136-46	27579-27586	βinfant	_	
136-47	27587-27593	affect	_	
136-48	27594-27595	=	_	
136-49	27596-27599	.56	_	
136-50	27599-27600	,	_	
136-51	27601-27604	95%	_	
136-52	27605-27607	CI	_	
136-53	27608-27609	=	_	
136-54	27610-27613	.47	_	
136-55	27614-27616	to	_	
136-56	27617-27620	.65	_	
136-57	27620-27621	,	_	
136-58	27622-27623	z	_	
136-59	27624-27625	=	_	
136-60	27626-27631	12.04	_	
136-61	27631-27632	,	_	
136-62	27633-27634	p	_	
136-63	27635-27636	<	_	
136-64	27637-27641	.001	_	
136-65	27641-27642	;	_	
136-66	27643-27648	Table	_	
136-67	27649-27652	VII	_	
136-68	27652-27653	)	_	
136-69	27653-27654	.	_	

#Text=The strength of this association varied as a function of infant identity (sad: βidentity x infant affect = .23, 95% CI = .10 to .37, z = 3.43, p < .001; distressed: βidentity x infant affect = .27, 95% CI = .14 to .39, z = 4.15, p < .001).
137-1	27655-27658	The	_	
137-2	27659-27667	strength	_	
137-3	27668-27670	of	_	
137-4	27671-27675	this	_	
137-5	27676-27687	association	_	
137-6	27688-27694	varied	_	
137-7	27695-27697	as	_	
137-8	27698-27699	a	_	
137-9	27700-27708	function	_	
137-10	27709-27711	of	_	
137-11	27712-27718	infant	_	
137-12	27719-27727	identity	_	
137-13	27728-27729	(	_	
137-14	27729-27732	sad	_	
137-15	27732-27733	:	_	
137-16	27734-27743	βidentity	_	
137-17	27744-27745	x	_	
137-18	27746-27752	infant	_	
137-19	27753-27759	affect	_	
137-20	27760-27761	=	_	
137-21	27762-27765	.23	_	
137-22	27765-27766	,	_	
137-23	27767-27770	95%	_	
137-24	27771-27773	CI	_	
137-25	27774-27775	=	_	
137-26	27776-27779	.10	_	
137-27	27780-27782	to	_	
137-28	27783-27786	.37	_	
137-29	27786-27787	,	_	
137-30	27788-27789	z	_	
137-31	27790-27791	=	_	
137-32	27792-27796	3.43	_	
137-33	27796-27797	,	_	
137-34	27798-27799	p	_	
137-35	27800-27801	<	_	
137-36	27802-27806	.001	_	
137-37	27806-27807	;	_	
137-38	27808-27818	distressed	_	
137-39	27818-27819	:	_	
137-40	27820-27829	βidentity	_	
137-41	27830-27831	x	_	
137-42	27832-27838	infant	_	
137-43	27839-27845	affect	_	
137-44	27846-27847	=	_	
137-45	27848-27851	.27	_	
137-46	27851-27852	,	_	
137-47	27853-27856	95%	_	
137-48	27857-27859	CI	_	
137-49	27860-27861	=	_	
137-50	27862-27865	.14	_	
137-51	27866-27868	to	_	
137-52	27869-27872	.39	_	
137-53	27872-27873	,	_	
137-54	27874-27875	z	_	
137-55	27876-27877	=	_	
137-56	27878-27882	4.15	_	
137-57	27882-27883	,	_	
137-58	27884-27885	p	_	
137-59	27886-27887	<	_	
137-60	27888-27892	.001	_	
137-61	27892-27893	)	_	
137-62	27893-27894	.	_	

#Text=However, in contrast to the ratings for happy faces, post-hoc probing of the moderation revealed that mothers’ self-reported negative affect increased more closely in line with their perceived increase in their own infant’s negative affect (sad: βown = .85, 95% CI = .74 to .96, z = 15.40, p < .001; distressed: βown = .82, 95% CI = .72 to .93, z = 15.66, p < .001) rather than that of an unknown infant (sad: βunknown = .62, 95% CI = .52 to .71, z = 12.69, p < .001; distressed: βunknown = .56, 95% CI = .47 to .65, z = 12.04, p < .001).
138-1	27895-27902	However	_	
138-2	27902-27903	,	_	
138-3	27904-27906	in	_	
138-4	27907-27915	contrast	_	
138-5	27916-27918	to	_	
138-6	27919-27922	the	_	
138-7	27923-27930	ratings	_	
138-8	27931-27934	for	_	
138-9	27935-27940	happy	_	
138-10	27941-27946	faces	_	
138-11	27946-27947	,	_	
138-12	27948-27956	post-hoc	_	
138-13	27957-27964	probing	_	
138-14	27965-27967	of	_	
138-15	27968-27971	the	_	
138-16	27972-27982	moderation	_	
138-17	27983-27991	revealed	_	
138-18	27992-27996	that	_	
138-19	27997-28004	mothers	_	
138-20	28004-28005	’	_	
138-21	28006-28019	self-reported	_	
138-22	28020-28028	negative	_	
138-23	28029-28035	affect	_	
138-24	28036-28045	increased	_	
138-25	28046-28050	more	_	
138-26	28051-28058	closely	_	
138-27	28059-28061	in	_	
138-28	28062-28066	line	_	
138-29	28067-28071	with	_	
138-30	28072-28077	their	_	
138-31	28078-28087	perceived	_	
138-32	28088-28096	increase	_	
138-33	28097-28099	in	_	
138-34	28100-28105	their	_	
138-35	28106-28109	own	_	
138-36	28110-28116	infant	_	
138-37	28116-28117	’	_	
138-38	28117-28118	s	_	
138-39	28119-28127	negative	_	
138-40	28128-28134	affect	_	
138-41	28135-28136	(	_	
138-42	28136-28139	sad	_	
138-43	28139-28140	:	_	
138-44	28141-28145	βown	_	
138-45	28146-28147	=	_	
138-46	28148-28151	.85	_	
138-47	28151-28152	,	_	
138-48	28153-28156	95%	_	
138-49	28157-28159	CI	_	
138-50	28160-28161	=	_	
138-51	28162-28165	.74	_	
138-52	28166-28168	to	_	
138-53	28169-28172	.96	_	
138-54	28172-28173	,	_	
138-55	28174-28175	z	_	
138-56	28176-28177	=	_	
138-57	28178-28183	15.40	_	
138-58	28183-28184	,	_	
138-59	28185-28186	p	_	
138-60	28187-28188	<	_	
138-61	28189-28193	.001	_	
138-62	28193-28194	;	_	
138-63	28195-28205	distressed	_	
138-64	28205-28206	:	_	
138-65	28207-28211	βown	_	
138-66	28212-28213	=	_	
138-67	28214-28217	.82	_	
138-68	28217-28218	,	_	
138-69	28219-28222	95%	_	
138-70	28223-28225	CI	_	
138-71	28226-28227	=	_	
138-72	28228-28231	.72	_	
138-73	28232-28234	to	_	
138-74	28235-28238	.93	_	
138-75	28238-28239	,	_	
138-76	28240-28241	z	_	
138-77	28242-28243	=	_	
138-78	28244-28249	15.66	_	
138-79	28249-28250	,	_	
138-80	28251-28252	p	_	
138-81	28253-28254	<	_	
138-82	28255-28259	.001	_	
138-83	28259-28260	)	_	
138-84	28261-28267	rather	_	
138-85	28268-28272	than	_	
138-86	28273-28277	that	_	
138-87	28278-28280	of	_	
138-88	28281-28283	an	_	
138-89	28284-28291	unknown	_	
138-90	28292-28298	infant	_	
138-91	28299-28300	(	_	
138-92	28300-28303	sad	_	
138-93	28303-28304	:	_	
138-94	28305-28313	βunknown	_	
138-95	28314-28315	=	_	
138-96	28316-28319	.62	_	
138-97	28319-28320	,	_	
138-98	28321-28324	95%	_	
138-99	28325-28327	CI	_	
138-100	28328-28329	=	_	
138-101	28330-28333	.52	_	
138-102	28334-28336	to	_	
138-103	28337-28340	.71	_	
138-104	28340-28341	,	_	
138-105	28342-28343	z	_	
138-106	28344-28345	=	_	
138-107	28346-28351	12.69	_	
138-108	28351-28352	,	_	
138-109	28353-28354	p	_	
138-110	28355-28356	<	_	
138-111	28357-28361	.001	_	
138-112	28361-28362	;	_	
138-113	28363-28373	distressed	_	
138-114	28373-28374	:	_	
138-115	28375-28383	βunknown	_	
138-116	28384-28385	=	_	
138-117	28386-28389	.56	_	
138-118	28389-28390	,	_	
138-119	28391-28394	95%	_	
138-120	28395-28397	CI	_	
138-121	28398-28399	=	_	
138-122	28400-28403	.47	_	
138-123	28404-28406	to	_	
138-124	28407-28410	.65	_	
138-125	28410-28411	,	_	
138-126	28412-28413	z	_	
138-127	28414-28415	=	_	
138-128	28416-28421	12.04	_	
138-129	28421-28422	,	_	
138-130	28423-28424	p	_	
138-131	28425-28426	<	_	
138-132	28427-28431	.001	_	
138-133	28431-28432	)	_	
138-134	28432-28433	.	_	

#Text=In other words, mothers’ own report of sadness and distress increased to a greater extent when perceiving an increase in sadness and distress in their own infant rather than in an unknown infant.
139-1	28434-28436	In	_	
139-2	28437-28442	other	_	
139-3	28443-28448	words	_	
139-4	28448-28449	,	_	
139-5	28450-28457	mothers	_	
139-6	28457-28458	’	_	
139-7	28459-28462	own	_	
139-8	28463-28469	report	_	
139-9	28470-28472	of	_	
139-10	28473-28480	sadness	_	
139-11	28481-28484	and	_	
139-12	28485-28493	distress	_	
139-13	28494-28503	increased	_	
139-14	28504-28506	to	_	
139-15	28507-28508	a	_	
139-16	28509-28516	greater	_	
139-17	28517-28523	extent	_	
139-18	28524-28528	when	_	
139-19	28529-28539	perceiving	_	
139-20	28540-28542	an	_	
139-21	28543-28551	increase	_	
139-22	28552-28554	in	_	
139-23	28555-28562	sadness	_	
139-24	28563-28566	and	_	
139-25	28567-28575	distress	_	
139-26	28576-28578	in	_	
139-27	28579-28584	their	_	
139-28	28585-28588	own	_	
139-29	28589-28595	infant	_	
139-30	28596-28602	rather	_	
139-31	28603-28607	than	_	
139-32	28608-28610	in	_	
139-33	28611-28613	an	_	
139-34	28614-28621	unknown	_	
139-35	28622-28628	infant	_	
139-36	28628-28629	.	_	

#Text=Discussion
#Text=When mothers are involved in substance addiction, the repercussions extend to their children.
140-1	28630-28640	Discussion	_	
140-2	28641-28645	When	_	
140-3	28646-28653	mothers	_	
140-4	28654-28657	are	_	
140-5	28658-28666	involved	_	
140-6	28667-28669	in	_	
140-7	28670-28679	substance	_	
140-8	28680-28689	addiction	_	
140-9	28689-28690	,	_	
140-10	28691-28694	the	_	
140-11	28695-28708	repercussions	_	
140-12	28709-28715	extend	_	
140-13	28716-28718	to	_	
140-14	28719-28724	their	_	
140-15	28725-28733	children	_	
140-16	28733-28734	.	_	

#Text=Until now, little work has elucidated the underlying neurobiology of this phenomenon.
141-1	28735-28740	Until	_	
141-2	28741-28744	now	_	
141-3	28744-28745	,	_	
141-4	28746-28752	little	_	
141-5	28753-28757	work	_	
141-6	28758-28761	has	_	
141-7	28762-28772	elucidated	_	
141-8	28773-28776	the	_	
141-9	28777-28787	underlying	_	
141-10	28788-28800	neurobiology	_	
141-11	28801-28803	of	_	
141-12	28804-28808	this	_	
141-13	28809-28819	phenomenon	_	
141-14	28819-28820	.	_	

#Text=Our results are the first, to our knowledge, to show that mothers with addictions demonstrate reduced hypothalamic and mesocorticolimbic responses to reward-related cues from their own infants.
142-1	28821-28824	Our	_	
142-2	28825-28832	results	_	
142-3	28833-28836	are	_	
142-4	28837-28840	the	_	
142-5	28841-28846	first	_	
142-6	28846-28847	,	_	
142-7	28848-28850	to	_	
142-8	28851-28854	our	_	
142-9	28855-28864	knowledge	_	
142-10	28864-28865	,	_	
142-11	28866-28868	to	_	
142-12	28869-28873	show	_	
142-13	28874-28878	that	_	
142-14	28879-28886	mothers	_	
142-15	28887-28891	with	_	
142-16	28892-28902	addictions	_	
142-17	28903-28914	demonstrate	_	
142-18	28915-28922	reduced	_	
142-19	28923-28935	hypothalamic	_	
142-20	28936-28939	and	_	
142-21	28940-28957	mesocorticolimbic	_	
142-22	28958-28967	responses	_	
142-23	28968-28970	to	_	
142-24	28971-28985	reward-related	_	
142-25	28986-28990	cues	_	
142-26	28991-28995	from	_	
142-27	28996-29001	their	_	
142-28	29002-29005	own	_	
142-29	29006-29013	infants	_	
142-30	29013-29014	.	_	

#Text=When viewing smiling face images of their own infants as compared to unknown infants, these mothers showed a striking pattern of decreased activation in key OT- and DA-innervated brain regions, including the hypothalamus, VS, and mPFC.
143-1	29015-29019	When	_	
143-2	29020-29027	viewing	_	
143-3	29028-29035	smiling	_	
143-4	29036-29040	face	_	
143-5	29041-29047	images	_	
143-6	29048-29050	of	_	
143-7	29051-29056	their	_	
143-8	29057-29060	own	_	
143-9	29061-29068	infants	_	
143-10	29069-29071	as	_	
143-11	29072-29080	compared	_	
143-12	29081-29083	to	_	
143-13	29084-29091	unknown	_	
143-14	29092-29099	infants	_	
143-15	29099-29100	,	_	
143-16	29101-29106	these	_	
143-17	29107-29114	mothers	_	
143-18	29115-29121	showed	_	
143-19	29122-29123	a	_	
143-20	29124-29132	striking	_	
143-21	29133-29140	pattern	_	
143-22	29141-29143	of	_	
143-23	29144-29153	decreased	_	
143-24	29154-29164	activation	_	
143-25	29165-29167	in	_	
143-26	29168-29171	key	_	
143-27	29172-29174	OT	_	
143-28	29174-29175	-	_	
143-29	29176-29179	and	_	
143-30	29180-29193	DA-innervated	_	
143-31	29194-29199	brain	_	
143-32	29200-29207	regions	_	
143-33	29207-29208	,	_	
143-34	29209-29218	including	_	
143-35	29219-29222	the	_	
143-36	29223-29235	hypothalamus	_	
143-37	29235-29236	,	_	
143-38	29237-29239	VS	_	
143-39	29239-29240	,	_	
143-40	29241-29244	and	_	
143-41	29245-29249	mPFC	_	
143-42	29249-29250	.	_	

#Text=Notably, in mothers without addictions, prior research has indicated a robust pattern of activation in these regions (; see Figure 5).
144-1	29251-29258	Notably	_	
144-2	29258-29259	,	_	
144-3	29260-29262	in	_	
144-4	29263-29270	mothers	_	
144-5	29271-29278	without	_	
144-6	29279-29289	addictions	_	
144-7	29289-29290	,	_	
144-8	29291-29296	prior	_	
144-9	29297-29305	research	_	
144-10	29306-29309	has	_	
144-11	29310-29319	indicated	_	
144-12	29320-29321	a	_	
144-13	29322-29328	robust	_	
144-14	29329-29336	pattern	_	
144-15	29337-29339	of	_	
144-16	29340-29350	activation	_	
144-17	29351-29353	in	_	
144-18	29354-29359	these	_	
144-19	29360-29367	regions	_	
144-20	29368-29369	(	_	
144-21	29369-29370	;	_	
144-22	29371-29374	see	_	
144-23	29375-29381	Figure	_	
144-24	29382-29383	5	_	
144-25	29383-29384	)	_	
144-26	29384-29385	.	_	

#Text=As expected, in mothers with addictions, these compromised hypothalamic and mesocorticolimbic activations were seen in response to happy, but not sad, faces of their own infants.
145-1	29386-29388	As	_	
145-2	29389-29397	expected	_	
145-3	29397-29398	,	_	
145-4	29399-29401	in	_	
145-5	29402-29409	mothers	_	
145-6	29410-29414	with	_	
145-7	29415-29425	addictions	_	
145-8	29425-29426	,	_	
145-9	29427-29432	these	_	
145-10	29433-29444	compromised	_	
145-11	29445-29457	hypothalamic	_	
145-12	29458-29461	and	_	
145-13	29462-29479	mesocorticolimbic	_	
145-14	29480-29491	activations	_	
145-15	29492-29496	were	_	
145-16	29497-29501	seen	_	
145-17	29502-29504	in	_	
145-18	29505-29513	response	_	
145-19	29514-29516	to	_	
145-20	29517-29522	happy	_	
145-21	29522-29523	,	_	
145-22	29524-29527	but	_	
145-23	29528-29531	not	_	
145-24	29532-29535	sad	_	
145-25	29535-29536	,	_	
145-26	29537-29542	faces	_	
145-27	29543-29545	of	_	
145-28	29546-29551	their	_	
145-29	29552-29555	own	_	
145-30	29556-29563	infants	_	
145-31	29563-29564	.	_	

#Text=Sad faces of own infants instead elicited a decreased activation in a small region of the right IPL and STG in these mothers.
146-1	29565-29568	Sad	_	
146-2	29569-29574	faces	_	
146-3	29575-29577	of	_	
146-4	29578-29581	own	_	
146-5	29582-29589	infants	_	
146-6	29590-29597	instead	_	
146-7	29598-29606	elicited	_	
146-8	29607-29608	a	_	
146-9	29609-29618	decreased	_	
146-10	29619-29629	activation	_	
146-11	29630-29632	in	_	
146-12	29633-29634	a	_	
146-13	29635-29640	small	_	
146-14	29641-29647	region	_	
146-15	29648-29650	of	_	
146-16	29651-29654	the	_	
146-17	29655-29660	right	_	
146-18	29661-29664	IPL	_	
146-19	29665-29668	and	_	
146-20	29669-29672	STG	_	
146-21	29673-29675	in	_	
146-22	29676-29681	these	_	
146-23	29682-29689	mothers	_	
146-24	29689-29690	.	_	

#Text=These regions form part of the neural network subserving social cognition/empathy, support maternal responsiveness to an array of affectively nuanced expressions from infants, and show increased activation in response to own compared to unknown, and sad compared to happy, infant cues in mothers without addictions.
147-1	29691-29696	These	_	
147-2	29697-29704	regions	_	
147-3	29705-29709	form	_	
147-4	29710-29714	part	_	
147-5	29715-29717	of	_	
147-6	29718-29721	the	_	
147-7	29722-29728	neural	_	
147-8	29729-29736	network	_	
147-9	29737-29747	subserving	_	
147-10	29748-29754	social	_	
147-11	29755-29764	cognition	_	
147-12	29764-29765	/	_	
147-13	29765-29772	empathy	_	
147-14	29772-29773	,	_	
147-15	29774-29781	support	_	
147-16	29782-29790	maternal	_	
147-17	29791-29805	responsiveness	_	
147-18	29806-29808	to	_	
147-19	29809-29811	an	_	
147-20	29812-29817	array	_	
147-21	29818-29820	of	_	
147-22	29821-29832	affectively	_	
147-23	29833-29840	nuanced	_	
147-24	29841-29852	expressions	_	
147-25	29853-29857	from	_	
147-26	29858-29865	infants	_	
147-27	29865-29866	,	_	
147-28	29867-29870	and	_	
147-29	29871-29875	show	_	
147-30	29876-29885	increased	_	
147-31	29886-29896	activation	_	
147-32	29897-29899	in	_	
147-33	29900-29908	response	_	
147-34	29909-29911	to	_	
147-35	29912-29915	own	_	
147-36	29916-29924	compared	_	
147-37	29925-29927	to	_	
147-38	29928-29935	unknown	_	
147-39	29935-29936	,	_	
147-40	29937-29940	and	_	
147-41	29941-29944	sad	_	
147-42	29945-29953	compared	_	
147-43	29954-29956	to	_	
147-44	29957-29962	happy	_	
147-45	29962-29963	,	_	
147-46	29964-29970	infant	_	
147-47	29971-29975	cues	_	
147-48	29976-29978	in	_	
147-49	29979-29986	mothers	_	
147-50	29987-29994	without	_	
147-51	29995-30005	addictions	_	
147-52	30005-30006	.	_	

#Text=The dysregulated maternal response of mothers with addictions was also evident in their behavioral ratings, which demonstrated that their positive affect tracked more closely with how positive they perceived unknown infants to be feeling compared to their own infants.
148-1	30007-30010	The	_	
148-2	30011-30023	dysregulated	_	
148-3	30024-30032	maternal	_	
148-4	30033-30041	response	_	
148-5	30042-30044	of	_	
148-6	30045-30052	mothers	_	
148-7	30053-30057	with	_	
148-8	30058-30068	addictions	_	
148-9	30069-30072	was	_	
148-10	30073-30077	also	_	
148-11	30078-30085	evident	_	
148-12	30086-30088	in	_	
148-13	30089-30094	their	_	
148-14	30095-30105	behavioral	_	
148-15	30106-30113	ratings	_	
148-16	30113-30114	,	_	
148-17	30115-30120	which	_	
148-18	30121-30133	demonstrated	_	
148-19	30134-30138	that	_	
148-20	30139-30144	their	_	
148-21	30145-30153	positive	_	
148-22	30154-30160	affect	_	
148-23	30161-30168	tracked	_	
148-24	30169-30173	more	_	
148-25	30174-30181	closely	_	
148-26	30182-30186	with	_	
148-27	30187-30190	how	_	
148-28	30191-30199	positive	_	
148-29	30200-30204	they	_	
148-30	30205-30214	perceived	_	
148-31	30215-30222	unknown	_	
148-32	30223-30230	infants	_	
148-33	30231-30233	to	_	
148-34	30234-30236	be	_	
148-35	30237-30244	feeling	_	
148-36	30245-30253	compared	_	
148-37	30254-30256	to	_	
148-38	30257-30262	their	_	
148-39	30263-30266	own	_	
148-40	30267-30274	infants	_	
148-41	30274-30275	.	_	

#Text=Of note, this pattern of dysregulation emerged only for happy, but not sad, faces, indicating that reward-related dysregulations may be particularly relevant for mothers with addictions, manifesting especially in reward-related attachment contexts.
149-1	30276-30278	Of	_	
149-2	30279-30283	note	_	
149-3	30283-30284	,	_	
149-4	30285-30289	this	_	
149-5	30290-30297	pattern	_	
149-6	30298-30300	of	_	
149-7	30301-30314	dysregulation	_	
149-8	30315-30322	emerged	_	
149-9	30323-30327	only	_	
149-10	30328-30331	for	_	
149-11	30332-30337	happy	_	
149-12	30337-30338	,	_	
149-13	30339-30342	but	_	
149-14	30343-30346	not	_	
149-15	30347-30350	sad	_	
149-16	30350-30351	,	_	
149-17	30352-30357	faces	_	
149-18	30357-30358	,	_	
149-19	30359-30369	indicating	_	
149-20	30370-30374	that	_	
149-21	30375-30389	reward-related	_	
149-22	30390-30404	dysregulations	_	
149-23	30405-30408	may	_	
149-24	30409-30411	be	_	
149-25	30412-30424	particularly	_	
149-26	30425-30433	relevant	_	
149-27	30434-30437	for	_	
149-28	30438-30445	mothers	_	
149-29	30446-30450	with	_	
149-30	30451-30461	addictions	_	
149-31	30461-30462	,	_	
149-32	30463-30474	manifesting	_	
149-33	30475-30485	especially	_	
149-34	30486-30488	in	_	
149-35	30489-30503	reward-related	_	
149-36	30504-30514	attachment	_	
149-37	30515-30523	contexts	_	
149-38	30523-30524	.	_	

#Text=Our findings are consistent with the literature from the general population that has underscored the role of diminished salience of natural rewards in addictions, while demonstrating for the first time in human mothers how such disruptions may undermine a critical aspect of their responsiveness to their infants.
150-1	30525-30528	Our	_	
150-2	30529-30537	findings	_	
150-3	30538-30541	are	_	
150-4	30542-30552	consistent	_	
150-5	30553-30557	with	_	
150-6	30558-30561	the	_	
150-7	30562-30572	literature	_	
150-8	30573-30577	from	_	
150-9	30578-30581	the	_	
150-10	30582-30589	general	_	
150-11	30590-30600	population	_	
150-12	30601-30605	that	_	
150-13	30606-30609	has	_	
150-14	30610-30621	underscored	_	
150-15	30622-30625	the	_	
150-16	30626-30630	role	_	
150-17	30631-30633	of	_	
150-18	30634-30644	diminished	_	
150-19	30645-30653	salience	_	
150-20	30654-30656	of	_	
150-21	30657-30664	natural	_	
150-22	30665-30672	rewards	_	
150-23	30673-30675	in	_	
150-24	30676-30686	addictions	_	
150-25	30686-30687	,	_	
150-26	30688-30693	while	_	
150-27	30694-30707	demonstrating	_	
150-28	30708-30711	for	_	
150-29	30712-30715	the	_	
150-30	30716-30721	first	_	
150-31	30722-30726	time	_	
150-32	30727-30729	in	_	
150-33	30730-30735	human	_	
150-34	30736-30743	mothers	_	
150-35	30744-30747	how	_	
150-36	30748-30752	such	_	
150-37	30753-30764	disruptions	_	
150-38	30765-30768	may	_	
150-39	30769-30778	undermine	_	
150-40	30779-30780	a	_	
150-41	30781-30789	critical	_	
150-42	30790-30796	aspect	_	
150-43	30797-30799	of	_	
150-44	30800-30805	their	_	
150-45	30806-30820	responsiveness	_	
150-46	30821-30823	to	_	
150-47	30824-30829	their	_	
150-48	30830-30837	infants	_	
150-49	30837-30838	.	_	

#Text=Rodent models have shown that pup cues are highly reinforcing to postpartum mothers, sufficient to compete with the hedonic properties of cocaine.
151-1	30839-30845	Rodent	_	
151-2	30846-30852	models	_	
151-3	30853-30857	have	_	
151-4	30858-30863	shown	_	
151-5	30864-30868	that	_	
151-6	30869-30872	pup	_	
151-7	30873-30877	cues	_	
151-8	30878-30881	are	_	
151-9	30882-30888	highly	_	
151-10	30889-30900	reinforcing	_	
151-11	30901-30903	to	_	
151-12	30904-30914	postpartum	_	
151-13	30915-30922	mothers	_	
151-14	30922-30923	,	_	
151-15	30924-30934	sufficient	_	
151-16	30935-30937	to	_	
151-17	30938-30945	compete	_	
151-18	30946-30950	with	_	
151-19	30951-30954	the	_	
151-20	30955-30962	hedonic	_	
151-21	30963-30973	properties	_	
151-22	30974-30976	of	_	
151-23	30977-30984	cocaine	_	
151-24	30984-30985	.	_	

#Text=Virgin females show activation of the mesocorticolimbic DA pathway upon cocaine administration, while the same pathway is deactivated to cocaine and activated to pup cues in postpartum lactating mothers.
152-1	30986-30992	Virgin	_	
152-2	30993-31000	females	_	
152-3	31001-31005	show	_	
152-4	31006-31016	activation	_	
152-5	31017-31019	of	_	
152-6	31020-31023	the	_	
152-7	31024-31041	mesocorticolimbic	_	
152-8	31042-31044	DA	_	
152-9	31045-31052	pathway	_	
152-10	31053-31057	upon	_	
152-11	31058-31065	cocaine	_	
152-12	31066-31080	administration	_	
152-13	31080-31081	,	_	
152-14	31082-31087	while	_	
152-15	31088-31091	the	_	
152-16	31092-31096	same	_	
152-17	31097-31104	pathway	_	
152-18	31105-31107	is	_	
152-19	31108-31119	deactivated	_	
152-20	31120-31122	to	_	
152-21	31123-31130	cocaine	_	
152-22	31131-31134	and	_	
152-23	31135-31144	activated	_	
152-24	31145-31147	to	_	
152-25	31148-31151	pup	_	
152-26	31152-31156	cues	_	
152-27	31157-31159	in	_	
152-28	31160-31170	postpartum	_	
152-29	31171-31180	lactating	_	
152-30	31181-31188	mothers	_	
152-31	31188-31189	.	_	

#Text=This difference pre- and post-parturition reflects a series of neuroadaptations primarily involving, but not limited to, the OT system, which occur during the transition to motherhood and ensure the reward salience of pup cues over other hedonic stimuli.
153-1	31190-31194	This	_	
153-2	31195-31205	difference	_	
153-3	31206-31209	pre	_	
153-4	31209-31210	-	_	
153-5	31211-31214	and	_	
153-6	31215-31231	post-parturition	_	
153-7	31232-31240	reflects	_	
153-8	31241-31242	a	_	
153-9	31243-31249	series	_	
153-10	31250-31252	of	_	
153-11	31253-31269	neuroadaptations	_	
153-12	31270-31279	primarily	_	
153-13	31280-31289	involving	_	
153-14	31289-31290	,	_	
153-15	31291-31294	but	_	
153-16	31295-31298	not	_	
153-17	31299-31306	limited	_	
153-18	31307-31309	to	_	
153-19	31309-31310	,	_	
153-20	31311-31314	the	_	
153-21	31315-31317	OT	_	
153-22	31318-31324	system	_	
153-23	31324-31325	,	_	
153-24	31326-31331	which	_	
153-25	31332-31337	occur	_	
153-26	31338-31344	during	_	
153-27	31345-31348	the	_	
153-28	31349-31359	transition	_	
153-29	31360-31362	to	_	
153-30	31363-31373	motherhood	_	
153-31	31374-31377	and	_	
153-32	31378-31384	ensure	_	
153-33	31385-31388	the	_	
153-34	31389-31395	reward	_	
153-35	31396-31404	salience	_	
153-36	31405-31407	of	_	
153-37	31408-31411	pup	_	
153-38	31412-31416	cues	_	
153-39	31417-31421	over	_	
153-40	31422-31427	other	_	
153-41	31428-31435	hedonic	_	
153-42	31436-31443	stimuli	_	
153-43	31443-31444	.	_	

#Text=It is in this respect that our findings in mothers with addictions are particularly noteworthy.
154-1	31445-31447	It	_	
154-2	31448-31450	is	_	
154-3	31451-31453	in	_	
154-4	31454-31458	this	_	
154-5	31459-31466	respect	_	
154-6	31467-31471	that	_	
154-7	31472-31475	our	_	
154-8	31476-31484	findings	_	
154-9	31485-31487	in	_	
154-10	31488-31495	mothers	_	
154-11	31496-31500	with	_	
154-12	31501-31511	addictions	_	
154-13	31512-31515	are	_	
154-14	31516-31528	particularly	_	
154-15	31529-31539	noteworthy	_	
154-16	31539-31540	.	_	

#Text=In contrast to the adaptive shifts that help promote mother-infant attachment during the postpartum period, postpartum mothers with addictions in our study showed a pattern of decreased hypothalamic and mesocorticolimbic activation to reward cues from their infants.
155-1	31541-31543	In	_	
155-2	31544-31552	contrast	_	
155-3	31553-31555	to	_	
155-4	31556-31559	the	_	
155-5	31560-31568	adaptive	_	
155-6	31569-31575	shifts	_	
155-7	31576-31580	that	_	
155-8	31581-31585	help	_	
155-9	31586-31593	promote	_	
155-10	31594-31607	mother-infant	_	
155-11	31608-31618	attachment	_	
155-12	31619-31625	during	_	
155-13	31626-31629	the	_	
155-14	31630-31640	postpartum	_	
155-15	31641-31647	period	_	
155-16	31647-31648	,	_	
155-17	31649-31659	postpartum	_	
155-18	31660-31667	mothers	_	
155-19	31668-31672	with	_	
155-20	31673-31683	addictions	_	
155-21	31684-31686	in	_	
155-22	31687-31690	our	_	
155-23	31691-31696	study	_	
155-24	31697-31703	showed	_	
155-25	31704-31705	a	_	
155-26	31706-31713	pattern	_	
155-27	31714-31716	of	_	
155-28	31717-31726	decreased	_	
155-29	31727-31739	hypothalamic	_	
155-30	31740-31743	and	_	
155-31	31744-31761	mesocorticolimbic	_	
155-32	31762-31772	activation	_	
155-33	31773-31775	to	_	
155-34	31776-31782	reward	_	
155-35	31783-31787	cues	_	
155-36	31788-31792	from	_	
155-37	31793-31798	their	_	
155-38	31799-31806	infants	_	
155-39	31806-31807	.	_	

#Text=This is consistent with the notion that substance use compromises maternal behavior by co-opting the mesocorticolimbic DA system and disrupting naturally occurring OT-related neuroadaptations.
156-1	31808-31812	This	_	
156-2	31813-31815	is	_	
156-3	31816-31826	consistent	_	
156-4	31827-31831	with	_	
156-5	31832-31835	the	_	
156-6	31836-31842	notion	_	
156-7	31843-31847	that	_	
156-8	31848-31857	substance	_	
156-9	31858-31861	use	_	
156-10	31862-31873	compromises	_	
156-11	31874-31882	maternal	_	
156-12	31883-31891	behavior	_	
156-13	31892-31894	by	_	
156-14	31895-31904	co-opting	_	
156-15	31905-31908	the	_	
156-16	31909-31926	mesocorticolimbic	_	
156-17	31927-31929	DA	_	
156-18	31930-31936	system	_	
156-19	31937-31940	and	_	
156-20	31941-31951	disrupting	_	
156-21	31952-31961	naturally	_	
156-22	31962-31971	occurring	_	
156-23	31972-31982	OT-related	_	
156-24	31983-31999	neuroadaptations	_	
156-25	31999-32000	.	_	

#Text=Alternatively, dysregulations of the OT- and DA-systems may have already been present in susceptible mothers even prior to the onset of addiction.
157-1	32001-32014	Alternatively	_	
157-2	32014-32015	,	_	
157-3	32016-32030	dysregulations	_	
157-4	32031-32033	of	_	
157-5	32034-32037	the	_	
157-6	32038-32040	OT	_	
157-7	32040-32041	-	_	
157-8	32042-32045	and	_	
157-9	32046-32056	DA-systems	_	
157-10	32057-32060	may	_	
157-11	32061-32065	have	_	
157-12	32066-32073	already	_	
157-13	32074-32078	been	_	
157-14	32079-32086	present	_	
157-15	32087-32089	in	_	
157-16	32090-32101	susceptible	_	
157-17	32102-32109	mothers	_	
157-18	32110-32114	even	_	
157-19	32115-32120	prior	_	
157-20	32121-32123	to	_	
157-21	32124-32127	the	_	
157-22	32128-32133	onset	_	
157-23	32134-32136	of	_	
157-24	32137-32146	addiction	_	
157-25	32146-32147	.	_	

#Text=In this case, the same neurobiological mechanisms that increase the mother’s susceptibility to addiction may also undermine her reward response to her infant and may have contributed to the pattern of findings reported here.
158-1	32148-32150	In	_	
158-2	32151-32155	this	_	
158-3	32156-32160	case	_	
158-4	32160-32161	,	_	
158-5	32162-32165	the	_	
158-6	32166-32170	same	_	
158-7	32171-32186	neurobiological	_	
158-8	32187-32197	mechanisms	_	
158-9	32198-32202	that	_	
158-10	32203-32211	increase	_	
158-11	32212-32215	the	_	
158-12	32216-32222	mother	_	
158-13	32222-32223	’	_	
158-14	32223-32224	s	_	
158-15	32225-32239	susceptibility	_	
158-16	32240-32242	to	_	
158-17	32243-32252	addiction	_	
158-18	32253-32256	may	_	
158-19	32257-32261	also	_	
158-20	32262-32271	undermine	_	
158-21	32272-32275	her	_	
158-22	32276-32282	reward	_	
158-23	32283-32291	response	_	
158-24	32292-32294	to	_	
158-25	32295-32298	her	_	
158-26	32299-32305	infant	_	
158-27	32306-32309	and	_	
158-28	32310-32313	may	_	
158-29	32314-32318	have	_	
158-30	32319-32330	contributed	_	
158-31	32331-32333	to	_	
158-32	32334-32337	the	_	
158-33	32338-32345	pattern	_	
158-34	32346-32348	of	_	
158-35	32349-32357	findings	_	
158-36	32358-32366	reported	_	
158-37	32367-32371	here	_	
158-38	32371-32372	.	_	

#Text=These hypotheses should be examined and substantiated in future longitudinal research.
159-1	32373-32378	These	_	
159-2	32379-32389	hypotheses	_	
159-3	32390-32396	should	_	
159-4	32397-32399	be	_	
159-5	32400-32408	examined	_	
159-6	32409-32412	and	_	
159-7	32413-32426	substantiated	_	
159-8	32427-32429	in	_	
159-9	32430-32436	future	_	
159-10	32437-32449	longitudinal	_	
159-11	32450-32458	research	_	
159-12	32458-32459	.	_	

#Text=Previously, the only other fMRI study of mothers with addictions reported a general pattern of reduced neural responsiveness to unknown infant face and cry stimuli.
160-1	32460-32470	Previously	_	
160-2	32470-32471	,	_	
160-3	32472-32475	the	_	
160-4	32476-32480	only	_	
160-5	32481-32486	other	_	
160-6	32487-32491	fMRI	_	
160-7	32492-32497	study	_	
160-8	32498-32500	of	_	
160-9	32501-32508	mothers	_	
160-10	32509-32513	with	_	
160-11	32514-32524	addictions	_	
160-12	32525-32533	reported	_	
160-13	32534-32535	a	_	
160-14	32536-32543	general	_	
160-15	32544-32551	pattern	_	
160-16	32552-32554	of	_	
160-17	32555-32562	reduced	_	
160-18	32563-32569	neural	_	
160-19	32570-32584	responsiveness	_	
160-20	32585-32587	to	_	
160-21	32588-32595	unknown	_	
160-22	32596-32602	infant	_	
160-23	32603-32607	face	_	
160-24	32608-32611	and	_	
160-25	32612-32615	cry	_	
160-26	32616-32623	stimuli	_	
160-27	32623-32624	.	_	

#Text=Using unknown faces and cries, this prior study observed reduced activations throughout prefrontal, limbic, and occipital regions for happy faces and similarly reduced prefrontal, limbic, posterior parietal, and occipital activations, including the IPL and STG, for sad faces and cries.
161-1	32625-32630	Using	_	
161-2	32631-32638	unknown	_	
161-3	32639-32644	faces	_	
161-4	32645-32648	and	_	
161-5	32649-32654	cries	_	
161-6	32654-32655	,	_	
161-7	32656-32660	this	_	
161-8	32661-32666	prior	_	
161-9	32667-32672	study	_	
161-10	32673-32681	observed	_	
161-11	32682-32689	reduced	_	
161-12	32690-32701	activations	_	
161-13	32702-32712	throughout	_	
161-14	32713-32723	prefrontal	_	
161-15	32723-32724	,	_	
161-16	32725-32731	limbic	_	
161-17	32731-32732	,	_	
161-18	32733-32736	and	_	
161-19	32737-32746	occipital	_	
161-20	32747-32754	regions	_	
161-21	32755-32758	for	_	
161-22	32759-32764	happy	_	
161-23	32765-32770	faces	_	
161-24	32771-32774	and	_	
161-25	32775-32784	similarly	_	
161-26	32785-32792	reduced	_	
161-27	32793-32803	prefrontal	_	
161-28	32803-32804	,	_	
161-29	32805-32811	limbic	_	
161-30	32811-32812	,	_	
161-31	32813-32822	posterior	_	
161-32	32823-32831	parietal	_	
161-33	32831-32832	,	_	
161-34	32833-32836	and	_	
161-35	32837-32846	occipital	_	
161-36	32847-32858	activations	_	
161-37	32858-32859	,	_	
161-38	32860-32869	including	_	
161-39	32870-32873	the	_	
161-40	32874-32877	IPL	_	
161-41	32878-32881	and	_	
161-42	32882-32885	STG	_	
161-43	32885-32886	,	_	
161-44	32887-32890	for	_	
161-45	32891-32894	sad	_	
161-46	32895-32900	faces	_	
161-47	32901-32904	and	_	
161-48	32905-32910	cries	_	
161-49	32910-32911	.	_	

#Text=Here, we have compared mothers’ neural responsiveness to own and unknown infant faces, documenting markedly reduced activations precisely in key OT- and DA-regions in response to happy faces of own infants, along with reduced activations in a small region of the IPL and STG in response to sad faces of own infants.
162-1	32912-32916	Here	_	
162-2	32916-32917	,	_	
162-3	32918-32920	we	_	
162-4	32921-32925	have	_	
162-5	32926-32934	compared	_	
162-6	32935-32942	mothers	_	
162-7	32942-32943	’	_	
162-8	32944-32950	neural	_	
162-9	32951-32965	responsiveness	_	
162-10	32966-32968	to	_	
162-11	32969-32972	own	_	
162-12	32973-32976	and	_	
162-13	32977-32984	unknown	_	
162-14	32985-32991	infant	_	
162-15	32992-32997	faces	_	
162-16	32997-32998	,	_	
162-17	32999-33010	documenting	_	
162-18	33011-33019	markedly	_	
162-19	33020-33027	reduced	_	
162-20	33028-33039	activations	_	
162-21	33040-33049	precisely	_	
162-22	33050-33052	in	_	
162-23	33053-33056	key	_	
162-24	33057-33059	OT	_	
162-25	33059-33060	-	_	
162-26	33061-33064	and	_	
162-27	33065-33075	DA-regions	_	
162-28	33076-33078	in	_	
162-29	33079-33087	response	_	
162-30	33088-33090	to	_	
162-31	33091-33096	happy	_	
162-32	33097-33102	faces	_	
162-33	33103-33105	of	_	
162-34	33106-33109	own	_	
162-35	33110-33117	infants	_	
162-36	33117-33118	,	_	
162-37	33119-33124	along	_	
162-38	33125-33129	with	_	
162-39	33130-33137	reduced	_	
162-40	33138-33149	activations	_	
162-41	33150-33152	in	_	
162-42	33153-33154	a	_	
162-43	33155-33160	small	_	
162-44	33161-33167	region	_	
162-45	33168-33170	of	_	
162-46	33171-33174	the	_	
162-47	33175-33178	IPL	_	
162-48	33179-33182	and	_	
162-49	33183-33186	STG	_	
162-50	33187-33189	in	_	
162-51	33190-33198	response	_	
162-52	33199-33201	to	_	
162-53	33202-33205	sad	_	
162-54	33206-33211	faces	_	
162-55	33212-33214	of	_	
162-56	33215-33218	own	_	
162-57	33219-33226	infants	_	
162-58	33226-33227	.	_	

#Text=The observed deactivations, or robust negative percent BOLD signals, seen in the OT- and DA-innervated regions are particularly noteworthy in two respects: first, they were specific to cues from the mothers’ own infants; and second, they were in response to what could arguably be considered the most rewarding cues from infants—their smiling faces.
163-1	33228-33231	The	_	
163-2	33232-33240	observed	_	
163-3	33241-33254	deactivations	_	
163-4	33254-33255	,	_	
163-5	33256-33258	or	_	
163-6	33259-33265	robust	_	
163-7	33266-33274	negative	_	
163-8	33275-33282	percent	_	
163-9	33283-33287	BOLD	_	
163-10	33288-33295	signals	_	
163-11	33295-33296	,	_	
163-12	33297-33301	seen	_	
163-13	33302-33304	in	_	
163-14	33305-33308	the	_	
163-15	33309-33311	OT	_	
163-16	33311-33312	-	_	
163-17	33313-33316	and	_	
163-18	33317-33330	DA-innervated	_	
163-19	33331-33338	regions	_	
163-20	33339-33342	are	_	
163-21	33343-33355	particularly	_	
163-22	33356-33366	noteworthy	_	
163-23	33367-33369	in	_	
163-24	33370-33373	two	_	
163-25	33374-33382	respects	_	
163-26	33382-33383	:	_	
163-27	33384-33389	first	_	
163-28	33389-33390	,	_	
163-29	33391-33395	they	_	
163-30	33396-33400	were	_	
163-31	33401-33409	specific	_	
163-32	33410-33412	to	_	
163-33	33413-33417	cues	_	
163-34	33418-33422	from	_	
163-35	33423-33426	the	_	
163-36	33427-33434	mothers	_	
163-37	33434-33435	’	_	
163-38	33436-33439	own	_	
163-39	33440-33447	infants	_	
163-40	33447-33448	;	_	
163-41	33449-33452	and	_	
163-42	33453-33459	second	_	
163-43	33459-33460	,	_	
163-44	33461-33465	they	_	
163-45	33466-33470	were	_	
163-46	33471-33473	in	_	
163-47	33474-33482	response	_	
163-48	33483-33485	to	_	
163-49	33486-33490	what	_	
163-50	33491-33496	could	_	
163-51	33497-33505	arguably	_	
163-52	33506-33508	be	_	
163-53	33509-33519	considered	_	
163-54	33520-33523	the	_	
163-55	33524-33528	most	_	
163-56	33529-33538	rewarding	_	
163-57	33539-33543	cues	_	
163-58	33544-33548	from	_	
163-59	33549-33562	infants—their	_	
163-60	33563-33570	smiling	_	
163-61	33571-33576	faces	_	
163-62	33576-33577	.	_	

#Text=Taken together, these studies indicate that the reward salience of infant cues may be generally reduced in mothers with addictions, but that this pattern may be most pronounced in the case of their own infants.
164-1	33578-33583	Taken	_	
164-2	33584-33592	together	_	
164-3	33592-33593	,	_	
164-4	33594-33599	these	_	
164-5	33600-33607	studies	_	
164-6	33608-33616	indicate	_	
164-7	33617-33621	that	_	
164-8	33622-33625	the	_	
164-9	33626-33632	reward	_	
164-10	33633-33641	salience	_	
164-11	33642-33644	of	_	
164-12	33645-33651	infant	_	
164-13	33652-33656	cues	_	
164-14	33657-33660	may	_	
164-15	33661-33663	be	_	
164-16	33664-33673	generally	_	
164-17	33674-33681	reduced	_	
164-18	33682-33684	in	_	
164-19	33685-33692	mothers	_	
164-20	33693-33697	with	_	
164-21	33698-33708	addictions	_	
164-22	33708-33709	,	_	
164-23	33710-33713	but	_	
164-24	33714-33718	that	_	
164-25	33719-33723	this	_	
164-26	33724-33731	pattern	_	
164-27	33732-33735	may	_	
164-28	33736-33738	be	_	
164-29	33739-33743	most	_	
164-30	33744-33754	pronounced	_	
164-31	33755-33757	in	_	
164-32	33758-33761	the	_	
164-33	33762-33766	case	_	
164-34	33767-33769	of	_	
164-35	33770-33775	their	_	
164-36	33776-33779	own	_	
164-37	33780-33787	infants	_	
164-38	33787-33788	.	_	

#Text=Why does reward-related disruption become more pronounced with the mother’s own infant?
165-1	33789-33792	Why	_	
165-2	33793-33797	does	_	
165-3	33798-33812	reward-related	_	
165-4	33813-33823	disruption	_	
165-5	33824-33830	become	_	
165-6	33831-33835	more	_	
165-7	33836-33846	pronounced	_	
165-8	33847-33851	with	_	
165-9	33852-33855	the	_	
165-10	33856-33862	mother	_	
165-11	33862-33863	’	_	
165-12	33863-33864	s	_	
165-13	33865-33868	own	_	
165-14	33869-33875	infant	_	
165-15	33875-33876	?	_	

#Text=Growing evidence suggests that neurobiological systems that underlie reward and attachment functions undergo significant alteration over the course of development via interaction with one’s early environment (see for review).
166-1	33877-33884	Growing	_	
166-2	33885-33893	evidence	_	
166-3	33894-33902	suggests	_	
166-4	33903-33907	that	_	
166-5	33908-33923	neurobiological	_	
166-6	33924-33931	systems	_	
166-7	33932-33936	that	_	
166-8	33937-33945	underlie	_	
166-9	33946-33952	reward	_	
166-10	33953-33956	and	_	
166-11	33957-33967	attachment	_	
166-12	33968-33977	functions	_	
166-13	33978-33985	undergo	_	
166-14	33986-33997	significant	_	
166-15	33998-34008	alteration	_	
166-16	34009-34013	over	_	
166-17	34014-34017	the	_	
166-18	34018-34024	course	_	
166-19	34025-34027	of	_	
166-20	34028-34039	development	_	
166-21	34040-34043	via	_	
166-22	34044-34055	interaction	_	
166-23	34056-34060	with	_	
166-24	34061-34064	one	_	
166-25	34064-34065	’	_	
166-26	34065-34066	s	_	
166-27	34067-34072	early	_	
166-28	34073-34084	environment	_	
166-29	34085-34086	(	_	
166-30	34086-34089	see	_	
166-31	34090-34093	for	_	
166-32	34094-34100	review	_	
166-33	34100-34101	)	_	
166-34	34101-34102	.	_	

#Text=Consistent with this, some mothers may have developed altered brain reward sensitivities over the course of their upbringing, which may have contributed to both reduced response to natural reward and increased susceptibility to addictive substances.
167-1	34103-34113	Consistent	_	
167-2	34114-34118	with	_	
167-3	34119-34123	this	_	
167-4	34123-34124	,	_	
167-5	34125-34129	some	_	
167-6	34130-34137	mothers	_	
167-7	34138-34141	may	_	
167-8	34142-34146	have	_	
167-9	34147-34156	developed	_	
167-10	34157-34164	altered	_	
167-11	34165-34170	brain	_	
167-12	34171-34177	reward	_	
167-13	34178-34191	sensitivities	_	
167-14	34192-34196	over	_	
167-15	34197-34200	the	_	
167-16	34201-34207	course	_	
167-17	34208-34210	of	_	
167-18	34211-34216	their	_	
167-19	34217-34227	upbringing	_	
167-20	34227-34228	,	_	
167-21	34229-34234	which	_	
167-22	34235-34238	may	_	
167-23	34239-34243	have	_	
167-24	34244-34255	contributed	_	
167-25	34256-34258	to	_	
167-26	34259-34263	both	_	
167-27	34264-34271	reduced	_	
167-28	34272-34280	response	_	
167-29	34281-34283	to	_	
167-30	34284-34291	natural	_	
167-31	34292-34298	reward	_	
167-32	34299-34302	and	_	
167-33	34303-34312	increased	_	
167-34	34313-34327	susceptibility	_	
167-35	34328-34330	to	_	
167-36	34331-34340	addictive	_	
167-37	34341-34351	substances	_	
167-38	34351-34352	.	_	

#Text=A key contribution of our work lies in demonstrating how these altered brain reward sensitivities, which have received intense scrutiny in the broader addiction literature, may intersect with and undermine the mother’s experience of attachment with her own infant, an experience which we essentially conceptualize as that of reward.
168-1	34353-34354	A	_	
168-2	34355-34358	key	_	
168-3	34359-34371	contribution	_	
168-4	34372-34374	of	_	
168-5	34375-34378	our	_	
168-6	34379-34383	work	_	
168-7	34384-34388	lies	_	
168-8	34389-34391	in	_	
168-9	34392-34405	demonstrating	_	
168-10	34406-34409	how	_	
168-11	34410-34415	these	_	
168-12	34416-34423	altered	_	
168-13	34424-34429	brain	_	
168-14	34430-34436	reward	_	
168-15	34437-34450	sensitivities	_	
168-16	34450-34451	,	_	
168-17	34452-34457	which	_	
168-18	34458-34462	have	_	
168-19	34463-34471	received	_	
168-20	34472-34479	intense	_	
168-21	34480-34488	scrutiny	_	
168-22	34489-34491	in	_	
168-23	34492-34495	the	_	
168-24	34496-34503	broader	_	
168-25	34504-34513	addiction	_	
168-26	34514-34524	literature	_	
168-27	34524-34525	,	_	
168-28	34526-34529	may	_	
168-29	34530-34539	intersect	_	
168-30	34540-34544	with	_	
168-31	34545-34548	and	_	
168-32	34549-34558	undermine	_	
168-33	34559-34562	the	_	
168-34	34563-34569	mother	_	
168-35	34569-34570	’	_	
168-36	34570-34571	s	_	
168-37	34572-34582	experience	_	
168-38	34583-34585	of	_	
168-39	34586-34596	attachment	_	
168-40	34597-34601	with	_	
168-41	34602-34605	her	_	
168-42	34606-34609	own	_	
168-43	34610-34616	infant	_	
168-44	34616-34617	,	_	
168-45	34618-34620	an	_	
168-46	34621-34631	experience	_	
168-47	34632-34637	which	_	
168-48	34638-34640	we	_	
168-49	34641-34652	essentially	_	
168-50	34653-34666	conceptualize	_	
168-51	34667-34669	as	_	
168-52	34670-34674	that	_	
168-53	34675-34677	of	_	
168-54	34678-34684	reward	_	
168-55	34684-34685	.	_	

#Text=Furthermore, the broader literature on addictions proposes that, once developed, substance addiction may be maintained via complex interactions between reward and stress neurocircuitries and their dysregulation.
169-1	34686-34697	Furthermore	_	
169-2	34697-34698	,	_	
169-3	34699-34702	the	_	
169-4	34703-34710	broader	_	
169-5	34711-34721	literature	_	
169-6	34722-34724	on	_	
169-7	34725-34735	addictions	_	
169-8	34736-34744	proposes	_	
169-9	34745-34749	that	_	
169-10	34749-34750	,	_	
169-11	34751-34755	once	_	
169-12	34756-34765	developed	_	
169-13	34765-34766	,	_	
169-14	34767-34776	substance	_	
169-15	34777-34786	addiction	_	
169-16	34787-34790	may	_	
169-17	34791-34793	be	_	
169-18	34794-34804	maintained	_	
169-19	34805-34808	via	_	
169-20	34809-34816	complex	_	
169-21	34817-34829	interactions	_	
169-22	34830-34837	between	_	
169-23	34838-34844	reward	_	
169-24	34845-34848	and	_	
169-25	34849-34855	stress	_	
169-26	34856-34872	neurocircuitries	_	
169-27	34873-34876	and	_	
169-28	34877-34882	their	_	
169-29	34883-34896	dysregulation	_	
169-30	34896-34897	.	_	

#Text=As addiction progresses, shifts may occur within the reward circuitry, which may promote addictive behaviors aimed at alleviating stress and discomfort experienced during periods of abstinence.
170-1	34898-34900	As	_	
170-2	34901-34910	addiction	_	
170-3	34911-34921	progresses	_	
170-4	34921-34922	,	_	
170-5	34923-34929	shifts	_	
170-6	34930-34933	may	_	
170-7	34934-34939	occur	_	
170-8	34940-34946	within	_	
170-9	34947-34950	the	_	
170-10	34951-34957	reward	_	
170-11	34958-34967	circuitry	_	
170-12	34967-34968	,	_	
170-13	34969-34974	which	_	
170-14	34975-34978	may	_	
170-15	34979-34986	promote	_	
170-16	34987-34996	addictive	_	
170-17	34997-35006	behaviors	_	
170-18	35007-35012	aimed	_	
170-19	35013-35015	at	_	
170-20	35016-35027	alleviating	_	
170-21	35028-35034	stress	_	
170-22	35035-35038	and	_	
170-23	35039-35049	discomfort	_	
170-24	35050-35061	experienced	_	
170-25	35062-35068	during	_	
170-26	35069-35076	periods	_	
170-27	35077-35079	of	_	
170-28	35080-35090	abstinence	_	
170-29	35090-35091	.	_	

#Text=In the face of such shifts, attachment cues (i.e., cues from one’s own infant) and the demands for care they signify may no longer be perceived as rewarding but instead evoke stress in mothers with addictions.
171-1	35092-35094	In	_	
171-2	35095-35098	the	_	
171-3	35099-35103	face	_	
171-4	35104-35106	of	_	
171-5	35107-35111	such	_	
171-6	35112-35118	shifts	_	
171-7	35118-35119	,	_	
171-8	35120-35130	attachment	_	
171-9	35131-35135	cues	_	
171-10	35136-35137	(	_	
171-11	35137-35140	i.e	_	
171-12	35140-35141	.	_	
171-13	35141-35142	,	_	
171-14	35143-35147	cues	_	
171-15	35148-35152	from	_	
171-16	35153-35156	one	_	
171-17	35156-35157	’	_	
171-18	35157-35158	s	_	
171-19	35159-35162	own	_	
171-20	35163-35169	infant	_	
171-21	35169-35170	)	_	
171-22	35171-35174	and	_	
171-23	35175-35178	the	_	
171-24	35179-35186	demands	_	
171-25	35187-35190	for	_	
171-26	35191-35195	care	_	
171-27	35196-35200	they	_	
171-28	35201-35208	signify	_	
171-29	35209-35212	may	_	
171-30	35213-35215	no	_	
171-31	35216-35222	longer	_	
171-32	35223-35225	be	_	
171-33	35226-35235	perceived	_	
171-34	35236-35238	as	_	
171-35	35239-35248	rewarding	_	
171-36	35249-35252	but	_	
171-37	35253-35260	instead	_	
171-38	35261-35266	evoke	_	
171-39	35267-35273	stress	_	
171-40	35274-35276	in	_	
171-41	35277-35284	mothers	_	
171-42	35285-35289	with	_	
171-43	35290-35300	addictions	_	
171-44	35300-35301	.	_	

#Text=The negative percent BOLD signals observed in our study specifically for the happy faces of own infants, as well as the affective ratings that were observed to be less ‘in-sync’ with own infant’s happy faces, may be reflections of such dysregulation.
172-1	35302-35305	The	_	
172-2	35306-35314	negative	_	
172-3	35315-35322	percent	_	
172-4	35323-35327	BOLD	_	
172-5	35328-35335	signals	_	
172-6	35336-35344	observed	_	
172-7	35345-35347	in	_	
172-8	35348-35351	our	_	
172-9	35352-35357	study	_	
172-10	35358-35370	specifically	_	
172-11	35371-35374	for	_	
172-12	35375-35378	the	_	
172-13	35379-35384	happy	_	
172-14	35385-35390	faces	_	
172-15	35391-35393	of	_	
172-16	35394-35397	own	_	
172-17	35398-35405	infants	_	
172-18	35405-35406	,	_	
172-19	35407-35409	as	_	
172-20	35410-35414	well	_	
172-21	35415-35417	as	_	
172-22	35418-35421	the	_	
172-23	35422-35431	affective	_	
172-24	35432-35439	ratings	_	
172-25	35440-35444	that	_	
172-26	35445-35449	were	_	
172-27	35450-35458	observed	_	
172-28	35459-35461	to	_	
172-29	35462-35464	be	_	
172-30	35465-35469	less	_	
172-31	35470-35471	‘	_	
172-32	35471-35478	in-sync	_	
172-33	35478-35479	’	_	
172-34	35480-35484	with	_	
172-35	35485-35488	own	_	
172-36	35489-35495	infant	_	
172-37	35495-35496	’	_	
172-38	35496-35497	s	_	
172-39	35498-35503	happy	_	
172-40	35504-35509	faces	_	
172-41	35509-35510	,	_	
172-42	35511-35514	may	_	
172-43	35515-35517	be	_	
172-44	35518-35529	reflections	_	
172-45	35530-35532	of	_	
172-46	35533-35537	such	_	
172-47	35538-35551	dysregulation	_	
172-48	35551-35552	.	_	

#Text=Rather than providing a sense of reward and facilitating a mother’s approach behavior toward her infant, infant signals may potentially evoke stress and/or intensify cravings for addictive substances that have previously provided mothers with relief from stress.
173-1	35553-35559	Rather	_	
173-2	35560-35564	than	_	
173-3	35565-35574	providing	_	
173-4	35575-35576	a	_	
173-5	35577-35582	sense	_	
173-6	35583-35585	of	_	
173-7	35586-35592	reward	_	
173-8	35593-35596	and	_	
173-9	35597-35609	facilitating	_	
173-10	35610-35611	a	_	
173-11	35612-35618	mother	_	
173-12	35618-35619	’	_	
173-13	35619-35620	s	_	
173-14	35621-35629	approach	_	
173-15	35630-35638	behavior	_	
173-16	35639-35645	toward	_	
173-17	35646-35649	her	_	
173-18	35650-35656	infant	_	
173-19	35656-35657	,	_	
173-20	35658-35664	infant	_	
173-21	35665-35672	signals	_	
173-22	35673-35676	may	_	
173-23	35677-35688	potentially	_	
173-24	35689-35694	evoke	_	
173-25	35695-35701	stress	_	
173-26	35702-35705	and	_	
173-27	35705-35706	/	_	
173-28	35706-35708	or	_	
173-29	35709-35718	intensify	_	
173-30	35719-35727	cravings	_	
173-31	35728-35731	for	_	
173-32	35732-35741	addictive	_	
173-33	35742-35752	substances	_	
173-34	35753-35757	that	_	
173-35	35758-35762	have	_	
173-36	35763-35773	previously	_	
173-37	35774-35782	provided	_	
173-38	35783-35790	mothers	_	
173-39	35791-35795	with	_	
173-40	35796-35802	relief	_	
173-41	35803-35807	from	_	
173-42	35808-35814	stress	_	
173-43	35814-35815	.	_	

#Text=This may be further compounded by heightened stress that these mothers encounter in their roles as mothers, exacerbated by feelings of shame and guilt associated with the perceived repercussions of their addictions on their behavior and competence as mothers.
174-1	35816-35820	This	_	
174-2	35821-35824	may	_	
174-3	35825-35827	be	_	
174-4	35828-35835	further	_	
174-5	35836-35846	compounded	_	
174-6	35847-35849	by	_	
174-7	35850-35860	heightened	_	
174-8	35861-35867	stress	_	
174-9	35868-35872	that	_	
174-10	35873-35878	these	_	
174-11	35879-35886	mothers	_	
174-12	35887-35896	encounter	_	
174-13	35897-35899	in	_	
174-14	35900-35905	their	_	
174-15	35906-35911	roles	_	
174-16	35912-35914	as	_	
174-17	35915-35922	mothers	_	
174-18	35922-35923	,	_	
174-19	35924-35935	exacerbated	_	
174-20	35936-35938	by	_	
174-21	35939-35947	feelings	_	
174-22	35948-35950	of	_	
174-23	35951-35956	shame	_	
174-24	35957-35960	and	_	
174-25	35961-35966	guilt	_	
174-26	35967-35977	associated	_	
174-27	35978-35982	with	_	
174-28	35983-35986	the	_	
174-29	35987-35996	perceived	_	
174-30	35997-36010	repercussions	_	
174-31	36011-36013	of	_	
174-32	36014-36019	their	_	
174-33	36020-36030	addictions	_	
174-34	36031-36033	on	_	
174-35	36034-36039	their	_	
174-36	36040-36048	behavior	_	
174-37	36049-36052	and	_	
174-38	36053-36063	competence	_	
174-39	36064-36066	as	_	
174-40	36067-36074	mothers	_	
174-41	36074-36075	.	_	

#Text=In this manner, in the case of maternal substance addiction, both substance use and disrupted maternal behavior may form a self-perpetuating feedback loop sustained by dysregulated reward and stress systems.
175-1	36076-36078	In	_	
175-2	36079-36083	this	_	
175-3	36084-36090	manner	_	
175-4	36090-36091	,	_	
175-5	36092-36094	in	_	
175-6	36095-36098	the	_	
175-7	36099-36103	case	_	
175-8	36104-36106	of	_	
175-9	36107-36115	maternal	_	
175-10	36116-36125	substance	_	
175-11	36126-36135	addiction	_	
175-12	36135-36136	,	_	
175-13	36137-36141	both	_	
175-14	36142-36151	substance	_	
175-15	36152-36155	use	_	
175-16	36156-36159	and	_	
175-17	36160-36169	disrupted	_	
175-18	36170-36178	maternal	_	
175-19	36179-36187	behavior	_	
175-20	36188-36191	may	_	
175-21	36192-36196	form	_	
175-22	36197-36198	a	_	
175-23	36199-36216	self-perpetuating	_	
175-24	36217-36225	feedback	_	
175-25	36226-36230	loop	_	
175-26	36231-36240	sustained	_	
175-27	36241-36243	by	_	
175-28	36244-36256	dysregulated	_	
175-29	36257-36263	reward	_	
175-30	36264-36267	and	_	
175-31	36268-36274	stress	_	
175-32	36275-36282	systems	_	
175-33	36282-36283	.	_	

#Text=While the present study focused on reward-system-related dysregulation, it should be noted that stress-related dysregulation is as central to maternal addiction as reward-related dysregulation.
176-1	36284-36289	While	_	
176-2	36290-36293	the	_	
176-3	36294-36301	present	_	
176-4	36302-36307	study	_	
176-5	36308-36315	focused	_	
176-6	36316-36318	on	_	
176-7	36319-36340	reward-system-related	_	
176-8	36341-36354	dysregulation	_	
176-9	36354-36355	,	_	
176-10	36356-36358	it	_	
176-11	36359-36365	should	_	
176-12	36366-36368	be	_	
176-13	36369-36374	noted	_	
176-14	36375-36379	that	_	
176-15	36380-36394	stress-related	_	
176-16	36395-36408	dysregulation	_	
176-17	36409-36411	is	_	
176-18	36412-36414	as	_	
176-19	36415-36422	central	_	
176-20	36423-36425	to	_	
176-21	36426-36434	maternal	_	
176-22	36435-36444	addiction	_	
176-23	36445-36447	as	_	
176-24	36448-36462	reward-related	_	
176-25	36463-36476	dysregulation	_	
176-26	36476-36477	.	_	

#Text=In our sample, sad faces of the mothers’ own infants did not yield significant activations or deactivations in key OT- and DA-innervated brain regions, including the hypothalamus, VS, and mPFC.
177-1	36478-36480	In	_	
177-2	36481-36484	our	_	
177-3	36485-36491	sample	_	
177-4	36491-36492	,	_	
177-5	36493-36496	sad	_	
177-6	36497-36502	faces	_	
177-7	36503-36505	of	_	
177-8	36506-36509	the	_	
177-9	36510-36517	mothers	_	
177-10	36517-36518	’	_	
177-11	36519-36522	own	_	
177-12	36523-36530	infants	_	
177-13	36531-36534	did	_	
177-14	36535-36538	not	_	
177-15	36539-36544	yield	_	
177-16	36545-36556	significant	_	
177-17	36557-36568	activations	_	
177-18	36569-36571	or	_	
177-19	36572-36585	deactivations	_	
177-20	36586-36588	in	_	
177-21	36589-36592	key	_	
177-22	36593-36595	OT	_	
177-23	36595-36596	-	_	
177-24	36597-36600	and	_	
177-25	36601-36614	DA-innervated	_	
177-26	36615-36620	brain	_	
177-27	36621-36628	regions	_	
177-28	36628-36629	,	_	
177-29	36630-36639	including	_	
177-30	36640-36643	the	_	
177-31	36644-36656	hypothalamus	_	
177-32	36656-36657	,	_	
177-33	36658-36660	VS	_	
177-34	36660-36661	,	_	
177-35	36662-36665	and	_	
177-36	36666-36670	mPFC	_	
177-37	36670-36671	.	_	

#Text=This is consistent with prior research, including our own, that similarly documented no activations of these regions in mothers without addictions in response to sad faces of their own infants, although a few studies have observed activations (e.g.,).
178-1	36672-36676	This	_	
178-2	36677-36679	is	_	
178-3	36680-36690	consistent	_	
178-4	36691-36695	with	_	
178-5	36696-36701	prior	_	
178-6	36702-36710	research	_	
178-7	36710-36711	,	_	
178-8	36712-36721	including	_	
178-9	36722-36725	our	_	
178-10	36726-36729	own	_	
178-11	36729-36730	,	_	
178-12	36731-36735	that	_	
178-13	36736-36745	similarly	_	
178-14	36746-36756	documented	_	
178-15	36757-36759	no	_	
178-16	36760-36771	activations	_	
178-17	36772-36774	of	_	
178-18	36775-36780	these	_	
178-19	36781-36788	regions	_	
178-20	36789-36791	in	_	
178-21	36792-36799	mothers	_	
178-22	36800-36807	without	_	
178-23	36808-36818	addictions	_	
178-24	36819-36821	in	_	
178-25	36822-36830	response	_	
178-26	36831-36833	to	_	
178-27	36834-36837	sad	_	
178-28	36838-36843	faces	_	
178-29	36844-36846	of	_	
178-30	36847-36852	their	_	
178-31	36853-36856	own	_	
178-32	36857-36864	infants	_	
178-33	36864-36865	,	_	
178-34	36866-36874	although	_	
178-35	36875-36876	a	_	
178-36	36877-36880	few	_	
178-37	36881-36888	studies	_	
178-38	36889-36893	have	_	
178-39	36894-36902	observed	_	
178-40	36903-36914	activations	_	
178-41	36915-36916	(	_	
178-42	36916-36919	e.g	_	
178-43	36919-36920	.	_	
178-44	36920-36921	,	_	
178-45	36921-36922	)	_	
178-46	36922-36923	.	_	

#Text=While the lack of a control group precludes more conclusive inferences as to whether the absence of responses seen in these regions in mothers with addictions represents deviations from those observed in mothers without addictions, our data are consistent with the notion of the co-optation of the reward circuitry discussed above, which appears to uniquely perturb the processing of happy faces as opposed to sad faces.
179-1	36924-36929	While	_	
179-2	36930-36933	the	_	
179-3	36934-36938	lack	_	
179-4	36939-36941	of	_	
179-5	36942-36943	a	_	
179-6	36944-36951	control	_	
179-7	36952-36957	group	_	
179-8	36958-36967	precludes	_	
179-9	36968-36972	more	_	
179-10	36973-36983	conclusive	_	
179-11	36984-36994	inferences	_	
179-12	36995-36997	as	_	
179-13	36998-37000	to	_	
179-14	37001-37008	whether	_	
179-15	37009-37012	the	_	
179-16	37013-37020	absence	_	
179-17	37021-37023	of	_	
179-18	37024-37033	responses	_	
179-19	37034-37038	seen	_	
179-20	37039-37041	in	_	
179-21	37042-37047	these	_	
179-22	37048-37055	regions	_	
179-23	37056-37058	in	_	
179-24	37059-37066	mothers	_	
179-25	37067-37071	with	_	
179-26	37072-37082	addictions	_	
179-27	37083-37093	represents	_	
179-28	37094-37104	deviations	_	
179-29	37105-37109	from	_	
179-30	37110-37115	those	_	
179-31	37116-37124	observed	_	
179-32	37125-37127	in	_	
179-33	37128-37135	mothers	_	
179-34	37136-37143	without	_	
179-35	37144-37154	addictions	_	
179-36	37154-37155	,	_	
179-37	37156-37159	our	_	
179-38	37160-37164	data	_	
179-39	37165-37168	are	_	
179-40	37169-37179	consistent	_	
179-41	37180-37184	with	_	
179-42	37185-37188	the	_	
179-43	37189-37195	notion	_	
179-44	37196-37198	of	_	
179-45	37199-37202	the	_	
179-46	37203-37214	co-optation	_	
179-47	37215-37217	of	_	
179-48	37218-37221	the	_	
179-49	37222-37228	reward	_	
179-50	37229-37238	circuitry	_	
179-51	37239-37248	discussed	_	
179-52	37249-37254	above	_	
179-53	37254-37255	,	_	
179-54	37256-37261	which	_	
179-55	37262-37269	appears	_	
179-56	37270-37272	to	_	
179-57	37273-37281	uniquely	_	
179-58	37282-37289	perturb	_	
179-59	37290-37293	the	_	
179-60	37294-37304	processing	_	
179-61	37305-37307	of	_	
179-62	37308-37313	happy	_	
179-63	37314-37319	faces	_	
179-64	37320-37322	as	_	
179-65	37323-37330	opposed	_	
179-66	37331-37333	to	_	
179-67	37334-37337	sad	_	
179-68	37338-37343	faces	_	
179-69	37343-37344	.	_	

#Text=Despite our findings, we acknowledge that disruptions in maternal responses to an infant’s negative affective state are importantly linked to the infant’s socioemotional outcomes and may uniquely contribute to compromised maternal behavior seen in maternal addiction.
180-1	37345-37352	Despite	_	
180-2	37353-37356	our	_	
180-3	37357-37365	findings	_	
180-4	37365-37366	,	_	
180-5	37367-37369	we	_	
180-6	37370-37381	acknowledge	_	
180-7	37382-37386	that	_	
180-8	37387-37398	disruptions	_	
180-9	37399-37401	in	_	
180-10	37402-37410	maternal	_	
180-11	37411-37420	responses	_	
180-12	37421-37423	to	_	
180-13	37424-37426	an	_	
180-14	37427-37433	infant	_	
180-15	37433-37434	’	_	
180-16	37434-37435	s	_	
180-17	37436-37444	negative	_	
180-18	37445-37454	affective	_	
180-19	37455-37460	state	_	
180-20	37461-37464	are	_	
180-21	37465-37476	importantly	_	
180-22	37477-37483	linked	_	
180-23	37484-37486	to	_	
180-24	37487-37490	the	_	
180-25	37491-37497	infant	_	
180-26	37497-37498	’	_	
180-27	37498-37499	s	_	
180-28	37500-37514	socioemotional	_	
180-29	37515-37523	outcomes	_	
180-30	37524-37527	and	_	
180-31	37528-37531	may	_	
180-32	37532-37540	uniquely	_	
180-33	37541-37551	contribute	_	
180-34	37552-37554	to	_	
180-35	37555-37566	compromised	_	
180-36	37567-37575	maternal	_	
180-37	37576-37584	behavior	_	
180-38	37585-37589	seen	_	
180-39	37590-37592	in	_	
180-40	37593-37601	maternal	_	
180-41	37602-37611	addiction	_	
180-42	37611-37612	.	_	

#Text=It may be that regions that subserve social cognition/empathy—such as the IPL and STG—which were observed to be deactivated in our sample in response to sad faces, may contribute more to disrupted maternal attunement to infants’ negative affective states than the reward-related circuitry which has been the focus of this study.
181-1	37613-37615	It	_	
181-2	37616-37619	may	_	
181-3	37620-37622	be	_	
181-4	37623-37627	that	_	
181-5	37628-37635	regions	_	
181-6	37636-37640	that	_	
181-7	37641-37649	subserve	_	
181-8	37650-37656	social	_	
181-9	37657-37666	cognition	_	
181-10	37666-37667	/	_	
181-11	37667-37679	empathy—such	_	
181-12	37680-37682	as	_	
181-13	37683-37686	the	_	
181-14	37687-37690	IPL	_	
181-15	37691-37694	and	_	
181-16	37695-37704	STG—which	_	
181-17	37705-37709	were	_	
181-18	37710-37718	observed	_	
181-19	37719-37721	to	_	
181-20	37722-37724	be	_	
181-21	37725-37736	deactivated	_	
181-22	37737-37739	in	_	
181-23	37740-37743	our	_	
181-24	37744-37750	sample	_	
181-25	37751-37753	in	_	
181-26	37754-37762	response	_	
181-27	37763-37765	to	_	
181-28	37766-37769	sad	_	
181-29	37770-37775	faces	_	
181-30	37775-37776	,	_	
181-31	37777-37780	may	_	
181-32	37781-37791	contribute	_	
181-33	37792-37796	more	_	
181-34	37797-37799	to	_	
181-35	37800-37809	disrupted	_	
181-36	37810-37818	maternal	_	
181-37	37819-37829	attunement	_	
181-38	37830-37832	to	_	
181-39	37833-37840	infants	_	
181-40	37840-37841	’	_	
181-41	37842-37850	negative	_	
181-42	37851-37860	affective	_	
181-43	37861-37867	states	_	
181-44	37868-37872	than	_	
181-45	37873-37876	the	_	
181-46	37877-37891	reward-related	_	
181-47	37892-37901	circuitry	_	
181-48	37902-37907	which	_	
181-49	37908-37911	has	_	
181-50	37912-37916	been	_	
181-51	37917-37920	the	_	
181-52	37921-37926	focus	_	
181-53	37927-37929	of	_	
181-54	37930-37934	this	_	
181-55	37935-37940	study	_	
181-56	37940-37941	.	_	

#Text=This is in line with the recent data in nulliparous women documenting that happy cues of infants tap into an individual’s tendency to approach motivationally salient stimuli and activate regions associated with reward, while sad cues of infants tap into an individual’s tendency to withdraw from such stimuli and activate regions associated with empathy.
182-1	37942-37946	This	_	
182-2	37947-37949	is	_	
182-3	37950-37952	in	_	
182-4	37953-37957	line	_	
182-5	37958-37962	with	_	
182-6	37963-37966	the	_	
182-7	37967-37973	recent	_	
182-8	37974-37978	data	_	
182-9	37979-37981	in	_	
182-10	37982-37993	nulliparous	_	
182-11	37994-37999	women	_	
182-12	38000-38011	documenting	_	
182-13	38012-38016	that	_	
182-14	38017-38022	happy	_	
182-15	38023-38027	cues	_	
182-16	38028-38030	of	_	
182-17	38031-38038	infants	_	
182-18	38039-38042	tap	_	
182-19	38043-38047	into	_	
182-20	38048-38050	an	_	
182-21	38051-38061	individual	_	
182-22	38061-38062	’	_	
182-23	38062-38063	s	_	
182-24	38064-38072	tendency	_	
182-25	38073-38075	to	_	
182-26	38076-38084	approach	_	
182-27	38085-38099	motivationally	_	
182-28	38100-38107	salient	_	
182-29	38108-38115	stimuli	_	
182-30	38116-38119	and	_	
182-31	38120-38128	activate	_	
182-32	38129-38136	regions	_	
182-33	38137-38147	associated	_	
182-34	38148-38152	with	_	
182-35	38153-38159	reward	_	
182-36	38159-38160	,	_	
182-37	38161-38166	while	_	
182-38	38167-38170	sad	_	
182-39	38171-38175	cues	_	
182-40	38176-38178	of	_	
182-41	38179-38186	infants	_	
182-42	38187-38190	tap	_	
182-43	38191-38195	into	_	
182-44	38196-38198	an	_	
182-45	38199-38209	individual	_	
182-46	38209-38210	’	_	
182-47	38210-38211	s	_	
182-48	38212-38220	tendency	_	
182-49	38221-38223	to	_	
182-50	38224-38232	withdraw	_	
182-51	38233-38237	from	_	
182-52	38238-38242	such	_	
182-53	38243-38250	stimuli	_	
182-54	38251-38254	and	_	
182-55	38255-38263	activate	_	
182-56	38264-38271	regions	_	
182-57	38272-38282	associated	_	
182-58	38283-38287	with	_	
182-59	38288-38295	empathy	_	
182-60	38295-38296	.	_	

#Text=Additional research including a control group is warranted for a fuller and more systematic understanding of the neurocircuitry involved in stress-related dysregulation.
183-1	38297-38307	Additional	_	
183-2	38308-38316	research	_	
183-3	38317-38326	including	_	
183-4	38327-38328	a	_	
183-5	38329-38336	control	_	
183-6	38337-38342	group	_	
183-7	38343-38345	is	_	
183-8	38346-38355	warranted	_	
183-9	38356-38359	for	_	
183-10	38360-38361	a	_	
183-11	38362-38368	fuller	_	
183-12	38369-38372	and	_	
183-13	38373-38377	more	_	
183-14	38378-38388	systematic	_	
183-15	38389-38402	understanding	_	
183-16	38403-38405	of	_	
183-17	38406-38409	the	_	
183-18	38410-38424	neurocircuitry	_	
183-19	38425-38433	involved	_	
183-20	38434-38436	in	_	
183-21	38437-38451	stress-related	_	
183-22	38452-38465	dysregulation	_	
183-23	38465-38466	.	_	

#Text=Our findings presented here suggest a neurobiological account of why mothers with addictions may find it difficult to contend with the demands of caring for their infants.
184-1	38467-38470	Our	_	
184-2	38471-38479	findings	_	
184-3	38480-38489	presented	_	
184-4	38490-38494	here	_	
184-5	38495-38502	suggest	_	
184-6	38503-38504	a	_	
184-7	38505-38520	neurobiological	_	
184-8	38521-38528	account	_	
184-9	38529-38531	of	_	
184-10	38532-38535	why	_	
184-11	38536-38543	mothers	_	
184-12	38544-38548	with	_	
184-13	38549-38559	addictions	_	
184-14	38560-38563	may	_	
184-15	38564-38568	find	_	
184-16	38569-38571	it	_	
184-17	38572-38581	difficult	_	
184-18	38582-38584	to	_	
184-19	38585-38592	contend	_	
184-20	38593-38597	with	_	
184-21	38598-38601	the	_	
184-22	38602-38609	demands	_	
184-23	38610-38612	of	_	
184-24	38613-38619	caring	_	
184-25	38620-38623	for	_	
184-26	38624-38629	their	_	
184-27	38630-38637	infants	_	
184-28	38637-38638	.	_	

#Text=The transition to motherhood, while rewarding, can also be an inherently stressful period.
185-1	38639-38642	The	_	
185-2	38643-38653	transition	_	
185-3	38654-38656	to	_	
185-4	38657-38667	motherhood	_	
185-5	38667-38668	,	_	
185-6	38669-38674	while	_	
185-7	38675-38684	rewarding	_	
185-8	38684-38685	,	_	
185-9	38686-38689	can	_	
185-10	38690-38694	also	_	
185-11	38695-38697	be	_	
185-12	38698-38700	an	_	
185-13	38701-38711	inherently	_	
185-14	38712-38721	stressful	_	
185-15	38722-38728	period	_	
185-16	38728-38729	.	_	

#Text=It is the enhanced perceived appetitive value of infant cues, coupled with the sense of reward and pleasure experienced by the mother, that often help to sustain a mother’s attention and responsiveness to her infant during a critical developmental period.
186-1	38730-38732	It	_	
186-2	38733-38735	is	_	
186-3	38736-38739	the	_	
186-4	38740-38748	enhanced	_	
186-5	38749-38758	perceived	_	
186-6	38759-38769	appetitive	_	
186-7	38770-38775	value	_	
186-8	38776-38778	of	_	
186-9	38779-38785	infant	_	
186-10	38786-38790	cues	_	
186-11	38790-38791	,	_	
186-12	38792-38799	coupled	_	
186-13	38800-38804	with	_	
186-14	38805-38808	the	_	
186-15	38809-38814	sense	_	
186-16	38815-38817	of	_	
186-17	38818-38824	reward	_	
186-18	38825-38828	and	_	
186-19	38829-38837	pleasure	_	
186-20	38838-38849	experienced	_	
186-21	38850-38852	by	_	
186-22	38853-38856	the	_	
186-23	38857-38863	mother	_	
186-24	38863-38864	,	_	
186-25	38865-38869	that	_	
186-26	38870-38875	often	_	
186-27	38876-38880	help	_	
186-28	38881-38883	to	_	
186-29	38884-38891	sustain	_	
186-30	38892-38893	a	_	
186-31	38894-38900	mother	_	
186-32	38900-38901	’	_	
186-33	38901-38902	s	_	
186-34	38903-38912	attention	_	
186-35	38913-38916	and	_	
186-36	38917-38931	responsiveness	_	
186-37	38932-38934	to	_	
186-38	38935-38938	her	_	
186-39	38939-38945	infant	_	
186-40	38946-38952	during	_	
186-41	38953-38954	a	_	
186-42	38955-38963	critical	_	
186-43	38964-38977	developmental	_	
186-44	38978-38984	period	_	
186-45	38984-38985	.	_	

#Text=When the functions of the OT- and DA-innervated maternal circuitry go awry, as the data has suggested here in the case of substance addictions, mothers may be compromised in their abilities to care for their infants, and the risk for abuse and neglect may rise.
187-1	38986-38990	When	_	
187-2	38991-38994	the	_	
187-3	38995-39004	functions	_	
187-4	39005-39007	of	_	
187-5	39008-39011	the	_	
187-6	39012-39014	OT	_	
187-7	39014-39015	-	_	
187-8	39016-39019	and	_	
187-9	39020-39033	DA-innervated	_	
187-10	39034-39042	maternal	_	
187-11	39043-39052	circuitry	_	
187-12	39053-39055	go	_	
187-13	39056-39060	awry	_	
187-14	39060-39061	,	_	
187-15	39062-39064	as	_	
187-16	39065-39068	the	_	
187-17	39069-39073	data	_	
187-18	39074-39077	has	_	
187-19	39078-39087	suggested	_	
187-20	39088-39092	here	_	
187-21	39093-39095	in	_	
187-22	39096-39099	the	_	
187-23	39100-39104	case	_	
187-24	39105-39107	of	_	
187-25	39108-39117	substance	_	
187-26	39118-39128	addictions	_	
187-27	39128-39129	,	_	
187-28	39130-39137	mothers	_	
187-29	39138-39141	may	_	
187-30	39142-39144	be	_	
187-31	39145-39156	compromised	_	
187-32	39157-39159	in	_	
187-33	39160-39165	their	_	
187-34	39166-39175	abilities	_	
187-35	39176-39178	to	_	
187-36	39179-39183	care	_	
187-37	39184-39187	for	_	
187-38	39188-39193	their	_	
187-39	39194-39201	infants	_	
187-40	39201-39202	,	_	
187-41	39203-39206	and	_	
187-42	39207-39210	the	_	
187-43	39211-39215	risk	_	
187-44	39216-39219	for	_	
187-45	39220-39225	abuse	_	
187-46	39226-39229	and	_	
187-47	39230-39237	neglect	_	
187-48	39238-39241	may	_	
187-49	39242-39246	rise	_	
187-50	39246-39247	.	_	

#Text=Several limitations of the study should be recognized.
188-1	39248-39255	Several	_	
188-2	39256-39267	limitations	_	
188-3	39268-39270	of	_	
188-4	39271-39274	the	_	
188-5	39275-39280	study	_	
188-6	39281-39287	should	_	
188-7	39288-39290	be	_	
188-8	39291-39301	recognized	_	
188-9	39301-39302	.	_	

#Text=First, we did not include a matched control group of mothers without addictions and were therefore not able to directly examine between-group differences.
189-1	39303-39308	First	_	
189-2	39308-39309	,	_	
189-3	39310-39312	we	_	
189-4	39313-39316	did	_	
189-5	39317-39320	not	_	
189-6	39321-39328	include	_	
189-7	39329-39330	a	_	
189-8	39331-39338	matched	_	
189-9	39339-39346	control	_	
189-10	39347-39352	group	_	
189-11	39353-39355	of	_	
189-12	39356-39363	mothers	_	
189-13	39364-39371	without	_	
189-14	39372-39382	addictions	_	
189-15	39383-39386	and	_	
189-16	39387-39391	were	_	
189-17	39392-39401	therefore	_	
189-18	39402-39405	not	_	
189-19	39406-39410	able	_	
189-20	39411-39413	to	_	
189-21	39414-39422	directly	_	
189-22	39423-39430	examine	_	
189-23	39431-39444	between-group	_	
189-24	39445-39456	differences	_	
189-25	39456-39457	.	_	

#Text=However, comparisons with the hypothalamic and mesocorticolimbic activations shown by mothers without addictions in previous studies, both from our group and others, suggest that the observed deactivations are noteworthy abnormalities that may be characteristic of this group.
190-1	39458-39465	However	_	
190-2	39465-39466	,	_	
190-3	39467-39478	comparisons	_	
190-4	39479-39483	with	_	
190-5	39484-39487	the	_	
190-6	39488-39500	hypothalamic	_	
190-7	39501-39504	and	_	
190-8	39505-39522	mesocorticolimbic	_	
190-9	39523-39534	activations	_	
190-10	39535-39540	shown	_	
190-11	39541-39543	by	_	
190-12	39544-39551	mothers	_	
190-13	39552-39559	without	_	
190-14	39560-39570	addictions	_	
190-15	39571-39573	in	_	
190-16	39574-39582	previous	_	
190-17	39583-39590	studies	_	
190-18	39590-39591	,	_	
190-19	39592-39596	both	_	
190-20	39597-39601	from	_	
190-21	39602-39605	our	_	
190-22	39606-39611	group	_	
190-23	39612-39615	and	_	
190-24	39616-39622	others	_	
190-25	39622-39623	,	_	
190-26	39624-39631	suggest	_	
190-27	39632-39636	that	_	
190-28	39637-39640	the	_	
190-29	39641-39649	observed	_	
190-30	39650-39663	deactivations	_	
190-31	39664-39667	are	_	
190-32	39668-39678	noteworthy	_	
190-33	39679-39692	abnormalities	_	
190-34	39693-39697	that	_	
190-35	39698-39701	may	_	
190-36	39702-39704	be	_	
190-37	39705-39719	characteristic	_	
190-38	39720-39722	of	_	
190-39	39723-39727	this	_	
190-40	39728-39733	group	_	
190-41	39733-39734	.	_	

#Text=At the same time, without a direct comparison with a control group, we lack information as to whether the size of this effect would translate to a significant group difference.
191-1	39735-39737	At	_	
191-2	39738-39741	the	_	
191-3	39742-39746	same	_	
191-4	39747-39751	time	_	
191-5	39751-39752	,	_	
191-6	39753-39760	without	_	
191-7	39761-39762	a	_	
191-8	39763-39769	direct	_	
191-9	39770-39780	comparison	_	
191-10	39781-39785	with	_	
191-11	39786-39787	a	_	
191-12	39788-39795	control	_	
191-13	39796-39801	group	_	
191-14	39801-39802	,	_	
191-15	39803-39805	we	_	
191-16	39806-39810	lack	_	
191-17	39811-39822	information	_	
191-18	39823-39825	as	_	
191-19	39826-39828	to	_	
191-20	39829-39836	whether	_	
191-21	39837-39840	the	_	
191-22	39841-39845	size	_	
191-23	39846-39848	of	_	
191-24	39849-39853	this	_	
191-25	39854-39860	effect	_	
191-26	39861-39866	would	_	
191-27	39867-39876	translate	_	
191-28	39877-39879	to	_	
191-29	39880-39881	a	_	
191-30	39882-39893	significant	_	
191-31	39894-39899	group	_	
191-32	39900-39910	difference	_	
191-33	39910-39911	.	_	

#Text=This remains a critical area for future research.
192-1	39912-39916	This	_	
192-2	39917-39924	remains	_	
192-3	39925-39926	a	_	
192-4	39927-39935	critical	_	
192-5	39936-39940	area	_	
192-6	39941-39944	for	_	
192-7	39945-39951	future	_	
192-8	39952-39960	research	_	
192-9	39960-39961	.	_	

#Text=Future studies should also examine in further detail differential patterns of (de)activations in the neurocircuitries involved in social cognition/empathy in mothers with and without addictions.
193-1	39962-39968	Future	_	
193-2	39969-39976	studies	_	
193-3	39977-39983	should	_	
193-4	39984-39988	also	_	
193-5	39989-39996	examine	_	
193-6	39997-39999	in	_	
193-7	40000-40007	further	_	
193-8	40008-40014	detail	_	
193-9	40015-40027	differential	_	
193-10	40028-40036	patterns	_	
193-11	40037-40039	of	_	
193-12	40040-40041	(	_	
193-13	40041-40043	de	_	
193-14	40043-40044	)	_	
193-15	40044-40055	activations	_	
193-16	40056-40058	in	_	
193-17	40059-40062	the	_	
193-18	40063-40079	neurocircuitries	_	
193-19	40080-40088	involved	_	
193-20	40089-40091	in	_	
193-21	40092-40098	social	_	
193-22	40099-40108	cognition	_	
193-23	40108-40109	/	_	
193-24	40109-40116	empathy	_	
193-25	40117-40119	in	_	
193-26	40120-40127	mothers	_	
193-27	40128-40132	with	_	
193-28	40133-40136	and	_	
193-29	40137-40144	without	_	
193-30	40145-40155	addictions	_	
193-31	40155-40156	.	_	

#Text=Second, our sample showed variability in substance-use characteristics, including the duration and extent of substance use, as well as specific classes of substances used.
194-1	40157-40163	Second	_	
194-2	40163-40164	,	_	
194-3	40165-40168	our	_	
194-4	40169-40175	sample	_	
194-5	40176-40182	showed	_	
194-6	40183-40194	variability	_	
194-7	40195-40197	in	_	
194-8	40198-40211	substance-use	_	
194-9	40212-40227	characteristics	_	
194-10	40227-40228	,	_	
194-11	40229-40238	including	_	
194-12	40239-40242	the	_	
194-13	40243-40251	duration	_	
194-14	40252-40255	and	_	
194-15	40256-40262	extent	_	
194-16	40263-40265	of	_	
194-17	40266-40275	substance	_	
194-18	40276-40279	use	_	
194-19	40279-40280	,	_	
194-20	40281-40283	as	_	
194-21	40284-40288	well	_	
194-22	40289-40291	as	_	
194-23	40292-40300	specific	_	
194-24	40301-40308	classes	_	
194-25	40309-40311	of	_	
194-26	40312-40322	substances	_	
194-27	40323-40327	used	_	
194-28	40327-40328	.	_	

#Text=Our study focused on examining maternal brain responses in the context of a general process of substance addiction, and our small sample size precluded the investigation of potential effects specifically associated with individual substances or substance-use chronicity.
195-1	40329-40332	Our	_	
195-2	40333-40338	study	_	
195-3	40339-40346	focused	_	
195-4	40347-40349	on	_	
195-5	40350-40359	examining	_	
195-6	40360-40368	maternal	_	
195-7	40369-40374	brain	_	
195-8	40375-40384	responses	_	
195-9	40385-40387	in	_	
195-10	40388-40391	the	_	
195-11	40392-40399	context	_	
195-12	40400-40402	of	_	
195-13	40403-40404	a	_	
195-14	40405-40412	general	_	
195-15	40413-40420	process	_	
195-16	40421-40423	of	_	
195-17	40424-40433	substance	_	
195-18	40434-40443	addiction	_	
195-19	40443-40444	,	_	
195-20	40445-40448	and	_	
195-21	40449-40452	our	_	
195-22	40453-40458	small	_	
195-23	40459-40465	sample	_	
195-24	40466-40470	size	_	
195-25	40471-40480	precluded	_	
195-26	40481-40484	the	_	
195-27	40485-40498	investigation	_	
195-28	40499-40501	of	_	
195-29	40502-40511	potential	_	
195-30	40512-40519	effects	_	
195-31	40520-40532	specifically	_	
195-32	40533-40543	associated	_	
195-33	40544-40548	with	_	
195-34	40549-40559	individual	_	
195-35	40560-40570	substances	_	
195-36	40571-40573	or	_	
195-37	40574-40587	substance-use	_	
195-38	40588-40598	chronicity	_	
195-39	40598-40599	.	_	

#Text=Given substantial preclinical and human data underscoring the role of altered reward sensitivities, particularly the diminished salience of natural rewards, in the process of addiction, we anticipate that abnormalities reported here may be represented to a greater or lesser degree across a range of substances.
196-1	40600-40605	Given	_	
196-2	40606-40617	substantial	_	
196-3	40618-40629	preclinical	_	
196-4	40630-40633	and	_	
196-5	40634-40639	human	_	
196-6	40640-40644	data	_	
196-7	40645-40657	underscoring	_	
196-8	40658-40661	the	_	
196-9	40662-40666	role	_	
196-10	40667-40669	of	_	
196-11	40670-40677	altered	_	
196-12	40678-40684	reward	_	
196-13	40685-40698	sensitivities	_	
196-14	40698-40699	,	_	
196-15	40700-40712	particularly	_	
196-16	40713-40716	the	_	
196-17	40717-40727	diminished	_	
196-18	40728-40736	salience	_	
196-19	40737-40739	of	_	
196-20	40740-40747	natural	_	
196-21	40748-40755	rewards	_	
196-22	40755-40756	,	_	
196-23	40757-40759	in	_	
196-24	40760-40763	the	_	
196-25	40764-40771	process	_	
196-26	40772-40774	of	_	
196-27	40775-40784	addiction	_	
196-28	40784-40785	,	_	
196-29	40786-40788	we	_	
196-30	40789-40799	anticipate	_	
196-31	40800-40804	that	_	
196-32	40805-40818	abnormalities	_	
196-33	40819-40827	reported	_	
196-34	40828-40832	here	_	
196-35	40833-40836	may	_	
196-36	40837-40839	be	_	
196-37	40840-40851	represented	_	
196-38	40852-40854	to	_	
196-39	40855-40856	a	_	
196-40	40857-40864	greater	_	
196-41	40865-40867	or	_	
196-42	40868-40874	lesser	_	
196-43	40875-40881	degree	_	
196-44	40882-40888	across	_	
196-45	40889-40890	a	_	
196-46	40891-40896	range	_	
196-47	40897-40899	of	_	
196-48	40900-40910	substances	_	
196-49	40910-40911	.	_	

#Text=However, the specific nature of pre-existing OT- and DA-related dysregulations in mothers may have led to differential susceptibility to distinct classes of substances, which, in turn, may have produced unique patterns of neuroadaptations, including those affecting the maternal circuitry, over the course of repeated substance use.
197-1	40912-40919	However	_	
197-2	40919-40920	,	_	
197-3	40921-40924	the	_	
197-4	40925-40933	specific	_	
197-5	40934-40940	nature	_	
197-6	40941-40943	of	_	
197-7	40944-40956	pre-existing	_	
197-8	40957-40959	OT	_	
197-9	40959-40960	-	_	
197-10	40961-40964	and	_	
197-11	40965-40975	DA-related	_	
197-12	40976-40990	dysregulations	_	
197-13	40991-40993	in	_	
197-14	40994-41001	mothers	_	
197-15	41002-41005	may	_	
197-16	41006-41010	have	_	
197-17	41011-41014	led	_	
197-18	41015-41017	to	_	
197-19	41018-41030	differential	_	
197-20	41031-41045	susceptibility	_	
197-21	41046-41048	to	_	
197-22	41049-41057	distinct	_	
197-23	41058-41065	classes	_	
197-24	41066-41068	of	_	
197-25	41069-41079	substances	_	
197-26	41079-41080	,	_	
197-27	41081-41086	which	_	
197-28	41086-41087	,	_	
197-29	41088-41090	in	_	
197-30	41091-41095	turn	_	
197-31	41095-41096	,	_	
197-32	41097-41100	may	_	
197-33	41101-41105	have	_	
197-34	41106-41114	produced	_	
197-35	41115-41121	unique	_	
197-36	41122-41130	patterns	_	
197-37	41131-41133	of	_	
197-38	41134-41150	neuroadaptations	_	
197-39	41150-41151	,	_	
197-40	41152-41161	including	_	
197-41	41162-41167	those	_	
197-42	41168-41177	affecting	_	
197-43	41178-41181	the	_	
197-44	41182-41190	maternal	_	
197-45	41191-41200	circuitry	_	
197-46	41200-41201	,	_	
197-47	41202-41206	over	_	
197-48	41207-41210	the	_	
197-49	41211-41217	course	_	
197-50	41218-41220	of	_	
197-51	41221-41229	repeated	_	
197-52	41230-41239	substance	_	
197-53	41240-41243	use	_	
197-54	41243-41244	.	_	

#Text=In future studies with larger samples, it would be of interest to investigate unique and shared effects of individual substances as well as effects associated with the severity and chronicity of substance use.
198-1	41245-41247	In	_	
198-2	41248-41254	future	_	
198-3	41255-41262	studies	_	
198-4	41263-41267	with	_	
198-5	41268-41274	larger	_	
198-6	41275-41282	samples	_	
198-7	41282-41283	,	_	
198-8	41284-41286	it	_	
198-9	41287-41292	would	_	
198-10	41293-41295	be	_	
198-11	41296-41298	of	_	
198-12	41299-41307	interest	_	
198-13	41308-41310	to	_	
198-14	41311-41322	investigate	_	
198-15	41323-41329	unique	_	
198-16	41330-41333	and	_	
198-17	41334-41340	shared	_	
198-18	41341-41348	effects	_	
198-19	41349-41351	of	_	
198-20	41352-41362	individual	_	
198-21	41363-41373	substances	_	
198-22	41374-41376	as	_	
198-23	41377-41381	well	_	
198-24	41382-41384	as	_	
198-25	41385-41392	effects	_	
198-26	41393-41403	associated	_	
198-27	41404-41408	with	_	
198-28	41409-41412	the	_	
198-29	41413-41421	severity	_	
198-30	41422-41425	and	_	
198-31	41426-41436	chronicity	_	
198-32	41437-41439	of	_	
198-33	41440-41449	substance	_	
198-34	41450-41453	use	_	
198-35	41453-41454	.	_	

#Text=Third, the present study does not examine which aspects of this sample—addiction severity, associated sociodemographic characteristics (e.g., low SES), attachment disturbance, or unresolved trauma prevalent in this population—may account for the findings reported here.
199-1	41455-41460	Third	_	
199-2	41460-41461	,	_	
199-3	41462-41465	the	_	
199-4	41466-41473	present	_	
199-5	41474-41479	study	_	
199-6	41480-41484	does	_	
199-7	41485-41488	not	_	
199-8	41489-41496	examine	_	
199-9	41497-41502	which	_	
199-10	41503-41510	aspects	_	
199-11	41511-41513	of	_	
199-12	41514-41518	this	_	
199-13	41519-41535	sample—addiction	_	
199-14	41536-41544	severity	_	
199-15	41544-41545	,	_	
199-16	41546-41556	associated	_	
199-17	41557-41573	sociodemographic	_	
199-18	41574-41589	characteristics	_	
199-19	41590-41591	(	_	
199-20	41591-41594	e.g	_	
199-21	41594-41595	.	_	
199-22	41595-41596	,	_	
199-23	41597-41600	low	_	
199-24	41601-41604	SES	_	
199-25	41604-41605	)	_	
199-26	41605-41606	,	_	
199-27	41607-41617	attachment	_	
199-28	41618-41629	disturbance	_	
199-29	41629-41630	,	_	
199-30	41631-41633	or	_	
199-31	41634-41644	unresolved	_	
199-32	41645-41651	trauma	_	
199-33	41652-41661	prevalent	_	
199-34	41662-41664	in	_	
199-35	41665-41669	this	_	
199-36	41670-41684	population—may	_	
199-37	41685-41692	account	_	
199-38	41693-41696	for	_	
199-39	41697-41700	the	_	
199-40	41701-41709	findings	_	
199-41	41710-41718	reported	_	
199-42	41719-41723	here	_	
199-43	41723-41724	.	_	

#Text=Although these factors often co-occur and it is important to document the features associated with this constellation of maternal characteristics, it would be of interest to tease apart associations and interactions amongst these factors.
200-1	41725-41733	Although	_	
200-2	41734-41739	these	_	
200-3	41740-41747	factors	_	
200-4	41748-41753	often	_	
200-5	41754-41762	co-occur	_	
200-6	41763-41766	and	_	
200-7	41767-41769	it	_	
200-8	41770-41772	is	_	
200-9	41773-41782	important	_	
200-10	41783-41785	to	_	
200-11	41786-41794	document	_	
200-12	41795-41798	the	_	
200-13	41799-41807	features	_	
200-14	41808-41818	associated	_	
200-15	41819-41823	with	_	
200-16	41824-41828	this	_	
200-17	41829-41842	constellation	_	
200-18	41843-41845	of	_	
200-19	41846-41854	maternal	_	
200-20	41855-41870	characteristics	_	
200-21	41870-41871	,	_	
200-22	41872-41874	it	_	
200-23	41875-41880	would	_	
200-24	41881-41883	be	_	
200-25	41884-41886	of	_	
200-26	41887-41895	interest	_	
200-27	41896-41898	to	_	
200-28	41899-41904	tease	_	
200-29	41905-41910	apart	_	
200-30	41911-41923	associations	_	
200-31	41924-41927	and	_	
200-32	41928-41940	interactions	_	
200-33	41941-41948	amongst	_	
200-34	41949-41954	these	_	
200-35	41955-41962	factors	_	
200-36	41962-41963	.	_	

#Text=Fourth, we did not collect systematic information on co-occurring psychiatric disorders.
201-1	41964-41970	Fourth	_	
201-2	41970-41971	,	_	
201-3	41972-41974	we	_	
201-4	41975-41978	did	_	
201-5	41979-41982	not	_	
201-6	41983-41990	collect	_	
201-7	41991-42001	systematic	_	
201-8	42002-42013	information	_	
201-9	42014-42016	on	_	
201-10	42017-42029	co-occurring	_	
201-11	42030-42041	psychiatric	_	
201-12	42042-42051	disorders	_	
201-13	42051-42052	.	_	

#Text=Further studies are warranted to investigate and clarify possible contributions of co-occurring disorders to the findings reported here.
202-1	42053-42060	Further	_	
202-2	42061-42068	studies	_	
202-3	42069-42072	are	_	
202-4	42073-42082	warranted	_	
202-5	42083-42085	to	_	
202-6	42086-42097	investigate	_	
202-7	42098-42101	and	_	
202-8	42102-42109	clarify	_	
202-9	42110-42118	possible	_	
202-10	42119-42132	contributions	_	
202-11	42133-42135	of	_	
202-12	42136-42148	co-occurring	_	
202-13	42149-42158	disorders	_	
202-14	42159-42161	to	_	
202-15	42162-42165	the	_	
202-16	42166-42174	findings	_	
202-17	42175-42183	reported	_	
202-18	42184-42188	here	_	
202-19	42188-42189	.	_	

#Text=Fifth, we did not directly measure the quality of infant-directed maternal behavior and hence acknowledge that the association proposed here between compromised reward-related maternal brain response and disrupted maternal care is only speculative.
203-1	42190-42195	Fifth	_	
203-2	42195-42196	,	_	
203-3	42197-42199	we	_	
203-4	42200-42203	did	_	
203-5	42204-42207	not	_	
203-6	42208-42216	directly	_	
203-7	42217-42224	measure	_	
203-8	42225-42228	the	_	
203-9	42229-42236	quality	_	
203-10	42237-42239	of	_	
203-11	42240-42255	infant-directed	_	
203-12	42256-42264	maternal	_	
203-13	42265-42273	behavior	_	
203-14	42274-42277	and	_	
203-15	42278-42283	hence	_	
203-16	42284-42295	acknowledge	_	
203-17	42296-42300	that	_	
203-18	42301-42304	the	_	
203-19	42305-42316	association	_	
203-20	42317-42325	proposed	_	
203-21	42326-42330	here	_	
203-22	42331-42338	between	_	
203-23	42339-42350	compromised	_	
203-24	42351-42365	reward-related	_	
203-25	42366-42374	maternal	_	
203-26	42375-42380	brain	_	
203-27	42381-42389	response	_	
203-28	42390-42393	and	_	
203-29	42394-42403	disrupted	_	
203-30	42404-42412	maternal	_	
203-31	42413-42417	care	_	
203-32	42418-42420	is	_	
203-33	42421-42425	only	_	
203-34	42426-42437	speculative	_	
203-35	42437-42438	.	_	

#Text=A larger study with concurrent brain and behavioral measures is necessary to further corroborate this link.
204-1	42439-42440	A	_	
204-2	42441-42447	larger	_	
204-3	42448-42453	study	_	
204-4	42454-42458	with	_	
204-5	42459-42469	concurrent	_	
204-6	42470-42475	brain	_	
204-7	42476-42479	and	_	
204-8	42480-42490	behavioral	_	
204-9	42491-42499	measures	_	
204-10	42500-42502	is	_	
204-11	42503-42512	necessary	_	
204-12	42513-42515	to	_	
204-13	42516-42523	further	_	
204-14	42524-42535	corroborate	_	
204-15	42536-42540	this	_	
204-16	42541-42545	link	_	
204-17	42545-42546	.	_	

#Text=In a sufficiently large sample, it would be fruitful to examine whether compromised DA- and OT-related activations relate to aberrant behavioral characteristics in mothers.
205-1	42547-42549	In	_	
205-2	42550-42551	a	_	
205-3	42552-42564	sufficiently	_	
205-4	42565-42570	large	_	
205-5	42571-42577	sample	_	
205-6	42577-42578	,	_	
205-7	42579-42581	it	_	
205-8	42582-42587	would	_	
205-9	42588-42590	be	_	
205-10	42591-42599	fruitful	_	
205-11	42600-42602	to	_	
205-12	42603-42610	examine	_	
205-13	42611-42618	whether	_	
205-14	42619-42630	compromised	_	
205-15	42631-42633	DA	_	
205-16	42633-42634	-	_	
205-17	42635-42638	and	_	
205-18	42639-42649	OT-related	_	
205-19	42650-42661	activations	_	
205-20	42662-42668	relate	_	
205-21	42669-42671	to	_	
205-22	42672-42680	aberrant	_	
205-23	42681-42691	behavioral	_	
205-24	42692-42707	characteristics	_	
205-25	42708-42710	in	_	
205-26	42711-42718	mothers	_	
205-27	42718-42719	.	_	

#Text=Finally, additional limitations include a small sample size as well as variability seen in maternal age (27.8 ± 5.6 years), infant age (5.0 ± 2.9 months at the time face images were recorded), and the time elapsed since delivery (6.0 ± 3.4 months at the time of the scan).
206-1	42720-42727	Finally	_	
206-2	42727-42728	,	_	
206-3	42729-42739	additional	_	
206-4	42740-42751	limitations	_	
206-5	42752-42759	include	_	
206-6	42760-42761	a	_	
206-7	42762-42767	small	_	
206-8	42768-42774	sample	_	
206-9	42775-42779	size	_	
206-10	42780-42782	as	_	
206-11	42783-42787	well	_	
206-12	42788-42790	as	_	
206-13	42791-42802	variability	_	
206-14	42803-42807	seen	_	
206-15	42808-42810	in	_	
206-16	42811-42819	maternal	_	
206-17	42820-42823	age	_	
206-18	42824-42825	(	_	
206-19	42825-42829	27.8	_	
206-20	42830-42831	±	_	
206-21	42832-42835	5.6	_	
206-22	42836-42841	years	_	
206-23	42841-42842	)	_	
206-24	42842-42843	,	_	
206-25	42844-42850	infant	_	
206-26	42851-42854	age	_	
206-27	42855-42856	(	_	
206-28	42856-42859	5.0	_	
206-29	42860-42861	±	_	
206-30	42862-42865	2.9	_	
206-31	42866-42872	months	_	
206-32	42873-42875	at	_	
206-33	42876-42879	the	_	
206-34	42880-42884	time	_	
206-35	42885-42889	face	_	
206-36	42890-42896	images	_	
206-37	42897-42901	were	_	
206-38	42902-42910	recorded	_	
206-39	42910-42911	)	_	
206-40	42911-42912	,	_	
206-41	42913-42916	and	_	
206-42	42917-42920	the	_	
206-43	42921-42925	time	_	
206-44	42926-42933	elapsed	_	
206-45	42934-42939	since	_	
206-46	42940-42948	delivery	_	
206-47	42949-42950	(	_	
206-48	42950-42953	6.0	_	
206-49	42954-42955	±	_	
206-50	42956-42959	3.4	_	
206-51	42960-42966	months	_	
206-52	42967-42969	at	_	
206-53	42970-42973	the	_	
206-54	42974-42978	time	_	
206-55	42979-42981	of	_	
206-56	42982-42985	the	_	
206-57	42986-42990	scan	_	
206-58	42990-42991	)	_	
206-59	42991-42992	.	_	

#Text=The maternal brain is understood to undergo structural and functional changes over the course of the postpartum period in interaction with the amount of exposure and experience the mother has with her infant.
207-1	42993-42996	The	_	
207-2	42997-43005	maternal	_	
207-3	43006-43011	brain	_	
207-4	43012-43014	is	_	
207-5	43015-43025	understood	_	
207-6	43026-43028	to	_	
207-7	43029-43036	undergo	_	
207-8	43037-43047	structural	_	
207-9	43048-43051	and	_	
207-10	43052-43062	functional	_	
207-11	43063-43070	changes	_	
207-12	43071-43075	over	_	
207-13	43076-43079	the	_	
207-14	43080-43086	course	_	
207-15	43087-43089	of	_	
207-16	43090-43093	the	_	
207-17	43094-43104	postpartum	_	
207-18	43105-43111	period	_	
207-19	43112-43114	in	_	
207-20	43115-43126	interaction	_	
207-21	43127-43131	with	_	
207-22	43132-43135	the	_	
207-23	43136-43142	amount	_	
207-24	43143-43145	of	_	
207-25	43146-43154	exposure	_	
207-26	43155-43158	and	_	
207-27	43159-43169	experience	_	
207-28	43170-43173	the	_	
207-29	43174-43180	mother	_	
207-30	43181-43184	has	_	
207-31	43185-43189	with	_	
207-32	43190-43193	her	_	
207-33	43194-43200	infant	_	
207-34	43200-43201	.	_	

#Text=While there may have been developmental variability between younger and older infants (e.g., older infants may have been more expressive in their facial affect), all own and unknown infant face images were matched on infant age and affect intensity, allowing us to reasonably speculate that differences observed in maternal brain responses to own and unknown infant faces were likely a function of infant identity.
208-1	43202-43207	While	_	
208-2	43208-43213	there	_	
208-3	43214-43217	may	_	
208-4	43218-43222	have	_	
208-5	43223-43227	been	_	
208-6	43228-43241	developmental	_	
208-7	43242-43253	variability	_	
208-8	43254-43261	between	_	
208-9	43262-43269	younger	_	
208-10	43270-43273	and	_	
208-11	43274-43279	older	_	
208-12	43280-43287	infants	_	
208-13	43288-43289	(	_	
208-14	43289-43292	e.g	_	
208-15	43292-43293	.	_	
208-16	43293-43294	,	_	
208-17	43295-43300	older	_	
208-18	43301-43308	infants	_	
208-19	43309-43312	may	_	
208-20	43313-43317	have	_	
208-21	43318-43322	been	_	
208-22	43323-43327	more	_	
208-23	43328-43338	expressive	_	
208-24	43339-43341	in	_	
208-25	43342-43347	their	_	
208-26	43348-43354	facial	_	
208-27	43355-43361	affect	_	
208-28	43361-43362	)	_	
208-29	43362-43363	,	_	
208-30	43364-43367	all	_	
208-31	43368-43371	own	_	
208-32	43372-43375	and	_	
208-33	43376-43383	unknown	_	
208-34	43384-43390	infant	_	
208-35	43391-43395	face	_	
208-36	43396-43402	images	_	
208-37	43403-43407	were	_	
208-38	43408-43415	matched	_	
208-39	43416-43418	on	_	
208-40	43419-43425	infant	_	
208-41	43426-43429	age	_	
208-42	43430-43433	and	_	
208-43	43434-43440	affect	_	
208-44	43441-43450	intensity	_	
208-45	43450-43451	,	_	
208-46	43452-43460	allowing	_	
208-47	43461-43463	us	_	
208-48	43464-43466	to	_	
208-49	43467-43477	reasonably	_	
208-50	43478-43487	speculate	_	
208-51	43488-43492	that	_	
208-52	43493-43504	differences	_	
208-53	43505-43513	observed	_	
208-54	43514-43516	in	_	
208-55	43517-43525	maternal	_	
208-56	43526-43531	brain	_	
208-57	43532-43541	responses	_	
208-58	43542-43544	to	_	
208-59	43545-43548	own	_	
208-60	43549-43552	and	_	
208-61	43553-43560	unknown	_	
208-62	43561-43567	infant	_	
208-63	43568-43573	faces	_	
208-64	43574-43578	were	_	
208-65	43579-43585	likely	_	
208-66	43586-43587	a	_	
208-67	43588-43596	function	_	
208-68	43597-43599	of	_	
208-69	43600-43606	infant	_	
208-70	43607-43615	identity	_	
208-71	43615-43616	.	_	

#Text=Furthermore, while maternal age and the amount of maternal contact with the infant may have added to possible inter-individual variations in maternal neurobiology among our participants, our findings of striking deactivations in key OT- and DA-innervated brain regions were only seen in response to happy, but not sad, faces of the mothers’ own infants.
209-1	43617-43628	Furthermore	_	
209-2	43628-43629	,	_	
209-3	43630-43635	while	_	
209-4	43636-43644	maternal	_	
209-5	43645-43648	age	_	
209-6	43649-43652	and	_	
209-7	43653-43656	the	_	
209-8	43657-43663	amount	_	
209-9	43664-43666	of	_	
209-10	43667-43675	maternal	_	
209-11	43676-43683	contact	_	
209-12	43684-43688	with	_	
209-13	43689-43692	the	_	
209-14	43693-43699	infant	_	
209-15	43700-43703	may	_	
209-16	43704-43708	have	_	
209-17	43709-43714	added	_	
209-18	43715-43717	to	_	
209-19	43718-43726	possible	_	
209-20	43727-43743	inter-individual	_	
209-21	43744-43754	variations	_	
209-22	43755-43757	in	_	
209-23	43758-43766	maternal	_	
209-24	43767-43779	neurobiology	_	
209-25	43780-43785	among	_	
209-26	43786-43789	our	_	
209-27	43790-43802	participants	_	
209-28	43802-43803	,	_	
209-29	43804-43807	our	_	
209-30	43808-43816	findings	_	
209-31	43817-43819	of	_	
209-32	43820-43828	striking	_	
209-33	43829-43842	deactivations	_	
209-34	43843-43845	in	_	
209-35	43846-43849	key	_	
209-36	43850-43852	OT	_	
209-37	43852-43853	-	_	
209-38	43854-43857	and	_	
209-39	43858-43871	DA-innervated	_	
209-40	43872-43877	brain	_	
209-41	43878-43885	regions	_	
209-42	43886-43890	were	_	
209-43	43891-43895	only	_	
209-44	43896-43900	seen	_	
209-45	43901-43903	in	_	
209-46	43904-43912	response	_	
209-47	43913-43915	to	_	
209-48	43916-43921	happy	_	
209-49	43921-43922	,	_	
209-50	43923-43926	but	_	
209-51	43927-43930	not	_	
209-52	43931-43934	sad	_	
209-53	43934-43935	,	_	
209-54	43936-43941	faces	_	
209-55	43942-43944	of	_	
209-56	43945-43948	the	_	
209-57	43949-43956	mothers	_	
209-58	43956-43957	’	_	
209-59	43958-43961	own	_	
209-60	43962-43969	infants	_	
209-61	43969-43970	.	_	

#Text=We believe that this corroborates our understanding that findings observed here in mothers with addictions are less likely to be a function of maternal age or postpartum exposure, but can reasonably be interpreted as a reflection of reward-related dysregulations manifesting specifically in reward-related attachment contexts.
210-1	43971-43973	We	_	
210-2	43974-43981	believe	_	
210-3	43982-43986	that	_	
210-4	43987-43991	this	_	
210-5	43992-44004	corroborates	_	
210-6	44005-44008	our	_	
210-7	44009-44022	understanding	_	
210-8	44023-44027	that	_	
210-9	44028-44036	findings	_	
210-10	44037-44045	observed	_	
210-11	44046-44050	here	_	
210-12	44051-44053	in	_	
210-13	44054-44061	mothers	_	
210-14	44062-44066	with	_	
210-15	44067-44077	addictions	_	
210-16	44078-44081	are	_	
210-17	44082-44086	less	_	
210-18	44087-44093	likely	_	
210-19	44094-44096	to	_	
210-20	44097-44099	be	_	
210-21	44100-44101	a	_	
210-22	44102-44110	function	_	
210-23	44111-44113	of	_	
210-24	44114-44122	maternal	_	
210-25	44123-44126	age	_	
210-26	44127-44129	or	_	
210-27	44130-44140	postpartum	_	
210-28	44141-44149	exposure	_	
210-29	44149-44150	,	_	
210-30	44151-44154	but	_	
210-31	44155-44158	can	_	
210-32	44159-44169	reasonably	_	
210-33	44170-44172	be	_	
210-34	44173-44184	interpreted	_	
210-35	44185-44187	as	_	
210-36	44188-44189	a	_	
210-37	44190-44200	reflection	_	
210-38	44201-44203	of	_	
210-39	44204-44218	reward-related	_	
210-40	44219-44233	dysregulations	_	
210-41	44234-44245	manifesting	_	
210-42	44246-44258	specifically	_	
210-43	44259-44261	in	_	
210-44	44262-44276	reward-related	_	
210-45	44277-44287	attachment	_	
210-46	44288-44296	contexts	_	
210-47	44296-44297	.	_	

#Text=However, accounting for the role of the amount of maternal exposure, contact, and experience with the infant is critical in the study of maternal postpartum neuroadaptation and would be important to address in future research relating to mothers with addictions.
211-1	44298-44305	However	_	
211-2	44305-44306	,	_	
211-3	44307-44317	accounting	_	
211-4	44318-44321	for	_	
211-5	44322-44325	the	_	
211-6	44326-44330	role	_	
211-7	44331-44333	of	_	
211-8	44334-44337	the	_	
211-9	44338-44344	amount	_	
211-10	44345-44347	of	_	
211-11	44348-44356	maternal	_	
211-12	44357-44365	exposure	_	
211-13	44365-44366	,	_	
211-14	44367-44374	contact	_	
211-15	44374-44375	,	_	
211-16	44376-44379	and	_	
211-17	44380-44390	experience	_	
211-18	44391-44395	with	_	
211-19	44396-44399	the	_	
211-20	44400-44406	infant	_	
211-21	44407-44409	is	_	
211-22	44410-44418	critical	_	
211-23	44419-44421	in	_	
211-24	44422-44425	the	_	
211-25	44426-44431	study	_	
211-26	44432-44434	of	_	
211-27	44435-44443	maternal	_	
211-28	44444-44454	postpartum	_	
211-29	44455-44470	neuroadaptation	_	
211-30	44471-44474	and	_	
211-31	44475-44480	would	_	
211-32	44481-44483	be	_	
211-33	44484-44493	important	_	
211-34	44494-44496	to	_	
211-35	44497-44504	address	_	
211-36	44505-44507	in	_	
211-37	44508-44514	future	_	
211-38	44515-44523	research	_	
211-39	44524-44532	relating	_	
211-40	44533-44535	to	_	
211-41	44536-44543	mothers	_	
211-42	44544-44548	with	_	
211-43	44549-44559	addictions	_	
211-44	44559-44560	.	_	

#Text=The present study marks one of the first attempts to delineate neurobiological correlates of disrupted mothering in mothers with addictions.
212-1	44561-44564	The	_	
212-2	44565-44572	present	_	
212-3	44573-44578	study	_	
212-4	44579-44584	marks	_	
212-5	44585-44588	one	_	
212-6	44589-44591	of	_	
212-7	44592-44595	the	_	
212-8	44596-44601	first	_	
212-9	44602-44610	attempts	_	
212-10	44611-44613	to	_	
212-11	44614-44623	delineate	_	
212-12	44624-44639	neurobiological	_	
212-13	44640-44650	correlates	_	
212-14	44651-44653	of	_	
212-15	44654-44663	disrupted	_	
212-16	44664-44673	mothering	_	
212-17	44674-44676	in	_	
212-18	44677-44684	mothers	_	
212-19	44685-44689	with	_	
212-20	44690-44700	addictions	_	
212-21	44700-44701	.	_	

#Text=The data suggest that mothers with substance addictions, even during intermittent periods of sobriety, demonstrate markedly reduced response to naturally rewarding cues from their infants.
213-1	44702-44705	The	_	
213-2	44706-44710	data	_	
213-3	44711-44718	suggest	_	
213-4	44719-44723	that	_	
213-5	44724-44731	mothers	_	
213-6	44732-44736	with	_	
213-7	44737-44746	substance	_	
213-8	44747-44757	addictions	_	
213-9	44757-44758	,	_	
213-10	44759-44763	even	_	
213-11	44764-44770	during	_	
213-12	44771-44783	intermittent	_	
213-13	44784-44791	periods	_	
213-14	44792-44794	of	_	
213-15	44795-44803	sobriety	_	
213-16	44803-44804	,	_	
213-17	44805-44816	demonstrate	_	
213-18	44817-44825	markedly	_	
213-19	44826-44833	reduced	_	
213-20	44834-44842	response	_	
213-21	44843-44845	to	_	
213-22	44846-44855	naturally	_	
213-23	44856-44865	rewarding	_	
213-24	44866-44870	cues	_	
213-25	44871-44875	from	_	
213-26	44876-44881	their	_	
213-27	44882-44889	infants	_	
213-28	44889-44890	.	_	

#Text=The deactivations observed here may help to explain the link between maternal substance use and impaired maternal caregiving.
214-1	44891-44894	The	_	
214-2	44895-44908	deactivations	_	
214-3	44909-44917	observed	_	
214-4	44918-44922	here	_	
214-5	44923-44926	may	_	
214-6	44927-44931	help	_	
214-7	44932-44934	to	_	
214-8	44935-44942	explain	_	
214-9	44943-44946	the	_	
214-10	44947-44951	link	_	
214-11	44952-44959	between	_	
214-12	44960-44968	maternal	_	
214-13	44969-44978	substance	_	
214-14	44979-44982	use	_	
214-15	44983-44986	and	_	
214-16	44987-44995	impaired	_	
214-17	44996-45004	maternal	_	
214-18	45005-45015	caregiving	_	
214-19	45015-45016	.	_	

#Text=Our findings point to the mother-infant relationship as an important element and context for intervention for mothers with addictions, who are often treated in isolation from their infants.
215-1	45017-45020	Our	_	
215-2	45021-45029	findings	_	
215-3	45030-45035	point	_	
215-4	45036-45038	to	_	
215-5	45039-45042	the	_	
215-6	45043-45056	mother-infant	_	
215-7	45057-45069	relationship	_	
215-8	45070-45072	as	_	
215-9	45073-45075	an	_	
215-10	45076-45085	important	_	
215-11	45086-45093	element	_	
215-12	45094-45097	and	_	
215-13	45098-45105	context	_	
215-14	45106-45109	for	_	
215-15	45110-45122	intervention	_	
215-16	45123-45126	for	_	
215-17	45127-45134	mothers	_	
215-18	45135-45139	with	_	
215-19	45140-45150	addictions	_	
215-20	45150-45151	,	_	
215-21	45152-45155	who	_	
215-22	45156-45159	are	_	
215-23	45160-45165	often	_	
215-24	45166-45173	treated	_	
215-25	45174-45176	in	_	
215-26	45177-45186	isolation	_	
215-27	45187-45191	from	_	
215-28	45192-45197	their	_	
215-29	45198-45205	infants	_	
215-30	45205-45206	.	_	

#Text=Understanding the neurobiological relationship between substance addictions and impaired maternal responses may facilitate earlier and more refined interventions to help support mothers with substance addictions and the infants in their care.
216-1	45207-45220	Understanding	_	
216-2	45221-45224	the	_	
216-3	45225-45240	neurobiological	_	
216-4	45241-45253	relationship	_	
216-5	45254-45261	between	_	
216-6	45262-45271	substance	_	
216-7	45272-45282	addictions	_	
216-8	45283-45286	and	_	
216-9	45287-45295	impaired	_	
216-10	45296-45304	maternal	_	
216-11	45305-45314	responses	_	
216-12	45315-45318	may	_	
216-13	45319-45329	facilitate	_	
216-14	45330-45337	earlier	_	
216-15	45338-45341	and	_	
216-16	45342-45346	more	_	
216-17	45347-45354	refined	_	
216-18	45355-45368	interventions	_	
216-19	45369-45371	to	_	
216-20	45372-45376	help	_	
216-21	45377-45384	support	_	
216-22	45385-45392	mothers	_	
216-23	45393-45397	with	_	
216-24	45398-45407	substance	_	
216-25	45408-45418	addictions	_	
216-26	45419-45422	and	_	
216-27	45423-45426	the	_	
216-28	45427-45434	infants	_	
216-29	45435-45437	in	_	
216-30	45438-45443	their	_	
216-31	45444-45448	care	_	
216-32	45448-45449	.	_	

#Text=The focus of treatment at this inpatient facility centered around co-habitation of mothers and infants, which was integrated into the mothers’ treatment program.
217-1	45450-45453	The	_	
217-2	45454-45459	focus	_	
217-3	45460-45462	of	_	
217-4	45463-45472	treatment	_	
217-5	45473-45475	at	_	
217-6	45476-45480	this	_	
217-7	45481-45490	inpatient	_	
217-8	45491-45499	facility	_	
217-9	45500-45508	centered	_	
217-10	45509-45515	around	_	
217-11	45516-45529	co-habitation	_	
217-12	45530-45532	of	_	
217-13	45533-45540	mothers	_	
217-14	45541-45544	and	_	
217-15	45545-45552	infants	_	
217-16	45552-45553	,	_	
217-17	45554-45559	which	_	
217-18	45560-45563	was	_	
217-19	45564-45574	integrated	_	
217-20	45575-45579	into	_	
217-21	45580-45583	the	_	
217-22	45584-45591	mothers	_	
217-23	45591-45592	’	_	
217-24	45593-45602	treatment	_	
217-25	45603-45610	program	_	
217-26	45610-45611	.	_	

#Text=All mothers cohabitated with at least one child, typically the child from their most recent pregnancy.
218-1	45612-45615	All	_	
218-2	45616-45623	mothers	_	
218-3	45624-45635	cohabitated	_	
218-4	45636-45640	with	_	
218-5	45641-45643	at	_	
218-6	45644-45649	least	_	
218-7	45650-45653	one	_	
218-8	45654-45659	child	_	
218-9	45659-45660	,	_	
218-10	45661-45670	typically	_	
218-11	45671-45674	the	_	
218-12	45675-45680	child	_	
218-13	45681-45685	from	_	
218-14	45686-45691	their	_	
218-15	45692-45696	most	_	
218-16	45697-45703	recent	_	
218-17	45704-45713	pregnancy	_	
218-18	45713-45714	.	_	

#Text=Additional children, of up to the age of 13, were also encouraged to accompany and reside with mothers during treatment.
219-1	45715-45725	Additional	_	
219-2	45726-45734	children	_	
219-3	45734-45735	,	_	
219-4	45736-45738	of	_	
219-5	45739-45741	up	_	
219-6	45742-45744	to	_	
219-7	45745-45748	the	_	
219-8	45749-45752	age	_	
219-9	45753-45755	of	_	
219-10	45756-45758	13	_	
219-11	45758-45759	,	_	
219-12	45760-45764	were	_	
219-13	45765-45769	also	_	
219-14	45770-45780	encouraged	_	
219-15	45781-45783	to	_	
219-16	45784-45793	accompany	_	
219-17	45794-45797	and	_	
219-18	45798-45804	reside	_	
219-19	45805-45809	with	_	
219-20	45810-45817	mothers	_	
219-21	45818-45824	during	_	
219-22	45825-45834	treatment	_	
219-23	45834-45835	.	_	

#Text=Mothers placed infants in on-campus childcare for 35 hours per week.
220-1	45836-45843	Mothers	_	
220-2	45844-45850	placed	_	
220-3	45851-45858	infants	_	
220-4	45859-45861	in	_	
220-5	45862-45871	on-campus	_	
220-6	45872-45881	childcare	_	
220-7	45882-45885	for	_	
220-8	45886-45888	35	_	
220-9	45889-45894	hours	_	
220-10	45895-45898	per	_	
220-11	45899-45903	week	_	
220-12	45903-45904	.	_	

#Text=Infants spent the remainder of the week with their mother in treatment.
221-1	45905-45912	Infants	_	
221-2	45913-45918	spent	_	
221-3	45919-45922	the	_	
221-4	45923-45932	remainder	_	
221-5	45933-45935	of	_	
221-6	45936-45939	the	_	
221-7	45940-45944	week	_	
221-8	45945-45949	with	_	
221-9	45950-45955	their	_	
221-10	45956-45962	mother	_	
221-11	45963-45965	in	_	
221-12	45966-45975	treatment	_	
221-13	45975-45976	.	_	

#Text=The standard treatment program was 90 days inpatient, with the option of completing up to 70 additional days of outpatient, which was co-located on the same campus.
222-1	45977-45980	The	_	
222-2	45981-45989	standard	_	
222-3	45990-45999	treatment	_	
222-4	46000-46007	program	_	
222-5	46008-46011	was	_	
222-6	46012-46014	90	_	
222-7	46015-46019	days	_	
222-8	46020-46029	inpatient	_	
222-9	46029-46030	,	_	
222-10	46031-46035	with	_	
222-11	46036-46039	the	_	
222-12	46040-46046	option	_	
222-13	46047-46049	of	_	
222-14	46050-46060	completing	_	
222-15	46061-46063	up	_	
222-16	46064-46066	to	_	
222-17	46067-46069	70	_	
222-18	46070-46080	additional	_	
222-19	46081-46085	days	_	
222-20	46086-46088	of	_	
222-21	46089-46099	outpatient	_	
222-22	46099-46100	,	_	
222-23	46101-46106	which	_	
222-24	46107-46110	was	_	
222-25	46111-46121	co-located	_	
222-26	46122-46124	on	_	
222-27	46125-46128	the	_	
222-28	46129-46133	same	_	
222-29	46134-46140	campus	_	
222-30	46140-46141	.	_	

#Text=Mothers returned home at the conclusion of treatment.
223-1	46142-46149	Mothers	_	
223-2	46150-46158	returned	_	
223-3	46159-46163	home	_	
223-4	46164-46166	at	_	
223-5	46167-46170	the	_	
223-6	46171-46181	conclusion	_	
223-7	46182-46184	of	_	
223-8	46185-46194	treatment	_	
223-9	46194-46195	.	_	

#Text=Participants’ average length of stay at the treatment facility prior to the scanning visit was approximately 110 (M = 109.6 ± 59.5) days.
224-1	46196-46208	Participants	_	
224-2	46208-46209	’	_	
224-3	46210-46217	average	_	
224-4	46218-46224	length	_	
224-5	46225-46227	of	_	
224-6	46228-46232	stay	_	
224-7	46233-46235	at	_	
224-8	46236-46239	the	_	
224-9	46240-46249	treatment	_	
224-10	46250-46258	facility	_	
224-11	46259-46264	prior	_	
224-12	46265-46267	to	_	
224-13	46268-46271	the	_	
224-14	46272-46280	scanning	_	
224-15	46281-46286	visit	_	
224-16	46287-46290	was	_	
224-17	46291-46304	approximately	_	
224-18	46305-46308	110	_	
224-19	46309-46310	(	_	
224-20	46310-46311	M	_	
224-21	46312-46313	=	_	
224-22	46314-46319	109.6	_	
224-23	46320-46321	±	_	
224-24	46322-46326	59.5	_	
224-25	46326-46327	)	_	
224-26	46328-46332	days	_	
224-27	46332-46333	.	_	

#Text=Besides the time spent in on-campus childcare (35 hours per week), no other mother-infant separation took place prior to the mother’s scanning visit.
225-1	46334-46341	Besides	_	
225-2	46342-46345	the	_	
225-3	46346-46350	time	_	
225-4	46351-46356	spent	_	
225-5	46357-46359	in	_	
225-6	46360-46369	on-campus	_	
225-7	46370-46379	childcare	_	
225-8	46380-46381	(	_	
225-9	46381-46383	35	_	
225-10	46384-46389	hours	_	
225-11	46390-46393	per	_	
225-12	46394-46398	week	_	
225-13	46398-46399	)	_	
225-14	46399-46400	,	_	
225-15	46401-46403	no	_	
225-16	46404-46409	other	_	
225-17	46410-46423	mother-infant	_	
225-18	46424-46434	separation	_	
225-19	46435-46439	took	_	
225-20	46440-46445	place	_	
225-21	46446-46451	prior	_	
225-22	46452-46454	to	_	
225-23	46455-46458	the	_	
225-24	46459-46465	mother	_	
225-25	46465-46466	’	_	
225-26	46466-46467	s	_	
225-27	46468-46476	scanning	_	
225-28	46477-46482	visit	_	
225-29	46482-46483	.	_	

#Text=Disclosures         
#Text=The authors report no conflicts of interest with respect to the content of this manuscript.
226-1	46495-46506	Disclosures	_	
226-2	46516-46519	The	_	
226-3	46520-46527	authors	_	
226-4	46528-46534	report	_	
226-5	46535-46537	no	_	
226-6	46538-46547	conflicts	_	
226-7	46548-46550	of	_	
226-8	46551-46559	interest	_	
226-9	46560-46564	with	_	
226-10	46565-46572	respect	_	
226-11	46573-46575	to	_	
226-12	46576-46579	the	_	
226-13	46580-46587	content	_	
226-14	46588-46590	of	_	
226-15	46591-46595	this	_	
226-16	46596-46606	manuscript	_	
226-17	46606-46607	.	_	

#Text=Dr.
227-1	46608-46610	Dr	_	
227-2	46610-46611	.	_	

#Text=Potenza has received financial support or compensation for the following: Dr.
228-1	46612-46619	Potenza	_	
228-2	46620-46623	has	_	
228-3	46624-46632	received	_	
228-4	46633-46642	financial	_	
228-5	46643-46650	support	_	
228-6	46651-46653	or	_	
228-7	46654-46666	compensation	_	
228-8	46667-46670	for	_	
228-9	46671-46674	the	_	
228-10	46675-46684	following	_	
228-11	46684-46685	:	_	
228-12	46686-46688	Dr	_	
228-13	46688-46689	.	_	

#Text=Potenza has consulted for Ironwood, Lundbeck, Shire, INSYS, RiverMend Health, Lakelight Therapeutics/Opiant and Jazz Pharmacetuicals; has received research support to Yale from Mohegan Sun Casino, the National Center for Responsible Gaming, and Pfizer; and has consulted for legal entities on issues related to addictive disorders.
229-1	46690-46697	Potenza	_	
229-2	46698-46701	has	_	
229-3	46702-46711	consulted	_	
229-4	46712-46715	for	_	
229-5	46716-46724	Ironwood	_	
229-6	46724-46725	,	_	
229-7	46726-46734	Lundbeck	_	
229-8	46734-46735	,	_	
229-9	46736-46741	Shire	_	
229-10	46741-46742	,	_	
229-11	46743-46748	INSYS	_	
229-12	46748-46749	,	_	
229-13	46750-46759	RiverMend	_	
229-14	46760-46766	Health	_	
229-15	46766-46767	,	_	
229-16	46768-46777	Lakelight	_	
229-17	46778-46790	Therapeutics	_	
229-18	46790-46791	/	_	
229-19	46791-46797	Opiant	_	
229-20	46798-46801	and	_	
229-21	46802-46806	Jazz	_	
229-22	46807-46822	Pharmacetuicals	_	
229-23	46822-46823	;	_	
229-24	46824-46827	has	_	
229-25	46828-46836	received	_	
229-26	46837-46845	research	_	
229-27	46846-46853	support	_	
229-28	46854-46856	to	_	
229-29	46857-46861	Yale	_	
229-30	46862-46866	from	_	
229-31	46867-46874	Mohegan	_	
229-32	46875-46878	Sun	_	
229-33	46879-46885	Casino	_	
229-34	46885-46886	,	_	
229-35	46887-46890	the	_	
229-36	46891-46899	National	_	
229-37	46900-46906	Center	_	
229-38	46907-46910	for	_	
229-39	46911-46922	Responsible	_	
229-40	46923-46929	Gaming	_	
229-41	46929-46930	,	_	
229-42	46931-46934	and	_	
229-43	46935-46941	Pfizer	_	
229-44	46941-46942	;	_	
229-45	46943-46946	and	_	
229-46	46947-46950	has	_	
229-47	46951-46960	consulted	_	
229-48	46961-46964	for	_	
229-49	46965-46970	legal	_	
229-50	46971-46979	entities	_	
229-51	46980-46982	on	_	
229-52	46983-46989	issues	_	
229-53	46990-46997	related	_	
229-54	46998-47000	to	_	
229-55	47001-47010	addictive	_	
229-56	47011-47020	disorders	_	
229-57	47020-47021	.	_	

#Text=Hormones that increase maternal responsiveness affect accumbal dopaminergic responses to pup- and food-stimuli in the female rat
#Text=Medial prefrontal cortex lesions in the female rat affect sexual and maternal behavior and their sequential organization
#Text=
#Text=Specifying the neurobiological basis of human attachment: brain, hormones, and behavior in synchronous and intrusive mothers
#Text=Synchrony and specificity in the maternal and the paternal brain: relations to oxytocin and vasopressin
#Text=Anticipatory reward processing in addicted populations: a focus on the monetary incentive delay task
#Text=Annual Research Review: All mothers are not created equal: neural and psychobiological perspectives on mothering and the importance of individual differences
#Text=Maternal affect and quality of parenting experiences are related to amygdala response to infant faces
#Text=Preventing child abuse and neglect with parent training: evidence and opportunities
#Text=Central lactogenic regulation of maternal behavior in rats: steroid dependence, hormone specificity, and behavioral potencies of rat prolactin and rat placental lactogen I
#Text=Endocrine induced changes in brain function during pregnancy
#Text=Individual differences underlying susceptibility to addiction: Role for the endogenous oxytocin system
#Text=
#Text=Naturally occurring variations in maternal behavior in the rat are associated with differences in estrogen-inducible central oxytocin receptors
#Text=Variations in nucleus accumbens dopamine associated with individual differences in maternal behavior in the rat
#Text=Is the statistic value all we should care about in neuroimaging?
230-1	47022-47030	Hormones	_	
230-2	47031-47035	that	_	
230-3	47036-47044	increase	_	
230-4	47045-47053	maternal	_	
230-5	47054-47068	responsiveness	_	
230-6	47069-47075	affect	_	
230-7	47076-47084	accumbal	_	
230-8	47085-47097	dopaminergic	_	
230-9	47098-47107	responses	_	
230-10	47108-47110	to	_	
230-11	47111-47114	pup	_	
230-12	47114-47115	-	_	
230-13	47116-47119	and	_	
230-14	47120-47132	food-stimuli	_	
230-15	47133-47135	in	_	
230-16	47136-47139	the	_	
230-17	47140-47146	female	_	
230-18	47147-47150	rat	_	
230-19	47151-47157	Medial	_	
230-20	47158-47168	prefrontal	_	
230-21	47169-47175	cortex	_	
230-22	47176-47183	lesions	_	
230-23	47184-47186	in	_	
230-24	47187-47190	the	_	
230-25	47191-47197	female	_	
230-26	47198-47201	rat	_	
230-27	47202-47208	affect	_	
230-28	47209-47215	sexual	_	
230-29	47216-47219	and	_	
230-30	47220-47228	maternal	_	
230-31	47229-47237	behavior	_	
230-32	47238-47241	and	_	
230-33	47242-47247	their	_	
230-34	47248-47258	sequential	_	
230-35	47259-47271	organization	_	
230-36	47273-47283	Specifying	_	
230-37	47284-47287	the	_	
230-38	47288-47303	neurobiological	_	
230-39	47304-47309	basis	_	
230-40	47310-47312	of	_	
230-41	47313-47318	human	_	
230-42	47319-47329	attachment	_	
230-43	47329-47330	:	_	
230-44	47331-47336	brain	_	
230-45	47336-47337	,	_	
230-46	47338-47346	hormones	_	
230-47	47346-47347	,	_	
230-48	47348-47351	and	_	
230-49	47352-47360	behavior	_	
230-50	47361-47363	in	_	
230-51	47364-47375	synchronous	_	
230-52	47376-47379	and	_	
230-53	47380-47389	intrusive	_	
230-54	47390-47397	mothers	_	
230-55	47398-47407	Synchrony	_	
230-56	47408-47411	and	_	
230-57	47412-47423	specificity	_	
230-58	47424-47426	in	_	
230-59	47427-47430	the	_	
230-60	47431-47439	maternal	_	
230-61	47440-47443	and	_	
230-62	47444-47447	the	_	
230-63	47448-47456	paternal	_	
230-64	47457-47462	brain	_	
230-65	47462-47463	:	_	
230-66	47464-47473	relations	_	
230-67	47474-47476	to	_	
230-68	47477-47485	oxytocin	_	
230-69	47486-47489	and	_	
230-70	47490-47501	vasopressin	_	
230-71	47502-47514	Anticipatory	_	
230-72	47515-47521	reward	_	
230-73	47522-47532	processing	_	
230-74	47533-47535	in	_	
230-75	47536-47544	addicted	_	
230-76	47545-47556	populations	_	
230-77	47556-47557	:	_	
230-78	47558-47559	a	_	
230-79	47560-47565	focus	_	
230-80	47566-47568	on	_	
230-81	47569-47572	the	_	
230-82	47573-47581	monetary	_	
230-83	47582-47591	incentive	_	
230-84	47592-47597	delay	_	
230-85	47598-47602	task	_	
230-86	47603-47609	Annual	_	
230-87	47610-47618	Research	_	
230-88	47619-47625	Review	_	
230-89	47625-47626	:	_	
230-90	47627-47630	All	_	
230-91	47631-47638	mothers	_	
230-92	47639-47642	are	_	
230-93	47643-47646	not	_	
230-94	47647-47654	created	_	
230-95	47655-47660	equal	_	
230-96	47660-47661	:	_	
230-97	47662-47668	neural	_	
230-98	47669-47672	and	_	
230-99	47673-47689	psychobiological	_	
230-100	47690-47702	perspectives	_	
230-101	47703-47705	on	_	
230-102	47706-47715	mothering	_	
230-103	47716-47719	and	_	
230-104	47720-47723	the	_	
230-105	47724-47734	importance	_	
230-106	47735-47737	of	_	
230-107	47738-47748	individual	_	
230-108	47749-47760	differences	_	
230-109	47761-47769	Maternal	_	
230-110	47770-47776	affect	_	
230-111	47777-47780	and	_	
230-112	47781-47788	quality	_	
230-113	47789-47791	of	_	
230-114	47792-47801	parenting	_	
230-115	47802-47813	experiences	_	
230-116	47814-47817	are	_	
230-117	47818-47825	related	_	
230-118	47826-47828	to	_	
230-119	47829-47837	amygdala	_	
230-120	47838-47846	response	_	
230-121	47847-47849	to	_	
230-122	47850-47856	infant	_	
230-123	47857-47862	faces	_	
230-124	47863-47873	Preventing	_	
230-125	47874-47879	child	_	
230-126	47880-47885	abuse	_	
230-127	47886-47889	and	_	
230-128	47890-47897	neglect	_	
230-129	47898-47902	with	_	
230-130	47903-47909	parent	_	
230-131	47910-47918	training	_	
230-132	47918-47919	:	_	
230-133	47920-47928	evidence	_	
230-134	47929-47932	and	_	
230-135	47933-47946	opportunities	_	
230-136	47947-47954	Central	_	
230-137	47955-47965	lactogenic	_	
230-138	47966-47976	regulation	_	
230-139	47977-47979	of	_	
230-140	47980-47988	maternal	_	
230-141	47989-47997	behavior	_	
230-142	47998-48000	in	_	
230-143	48001-48005	rats	_	
230-144	48005-48006	:	_	
230-145	48007-48014	steroid	_	
230-146	48015-48025	dependence	_	
230-147	48025-48026	,	_	
230-148	48027-48034	hormone	_	
230-149	48035-48046	specificity	_	
230-150	48046-48047	,	_	
230-151	48048-48051	and	_	
230-152	48052-48062	behavioral	_	
230-153	48063-48072	potencies	_	
230-154	48073-48075	of	_	
230-155	48076-48079	rat	_	
230-156	48080-48089	prolactin	_	
230-157	48090-48093	and	_	
230-158	48094-48097	rat	_	
230-159	48098-48107	placental	_	
230-160	48108-48116	lactogen	_	
230-161	48117-48118	I	_	
230-162	48119-48128	Endocrine	_	
230-163	48129-48136	induced	_	
230-164	48137-48144	changes	_	
230-165	48145-48147	in	_	
230-166	48148-48153	brain	_	
230-167	48154-48162	function	_	
230-168	48163-48169	during	_	
230-169	48170-48179	pregnancy	_	
230-170	48180-48190	Individual	_	
230-171	48191-48202	differences	_	
230-172	48203-48213	underlying	_	
230-173	48214-48228	susceptibility	_	
230-174	48229-48231	to	_	
230-175	48232-48241	addiction	_	
230-176	48241-48242	:	_	
230-177	48243-48247	Role	_	
230-178	48248-48251	for	_	
230-179	48252-48255	the	_	
230-180	48256-48266	endogenous	_	
230-181	48267-48275	oxytocin	_	
230-182	48276-48282	system	_	
230-183	48284-48293	Naturally	_	
230-184	48294-48303	occurring	_	
230-185	48304-48314	variations	_	
230-186	48315-48317	in	_	
230-187	48318-48326	maternal	_	
230-188	48327-48335	behavior	_	
230-189	48336-48338	in	_	
230-190	48339-48342	the	_	
230-191	48343-48346	rat	_	
230-192	48347-48350	are	_	
230-193	48351-48361	associated	_	
230-194	48362-48366	with	_	
230-195	48367-48378	differences	_	
230-196	48379-48381	in	_	
230-197	48382-48400	estrogen-inducible	_	
230-198	48401-48408	central	_	
230-199	48409-48417	oxytocin	_	
230-200	48418-48427	receptors	_	
230-201	48428-48438	Variations	_	
230-202	48439-48441	in	_	
230-203	48442-48449	nucleus	_	
230-204	48450-48459	accumbens	_	
230-205	48460-48468	dopamine	_	
230-206	48469-48479	associated	_	
230-207	48480-48484	with	_	
230-208	48485-48495	individual	_	
230-209	48496-48507	differences	_	
230-210	48508-48510	in	_	
230-211	48511-48519	maternal	_	
230-212	48520-48528	behavior	_	
230-213	48529-48531	in	_	
230-214	48532-48535	the	_	
230-215	48536-48539	rat	_	
230-216	48540-48542	Is	_	
230-217	48543-48546	the	_	
230-218	48547-48556	statistic	_	
230-219	48557-48562	value	_	
230-220	48563-48566	all	_	
230-221	48567-48569	we	_	
230-222	48570-48576	should	_	
230-223	48577-48581	care	_	
230-224	48582-48587	about	_	
230-225	48588-48590	in	_	
230-226	48591-48603	neuroimaging	_	
230-227	48603-48604	?	_	

#Text=Emotion displays in two-year-olds during mishaps
#Text=The role of the right temporoparietal junction in social interaction: how low-level computational processes contribute to meta-cognition
#Text=Inactivation or inhibition of neuronal activity in the medial prefrontal cortex largely reduces pup retrieval and grouping in maternal rats
#Text=Development of cocaine sensitization before pregnancy affects subsequent maternal retrieval of pups and prefrontal cortical activity during nursing
#Text=Pup suckling is more rewarding than cocaine: evidence from functional magnetic resonance imaging and three-dimensional computational analysis
#Text=The neurobiology of substance and behavioral addictions
#Text=Convergence and segregation of ventral striatal inputs and outputs
#Text=Gestational treatment with cocaine and fluoxetine alters oxytocin receptor number and binding affinity in lactating rat dams
#Text=Chronic gestational cocaine treatment decreases oxytocin levels in the medial preoptic area, ventral tegmental area and hippocampus in Sprague-Dawley rats
#Text=The neural basis of addiction: a pathology of motivation and choice
#Text=The plasticity of human maternal brain: longitudinal changes in brain anatomy during the early postpartum period
#Text=The maternal brain and its plasticity in humans
#Text=Mothers’ unresolved trauma blunts amygdala response to infant distress
#Text=Maternal oxytocin response predicts mother-to-infant gaze
#Text=Early adverse experience and substance addiction: dopamine, oxytocin, and glucocorticoid pathways
#Text=Oxytocin and maternal brain plasticity
#Text=Addiction as a stress surfeit disorder
#Text=Neurocircuitry of addiction
#Text=The effects of drug abuse on pregnancy
#Text=Maternal neural responses to infant cries and faces: relationships with substance use
#Text=Neural basis of maternal communication and emotional expression processing during infant preverbal stage
#Text=The nucleus accumbens shell is critical for normal expression of pup-retrieval in postpartum female rats
#Text=Deficits in plasma oxytocin responses and increased negative affect, stress, and blood pressure in mothers with cocaine exposure during pregnancy
#Text=Responsiveness to drug cues and natural rewards in opiate addiction: associations with later heroin use
#Text=Drug-evoked synaptic plasticity in addiction: from molecular changes to circuit remodeling
#Text=
#Text=Births: Final data for 2013
#Text=Preference for cocaine-versus pup-associated cues differentially activates neurons expressing either Fos or cocaine- and amphetamine-regulated transcript in lactating, maternal rodents
#Text=Methamphetamine dependent individuals show attenuated brain response to pleasant interoceptive stimuli
#Text=The Fifth Edition of the Addiction Severity Index
#Text=Regional brain responses in nulliparous women to emotional infant stimuli
#Text=
#Text=Effects of cocaine on maternal behavior and neurochemistry
#Text=The functional neuroanatomy of maternal love: mother’s response to infant’s attachment behaviors
#Text=The effects of D1 or D2 dopamine receptor antagonism in the medial preoptic area, ventral pallidum, or nucleus accumbens on the maternal retrieval response and other aspects of maternal behavior in rats
#Text=Medial preoptic area and onset of maternal behavior in the rat
#Text=Maternity: neural mechanisms, motivational processes, and physiological adaptations
#Text=Oxytocin activates the postpartum onset of rat maternal behavior in the ventral tegmental and medial preoptic areas
#Text=Functional mapping of the neural circuitry of rat maternal motivation: effects of site-specific transient neural inactivation
#Text=Misconceptions in the use of the General Linear Model applied to functional MRI: a tutorial for junior neuro-imagers
#Text=Guidelines for reporting an fMRI study
#Text=The biology of mammalian parenting and its effect on offspring social development
#Text=Disruption of maternal parenting circuitry by addictive process: rewiring of reward and stress systems
#Text=Parenting and addiction: Neurobiological insights
#Text=Oxytocin in the medial prefrontal cortex regulates maternal care, maternal aggression and anxiety during the postpartum period
#Text=Cortico-Basal Ganglia reward network: microcircuitry
#Text=The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview
#Text=A functional neuroanatomical investigation of the role of the medial preoptic area in neural circuits regulating maternal behavior
#Text=Dopamine D1 receptor stimulation of the nucleus accumbens or the medial preoptic area promotes the onset of maternal behavior in pregnancy-terminated rats
#Text=Hypothalamic interaction with the mesolimbic DA system in the control of the maternal and sexual behaviors in rats
#Text=Adult attachment predicts maternal brain and oxytocin response to infant cues
#Text=Mothers’ amygdala response to positive or negative infant affect is modulated by personal relevance
#Text=What’s in a smile?
231-1	48606-48613	Emotion	_	
231-2	48614-48622	displays	_	
231-3	48623-48625	in	_	
231-4	48626-48639	two-year-olds	_	
231-5	48640-48646	during	_	
231-6	48647-48654	mishaps	_	
231-7	48655-48658	The	_	
231-8	48659-48663	role	_	
231-9	48664-48666	of	_	
231-10	48667-48670	the	_	
231-11	48671-48676	right	_	
231-12	48677-48692	temporoparietal	_	
231-13	48693-48701	junction	_	
231-14	48702-48704	in	_	
231-15	48705-48711	social	_	
231-16	48712-48723	interaction	_	
231-17	48723-48724	:	_	
231-18	48725-48728	how	_	
231-19	48729-48738	low-level	_	
231-20	48739-48752	computational	_	
231-21	48753-48762	processes	_	
231-22	48763-48773	contribute	_	
231-23	48774-48776	to	_	
231-24	48777-48791	meta-cognition	_	
231-25	48792-48804	Inactivation	_	
231-26	48805-48807	or	_	
231-27	48808-48818	inhibition	_	
231-28	48819-48821	of	_	
231-29	48822-48830	neuronal	_	
231-30	48831-48839	activity	_	
231-31	48840-48842	in	_	
231-32	48843-48846	the	_	
231-33	48847-48853	medial	_	
231-34	48854-48864	prefrontal	_	
231-35	48865-48871	cortex	_	
231-36	48872-48879	largely	_	
231-37	48880-48887	reduces	_	
231-38	48888-48891	pup	_	
231-39	48892-48901	retrieval	_	
231-40	48902-48905	and	_	
231-41	48906-48914	grouping	_	
231-42	48915-48917	in	_	
231-43	48918-48926	maternal	_	
231-44	48927-48931	rats	_	
231-45	48932-48943	Development	_	
231-46	48944-48946	of	_	
231-47	48947-48954	cocaine	_	
231-48	48955-48968	sensitization	_	
231-49	48969-48975	before	_	
231-50	48976-48985	pregnancy	_	
231-51	48986-48993	affects	_	
231-52	48994-49004	subsequent	_	
231-53	49005-49013	maternal	_	
231-54	49014-49023	retrieval	_	
231-55	49024-49026	of	_	
231-56	49027-49031	pups	_	
231-57	49032-49035	and	_	
231-58	49036-49046	prefrontal	_	
231-59	49047-49055	cortical	_	
231-60	49056-49064	activity	_	
231-61	49065-49071	during	_	
231-62	49072-49079	nursing	_	
231-63	49080-49083	Pup	_	
231-64	49084-49092	suckling	_	
231-65	49093-49095	is	_	
231-66	49096-49100	more	_	
231-67	49101-49110	rewarding	_	
231-68	49111-49115	than	_	
231-69	49116-49123	cocaine	_	
231-70	49123-49124	:	_	
231-71	49125-49133	evidence	_	
231-72	49134-49138	from	_	
231-73	49139-49149	functional	_	
231-74	49150-49158	magnetic	_	
231-75	49159-49168	resonance	_	
231-76	49169-49176	imaging	_	
231-77	49177-49180	and	_	
231-78	49181-49198	three-dimensional	_	
231-79	49199-49212	computational	_	
231-80	49213-49221	analysis	_	
231-81	49222-49225	The	_	
231-82	49226-49238	neurobiology	_	
231-83	49239-49241	of	_	
231-84	49242-49251	substance	_	
231-85	49252-49255	and	_	
231-86	49256-49266	behavioral	_	
231-87	49267-49277	addictions	_	
231-88	49278-49289	Convergence	_	
231-89	49290-49293	and	_	
231-90	49294-49305	segregation	_	
231-91	49306-49308	of	_	
231-92	49309-49316	ventral	_	
231-93	49317-49325	striatal	_	
231-94	49326-49332	inputs	_	
231-95	49333-49336	and	_	
231-96	49337-49344	outputs	_	
231-97	49345-49356	Gestational	_	
231-98	49357-49366	treatment	_	
231-99	49367-49371	with	_	
231-100	49372-49379	cocaine	_	
231-101	49380-49383	and	_	
231-102	49384-49394	fluoxetine	_	
231-103	49395-49401	alters	_	
231-104	49402-49410	oxytocin	_	
231-105	49411-49419	receptor	_	
231-106	49420-49426	number	_	
231-107	49427-49430	and	_	
231-108	49431-49438	binding	_	
231-109	49439-49447	affinity	_	
231-110	49448-49450	in	_	
231-111	49451-49460	lactating	_	
231-112	49461-49464	rat	_	
231-113	49465-49469	dams	_	
231-114	49470-49477	Chronic	_	
231-115	49478-49489	gestational	_	
231-116	49490-49497	cocaine	_	
231-117	49498-49507	treatment	_	
231-118	49508-49517	decreases	_	
231-119	49518-49526	oxytocin	_	
231-120	49527-49533	levels	_	
231-121	49534-49536	in	_	
231-122	49537-49540	the	_	
231-123	49541-49547	medial	_	
231-124	49548-49556	preoptic	_	
231-125	49557-49561	area	_	
231-126	49561-49562	,	_	
231-127	49563-49570	ventral	_	
231-128	49571-49580	tegmental	_	
231-129	49581-49585	area	_	
231-130	49586-49589	and	_	
231-131	49590-49601	hippocampus	_	
231-132	49602-49604	in	_	
231-133	49605-49619	Sprague-Dawley	_	
231-134	49620-49624	rats	_	
231-135	49625-49628	The	_	
231-136	49629-49635	neural	_	
231-137	49636-49641	basis	_	
231-138	49642-49644	of	_	
231-139	49645-49654	addiction	_	
231-140	49654-49655	:	_	
231-141	49656-49657	a	_	
231-142	49658-49667	pathology	_	
231-143	49668-49670	of	_	
231-144	49671-49681	motivation	_	
231-145	49682-49685	and	_	
231-146	49686-49692	choice	_	
231-147	49693-49696	The	_	
231-148	49697-49707	plasticity	_	
231-149	49708-49710	of	_	
231-150	49711-49716	human	_	
231-151	49717-49725	maternal	_	
231-152	49726-49731	brain	_	
231-153	49731-49732	:	_	
231-154	49733-49745	longitudinal	_	
231-155	49746-49753	changes	_	
231-156	49754-49756	in	_	
231-157	49757-49762	brain	_	
231-158	49763-49770	anatomy	_	
231-159	49771-49777	during	_	
231-160	49778-49781	the	_	
231-161	49782-49787	early	_	
231-162	49788-49798	postpartum	_	
231-163	49799-49805	period	_	
231-164	49806-49809	The	_	
231-165	49810-49818	maternal	_	
231-166	49819-49824	brain	_	
231-167	49825-49828	and	_	
231-168	49829-49832	its	_	
231-169	49833-49843	plasticity	_	
231-170	49844-49846	in	_	
231-171	49847-49853	humans	_	
231-172	49854-49861	Mothers	_	
231-173	49861-49862	’	_	
231-174	49863-49873	unresolved	_	
231-175	49874-49880	trauma	_	
231-176	49881-49887	blunts	_	
231-177	49888-49896	amygdala	_	
231-178	49897-49905	response	_	
231-179	49906-49908	to	_	
231-180	49909-49915	infant	_	
231-181	49916-49924	distress	_	
231-182	49925-49933	Maternal	_	
231-183	49934-49942	oxytocin	_	
231-184	49943-49951	response	_	
231-185	49952-49960	predicts	_	
231-186	49961-49977	mother-to-infant	_	
231-187	49978-49982	gaze	_	
231-188	49983-49988	Early	_	
231-189	49989-49996	adverse	_	
231-190	49997-50007	experience	_	
231-191	50008-50011	and	_	
231-192	50012-50021	substance	_	
231-193	50022-50031	addiction	_	
231-194	50031-50032	:	_	
231-195	50033-50041	dopamine	_	
231-196	50041-50042	,	_	
231-197	50043-50051	oxytocin	_	
231-198	50051-50052	,	_	
231-199	50053-50056	and	_	
231-200	50057-50071	glucocorticoid	_	
231-201	50072-50080	pathways	_	
231-202	50081-50089	Oxytocin	_	
231-203	50090-50093	and	_	
231-204	50094-50102	maternal	_	
231-205	50103-50108	brain	_	
231-206	50109-50119	plasticity	_	
231-207	50120-50129	Addiction	_	
231-208	50130-50132	as	_	
231-209	50133-50134	a	_	
231-210	50135-50141	stress	_	
231-211	50142-50149	surfeit	_	
231-212	50150-50158	disorder	_	
231-213	50159-50173	Neurocircuitry	_	
231-214	50174-50176	of	_	
231-215	50177-50186	addiction	_	
231-216	50187-50190	The	_	
231-217	50191-50198	effects	_	
231-218	50199-50201	of	_	
231-219	50202-50206	drug	_	
231-220	50207-50212	abuse	_	
231-221	50213-50215	on	_	
231-222	50216-50225	pregnancy	_	
231-223	50226-50234	Maternal	_	
231-224	50235-50241	neural	_	
231-225	50242-50251	responses	_	
231-226	50252-50254	to	_	
231-227	50255-50261	infant	_	
231-228	50262-50267	cries	_	
231-229	50268-50271	and	_	
231-230	50272-50277	faces	_	
231-231	50277-50278	:	_	
231-232	50279-50292	relationships	_	
231-233	50293-50297	with	_	
231-234	50298-50307	substance	_	
231-235	50308-50311	use	_	
231-236	50312-50318	Neural	_	
231-237	50319-50324	basis	_	
231-238	50325-50327	of	_	
231-239	50328-50336	maternal	_	
231-240	50337-50350	communication	_	
231-241	50351-50354	and	_	
231-242	50355-50364	emotional	_	
231-243	50365-50375	expression	_	
231-244	50376-50386	processing	_	
231-245	50387-50393	during	_	
231-246	50394-50400	infant	_	
231-247	50401-50410	preverbal	_	
231-248	50411-50416	stage	_	
231-249	50417-50420	The	_	
231-250	50421-50428	nucleus	_	
231-251	50429-50438	accumbens	_	
231-252	50439-50444	shell	_	
231-253	50445-50447	is	_	
231-254	50448-50456	critical	_	
231-255	50457-50460	for	_	
231-256	50461-50467	normal	_	
231-257	50468-50478	expression	_	
231-258	50479-50481	of	_	
231-259	50482-50495	pup-retrieval	_	
231-260	50496-50498	in	_	
231-261	50499-50509	postpartum	_	
231-262	50510-50516	female	_	
231-263	50517-50521	rats	_	
231-264	50522-50530	Deficits	_	
231-265	50531-50533	in	_	
231-266	50534-50540	plasma	_	
231-267	50541-50549	oxytocin	_	
231-268	50550-50559	responses	_	
231-269	50560-50563	and	_	
231-270	50564-50573	increased	_	
231-271	50574-50582	negative	_	
231-272	50583-50589	affect	_	
231-273	50589-50590	,	_	
231-274	50591-50597	stress	_	
231-275	50597-50598	,	_	
231-276	50599-50602	and	_	
231-277	50603-50608	blood	_	
231-278	50609-50617	pressure	_	
231-279	50618-50620	in	_	
231-280	50621-50628	mothers	_	
231-281	50629-50633	with	_	
231-282	50634-50641	cocaine	_	
231-283	50642-50650	exposure	_	
231-284	50651-50657	during	_	
231-285	50658-50667	pregnancy	_	
231-286	50668-50682	Responsiveness	_	
231-287	50683-50685	to	_	
231-288	50686-50690	drug	_	
231-289	50691-50695	cues	_	
231-290	50696-50699	and	_	
231-291	50700-50707	natural	_	
231-292	50708-50715	rewards	_	
231-293	50716-50718	in	_	
231-294	50719-50725	opiate	_	
231-295	50726-50735	addiction	_	
231-296	50735-50736	:	_	
231-297	50737-50749	associations	_	
231-298	50750-50754	with	_	
231-299	50755-50760	later	_	
231-300	50761-50767	heroin	_	
231-301	50768-50771	use	_	
231-302	50772-50783	Drug-evoked	_	
231-303	50784-50792	synaptic	_	
231-304	50793-50803	plasticity	_	
231-305	50804-50806	in	_	
231-306	50807-50816	addiction	_	
231-307	50816-50817	:	_	
231-308	50818-50822	from	_	
231-309	50823-50832	molecular	_	
231-310	50833-50840	changes	_	
231-311	50841-50843	to	_	
231-312	50844-50851	circuit	_	
231-313	50852-50862	remodeling	_	
231-314	50864-50870	Births	_	
231-315	50870-50871	:	_	
231-316	50872-50877	Final	_	
231-317	50878-50882	data	_	
231-318	50883-50886	for	_	
231-319	50887-50891	2013	_	
231-320	50892-50902	Preference	_	
231-321	50903-50906	for	_	
231-322	50907-50921	cocaine-versus	_	
231-323	50922-50936	pup-associated	_	
231-324	50937-50941	cues	_	
231-325	50942-50956	differentially	_	
231-326	50957-50966	activates	_	
231-327	50967-50974	neurons	_	
231-328	50975-50985	expressing	_	
231-329	50986-50992	either	_	
231-330	50993-50996	Fos	_	
231-331	50997-50999	or	_	
231-332	51000-51007	cocaine	_	
231-333	51007-51008	-	_	
231-334	51009-51012	and	_	
231-335	51013-51034	amphetamine-regulated	_	
231-336	51035-51045	transcript	_	
231-337	51046-51048	in	_	
231-338	51049-51058	lactating	_	
231-339	51058-51059	,	_	
231-340	51060-51068	maternal	_	
231-341	51069-51076	rodents	_	
231-342	51077-51092	Methamphetamine	_	
231-343	51093-51102	dependent	_	
231-344	51103-51114	individuals	_	
231-345	51115-51119	show	_	
231-346	51120-51130	attenuated	_	
231-347	51131-51136	brain	_	
231-348	51137-51145	response	_	
231-349	51146-51148	to	_	
231-350	51149-51157	pleasant	_	
231-351	51158-51171	interoceptive	_	
231-352	51172-51179	stimuli	_	
231-353	51180-51183	The	_	
231-354	51184-51189	Fifth	_	
231-355	51190-51197	Edition	_	
231-356	51198-51200	of	_	
231-357	51201-51204	the	_	
231-358	51205-51214	Addiction	_	
231-359	51215-51223	Severity	_	
231-360	51224-51229	Index	_	
231-361	51230-51238	Regional	_	
231-362	51239-51244	brain	_	
231-363	51245-51254	responses	_	
231-364	51255-51257	in	_	
231-365	51258-51269	nulliparous	_	
231-366	51270-51275	women	_	
231-367	51276-51278	to	_	
231-368	51279-51288	emotional	_	
231-369	51289-51295	infant	_	
231-370	51296-51303	stimuli	_	
231-371	51305-51312	Effects	_	
231-372	51313-51315	of	_	
231-373	51316-51323	cocaine	_	
231-374	51324-51326	on	_	
231-375	51327-51335	maternal	_	
231-376	51336-51344	behavior	_	
231-377	51345-51348	and	_	
231-378	51349-51363	neurochemistry	_	
231-379	51364-51367	The	_	
231-380	51368-51378	functional	_	
231-381	51379-51391	neuroanatomy	_	
231-382	51392-51394	of	_	
231-383	51395-51403	maternal	_	
231-384	51404-51408	love	_	
231-385	51408-51409	:	_	
231-386	51410-51416	mother	_	
231-387	51416-51417	’	_	
231-388	51417-51418	s	_	
231-389	51419-51427	response	_	
231-390	51428-51430	to	_	
231-391	51431-51437	infant	_	
231-392	51437-51438	’	_	
231-393	51438-51439	s	_	
231-394	51440-51450	attachment	_	
231-395	51451-51460	behaviors	_	
231-396	51461-51464	The	_	
231-397	51465-51472	effects	_	
231-398	51473-51475	of	_	
231-399	51476-51478	D1	_	
231-400	51479-51481	or	_	
231-401	51482-51484	D2	_	
231-402	51485-51493	dopamine	_	
231-403	51494-51502	receptor	_	
231-404	51503-51513	antagonism	_	
231-405	51514-51516	in	_	
231-406	51517-51520	the	_	
231-407	51521-51527	medial	_	
231-408	51528-51536	preoptic	_	
231-409	51537-51541	area	_	
231-410	51541-51542	,	_	
231-411	51543-51550	ventral	_	
231-412	51551-51559	pallidum	_	
231-413	51559-51560	,	_	
231-414	51561-51563	or	_	
231-415	51564-51571	nucleus	_	
231-416	51572-51581	accumbens	_	
231-417	51582-51584	on	_	
231-418	51585-51588	the	_	
231-419	51589-51597	maternal	_	
231-420	51598-51607	retrieval	_	
231-421	51608-51616	response	_	
231-422	51617-51620	and	_	
231-423	51621-51626	other	_	
231-424	51627-51634	aspects	_	
231-425	51635-51637	of	_	
231-426	51638-51646	maternal	_	
231-427	51647-51655	behavior	_	
231-428	51656-51658	in	_	
231-429	51659-51663	rats	_	
231-430	51664-51670	Medial	_	
231-431	51671-51679	preoptic	_	
231-432	51680-51684	area	_	
231-433	51685-51688	and	_	
231-434	51689-51694	onset	_	
231-435	51695-51697	of	_	
231-436	51698-51706	maternal	_	
231-437	51707-51715	behavior	_	
231-438	51716-51718	in	_	
231-439	51719-51722	the	_	
231-440	51723-51726	rat	_	
231-441	51727-51736	Maternity	_	
231-442	51736-51737	:	_	
231-443	51738-51744	neural	_	
231-444	51745-51755	mechanisms	_	
231-445	51755-51756	,	_	
231-446	51757-51769	motivational	_	
231-447	51770-51779	processes	_	
231-448	51779-51780	,	_	
231-449	51781-51784	and	_	
231-450	51785-51798	physiological	_	
231-451	51799-51810	adaptations	_	
231-452	51811-51819	Oxytocin	_	
231-453	51820-51829	activates	_	
231-454	51830-51833	the	_	
231-455	51834-51844	postpartum	_	
231-456	51845-51850	onset	_	
231-457	51851-51853	of	_	
231-458	51854-51857	rat	_	
231-459	51858-51866	maternal	_	
231-460	51867-51875	behavior	_	
231-461	51876-51878	in	_	
231-462	51879-51882	the	_	
231-463	51883-51890	ventral	_	
231-464	51891-51900	tegmental	_	
231-465	51901-51904	and	_	
231-466	51905-51911	medial	_	
231-467	51912-51920	preoptic	_	
231-468	51921-51926	areas	_	
231-469	51927-51937	Functional	_	
231-470	51938-51945	mapping	_	
231-471	51946-51948	of	_	
231-472	51949-51952	the	_	
231-473	51953-51959	neural	_	
231-474	51960-51969	circuitry	_	
231-475	51970-51972	of	_	
231-476	51973-51976	rat	_	
231-477	51977-51985	maternal	_	
231-478	51986-51996	motivation	_	
231-479	51996-51997	:	_	
231-480	51998-52005	effects	_	
231-481	52006-52008	of	_	
231-482	52009-52022	site-specific	_	
231-483	52023-52032	transient	_	
231-484	52033-52039	neural	_	
231-485	52040-52052	inactivation	_	
231-486	52053-52067	Misconceptions	_	
231-487	52068-52070	in	_	
231-488	52071-52074	the	_	
231-489	52075-52078	use	_	
231-490	52079-52081	of	_	
231-491	52082-52085	the	_	
231-492	52086-52093	General	_	
231-493	52094-52100	Linear	_	
231-494	52101-52106	Model	_	
231-495	52107-52114	applied	_	
231-496	52115-52117	to	_	
231-497	52118-52128	functional	_	
231-498	52129-52132	MRI	_	
231-499	52132-52133	:	_	
231-500	52134-52135	a	_	
231-501	52136-52144	tutorial	_	
231-502	52145-52148	for	_	
231-503	52149-52155	junior	_	
231-504	52156-52169	neuro-imagers	_	
231-505	52170-52180	Guidelines	_	
231-506	52181-52184	for	_	
231-507	52185-52194	reporting	_	
231-508	52195-52197	an	_	
231-509	52198-52202	fMRI	_	
231-510	52203-52208	study	_	
231-511	52209-52212	The	_	
231-512	52213-52220	biology	_	
231-513	52221-52223	of	_	
231-514	52224-52233	mammalian	_	
231-515	52234-52243	parenting	_	
231-516	52244-52247	and	_	
231-517	52248-52251	its	_	
231-518	52252-52258	effect	_	
231-519	52259-52261	on	_	
231-520	52262-52271	offspring	_	
231-521	52272-52278	social	_	
231-522	52279-52290	development	_	
231-523	52291-52301	Disruption	_	
231-524	52302-52304	of	_	
231-525	52305-52313	maternal	_	
231-526	52314-52323	parenting	_	
231-527	52324-52333	circuitry	_	
231-528	52334-52336	by	_	
231-529	52337-52346	addictive	_	
231-530	52347-52354	process	_	
231-531	52354-52355	:	_	
231-532	52356-52364	rewiring	_	
231-533	52365-52367	of	_	
231-534	52368-52374	reward	_	
231-535	52375-52378	and	_	
231-536	52379-52385	stress	_	
231-537	52386-52393	systems	_	
231-538	52394-52403	Parenting	_	
231-539	52404-52407	and	_	
231-540	52408-52417	addiction	_	
231-541	52417-52418	:	_	
231-542	52419-52434	Neurobiological	_	
231-543	52435-52443	insights	_	
231-544	52444-52452	Oxytocin	_	
231-545	52453-52455	in	_	
231-546	52456-52459	the	_	
231-547	52460-52466	medial	_	
231-548	52467-52477	prefrontal	_	
231-549	52478-52484	cortex	_	
231-550	52485-52494	regulates	_	
231-551	52495-52503	maternal	_	
231-552	52504-52508	care	_	
231-553	52508-52509	,	_	
231-554	52510-52518	maternal	_	
231-555	52519-52529	aggression	_	
231-556	52530-52533	and	_	
231-557	52534-52541	anxiety	_	
231-558	52542-52548	during	_	
231-559	52549-52552	the	_	
231-560	52553-52563	postpartum	_	
231-561	52564-52570	period	_	
231-562	52571-52584	Cortico-Basal	_	
231-563	52585-52592	Ganglia	_	
231-564	52593-52599	reward	_	
231-565	52600-52607	network	_	
231-566	52607-52608	:	_	
231-567	52609-52623	microcircuitry	_	
231-568	52624-52627	The	_	
231-569	52628-52646	Mini-International	_	
231-570	52647-52663	Neuropsychiatric	_	
231-571	52664-52673	Interview	_	
231-572	52674-52675	(	_	
231-573	52675-52682	M.I.N.I	_	
231-574	52682-52683	.	_	
231-575	52683-52684	)	_	
231-576	52684-52685	:	_	
231-577	52686-52689	the	_	
231-578	52690-52701	development	_	
231-579	52702-52705	and	_	
231-580	52706-52716	validation	_	
231-581	52717-52719	of	_	
231-582	52720-52721	a	_	
231-583	52722-52732	structured	_	
231-584	52733-52743	diagnostic	_	
231-585	52744-52755	psychiatric	_	
231-586	52756-52765	interview	_	
231-587	52766-52767	A	_	
231-588	52768-52778	functional	_	
231-589	52779-52794	neuroanatomical	_	
231-590	52795-52808	investigation	_	
231-591	52809-52811	of	_	
231-592	52812-52815	the	_	
231-593	52816-52820	role	_	
231-594	52821-52823	of	_	
231-595	52824-52827	the	_	
231-596	52828-52834	medial	_	
231-597	52835-52843	preoptic	_	
231-598	52844-52848	area	_	
231-599	52849-52851	in	_	
231-600	52852-52858	neural	_	
231-601	52859-52867	circuits	_	
231-602	52868-52878	regulating	_	
231-603	52879-52887	maternal	_	
231-604	52888-52896	behavior	_	
231-605	52897-52905	Dopamine	_	
231-606	52906-52908	D1	_	
231-607	52909-52917	receptor	_	
231-608	52918-52929	stimulation	_	
231-609	52930-52932	of	_	
231-610	52933-52936	the	_	
231-611	52937-52944	nucleus	_	
231-612	52945-52954	accumbens	_	
231-613	52955-52957	or	_	
231-614	52958-52961	the	_	
231-615	52962-52968	medial	_	
231-616	52969-52977	preoptic	_	
231-617	52978-52982	area	_	
231-618	52983-52991	promotes	_	
231-619	52992-52995	the	_	
231-620	52996-53001	onset	_	
231-621	53002-53004	of	_	
231-622	53005-53013	maternal	_	
231-623	53014-53022	behavior	_	
231-624	53023-53025	in	_	
231-625	53026-53046	pregnancy-terminated	_	
231-626	53047-53051	rats	_	
231-627	53052-53064	Hypothalamic	_	
231-628	53065-53076	interaction	_	
231-629	53077-53081	with	_	
231-630	53082-53085	the	_	
231-631	53086-53096	mesolimbic	_	
231-632	53097-53099	DA	_	
231-633	53100-53106	system	_	
231-634	53107-53109	in	_	
231-635	53110-53113	the	_	
231-636	53114-53121	control	_	
231-637	53122-53124	of	_	
231-638	53125-53128	the	_	
231-639	53129-53137	maternal	_	
231-640	53138-53141	and	_	
231-641	53142-53148	sexual	_	
231-642	53149-53158	behaviors	_	
231-643	53159-53161	in	_	
231-644	53162-53166	rats	_	
231-645	53167-53172	Adult	_	
231-646	53173-53183	attachment	_	
231-647	53184-53192	predicts	_	
231-648	53193-53201	maternal	_	
231-649	53202-53207	brain	_	
231-650	53208-53211	and	_	
231-651	53212-53220	oxytocin	_	
231-652	53221-53229	response	_	
231-653	53230-53232	to	_	
231-654	53233-53239	infant	_	
231-655	53240-53244	cues	_	
231-656	53245-53252	Mothers	_	
231-657	53252-53253	’	_	
231-658	53254-53262	amygdala	_	
231-659	53263-53271	response	_	
231-660	53272-53274	to	_	
231-661	53275-53283	positive	_	
231-662	53284-53286	or	_	
231-663	53287-53295	negative	_	
231-664	53296-53302	infant	_	
231-665	53303-53309	affect	_	
231-666	53310-53312	is	_	
231-667	53313-53322	modulated	_	
231-668	53323-53325	by	_	
231-669	53326-53334	personal	_	
231-670	53335-53344	relevance	_	
231-671	53345-53349	What	_	
231-672	53349-53350	’	_	
231-673	53350-53351	s	_	
231-674	53352-53354	in	_	
231-675	53355-53356	a	_	
231-676	53357-53362	smile	_	
231-677	53362-53363	?	_	

#Text=Maternal brain responses to infant facial cues
#Text=Cocaine addiction in mothers: potential effects on maternal care and infant development
#Text=
#Text=
#Text=The Mothers and Toddlers Program, an attachment-based parenting intervention for substance using women: post-treatment results from a randomized clinical pilot
#Text=Approaching the biology of human parental attachment: brain imaging, oxytocin and coordinated assessments of mothers and fathers
#Text=Brain basis of early parent-infant interactions: psychology, physiology, and in vivo functional neuroimaging studies
#Text=
#Text=Microinfusion of cocaine into the medial preoptic area or nucleus accumbens transiently impairs maternal behavior in the rat
#Text=Differential projections of the infralimbic and prelimbic cortex in the rat
#Text=Addiction: making the connection between behavioral changes and neuronal plasticity in specific pathways
#Text=
#Text=Hypothalamic and mesocorticolimbic regulation of maternal brain response to infant cues.
232-1	53364-53372	Maternal	_	
232-2	53373-53378	brain	_	
232-3	53379-53388	responses	_	
232-4	53389-53391	to	_	
232-5	53392-53398	infant	_	
232-6	53399-53405	facial	_	
232-7	53406-53410	cues	_	
232-8	53411-53418	Cocaine	_	
232-9	53419-53428	addiction	_	
232-10	53429-53431	in	_	
232-11	53432-53439	mothers	_	
232-12	53439-53440	:	_	
232-13	53441-53450	potential	_	
232-14	53451-53458	effects	_	
232-15	53459-53461	on	_	
232-16	53462-53470	maternal	_	
232-17	53471-53475	care	_	
232-18	53476-53479	and	_	
232-19	53480-53486	infant	_	
232-20	53487-53498	development	_	
232-21	53501-53504	The	_	
232-22	53505-53512	Mothers	_	
232-23	53513-53516	and	_	
232-24	53517-53525	Toddlers	_	
232-25	53526-53533	Program	_	
232-26	53533-53534	,	_	
232-27	53535-53537	an	_	
232-28	53538-53554	attachment-based	_	
232-29	53555-53564	parenting	_	
232-30	53565-53577	intervention	_	
232-31	53578-53581	for	_	
232-32	53582-53591	substance	_	
232-33	53592-53597	using	_	
232-34	53598-53603	women	_	
232-35	53603-53604	:	_	
232-36	53605-53619	post-treatment	_	
232-37	53620-53627	results	_	
232-38	53628-53632	from	_	
232-39	53633-53634	a	_	
232-40	53635-53645	randomized	_	
232-41	53646-53654	clinical	_	
232-42	53655-53660	pilot	_	
232-43	53661-53672	Approaching	_	
232-44	53673-53676	the	_	
232-45	53677-53684	biology	_	
232-46	53685-53687	of	_	
232-47	53688-53693	human	_	
232-48	53694-53702	parental	_	
232-49	53703-53713	attachment	_	
232-50	53713-53714	:	_	
232-51	53715-53720	brain	_	
232-52	53721-53728	imaging	_	
232-53	53728-53729	,	_	
232-54	53730-53738	oxytocin	_	
232-55	53739-53742	and	_	
232-56	53743-53754	coordinated	_	
232-57	53755-53766	assessments	_	
232-58	53767-53769	of	_	
232-59	53770-53777	mothers	_	
232-60	53778-53781	and	_	
232-61	53782-53789	fathers	_	
232-62	53790-53795	Brain	_	
232-63	53796-53801	basis	_	
232-64	53802-53804	of	_	
232-65	53805-53810	early	_	
232-66	53811-53824	parent-infant	_	
232-67	53825-53837	interactions	_	
232-68	53837-53838	:	_	
232-69	53839-53849	psychology	_	
232-70	53849-53850	,	_	
232-71	53851-53861	physiology	_	
232-72	53861-53862	,	_	
232-73	53863-53866	and	_	
232-74	53867-53869	in	_	
232-75	53870-53874	vivo	_	
232-76	53875-53885	functional	_	
232-77	53886-53898	neuroimaging	_	
232-78	53899-53906	studies	_	
232-79	53908-53921	Microinfusion	_	
232-80	53922-53924	of	_	
232-81	53925-53932	cocaine	_	
232-82	53933-53937	into	_	
232-83	53938-53941	the	_	
232-84	53942-53948	medial	_	
232-85	53949-53957	preoptic	_	
232-86	53958-53962	area	_	
232-87	53963-53965	or	_	
232-88	53966-53973	nucleus	_	
232-89	53974-53983	accumbens	_	
232-90	53984-53995	transiently	_	
232-91	53996-54003	impairs	_	
232-92	54004-54012	maternal	_	
232-93	54013-54021	behavior	_	
232-94	54022-54024	in	_	
232-95	54025-54028	the	_	
232-96	54029-54032	rat	_	
232-97	54033-54045	Differential	_	
232-98	54046-54057	projections	_	
232-99	54058-54060	of	_	
232-100	54061-54064	the	_	
232-101	54065-54076	infralimbic	_	
232-102	54077-54080	and	_	
232-103	54081-54090	prelimbic	_	
232-104	54091-54097	cortex	_	
232-105	54098-54100	in	_	
232-106	54101-54104	the	_	
232-107	54105-54108	rat	_	
232-108	54109-54118	Addiction	_	
232-109	54118-54119	:	_	
232-110	54120-54126	making	_	
232-111	54127-54130	the	_	
232-112	54131-54141	connection	_	
232-113	54142-54149	between	_	
232-114	54150-54160	behavioral	_	
232-115	54161-54168	changes	_	
232-116	54169-54172	and	_	
232-117	54173-54181	neuronal	_	
232-118	54182-54192	plasticity	_	
232-119	54193-54195	in	_	
232-120	54196-54204	specific	_	
232-121	54205-54213	pathways	_	
232-122	54215-54227	Hypothalamic	_	
232-123	54228-54231	and	_	
232-124	54232-54249	mesocorticolimbic	_	
232-125	54250-54260	regulation	_	
232-126	54261-54263	of	_	
232-127	54264-54272	maternal	_	
232-128	54273-54278	brain	_	
232-129	54279-54287	response	_	
232-130	54288-54290	to	_	
232-131	54291-54297	infant	_	
232-132	54298-54302	cues	_	
232-133	54302-54303	.	_	

#Text=These OT- and DA-innervated brain regions are critical for the occurrence of maternal behavior.
233-1	54304-54309	These	_	
233-2	54310-54312	OT	_	
233-3	54312-54313	-	_	
233-4	54314-54317	and	_	
233-5	54318-54331	DA-innervated	_	
233-6	54332-54337	brain	_	
233-7	54338-54345	regions	_	
233-8	54346-54349	are	_	
233-9	54350-54358	critical	_	
233-10	54359-54362	for	_	
233-11	54363-54366	the	_	
233-12	54367-54377	occurrence	_	
233-13	54378-54380	of	_	
233-14	54381-54389	maternal	_	
233-15	54390-54398	behavior	_	
233-16	54398-54399	.	_	

#Text=Brain schematic by P.
234-1	54400-54405	Brain	_	
234-2	54406-54415	schematic	_	
234-3	54416-54418	by	_	
234-4	54419-54420	P	_	
234-5	54420-54421	.	_	

#Text=J.
235-1	54422-54423	J	_	
235-2	54423-54424	.	_	

#Text=Lynch (2006; CC BY 2.5).
236-1	54425-54430	Lynch	_	
236-2	54431-54432	(	_	
236-3	54432-54436	2006	_	
236-4	54436-54437	;	_	
236-5	54438-54440	CC	_	
236-6	54441-54443	BY	_	
236-7	54444-54447	2.5	_	
236-8	54447-54448	)	_	
236-9	54448-54449	.	_	

#Text=Infant face images used in the study.
237-1	54450-54456	Infant	_	
237-2	54457-54461	face	_	
237-3	54462-54468	images	_	
237-4	54469-54473	used	_	
237-5	54474-54476	in	_	
237-6	54477-54480	the	_	
237-7	54481-54486	study	_	
237-8	54486-54487	.	_	

#Text=Reduced maternal brain response in mothers with addictions evidenced by a single cluster of deactivation observed for the own-happy versus unknown-happy contrast, encompassing the hypothalamic, bilateral VS, and bilateral vmPFC regions (258 voxels, p < .01, FDR-corrected q < .05; Panel A).
238-1	54488-54495	Reduced	_	
238-2	54496-54504	maternal	_	
238-3	54505-54510	brain	_	
238-4	54511-54519	response	_	
238-5	54520-54522	in	_	
238-6	54523-54530	mothers	_	
238-7	54531-54535	with	_	
238-8	54536-54546	addictions	_	
238-9	54547-54556	evidenced	_	
238-10	54557-54559	by	_	
238-11	54560-54561	a	_	
238-12	54562-54568	single	_	
238-13	54569-54576	cluster	_	
238-14	54577-54579	of	_	
238-15	54580-54592	deactivation	_	
238-16	54593-54601	observed	_	
238-17	54602-54605	for	_	
238-18	54606-54609	the	_	
238-19	54610-54619	own-happy	_	
238-20	54620-54626	versus	_	
238-21	54627-54640	unknown-happy	_	
238-22	54641-54649	contrast	_	
238-23	54649-54650	,	_	
238-24	54651-54663	encompassing	_	
238-25	54664-54667	the	_	
238-26	54668-54680	hypothalamic	_	
238-27	54680-54681	,	_	
238-28	54682-54691	bilateral	_	
238-29	54692-54694	VS	_	
238-30	54694-54695	,	_	
238-31	54696-54699	and	_	
238-32	54700-54709	bilateral	_	
238-33	54710-54715	vmPFC	_	
238-34	54716-54723	regions	_	
238-35	54724-54725	(	_	
238-36	54725-54728	258	_	
238-37	54729-54735	voxels	_	
238-38	54735-54736	,	_	
238-39	54737-54738	p	_	
238-40	54739-54740	<	_	
238-41	54741-54744	.01	_	
238-42	54744-54745	,	_	
238-43	54746-54759	FDR-corrected	_	
238-44	54760-54761	q	_	
238-45	54762-54763	<	_	
238-46	54764-54767	.05	_	
238-47	54767-54768	;	_	
238-48	54769-54774	Panel	_	
238-49	54775-54776	A	_	
238-50	54776-54777	)	_	
238-51	54777-54778	.	_	

#Text=Striking deactivation is observed when mothers with addictions view their own infant’s smiling faces, compared with unknown infant faces (Panel B).
239-1	54779-54787	Striking	_	
239-2	54788-54800	deactivation	_	
239-3	54801-54803	is	_	
239-4	54804-54812	observed	_	
239-5	54813-54817	when	_	
239-6	54818-54825	mothers	_	
239-7	54826-54830	with	_	
239-8	54831-54841	addictions	_	
239-9	54842-54846	view	_	
239-10	54847-54852	their	_	
239-11	54853-54856	own	_	
239-12	54857-54863	infant	_	
239-13	54863-54864	’	_	
239-14	54864-54865	s	_	
239-15	54866-54873	smiling	_	
239-16	54874-54879	faces	_	
239-17	54879-54880	,	_	
239-18	54881-54889	compared	_	
239-19	54890-54894	with	_	
239-20	54895-54902	unknown	_	
239-21	54903-54909	infant	_	
239-22	54910-54915	faces	_	
239-23	54916-54917	(	_	
239-24	54917-54922	Panel	_	
239-25	54923-54924	B	_	
239-26	54924-54925	)	_	
239-27	54925-54926	.	_	

#Text=For a post-hoc examination of local peaks within the deactivated cluster, percent BOLD signal values were extracted from cubes centered at the peak voxels of each anatomical region and extending up to ± 10 voxels per dimension, unless limited by the spatial extent of activation.
240-1	54927-54930	For	_	
240-2	54931-54932	a	_	
240-3	54933-54941	post-hoc	_	
240-4	54942-54953	examination	_	
240-5	54954-54956	of	_	
240-6	54957-54962	local	_	
240-7	54963-54968	peaks	_	
240-8	54969-54975	within	_	
240-9	54976-54979	the	_	
240-10	54980-54991	deactivated	_	
240-11	54992-54999	cluster	_	
240-12	54999-55000	,	_	
240-13	55001-55008	percent	_	
240-14	55009-55013	BOLD	_	
240-15	55014-55020	signal	_	
240-16	55021-55027	values	_	
240-17	55028-55032	were	_	
240-18	55033-55042	extracted	_	
240-19	55043-55047	from	_	
240-20	55048-55053	cubes	_	
240-21	55054-55062	centered	_	
240-22	55063-55065	at	_	
240-23	55066-55069	the	_	
240-24	55070-55074	peak	_	
240-25	55075-55081	voxels	_	
240-26	55082-55084	of	_	
240-27	55085-55089	each	_	
240-28	55090-55100	anatomical	_	
240-29	55101-55107	region	_	
240-30	55108-55111	and	_	
240-31	55112-55121	extending	_	
240-32	55122-55124	up	_	
240-33	55125-55127	to	_	
240-34	55128-55129	±	_	
240-35	55130-55132	10	_	
240-36	55133-55139	voxels	_	
240-37	55140-55143	per	_	
240-38	55144-55153	dimension	_	
240-39	55153-55154	,	_	
240-40	55155-55161	unless	_	
240-41	55162-55169	limited	_	
240-42	55170-55172	by	_	
240-43	55173-55176	the	_	
240-44	55177-55184	spatial	_	
240-45	55185-55191	extent	_	
240-46	55192-55194	of	_	
240-47	55195-55205	activation	_	
240-48	55205-55206	.	_	

#Text=Peak Talairach coordinates: hypothalamus, (−2, 1, −3); R VS, (8, 10, −3); L VS, (−13, 19, 3); R vmPFC, (11, 34, 6), L vmPFC, (−16, 37, 3).
241-1	55207-55211	Peak	_	
241-2	55212-55221	Talairach	_	
241-3	55222-55233	coordinates	_	
241-4	55233-55234	:	_	
241-5	55235-55247	hypothalamus	_	
241-6	55247-55248	,	_	
241-7	55249-55250	(	_	
241-8	55250-55251	−	_	
241-9	55251-55252	2	_	
241-10	55252-55253	,	_	
241-11	55254-55255	1	_	
241-12	55255-55256	,	_	
241-13	55257-55258	−	_	
241-14	55258-55259	3	_	
241-15	55259-55260	)	_	
241-16	55260-55261	;	_	
241-17	55262-55263	R	_	
241-18	55264-55266	VS	_	
241-19	55266-55267	,	_	
241-20	55268-55269	(	_	
241-21	55269-55270	8	_	
241-22	55270-55271	,	_	
241-23	55272-55274	10	_	
241-24	55274-55275	,	_	
241-25	55276-55277	−	_	
241-26	55277-55278	3	_	
241-27	55278-55279	)	_	
241-28	55279-55280	;	_	
241-29	55281-55282	L	_	
241-30	55283-55285	VS	_	
241-31	55285-55286	,	_	
241-32	55287-55288	(	_	
241-33	55288-55289	−	_	
241-34	55289-55291	13	_	
241-35	55291-55292	,	_	
241-36	55293-55295	19	_	
241-37	55295-55296	,	_	
241-38	55297-55298	3	_	
241-39	55298-55299	)	_	
241-40	55299-55300	;	_	
241-41	55301-55302	R	_	
241-42	55303-55308	vmPFC	_	
241-43	55308-55309	,	_	
241-44	55310-55311	(	_	
241-45	55311-55313	11	_	
241-46	55313-55314	,	_	
241-47	55315-55317	34	_	
241-48	55317-55318	,	_	
241-49	55319-55320	6	_	
241-50	55320-55321	)	_	
241-51	55321-55322	,	_	
241-52	55323-55324	L	_	
241-53	55325-55330	vmPFC	_	
241-54	55330-55331	,	_	
241-55	55332-55333	(	_	
241-56	55333-55334	−	_	
241-57	55334-55336	16	_	
241-58	55336-55337	,	_	
241-59	55338-55340	37	_	
241-60	55340-55341	,	_	
241-61	55342-55343	3	_	
241-62	55343-55344	)	_	
241-63	55344-55345	.	_	

#Text=Error bars represent the standard error of the mean.
242-1	55346-55351	Error	_	
242-2	55352-55356	bars	_	
242-3	55357-55366	represent	_	
242-4	55367-55370	the	_	
242-5	55371-55379	standard	_	
242-6	55380-55385	error	_	
242-7	55386-55388	of	_	
242-8	55389-55392	the	_	
242-9	55393-55397	mean	_	
242-10	55397-55398	.	_	

#Text=VS = ventral striatum; vmPFC = ventromedial prefrontal cortex; R: right; L: left.
243-1	55399-55401	VS	_	
243-2	55402-55403	=	_	
243-3	55404-55411	ventral	_	
243-4	55412-55420	striatum	_	
243-5	55420-55421	;	_	
243-6	55422-55427	vmPFC	_	
243-7	55428-55429	=	_	
243-8	55430-55442	ventromedial	_	
243-9	55443-55453	prefrontal	_	
243-10	55454-55460	cortex	_	
243-11	55460-55461	;	_	
243-12	55462-55463	R	_	
243-13	55463-55464	:	_	
243-14	55465-55470	right	_	
243-15	55470-55471	;	_	
243-16	55472-55473	L	_	
243-17	55473-55474	:	_	
243-18	55475-55479	left	_	
243-19	55479-55480	.	_	

#Text=Striatal activation limited to the dorsal striatum, in response to own-happy versus unknown-happy infant faces (p < .02, FDR-corrected q < .05).
244-1	55481-55489	Striatal	_	
244-2	55490-55500	activation	_	
244-3	55501-55508	limited	_	
244-4	55509-55511	to	_	
244-5	55512-55515	the	_	
244-6	55516-55522	dorsal	_	
244-7	55523-55531	striatum	_	
244-8	55531-55532	,	_	
244-9	55533-55535	in	_	
244-10	55536-55544	response	_	
244-11	55545-55547	to	_	
244-12	55548-55557	own-happy	_	
244-13	55558-55564	versus	_	
244-14	55565-55578	unknown-happy	_	
244-15	55579-55585	infant	_	
244-16	55586-55591	faces	_	
244-17	55592-55593	(	_	
244-18	55593-55594	p	_	
244-19	55595-55596	<	_	
244-20	55597-55600	.02	_	
244-21	55600-55601	,	_	
244-22	55602-55615	FDR-corrected	_	
244-23	55616-55617	q	_	
244-24	55618-55619	<	_	
244-25	55620-55623	.05	_	
244-26	55623-55624	)	_	
244-27	55624-55625	.	_	

#Text=A contrasting pattern of deactivation is seen in the ventral striatum.
245-1	55626-55627	A	_	
245-2	55628-55639	contrasting	_	
245-3	55640-55647	pattern	_	
245-4	55648-55650	of	_	
245-5	55651-55663	deactivation	_	
245-6	55664-55666	is	_	
245-7	55667-55671	seen	_	
245-8	55672-55674	in	_	
245-9	55675-55678	the	_	
245-10	55679-55686	ventral	_	
245-11	55687-55695	striatum	_	
245-12	55695-55696	.	_	

#Text=Mothers with addictions (Panel A; N = 36) show decreased activation in the hypothalamus, VS, and vmPFC, which appear different from activations previously observed in mothers without addictions (Panel B; N = 39) in corresponding regions.
246-1	55697-55704	Mothers	_	
246-2	55705-55709	with	_	
246-3	55710-55720	addictions	_	
246-4	55721-55722	(	_	
246-5	55722-55727	Panel	_	
246-6	55728-55729	A	_	
246-7	55729-55730	;	_	
246-8	55731-55732	N	_	
246-9	55733-55734	=	_	
246-10	55735-55737	36	_	
246-11	55737-55738	)	_	
246-12	55739-55743	show	_	
246-13	55744-55753	decreased	_	
246-14	55754-55764	activation	_	
246-15	55765-55767	in	_	
246-16	55768-55771	the	_	
246-17	55772-55784	hypothalamus	_	
246-18	55784-55785	,	_	
246-19	55786-55788	VS	_	
246-20	55788-55789	,	_	
246-21	55790-55793	and	_	
246-22	55794-55799	vmPFC	_	
246-23	55799-55800	,	_	
246-24	55801-55806	which	_	
246-25	55807-55813	appear	_	
246-26	55814-55823	different	_	
246-27	55824-55828	from	_	
246-28	55829-55840	activations	_	
246-29	55841-55851	previously	_	
246-30	55852-55860	observed	_	
246-31	55861-55863	in	_	
246-32	55864-55871	mothers	_	
246-33	55872-55879	without	_	
246-34	55880-55890	addictions	_	
246-35	55891-55892	(	_	
246-36	55892-55897	Panel	_	
246-37	55898-55899	B	_	
246-38	55899-55900	;	_	
246-39	55901-55902	N	_	
246-40	55903-55904	=	_	
246-41	55905-55907	39	_	
246-42	55907-55908	)	_	
246-43	55909-55911	in	_	
246-44	55912-55925	corresponding	_	
246-45	55926-55933	regions	_	
246-46	55933-55934	.	_	

#Text=Activation maps for mothers without addictions were generated from our previously published data and are reprinted here for comparison.
247-1	55935-55945	Activation	_	
247-2	55946-55950	maps	_	
247-3	55951-55954	for	_	
247-4	55955-55962	mothers	_	
247-5	55963-55970	without	_	
247-6	55971-55981	addictions	_	
247-7	55982-55986	were	_	
247-8	55987-55996	generated	_	
247-9	55997-56001	from	_	
247-10	56002-56005	our	_	
247-11	56006-56016	previously	_	
247-12	56017-56026	published	_	
247-13	56027-56031	data	_	
247-14	56032-56035	and	_	
247-15	56036-56039	are	_	
247-16	56040-56049	reprinted	_	
247-17	56050-56054	here	_	
247-18	56055-56058	for	_	
247-19	56059-56069	comparison	_	
247-20	56069-56070	.	_	

#Text=Both maps are thresholded at FDR-corrected q < .05.
248-1	56071-56075	Both	_	
248-2	56076-56080	maps	_	
248-3	56081-56084	are	_	
248-4	56085-56096	thresholded	_	
248-5	56097-56099	at	_	
248-6	56100-56113	FDR-corrected	_	
248-7	56114-56115	q	_	
248-8	56116-56117	<	_	
248-9	56118-56121	.05	_	
248-10	56121-56122	.	_	

#Text=Insets of averaged hemodynamic brain responses to own-happy and unknown-happy infant faces were obtained from cubes centered at the peak voxels of each anatomical region and extending up to ± 10 voxels per dimension, unless limited by the spatial extent of activation; y axis indicates % BOLD signal change shown with standard error bars; the two vertical lines represent the onset (0 sec) and offset (2 sec) times of the infant-face-stimulus presentation.
249-1	56123-56129	Insets	_	
249-2	56130-56132	of	_	
249-3	56133-56141	averaged	_	
249-4	56142-56153	hemodynamic	_	
249-5	56154-56159	brain	_	
249-6	56160-56169	responses	_	
249-7	56170-56172	to	_	
249-8	56173-56182	own-happy	_	
249-9	56183-56186	and	_	
249-10	56187-56200	unknown-happy	_	
249-11	56201-56207	infant	_	
249-12	56208-56213	faces	_	
249-13	56214-56218	were	_	
249-14	56219-56227	obtained	_	
249-15	56228-56232	from	_	
249-16	56233-56238	cubes	_	
249-17	56239-56247	centered	_	
249-18	56248-56250	at	_	
249-19	56251-56254	the	_	
249-20	56255-56259	peak	_	
249-21	56260-56266	voxels	_	
249-22	56267-56269	of	_	
249-23	56270-56274	each	_	
249-24	56275-56285	anatomical	_	
249-25	56286-56292	region	_	
249-26	56293-56296	and	_	
249-27	56297-56306	extending	_	
249-28	56307-56309	up	_	
249-29	56310-56312	to	_	
249-30	56313-56314	±	_	
249-31	56315-56317	10	_	
249-32	56318-56324	voxels	_	
249-33	56325-56328	per	_	
249-34	56329-56338	dimension	_	
249-35	56338-56339	,	_	
249-36	56340-56346	unless	_	
249-37	56347-56354	limited	_	
249-38	56355-56357	by	_	
249-39	56358-56361	the	_	
249-40	56362-56369	spatial	_	
249-41	56370-56376	extent	_	
249-42	56377-56379	of	_	
249-43	56380-56390	activation	_	
249-44	56390-56391	;	_	
249-45	56392-56393	y	_	
249-46	56394-56398	axis	_	
249-47	56399-56408	indicates	_	
249-48	56409-56410	%	_	
249-49	56411-56415	BOLD	_	
249-50	56416-56422	signal	_	
249-51	56423-56429	change	_	
249-52	56430-56435	shown	_	
249-53	56436-56440	with	_	
249-54	56441-56449	standard	_	
249-55	56450-56455	error	_	
249-56	56456-56460	bars	_	
249-57	56460-56461	;	_	
249-58	56462-56465	the	_	
249-59	56466-56469	two	_	
249-60	56470-56478	vertical	_	
249-61	56479-56484	lines	_	
249-62	56485-56494	represent	_	
249-63	56495-56498	the	_	
249-64	56499-56504	onset	_	
249-65	56505-56506	(	_	
249-66	56506-56507	0	_	
249-67	56508-56511	sec	_	
249-68	56511-56512	)	_	
249-69	56513-56516	and	_	
249-70	56517-56523	offset	_	
249-71	56524-56525	(	_	
249-72	56525-56526	2	_	
249-73	56527-56530	sec	_	
249-74	56530-56531	)	_	
249-75	56532-56537	times	_	
249-76	56538-56540	of	_	
249-77	56541-56544	the	_	
249-78	56545-56565	infant-face-stimulus	_	
249-79	56566-56578	presentation	_	
249-80	56578-56579	.	_	

#Text=VS = ventral striatum; vmPFC = ventromedial prefrontal cortex.
250-1	56580-56582	VS	_	
250-2	56583-56584	=	_	
250-3	56585-56592	ventral	_	
250-4	56593-56601	striatum	_	
250-5	56601-56602	;	_	
250-6	56603-56608	vmPFC	_	
250-7	56609-56610	=	_	
250-8	56611-56623	ventromedial	_	
250-9	56624-56634	prefrontal	_	
250-10	56635-56641	cortex	_	
250-11	56641-56642	.	_	

#Text=Sociodemographic characteristics of mothers and infants (N = 36)
#Text=Maternal age, mean ± SD\t27.8 ± 5.6\t \tInfant sex, n (%)\t \t Male\t18 (50.0)\t \t Female\t18 (50.0)\t \tMaternal parity, n (%)\t \t Primiparous\t15 (41.7)\t \t Multiparous\t21 (58.3)\t \tMaternal ethnicity a, n (%)\t \t Hispanic or Latino\t12 (33.3)\t \t Not Hispanic or Latino\t23 (63.9)\t \tMaternal race a, n (%)\t \t White\t17 (47.2)\t \t Black or African American\t11 (30.6)\t \t Other\t4 (11.1)\t \tMarital status a, n (%)\t \t Single/never married\t17 (47.2)\t \t Living together\t11 (30.6)\t \t Separated/divorced/widowed\t6 (16.7)\t \tMaternal education a, n (%)\t \t Junior high school (7 to 9th grade)\t7 (19.4)\t \t Some high school\t9 (25.0)\t \t High school graduate\t7 (19.4)\t \t Some college or higher\t12 (33.4)\t \tAnnual family income a, n (%)\t \t < $15,000\t23 (63.9)\t \t $15,000 to 30,000\t8 (22.2)\t \t $30,001 to 45,000\t3 (8.3)\t \t > $100,000\t1 (2.8)\t \tBreastfeeding status, n (%)\t \t Still breastfeeding\t1 (2.8)\t \t Not breastfeeding\t35 (97.2)\t \t
#Text=Percentages do not total 100% due to missing data.
251-1	56643-56659	Sociodemographic	_	
251-2	56660-56675	characteristics	_	
251-3	56676-56678	of	_	
251-4	56679-56686	mothers	_	
251-5	56687-56690	and	_	
251-6	56691-56698	infants	_	
251-7	56699-56700	(	_	
251-8	56700-56701	N	_	
251-9	56702-56703	=	_	
251-10	56704-56706	36	_	
251-11	56706-56707	)	_	
251-12	56708-56716	Maternal	_	
251-13	56717-56720	age	_	
251-14	56720-56721	,	_	
251-15	56722-56726	mean	_	
251-16	56727-56728	±	_	
251-17	56729-56731	SD	_	
251-18	56732-56736	27.8	_	
251-19	56737-56738	±	_	
251-20	56739-56742	5.6	_	
251-21	56745-56751	Infant	_	
251-22	56752-56755	sex	_	
251-23	56755-56756	,	_	
251-24	56757-56758	n	_	
251-25	56759-56760	(	_	
251-26	56760-56761	%	_	
251-27	56761-56762	)	_	
251-28	56766-56770	Male	_	
251-29	56771-56773	18	_	
251-30	56774-56775	(	_	
251-31	56775-56779	50.0	_	
251-32	56779-56780	)	_	
251-33	56784-56790	Female	_	
251-34	56791-56793	18	_	
251-35	56794-56795	(	_	
251-36	56795-56799	50.0	_	
251-37	56799-56800	)	_	
251-38	56803-56811	Maternal	_	
251-39	56812-56818	parity	_	
251-40	56818-56819	,	_	
251-41	56820-56821	n	_	
251-42	56822-56823	(	_	
251-43	56823-56824	%	_	
251-44	56824-56825	)	_	
251-45	56829-56840	Primiparous	_	
251-46	56841-56843	15	_	
251-47	56844-56845	(	_	
251-48	56845-56849	41.7	_	
251-49	56849-56850	)	_	
251-50	56854-56865	Multiparous	_	
251-51	56866-56868	21	_	
251-52	56869-56870	(	_	
251-53	56870-56874	58.3	_	
251-54	56874-56875	)	_	
251-55	56878-56886	Maternal	_	
251-56	56887-56896	ethnicity	_	
251-57	56897-56898	a	_	
251-58	56898-56899	,	_	
251-59	56900-56901	n	_	
251-60	56902-56903	(	_	
251-61	56903-56904	%	_	
251-62	56904-56905	)	_	
251-63	56909-56917	Hispanic	_	
251-64	56918-56920	or	_	
251-65	56921-56927	Latino	_	
251-66	56928-56930	12	_	
251-67	56931-56932	(	_	
251-68	56932-56936	33.3	_	
251-69	56936-56937	)	_	
251-70	56941-56944	Not	_	
251-71	56945-56953	Hispanic	_	
251-72	56954-56956	or	_	
251-73	56957-56963	Latino	_	
251-74	56964-56966	23	_	
251-75	56967-56968	(	_	
251-76	56968-56972	63.9	_	
251-77	56972-56973	)	_	
251-78	56976-56984	Maternal	_	
251-79	56985-56989	race	_	
251-80	56990-56991	a	_	
251-81	56991-56992	,	_	
251-82	56993-56994	n	_	
251-83	56995-56996	(	_	
251-84	56996-56997	%	_	
251-85	56997-56998	)	_	
251-86	57002-57007	White	_	
251-87	57008-57010	17	_	
251-88	57011-57012	(	_	
251-89	57012-57016	47.2	_	
251-90	57016-57017	)	_	
251-91	57021-57026	Black	_	
251-92	57027-57029	or	_	
251-93	57030-57037	African	_	
251-94	57038-57046	American	_	
251-95	57047-57049	11	_	
251-96	57050-57051	(	_	
251-97	57051-57055	30.6	_	
251-98	57055-57056	)	_	
251-99	57060-57065	Other	_	
251-100	57066-57067	4	_	
251-101	57068-57069	(	_	
251-102	57069-57073	11.1	_	
251-103	57073-57074	)	_	
251-104	57077-57084	Marital	_	
251-105	57085-57091	status	_	
251-106	57092-57093	a	_	
251-107	57093-57094	,	_	
251-108	57095-57096	n	_	
251-109	57097-57098	(	_	
251-110	57098-57099	%	_	
251-111	57099-57100	)	_	
251-112	57104-57110	Single	_	
251-113	57110-57111	/	_	
251-114	57111-57116	never	_	
251-115	57117-57124	married	_	
251-116	57125-57127	17	_	
251-117	57128-57129	(	_	
251-118	57129-57133	47.2	_	
251-119	57133-57134	)	_	
251-120	57138-57144	Living	_	
251-121	57145-57153	together	_	
251-122	57154-57156	11	_	
251-123	57157-57158	(	_	
251-124	57158-57162	30.6	_	
251-125	57162-57163	)	_	
251-126	57167-57176	Separated	_	
251-127	57176-57177	/	_	
251-128	57177-57185	divorced	_	
251-129	57185-57186	/	_	
251-130	57186-57193	widowed	_	
251-131	57194-57195	6	_	
251-132	57196-57197	(	_	
251-133	57197-57201	16.7	_	
251-134	57201-57202	)	_	
251-135	57205-57213	Maternal	_	
251-136	57214-57223	education	_	
251-137	57224-57225	a	_	
251-138	57225-57226	,	_	
251-139	57227-57228	n	_	
251-140	57229-57230	(	_	
251-141	57230-57231	%	_	
251-142	57231-57232	)	_	
251-143	57236-57242	Junior	_	
251-144	57243-57247	high	_	
251-145	57248-57254	school	_	
251-146	57255-57256	(	_	
251-147	57256-57257	7	_	
251-148	57258-57260	to	_	
251-149	57261-57264	9th	_	
251-150	57265-57270	grade	_	
251-151	57270-57271	)	_	
251-152	57272-57273	7	_	
251-153	57274-57275	(	_	
251-154	57275-57279	19.4	_	
251-155	57279-57280	)	_	
251-156	57284-57288	Some	_	
251-157	57289-57293	high	_	
251-158	57294-57300	school	_	
251-159	57301-57302	9	_	
251-160	57303-57304	(	_	
251-161	57304-57308	25.0	_	
251-162	57308-57309	)	_	
251-163	57313-57317	High	_	
251-164	57318-57324	school	_	
251-165	57325-57333	graduate	_	
251-166	57334-57335	7	_	
251-167	57336-57337	(	_	
251-168	57337-57341	19.4	_	
251-169	57341-57342	)	_	
251-170	57346-57350	Some	_	
251-171	57351-57358	college	_	
251-172	57359-57361	or	_	
251-173	57362-57368	higher	_	
251-174	57369-57371	12	_	
251-175	57372-57373	(	_	
251-176	57373-57377	33.4	_	
251-177	57377-57378	)	_	
251-178	57381-57387	Annual	_	
251-179	57388-57394	family	_	
251-180	57395-57401	income	_	
251-181	57402-57403	a	_	
251-182	57403-57404	,	_	
251-183	57405-57406	n	_	
251-184	57407-57408	(	_	
251-185	57408-57409	%	_	
251-186	57409-57410	)	_	
251-187	57414-57415	<	_	
251-188	57416-57423	$15,000	_	
251-189	57424-57426	23	_	
251-190	57427-57428	(	_	
251-191	57428-57432	63.9	_	
251-192	57432-57433	)	_	
251-193	57437-57444	$15,000	_	
251-194	57445-57447	to	_	
251-195	57448-57454	30,000	_	
251-196	57455-57456	8	_	
251-197	57457-57458	(	_	
251-198	57458-57462	22.2	_	
251-199	57462-57463	)	_	
251-200	57467-57474	$30,001	_	
251-201	57475-57477	to	_	
251-202	57478-57484	45,000	_	
251-203	57485-57486	3	_	
251-204	57487-57488	(	_	
251-205	57488-57491	8.3	_	
251-206	57491-57492	)	_	
251-207	57496-57497	>	_	
251-208	57498-57506	$100,000	_	
251-209	57507-57508	1	_	
251-210	57509-57510	(	_	
251-211	57510-57513	2.8	_	
251-212	57513-57514	)	_	
251-213	57517-57530	Breastfeeding	_	
251-214	57531-57537	status	_	
251-215	57537-57538	,	_	
251-216	57539-57540	n	_	
251-217	57541-57542	(	_	
251-218	57542-57543	%	_	
251-219	57543-57544	)	_	
251-220	57548-57553	Still	_	
251-221	57554-57567	breastfeeding	_	
251-222	57568-57569	1	_	
251-223	57570-57571	(	_	
251-224	57571-57574	2.8	_	
251-225	57574-57575	)	_	
251-226	57579-57582	Not	_	
251-227	57583-57596	breastfeeding	_	
251-228	57597-57599	35	_	
251-229	57600-57601	(	_	
251-230	57601-57605	97.2	_	
251-231	57605-57606	)	_	
251-232	57610-57621	Percentages	_	
251-233	57622-57624	do	_	
251-234	57625-57628	not	_	
251-235	57629-57634	total	_	
251-236	57635-57639	100%	_	
251-237	57640-57643	due	_	
251-238	57644-57646	to	_	
251-239	57647-57654	missing	_	
251-240	57655-57659	data	_	
251-241	57659-57660	.	_	

#Text=Substance-use characteristics of mothers (N = 36)
#Text=DSM-IV substance-use disorders a, n (%)\t \t Substance dependence\t33 (91.7)\t \t  Cocaine dependence\t16 (44.4)\t \t  Opioid dependence\t6 (16.7)\t \t  Amphetamine dependence\t5 (13.9)\t \t  Sedative, hypnotic, or anxiolytic dependence\t3 (8.3)\t \t  Cannabis dependence\t3 (8.3)\t \t Substance abuse\t3 (8.3)\t \t  Cannabis abuse\t3 (8.3)\t \tSubstance of choice, n (%)\t \t Cocaine\t16 (44.4)\t \t Narcotic\t6 (16.7)\t \t Cannabis\t6 (16.7)\t \t Stimulants\t5 (13.9)\t \t Tranquilizers\t3 (8.3)\t \tSubstance use during pregnancy, n (%)\t \t Nicotine\t30 (83.3)\t \t Alcohol\t21 (58.3)\t \t Cocaine\t21 (58.3)\t \t Cannabis\t18 (50.0)\t \t Sedatives\t13 (36.1)\t \t Opioids\t12 (33.3)\t \t Amphetamines\t7 (19.4)\t \t Others (Hallucinogens, Inhalants)\t3 (8.3)\t \tAlcohol-use severity b, n (%)\t \t Low level\t17 (47.2)\t \t Medium level\t8 (22.2)\t \t High level/possible dependency\t4 (11.2)\t \tTobacco-use severity c, n (%)\t \t Very low dependence\t12 (33.3)\t \t Low dependence\t8 (22.2)\t \t High/very high dependence\t9 (25.0)\t \tExtent of substance use d, mean ± SD (range)\t \t Last 30 days in controlled environment e (days used)\t \t  Illicit substance of choice\t0.14 ± 0.68 (0 to 4)\t \t   Cocaine\t0.07 ± 0.26 (0 to 1)\t \t   Narcotic\t0.80 ± 1.79 (0 to 4)\t \t   Cannabis\t0.00 ± 0.00 (0 to 0)\t \t   Stimulants\t0.00 ± 0.00 (0 to 0)\t \t   Tranquilizers\t0.00 ± 0.00 (0 to 0)\t \t  Any other illicit substance f\t0.19 ± 1.01 (0 to 6)\t \t Last 30 days prior to admission to controlled environment (days used)\t \t  Illicit substance of choice\t15.39 ± 12.73 (0 to 30)\t \t   Cocaine\t11.33 ± 11.35 (0 to 30)\t \t   Narcotic\t29.0 ± 2.24 (25 to 30)\t \t   Cannabis\t19.4 ± 14.72 (0 to 30)\t \t   Stimulants\t4.67 ± 8.08 (0 to 14)\t \t   Tranquilizers\t17 ± 14.73 (1 to 30)\t \t  Any other illicit substance f\t9.71 ± 11.08 (0 to 30)\t \t Pregnancy (days used of 270 total days)\t \t  Illicit substance of choice\t110.92 ± 107.55 (0 to 270)\t \t   Cocaine\t97.44 ± 102.90 (0 to 270)\t \t   Narcotic\t158.33 ± 130.24 (0 to 270)\t \t   Cannabis\t112.92 ± 106.64 (7.5 to 270)\t \t   Stimulants\t50.9 ± 48.84 (36 to 270)\t \t   Tranquilizers\t184.0 ± 148.96 (12 to 270)\t \t  Any other illicit substance f\t73.53 ± 103.85 (0 to 270)\t \t  Alcohol\t22.21 ± 35.83 (0 to 114)\t \t  Tobacco\t160.92 ± 114.59 (0 to 270)\t \t Lifetime (years used)\t \t  Illicit substance of choice\t7.94 ± 5.58 (0 to 29)\t \t   Cocaine\t9.27 ± 6.85 (1 to 29)\t \t   Narcotic\t7.0 ± 1.22 (5 to 8)\t \t   Cannabis\t10.8 ± 11.54 (0 to 30)\t \t   Stimulants\t6.67 ± 4.93 (1 to 10)\t \t   Tranquilizers\t6.0 ± 1.0 (5 to 7)\t \t  Total illicit substance g\t10.83 ± 5.75 (0 to 29)\t \t  Alcohol\t9.31 ± 7.75 (0 to 36)\t \t
#Text=DSM-IV-TR diagnoses of substance use disorders were given using the MINI.
252-1	57661-57674	Substance-use	_	
252-2	57675-57690	characteristics	_	
252-3	57691-57693	of	_	
252-4	57694-57701	mothers	_	
252-5	57702-57703	(	_	
252-6	57703-57704	N	_	
252-7	57705-57706	=	_	
252-8	57707-57709	36	_	
252-9	57709-57710	)	_	
252-10	57711-57717	DSM-IV	_	
252-11	57718-57731	substance-use	_	
252-12	57732-57741	disorders	_	
252-13	57742-57743	a	_	
252-14	57743-57744	,	_	
252-15	57745-57746	n	_	
252-16	57747-57748	(	_	
252-17	57748-57749	%	_	
252-18	57749-57750	)	_	
252-19	57754-57763	Substance	_	
252-20	57764-57774	dependence	_	
252-21	57775-57777	33	_	
252-22	57778-57779	(	_	
252-23	57779-57783	91.7	_	
252-24	57783-57784	)	_	
252-25	57789-57796	Cocaine	_	
252-26	57797-57807	dependence	_	
252-27	57808-57810	16	_	
252-28	57811-57812	(	_	
252-29	57812-57816	44.4	_	
252-30	57816-57817	)	_	
252-31	57822-57828	Opioid	_	
252-32	57829-57839	dependence	_	
252-33	57840-57841	6	_	
252-34	57842-57843	(	_	
252-35	57843-57847	16.7	_	
252-36	57847-57848	)	_	
252-37	57853-57864	Amphetamine	_	
252-38	57865-57875	dependence	_	
252-39	57876-57877	5	_	
252-40	57878-57879	(	_	
252-41	57879-57883	13.9	_	
252-42	57883-57884	)	_	
252-43	57889-57897	Sedative	_	
252-44	57897-57898	,	_	
252-45	57899-57907	hypnotic	_	
252-46	57907-57908	,	_	
252-47	57909-57911	or	_	
252-48	57912-57922	anxiolytic	_	
252-49	57923-57933	dependence	_	
252-50	57934-57935	3	_	
252-51	57936-57937	(	_	
252-52	57937-57940	8.3	_	
252-53	57940-57941	)	_	
252-54	57946-57954	Cannabis	_	
252-55	57955-57965	dependence	_	
252-56	57966-57967	3	_	
252-57	57968-57969	(	_	
252-58	57969-57972	8.3	_	
252-59	57972-57973	)	_	
252-60	57977-57986	Substance	_	
252-61	57987-57992	abuse	_	
252-62	57993-57994	3	_	
252-63	57995-57996	(	_	
252-64	57996-57999	8.3	_	
252-65	57999-58000	)	_	
252-66	58005-58013	Cannabis	_	
252-67	58014-58019	abuse	_	
252-68	58020-58021	3	_	
252-69	58022-58023	(	_	
252-70	58023-58026	8.3	_	
252-71	58026-58027	)	_	
252-72	58030-58039	Substance	_	
252-73	58040-58042	of	_	
252-74	58043-58049	choice	_	
252-75	58049-58050	,	_	
252-76	58051-58052	n	_	
252-77	58053-58054	(	_	
252-78	58054-58055	%	_	
252-79	58055-58056	)	_	
252-80	58060-58067	Cocaine	_	
252-81	58068-58070	16	_	
252-82	58071-58072	(	_	
252-83	58072-58076	44.4	_	
252-84	58076-58077	)	_	
252-85	58081-58089	Narcotic	_	
252-86	58090-58091	6	_	
252-87	58092-58093	(	_	
252-88	58093-58097	16.7	_	
252-89	58097-58098	)	_	
252-90	58102-58110	Cannabis	_	
252-91	58111-58112	6	_	
252-92	58113-58114	(	_	
252-93	58114-58118	16.7	_	
252-94	58118-58119	)	_	
252-95	58123-58133	Stimulants	_	
252-96	58134-58135	5	_	
252-97	58136-58137	(	_	
252-98	58137-58141	13.9	_	
252-99	58141-58142	)	_	
252-100	58146-58159	Tranquilizers	_	
252-101	58160-58161	3	_	
252-102	58162-58163	(	_	
252-103	58163-58166	8.3	_	
252-104	58166-58167	)	_	
252-105	58170-58179	Substance	_	
252-106	58180-58183	use	_	
252-107	58184-58190	during	_	
252-108	58191-58200	pregnancy	_	
252-109	58200-58201	,	_	
252-110	58202-58203	n	_	
252-111	58204-58205	(	_	
252-112	58205-58206	%	_	
252-113	58206-58207	)	_	
252-114	58211-58219	Nicotine	_	
252-115	58220-58222	30	_	
252-116	58223-58224	(	_	
252-117	58224-58228	83.3	_	
252-118	58228-58229	)	_	
252-119	58233-58240	Alcohol	_	
252-120	58241-58243	21	_	
252-121	58244-58245	(	_	
252-122	58245-58249	58.3	_	
252-123	58249-58250	)	_	
252-124	58254-58261	Cocaine	_	
252-125	58262-58264	21	_	
252-126	58265-58266	(	_	
252-127	58266-58270	58.3	_	
252-128	58270-58271	)	_	
252-129	58275-58283	Cannabis	_	
252-130	58284-58286	18	_	
252-131	58287-58288	(	_	
252-132	58288-58292	50.0	_	
252-133	58292-58293	)	_	
252-134	58297-58306	Sedatives	_	
252-135	58307-58309	13	_	
252-136	58310-58311	(	_	
252-137	58311-58315	36.1	_	
252-138	58315-58316	)	_	
252-139	58320-58327	Opioids	_	
252-140	58328-58330	12	_	
252-141	58331-58332	(	_	
252-142	58332-58336	33.3	_	
252-143	58336-58337	)	_	
252-144	58341-58353	Amphetamines	_	
252-145	58354-58355	7	_	
252-146	58356-58357	(	_	
252-147	58357-58361	19.4	_	
252-148	58361-58362	)	_	
252-149	58366-58372	Others	_	
252-150	58373-58374	(	_	
252-151	58374-58387	Hallucinogens	_	
252-152	58387-58388	,	_	
252-153	58389-58398	Inhalants	_	
252-154	58398-58399	)	_	
252-155	58400-58401	3	_	
252-156	58402-58403	(	_	
252-157	58403-58406	8.3	_	
252-158	58406-58407	)	_	
252-159	58410-58421	Alcohol-use	_	
252-160	58422-58430	severity	_	
252-161	58431-58432	b	_	
252-162	58432-58433	,	_	
252-163	58434-58435	n	_	
252-164	58436-58437	(	_	
252-165	58437-58438	%	_	
252-166	58438-58439	)	_	
252-167	58443-58446	Low	_	
252-168	58447-58452	level	_	
252-169	58453-58455	17	_	
252-170	58456-58457	(	_	
252-171	58457-58461	47.2	_	
252-172	58461-58462	)	_	
252-173	58466-58472	Medium	_	
252-174	58473-58478	level	_	
252-175	58479-58480	8	_	
252-176	58481-58482	(	_	
252-177	58482-58486	22.2	_	
252-178	58486-58487	)	_	
252-179	58491-58495	High	_	
252-180	58496-58501	level	_	
252-181	58501-58502	/	_	
252-182	58502-58510	possible	_	
252-183	58511-58521	dependency	_	
252-184	58522-58523	4	_	
252-185	58524-58525	(	_	
252-186	58525-58529	11.2	_	
252-187	58529-58530	)	_	
252-188	58533-58544	Tobacco-use	_	
252-189	58545-58553	severity	_	
252-190	58554-58555	c	_	
252-191	58555-58556	,	_	
252-192	58557-58558	n	_	
252-193	58559-58560	(	_	
252-194	58560-58561	%	_	
252-195	58561-58562	)	_	
252-196	58566-58570	Very	_	
252-197	58571-58574	low	_	
252-198	58575-58585	dependence	_	
252-199	58586-58588	12	_	
252-200	58589-58590	(	_	
252-201	58590-58594	33.3	_	
252-202	58594-58595	)	_	
252-203	58599-58602	Low	_	
252-204	58603-58613	dependence	_	
252-205	58614-58615	8	_	
252-206	58616-58617	(	_	
252-207	58617-58621	22.2	_	
252-208	58621-58622	)	_	
252-209	58626-58630	High	_	
252-210	58630-58631	/	_	
252-211	58631-58635	very	_	
252-212	58636-58640	high	_	
252-213	58641-58651	dependence	_	
252-214	58652-58653	9	_	
252-215	58654-58655	(	_	
252-216	58655-58659	25.0	_	
252-217	58659-58660	)	_	
252-218	58663-58669	Extent	_	
252-219	58670-58672	of	_	
252-220	58673-58682	substance	_	
252-221	58683-58686	use	_	
252-222	58687-58688	d	_	
252-223	58688-58689	,	_	
252-224	58690-58694	mean	_	
252-225	58695-58696	±	_	
252-226	58697-58699	SD	_	
252-227	58700-58701	(	_	
252-228	58701-58706	range	_	
252-229	58706-58707	)	_	
252-230	58711-58715	Last	_	
252-231	58716-58718	30	_	
252-232	58719-58723	days	_	
252-233	58724-58726	in	_	
252-234	58727-58737	controlled	_	
252-235	58738-58749	environment	_	
252-236	58750-58751	e	_	
252-237	58752-58753	(	_	
252-238	58753-58757	days	_	
252-239	58758-58762	used	_	
252-240	58762-58763	)	_	
252-241	58768-58775	Illicit	_	
252-242	58776-58785	substance	_	
252-243	58786-58788	of	_	
252-244	58789-58795	choice	_	
252-245	58796-58800	0.14	_	
252-246	58801-58802	±	_	
252-247	58803-58807	0.68	_	
252-248	58808-58809	(	_	
252-249	58809-58810	0	_	
252-250	58811-58813	to	_	
252-251	58814-58815	4	_	
252-252	58815-58816	)	_	
252-253	58822-58829	Cocaine	_	
252-254	58830-58834	0.07	_	
252-255	58835-58836	±	_	
252-256	58837-58841	0.26	_	
252-257	58842-58843	(	_	
252-258	58843-58844	0	_	
252-259	58845-58847	to	_	
252-260	58848-58849	1	_	
252-261	58849-58850	)	_	
252-262	58856-58864	Narcotic	_	
252-263	58865-58869	0.80	_	
252-264	58870-58871	±	_	
252-265	58872-58876	1.79	_	
252-266	58877-58878	(	_	
252-267	58878-58879	0	_	
252-268	58880-58882	to	_	
252-269	58883-58884	4	_	
252-270	58884-58885	)	_	
252-271	58891-58899	Cannabis	_	
252-272	58900-58904	0.00	_	
252-273	58905-58906	±	_	
252-274	58907-58911	0.00	_	
252-275	58912-58913	(	_	
252-276	58913-58914	0	_	
252-277	58915-58917	to	_	
252-278	58918-58919	0	_	
252-279	58919-58920	)	_	
252-280	58926-58936	Stimulants	_	
252-281	58937-58941	0.00	_	
252-282	58942-58943	±	_	
252-283	58944-58948	0.00	_	
252-284	58949-58950	(	_	
252-285	58950-58951	0	_	
252-286	58952-58954	to	_	
252-287	58955-58956	0	_	
252-288	58956-58957	)	_	
252-289	58963-58976	Tranquilizers	_	
252-290	58977-58981	0.00	_	
252-291	58982-58983	±	_	
252-292	58984-58988	0.00	_	
252-293	58989-58990	(	_	
252-294	58990-58991	0	_	
252-295	58992-58994	to	_	
252-296	58995-58996	0	_	
252-297	58996-58997	)	_	
252-298	59002-59005	Any	_	
252-299	59006-59011	other	_	
252-300	59012-59019	illicit	_	
252-301	59020-59029	substance	_	
252-302	59030-59031	f	_	
252-303	59032-59036	0.19	_	
252-304	59037-59038	±	_	
252-305	59039-59043	1.01	_	
252-306	59044-59045	(	_	
252-307	59045-59046	0	_	
252-308	59047-59049	to	_	
252-309	59050-59051	6	_	
252-310	59051-59052	)	_	
252-311	59056-59060	Last	_	
252-312	59061-59063	30	_	
252-313	59064-59068	days	_	
252-314	59069-59074	prior	_	
252-315	59075-59077	to	_	
252-316	59078-59087	admission	_	
252-317	59088-59090	to	_	
252-318	59091-59101	controlled	_	
252-319	59102-59113	environment	_	
252-320	59114-59115	(	_	
252-321	59115-59119	days	_	
252-322	59120-59124	used	_	
252-323	59124-59125	)	_	
252-324	59130-59137	Illicit	_	
252-325	59138-59147	substance	_	
252-326	59148-59150	of	_	
252-327	59151-59157	choice	_	
252-328	59158-59163	15.39	_	
252-329	59164-59165	±	_	
252-330	59166-59171	12.73	_	
252-331	59172-59173	(	_	
252-332	59173-59174	0	_	
252-333	59175-59177	to	_	
252-334	59178-59180	30	_	
252-335	59180-59181	)	_	
252-336	59187-59194	Cocaine	_	
252-337	59195-59200	11.33	_	
252-338	59201-59202	±	_	
252-339	59203-59208	11.35	_	
252-340	59209-59210	(	_	
252-341	59210-59211	0	_	
252-342	59212-59214	to	_	
252-343	59215-59217	30	_	
252-344	59217-59218	)	_	
252-345	59224-59232	Narcotic	_	
252-346	59233-59237	29.0	_	
252-347	59238-59239	±	_	
252-348	59240-59244	2.24	_	
252-349	59245-59246	(	_	
252-350	59246-59248	25	_	
252-351	59249-59251	to	_	
252-352	59252-59254	30	_	
252-353	59254-59255	)	_	
252-354	59261-59269	Cannabis	_	
252-355	59270-59274	19.4	_	
252-356	59275-59276	±	_	
252-357	59277-59282	14.72	_	
252-358	59283-59284	(	_	
252-359	59284-59285	0	_	
252-360	59286-59288	to	_	
252-361	59289-59291	30	_	
252-362	59291-59292	)	_	
252-363	59298-59308	Stimulants	_	
252-364	59309-59313	4.67	_	
252-365	59314-59315	±	_	
252-366	59316-59320	8.08	_	
252-367	59321-59322	(	_	
252-368	59322-59323	0	_	
252-369	59324-59326	to	_	
252-370	59327-59329	14	_	
252-371	59329-59330	)	_	
252-372	59336-59349	Tranquilizers	_	
252-373	59350-59352	17	_	
252-374	59353-59354	±	_	
252-375	59355-59360	14.73	_	
252-376	59361-59362	(	_	
252-377	59362-59363	1	_	
252-378	59364-59366	to	_	
252-379	59367-59369	30	_	
252-380	59369-59370	)	_	
252-381	59375-59378	Any	_	
252-382	59379-59384	other	_	
252-383	59385-59392	illicit	_	
252-384	59393-59402	substance	_	
252-385	59403-59404	f	_	
252-386	59405-59409	9.71	_	
252-387	59410-59411	±	_	
252-388	59412-59417	11.08	_	
252-389	59418-59419	(	_	
252-390	59419-59420	0	_	
252-391	59421-59423	to	_	
252-392	59424-59426	30	_	
252-393	59426-59427	)	_	
252-394	59431-59440	Pregnancy	_	
252-395	59441-59442	(	_	
252-396	59442-59446	days	_	
252-397	59447-59451	used	_	
252-398	59452-59454	of	_	
252-399	59455-59458	270	_	
252-400	59459-59464	total	_	
252-401	59465-59469	days	_	
252-402	59469-59470	)	_	
252-403	59475-59482	Illicit	_	
252-404	59483-59492	substance	_	
252-405	59493-59495	of	_	
252-406	59496-59502	choice	_	
252-407	59503-59509	110.92	_	
252-408	59510-59511	±	_	
252-409	59512-59518	107.55	_	
252-410	59519-59520	(	_	
252-411	59520-59521	0	_	
252-412	59522-59524	to	_	
252-413	59525-59528	270	_	
252-414	59528-59529	)	_	
252-415	59535-59542	Cocaine	_	
252-416	59543-59548	97.44	_	
252-417	59549-59550	±	_	
252-418	59551-59557	102.90	_	
252-419	59558-59559	(	_	
252-420	59559-59560	0	_	
252-421	59561-59563	to	_	
252-422	59564-59567	270	_	
252-423	59567-59568	)	_	
252-424	59574-59582	Narcotic	_	
252-425	59583-59589	158.33	_	
252-426	59590-59591	±	_	
252-427	59592-59598	130.24	_	
252-428	59599-59600	(	_	
252-429	59600-59601	0	_	
252-430	59602-59604	to	_	
252-431	59605-59608	270	_	
252-432	59608-59609	)	_	
252-433	59615-59623	Cannabis	_	
252-434	59624-59630	112.92	_	
252-435	59631-59632	±	_	
252-436	59633-59639	106.64	_	
252-437	59640-59641	(	_	
252-438	59641-59644	7.5	_	
252-439	59645-59647	to	_	
252-440	59648-59651	270	_	
252-441	59651-59652	)	_	
252-442	59658-59668	Stimulants	_	
252-443	59669-59673	50.9	_	
252-444	59674-59675	±	_	
252-445	59676-59681	48.84	_	
252-446	59682-59683	(	_	
252-447	59683-59685	36	_	
252-448	59686-59688	to	_	
252-449	59689-59692	270	_	
252-450	59692-59693	)	_	
252-451	59699-59712	Tranquilizers	_	
252-452	59713-59718	184.0	_	
252-453	59719-59720	±	_	
252-454	59721-59727	148.96	_	
252-455	59728-59729	(	_	
252-456	59729-59731	12	_	
252-457	59732-59734	to	_	
252-458	59735-59738	270	_	
252-459	59738-59739	)	_	
252-460	59744-59747	Any	_	
252-461	59748-59753	other	_	
252-462	59754-59761	illicit	_	
252-463	59762-59771	substance	_	
252-464	59772-59773	f	_	
252-465	59774-59779	73.53	_	
252-466	59780-59781	±	_	
252-467	59782-59788	103.85	_	
252-468	59789-59790	(	_	
252-469	59790-59791	0	_	
252-470	59792-59794	to	_	
252-471	59795-59798	270	_	
252-472	59798-59799	)	_	
252-473	59804-59811	Alcohol	_	
252-474	59812-59817	22.21	_	
252-475	59818-59819	±	_	
252-476	59820-59825	35.83	_	
252-477	59826-59827	(	_	
252-478	59827-59828	0	_	
252-479	59829-59831	to	_	
252-480	59832-59835	114	_	
252-481	59835-59836	)	_	
252-482	59841-59848	Tobacco	_	
252-483	59849-59855	160.92	_	
252-484	59856-59857	±	_	
252-485	59858-59864	114.59	_	
252-486	59865-59866	(	_	
252-487	59866-59867	0	_	
252-488	59868-59870	to	_	
252-489	59871-59874	270	_	
252-490	59874-59875	)	_	
252-491	59879-59887	Lifetime	_	
252-492	59888-59889	(	_	
252-493	59889-59894	years	_	
252-494	59895-59899	used	_	
252-495	59899-59900	)	_	
252-496	59905-59912	Illicit	_	
252-497	59913-59922	substance	_	
252-498	59923-59925	of	_	
252-499	59926-59932	choice	_	
252-500	59933-59937	7.94	_	
252-501	59938-59939	±	_	
252-502	59940-59944	5.58	_	
252-503	59945-59946	(	_	
252-504	59946-59947	0	_	
252-505	59948-59950	to	_	
252-506	59951-59953	29	_	
252-507	59953-59954	)	_	
252-508	59960-59967	Cocaine	_	
252-509	59968-59972	9.27	_	
252-510	59973-59974	±	_	
252-511	59975-59979	6.85	_	
252-512	59980-59981	(	_	
252-513	59981-59982	1	_	
252-514	59983-59985	to	_	
252-515	59986-59988	29	_	
252-516	59988-59989	)	_	
252-517	59995-60003	Narcotic	_	
252-518	60004-60007	7.0	_	
252-519	60008-60009	±	_	
252-520	60010-60014	1.22	_	
252-521	60015-60016	(	_	
252-522	60016-60017	5	_	
252-523	60018-60020	to	_	
252-524	60021-60022	8	_	
252-525	60022-60023	)	_	
252-526	60029-60037	Cannabis	_	
252-527	60038-60042	10.8	_	
252-528	60043-60044	±	_	
252-529	60045-60050	11.54	_	
252-530	60051-60052	(	_	
252-531	60052-60053	0	_	
252-532	60054-60056	to	_	
252-533	60057-60059	30	_	
252-534	60059-60060	)	_	
252-535	60066-60076	Stimulants	_	
252-536	60077-60081	6.67	_	
252-537	60082-60083	±	_	
252-538	60084-60088	4.93	_	
252-539	60089-60090	(	_	
252-540	60090-60091	1	_	
252-541	60092-60094	to	_	
252-542	60095-60097	10	_	
252-543	60097-60098	)	_	
252-544	60104-60117	Tranquilizers	_	
252-545	60118-60121	6.0	_	
252-546	60122-60123	±	_	
252-547	60124-60127	1.0	_	
252-548	60128-60129	(	_	
252-549	60129-60130	5	_	
252-550	60131-60133	to	_	
252-551	60134-60135	7	_	
252-552	60135-60136	)	_	
252-553	60141-60146	Total	_	
252-554	60147-60154	illicit	_	
252-555	60155-60164	substance	_	
252-556	60165-60166	g	_	
252-557	60167-60172	10.83	_	
252-558	60173-60174	±	_	
252-559	60175-60179	5.75	_	
252-560	60180-60181	(	_	
252-561	60181-60182	0	_	
252-562	60183-60185	to	_	
252-563	60186-60188	29	_	
252-564	60188-60189	)	_	
252-565	60194-60201	Alcohol	_	
252-566	60202-60206	9.31	_	
252-567	60207-60208	±	_	
252-568	60209-60213	7.75	_	
252-569	60214-60215	(	_	
252-570	60215-60216	0	_	
252-571	60217-60219	to	_	
252-572	60220-60222	36	_	
252-573	60222-60223	)	_	
252-574	60227-60236	DSM-IV-TR	_	
252-575	60237-60246	diagnoses	_	
252-576	60247-60249	of	_	
252-577	60250-60259	substance	_	
252-578	60260-60263	use	_	
252-579	60264-60273	disorders	_	
252-580	60274-60278	were	_	
252-581	60279-60284	given	_	
252-582	60285-60290	using	_	
252-583	60291-60294	the	_	
252-584	60295-60299	MINI	_	
252-585	60299-60300	.	_	

#Text=No mother received the diagnosis of substance dependence or abuse solely based on alcohol or tobacco use.
253-1	60301-60303	No	_	
253-2	60304-60310	mother	_	
253-3	60311-60319	received	_	
253-4	60320-60323	the	_	
253-5	60324-60333	diagnosis	_	
253-6	60334-60336	of	_	
253-7	60337-60346	substance	_	
253-8	60347-60357	dependence	_	
253-9	60358-60360	or	_	
253-10	60361-60366	abuse	_	
253-11	60367-60373	solely	_	
253-12	60374-60379	based	_	
253-13	60380-60382	on	_	
253-14	60383-60390	alcohol	_	
253-15	60391-60393	or	_	
253-16	60394-60401	tobacco	_	
253-17	60402-60405	use	_	
253-18	60405-60406	.	_	

#Text=Severity of alcohol problems was determined by the AUDIT.
254-1	60407-60415	Severity	_	
254-2	60416-60418	of	_	
254-3	60419-60426	alcohol	_	
254-4	60427-60435	problems	_	
254-5	60436-60439	was	_	
254-6	60440-60450	determined	_	
254-7	60451-60453	by	_	
254-8	60454-60457	the	_	
254-9	60458-60463	AUDIT	_	
254-10	60463-60464	.	_	

#Text=An AUDIT score of ≤ 7 represented a low level, 8 to 15 represented a medium level, and 16 ≤ represented a high level of alcohol problems.
255-1	60465-60467	An	_	
255-2	60468-60473	AUDIT	_	
255-3	60474-60479	score	_	
255-4	60480-60482	of	_	
255-5	60483-60484	≤	_	
255-6	60485-60486	7	_	
255-7	60487-60498	represented	_	
255-8	60499-60500	a	_	
255-9	60501-60504	low	_	
255-10	60505-60510	level	_	
255-11	60510-60511	,	_	
255-12	60512-60513	8	_	
255-13	60514-60516	to	_	
255-14	60517-60519	15	_	
255-15	60520-60531	represented	_	
255-16	60532-60533	a	_	
255-17	60534-60540	medium	_	
255-18	60541-60546	level	_	
255-19	60546-60547	,	_	
255-20	60548-60551	and	_	
255-21	60552-60554	16	_	
255-22	60555-60556	≤	_	
255-23	60557-60568	represented	_	
255-24	60569-60570	a	_	
255-25	60571-60575	high	_	
255-26	60576-60581	level	_	
255-27	60582-60584	of	_	
255-28	60585-60592	alcohol	_	
255-29	60593-60601	problems	_	
255-30	60601-60602	.	_	

#Text=The mean AUDIT score was 7.97 (SD = 7.24) for the current group of mothers.
256-1	60603-60606	The	_	
256-2	60607-60611	mean	_	
256-3	60612-60617	AUDIT	_	
256-4	60618-60623	score	_	
256-5	60624-60627	was	_	
256-6	60628-60632	7.97	_	
256-7	60633-60634	(	_	
256-8	60634-60636	SD	_	
256-9	60637-60638	=	_	
256-10	60639-60643	7.24	_	
256-11	60643-60644	)	_	
256-12	60645-60648	for	_	
256-13	60649-60652	the	_	
256-14	60653-60660	current	_	
256-15	60661-60666	group	_	
256-16	60667-60669	of	_	
256-17	60670-60677	mothers	_	
256-18	60677-60678	.	_	

#Text=Severity of tobacco use was assessed by the FTND.
257-1	60679-60687	Severity	_	
257-2	60688-60690	of	_	
257-3	60691-60698	tobacco	_	
257-4	60699-60702	use	_	
257-5	60703-60706	was	_	
257-6	60707-60715	assessed	_	
257-7	60716-60718	by	_	
257-8	60719-60722	the	_	
257-9	60723-60727	FTND	_	
257-10	60727-60728	.	_	

#Text=An FTND score of 0 to 2 indicated very low dependence, 3 to 4 indicated low dependence, 5 indicated medium dependence, 6 to 7 indicated high dependence, and 8 to 10 indicated very high dependence on nicotine.
258-1	60729-60731	An	_	
258-2	60732-60736	FTND	_	
258-3	60737-60742	score	_	
258-4	60743-60745	of	_	
258-5	60746-60747	0	_	
258-6	60748-60750	to	_	
258-7	60751-60752	2	_	
258-8	60753-60762	indicated	_	
258-9	60763-60767	very	_	
258-10	60768-60771	low	_	
258-11	60772-60782	dependence	_	
258-12	60782-60783	,	_	
258-13	60784-60785	3	_	
258-14	60786-60788	to	_	
258-15	60789-60790	4	_	
258-16	60791-60800	indicated	_	
258-17	60801-60804	low	_	
258-18	60805-60815	dependence	_	
258-19	60815-60816	,	_	
258-20	60817-60818	5	_	
258-21	60819-60828	indicated	_	
258-22	60829-60835	medium	_	
258-23	60836-60846	dependence	_	
258-24	60846-60847	,	_	
258-25	60848-60849	6	_	
258-26	60850-60852	to	_	
258-27	60853-60854	7	_	
258-28	60855-60864	indicated	_	
258-29	60865-60869	high	_	
258-30	60870-60880	dependence	_	
258-31	60880-60881	,	_	
258-32	60882-60885	and	_	
258-33	60886-60887	8	_	
258-34	60888-60890	to	_	
258-35	60891-60893	10	_	
258-36	60894-60903	indicated	_	
258-37	60904-60908	very	_	
258-38	60909-60913	high	_	
258-39	60914-60924	dependence	_	
258-40	60925-60927	on	_	
258-41	60928-60936	nicotine	_	
258-42	60936-60937	.	_	

#Text=The mean FTND score was 3.10 (SD = 2.88) for the current group.
259-1	60938-60941	The	_	
259-2	60942-60946	mean	_	
259-3	60947-60951	FTND	_	
259-4	60952-60957	score	_	
259-5	60958-60961	was	_	
259-6	60962-60966	3.10	_	
259-7	60967-60968	(	_	
259-8	60968-60970	SD	_	
259-9	60971-60972	=	_	
259-10	60973-60977	2.88	_	
259-11	60977-60978	)	_	
259-12	60979-60982	for	_	
259-13	60983-60986	the	_	
259-14	60987-60994	current	_	
259-15	60995-61000	group	_	
259-16	61000-61001	.	_	

#Text=Extent (frequency) of substance use was assessed using the ASI-Lite.
260-1	61002-61008	Extent	_	
260-2	61009-61010	(	_	
260-3	61010-61019	frequency	_	
260-4	61019-61020	)	_	
260-5	61021-61023	of	_	
260-6	61024-61033	substance	_	
260-7	61034-61037	use	_	
260-8	61038-61041	was	_	
260-9	61042-61050	assessed	_	
260-10	61051-61056	using	_	
260-11	61057-61060	the	_	
260-12	61061-61069	ASI-Lite	_	
260-13	61069-61070	.	_	

#Text=The reported values refer to the number of days or years used during the respective period.
261-1	61071-61074	The	_	
261-2	61075-61083	reported	_	
261-3	61084-61090	values	_	
261-4	61091-61096	refer	_	
261-5	61097-61099	to	_	
261-6	61100-61103	the	_	
261-7	61104-61110	number	_	
261-8	61111-61113	of	_	
261-9	61114-61118	days	_	
261-10	61119-61121	or	_	
261-11	61122-61127	years	_	
261-12	61128-61132	used	_	
261-13	61133-61139	during	_	
261-14	61140-61143	the	_	
261-15	61144-61154	respective	_	
261-16	61155-61161	period	_	
261-17	61161-61162	.	_	

#Text=Controlled environment refers to residential treatment or incarceration.
262-1	61163-61173	Controlled	_	
262-2	61174-61185	environment	_	
262-3	61186-61192	refers	_	
262-4	61193-61195	to	_	
262-5	61196-61207	residential	_	
262-6	61208-61217	treatment	_	
262-7	61218-61220	or	_	
262-8	61221-61234	incarceration	_	
262-9	61234-61235	.	_	

#Text=Any other illicit substance refers to any illicit substances other than substance of choice (excluding alcohol and tobacco)
#Text=Total illicit substance refers to any combination of illicit substances including substance of choice (excluding alcohol and tobacco).
263-1	61236-61239	Any	_	
263-2	61240-61245	other	_	
263-3	61246-61253	illicit	_	
263-4	61254-61263	substance	_	
263-5	61264-61270	refers	_	
263-6	61271-61273	to	_	
263-7	61274-61277	any	_	
263-8	61278-61285	illicit	_	
263-9	61286-61296	substances	_	
263-10	61297-61302	other	_	
263-11	61303-61307	than	_	
263-12	61308-61317	substance	_	
263-13	61318-61320	of	_	
263-14	61321-61327	choice	_	
263-15	61328-61329	(	_	
263-16	61329-61338	excluding	_	
263-17	61339-61346	alcohol	_	
263-18	61347-61350	and	_	
263-19	61351-61358	tobacco	_	
263-20	61358-61359	)	_	
263-21	61360-61365	Total	_	
263-22	61366-61373	illicit	_	
263-23	61374-61383	substance	_	
263-24	61384-61390	refers	_	
263-25	61391-61393	to	_	
263-26	61394-61397	any	_	
263-27	61398-61409	combination	_	
263-28	61410-61412	of	_	
263-29	61413-61420	illicit	_	
263-30	61421-61431	substances	_	
263-31	61432-61441	including	_	
263-32	61442-61451	substance	_	
263-33	61452-61454	of	_	
263-34	61455-61461	choice	_	
263-35	61462-61463	(	_	
263-36	61463-61472	excluding	_	
263-37	61473-61480	alcohol	_	
263-38	61481-61484	and	_	
263-39	61485-61492	tobacco	_	
263-40	61492-61493	)	_	
263-41	61493-61494	.	_	

#Text=Note.
264-1	61495-61499	Note	_	
264-2	61499-61500	.	_	

#Text=MINI = Mini International Neuropsychiatric Interview 6.0; ASI = Addiction Severity Index-Lite; AUDIT = Alcohol Use Disorders Identification Test; FTND = Fagerstrom Test for Nicotine Dependence.
265-1	61501-61505	MINI	_	
265-2	61506-61507	=	_	
265-3	61508-61512	Mini	_	
265-4	61513-61526	International	_	
265-5	61527-61543	Neuropsychiatric	_	
265-6	61544-61553	Interview	_	
265-7	61554-61557	6.0	_	
265-8	61557-61558	;	_	
265-9	61559-61562	ASI	_	
265-10	61563-61564	=	_	
265-11	61565-61574	Addiction	_	
265-12	61575-61583	Severity	_	
265-13	61584-61594	Index-Lite	_	
265-14	61594-61595	;	_	
265-15	61596-61601	AUDIT	_	
265-16	61602-61603	=	_	
265-17	61604-61611	Alcohol	_	
265-18	61612-61615	Use	_	
265-19	61616-61625	Disorders	_	
265-20	61626-61640	Identification	_	
265-21	61641-61645	Test	_	
265-22	61645-61646	;	_	
265-23	61647-61651	FTND	_	
265-24	61652-61653	=	_	
265-25	61654-61664	Fagerstrom	_	
265-26	61665-61669	Test	_	
265-27	61670-61673	for	_	
265-28	61674-61682	Nicotine	_	
265-29	61683-61693	Dependence	_	
265-30	61693-61694	.	_	

#Text=Brain activation in mothers with addictions to the contrast of own happy (OH) versus unknown happy (UH)
#Text=\tHemisphere\tTalairach coordinates a\tPeak t value\tp\tVolume b (mm3)\t \t\t \tx\ty\tz\t \tFrontal lobe\t \t Superior Frontal Gyrus\tRight\t2\t−5\t60\t7.99\t< .00000001\t507\t \t Precentral Gyrus\tRight\t41\t−2\t27\t7.21\t.00000002\t357\t \t Precentral Gyrus/Postcentral Gyrus\tLeft\t−43\t−17\t45\t6.19\t.00000043\t469\t \tParietal lobe\t \t Precentral Gyrus/Postcentral Gyrus\tRight\t50\t−17\t42\t9.24\t< .00000001\t1853\t \t Superior Parietal Lobule\tRight\t23\t−59\t30\t6.14\t.00000051\t360\t \tTemporal/Occipital lobe\t \t Fusiform Gyrus/Inferior Temporal Gyrus/Occipital Gyri\tLeft\t−28\t−47\t−18\t9.37\t< .00000001\t8044\t \t Occipital Gyri\tRight\t29\t−77\t0\t7.51\t.00000001\t2275\t \t Fusiform Gyrus\tRight\t32\t−44\t−15\t7.40\t.00000001\t2631\t \tSub-lobar regions\t \t Middle Cingulate Gyrus\tRight/Left\t−1\t−5\t33\t10.10\t< .00000001\t1395\t \t Limbic c\t\t\t\t\t\t\t2869\t \t  Dorsal Putamen/Globus Pallidus\tLeft\t−22\t−2\t−6\t8.77\t< .00000001\t\t \t  Parahippocampal Gyrus\tLeft\t−28\t−5\t−30\t6.59\t.00000013\t\t \t Insula/Inferior Frontal Gyrus\tLeft\t−40\t4\t12\t8.04\t< .00000001\t946\t \t Parahippocampal Gyrus/Lateral Amygdala\tRight\t23\t−5\t−27\t8.02\t< .00000001\t1531\t \t Midbrain/limbic c\t\t\t\t\t\t\t8895\t \t  Thalamus\tLeft\t−7\t−23\t6\t7.98\t< .00000001\t\t \t  Substantia Nigra\tRight\t4\t−26\t−9\t7.26\t.00000002\t\t \t  Thalamus\tRight\t2\t−14\t8\t7.01\t.00000004\t\t \t  Ventral Tegmental Area\tRight/Left\t−1\t−16\t−9\t6.90\t.00000005\t\t \t  Hippocampus\tRight\t23\t−23\t−6\t6.75\t.00000008\t\t \t  Substantia Nigra\tLeft\t−4\t−17\t−9\t6.48\t.00000018\t\t \t Globus Pallidus\tRight\t17\t−5\t−6\t6.59\t.00000013\t324\t \t Posterior Cingulate Gyrus\tLeft\t−4\t−53\t9\t6.36\t.00000026\t720\t \tCerebellum\t \t Anterior Lobe, Culmen\tRight\t29\t−50\t−21\t9.38\t< .00000001\t4395\t \t Anterior Lobe, Cerebellar Lingual\tLeft\t−4\t−44\t−9\t7.76\t< .00000001\t345\t \t Anterior Lobe, Culmen\tRight\t14\t−59\t−18\t6.25\t.00000036\t602\t \t Posterior Lobe, Cerebellar Tonsil\tLeft\t−7\t−50\t−30\t6.21\t.00000041\t494\t \t
#Text=Note.
266-1	61695-61700	Brain	_	
266-2	61701-61711	activation	_	
266-3	61712-61714	in	_	
266-4	61715-61722	mothers	_	
266-5	61723-61727	with	_	
266-6	61728-61738	addictions	_	
266-7	61739-61741	to	_	
266-8	61742-61745	the	_	
266-9	61746-61754	contrast	_	
266-10	61755-61757	of	_	
266-11	61758-61761	own	_	
266-12	61762-61767	happy	_	
266-13	61768-61769	(	_	
266-14	61769-61771	OH	_	
266-15	61771-61772	)	_	
266-16	61773-61779	versus	_	
266-17	61780-61787	unknown	_	
266-18	61788-61793	happy	_	
266-19	61794-61795	(	_	
266-20	61795-61797	UH	_	
266-21	61797-61798	)	_	
266-22	61800-61810	Hemisphere	_	
266-23	61811-61820	Talairach	_	
266-24	61821-61832	coordinates	_	
266-25	61833-61834	a	_	
266-26	61835-61839	Peak	_	
266-27	61840-61841	t	_	
266-28	61842-61847	value	_	
266-29	61848-61849	p	_	
266-30	61850-61856	Volume	_	
266-31	61857-61858	b	_	
266-32	61859-61860	(	_	
266-33	61860-61863	mm3	_	
266-34	61863-61864	)	_	
266-35	61870-61871	x	_	
266-36	61872-61873	y	_	
266-37	61874-61875	z	_	
266-38	61878-61885	Frontal	_	
266-39	61886-61890	lobe	_	
266-40	61894-61902	Superior	_	
266-41	61903-61910	Frontal	_	
266-42	61911-61916	Gyrus	_	
266-43	61917-61922	Right	_	
266-44	61923-61924	2	_	
266-45	61925-61926	−	_	
266-46	61926-61927	5	_	
266-47	61928-61930	60	_	
266-48	61931-61935	7.99	_	
266-49	61936-61937	<	_	
266-50	61938-61947	.00000001	_	
266-51	61948-61951	507	_	
266-52	61955-61965	Precentral	_	
266-53	61966-61971	Gyrus	_	
266-54	61972-61977	Right	_	
266-55	61978-61980	41	_	
266-56	61981-61982	−	_	
266-57	61982-61983	2	_	
266-58	61984-61986	27	_	
266-59	61987-61991	7.21	_	
266-60	61992-62001	.00000002	_	
266-61	62002-62005	357	_	
266-62	62009-62019	Precentral	_	
266-63	62020-62025	Gyrus	_	
266-64	62025-62026	/	_	
266-65	62026-62037	Postcentral	_	
266-66	62038-62043	Gyrus	_	
266-67	62044-62048	Left	_	
266-68	62049-62050	−	_	
266-69	62050-62052	43	_	
266-70	62053-62054	−	_	
266-71	62054-62056	17	_	
266-72	62057-62059	45	_	
266-73	62060-62064	6.19	_	
266-74	62065-62074	.00000043	_	
266-75	62075-62078	469	_	
266-76	62081-62089	Parietal	_	
266-77	62090-62094	lobe	_	
266-78	62098-62108	Precentral	_	
266-79	62109-62114	Gyrus	_	
266-80	62114-62115	/	_	
266-81	62115-62126	Postcentral	_	
266-82	62127-62132	Gyrus	_	
266-83	62133-62138	Right	_	
266-84	62139-62141	50	_	
266-85	62142-62143	−	_	
266-86	62143-62145	17	_	
266-87	62146-62148	42	_	
266-88	62149-62153	9.24	_	
266-89	62154-62155	<	_	
266-90	62156-62165	.00000001	_	
266-91	62166-62170	1853	_	
266-92	62174-62182	Superior	_	
266-93	62183-62191	Parietal	_	
266-94	62192-62198	Lobule	_	
266-95	62199-62204	Right	_	
266-96	62205-62207	23	_	
266-97	62208-62209	−	_	
266-98	62209-62211	59	_	
266-99	62212-62214	30	_	
266-100	62215-62219	6.14	_	
266-101	62220-62229	.00000051	_	
266-102	62230-62233	360	_	
266-103	62236-62244	Temporal	_	
266-104	62244-62245	/	_	
266-105	62245-62254	Occipital	_	
266-106	62255-62259	lobe	_	
266-107	62263-62271	Fusiform	_	
266-108	62272-62277	Gyrus	_	
266-109	62277-62278	/	_	
266-110	62278-62286	Inferior	_	
266-111	62287-62295	Temporal	_	
266-112	62296-62301	Gyrus	_	
266-113	62301-62302	/	_	
266-114	62302-62311	Occipital	_	
266-115	62312-62316	Gyri	_	
266-116	62317-62321	Left	_	
266-117	62322-62323	−	_	
266-118	62323-62325	28	_	
266-119	62326-62327	−	_	
266-120	62327-62329	47	_	
266-121	62330-62331	−	_	
266-122	62331-62333	18	_	
266-123	62334-62338	9.37	_	
266-124	62339-62340	<	_	
266-125	62341-62350	.00000001	_	
266-126	62351-62355	8044	_	
266-127	62359-62368	Occipital	_	
266-128	62369-62373	Gyri	_	
266-129	62374-62379	Right	_	
266-130	62380-62382	29	_	
266-131	62383-62384	−	_	
266-132	62384-62386	77	_	
266-133	62387-62388	0	_	
266-134	62389-62393	7.51	_	
266-135	62394-62403	.00000001	_	
266-136	62404-62408	2275	_	
266-137	62412-62420	Fusiform	_	
266-138	62421-62426	Gyrus	_	
266-139	62427-62432	Right	_	
266-140	62433-62435	32	_	
266-141	62436-62437	−	_	
266-142	62437-62439	44	_	
266-143	62440-62441	−	_	
266-144	62441-62443	15	_	
266-145	62444-62448	7.40	_	
266-146	62449-62458	.00000001	_	
266-147	62459-62463	2631	_	
266-148	62466-62475	Sub-lobar	_	
266-149	62476-62483	regions	_	
266-150	62487-62493	Middle	_	
266-151	62494-62503	Cingulate	_	
266-152	62504-62509	Gyrus	_	
266-153	62510-62515	Right	_	
266-154	62515-62516	/	_	
266-155	62516-62520	Left	_	
266-156	62521-62522	−	_	
266-157	62522-62523	1	_	
266-158	62524-62525	−	_	
266-159	62525-62526	5	_	
266-160	62527-62529	33	_	
266-161	62530-62535	10.10	_	
266-162	62536-62537	<	_	
266-163	62538-62547	.00000001	_	
266-164	62548-62552	1395	_	
266-165	62556-62562	Limbic	_	
266-166	62563-62564	c	_	
266-167	62571-62575	2869	_	
266-168	62580-62586	Dorsal	_	
266-169	62587-62594	Putamen	_	
266-170	62594-62595	/	_	
266-171	62595-62601	Globus	_	
266-172	62602-62610	Pallidus	_	
266-173	62611-62615	Left	_	
266-174	62616-62617	−	_	
266-175	62617-62619	22	_	
266-176	62620-62621	−	_	
266-177	62621-62622	2	_	
266-178	62623-62624	−	_	
266-179	62624-62625	6	_	
266-180	62626-62630	8.77	_	
266-181	62631-62632	<	_	
266-182	62633-62642	.00000001	_	
266-183	62648-62663	Parahippocampal	_	
266-184	62664-62669	Gyrus	_	
266-185	62670-62674	Left	_	
266-186	62675-62676	−	_	
266-187	62676-62678	28	_	
266-188	62679-62680	−	_	
266-189	62680-62681	5	_	
266-190	62682-62683	−	_	
266-191	62683-62685	30	_	
266-192	62686-62690	6.59	_	
266-193	62691-62700	.00000013	_	
266-194	62705-62711	Insula	_	
266-195	62711-62712	/	_	
266-196	62712-62720	Inferior	_	
266-197	62721-62728	Frontal	_	
266-198	62729-62734	Gyrus	_	
266-199	62735-62739	Left	_	
266-200	62740-62741	−	_	
266-201	62741-62743	40	_	
266-202	62744-62745	4	_	
266-203	62746-62748	12	_	
266-204	62749-62753	8.04	_	
266-205	62754-62755	<	_	
266-206	62756-62765	.00000001	_	
266-207	62766-62769	946	_	
266-208	62773-62788	Parahippocampal	_	
266-209	62789-62794	Gyrus	_	
266-210	62794-62795	/	_	
266-211	62795-62802	Lateral	_	
266-212	62803-62811	Amygdala	_	
266-213	62812-62817	Right	_	
266-214	62818-62820	23	_	
266-215	62821-62822	−	_	
266-216	62822-62823	5	_	
266-217	62824-62825	−	_	
266-218	62825-62827	27	_	
266-219	62828-62832	8.02	_	
266-220	62833-62834	<	_	
266-221	62835-62844	.00000001	_	
266-222	62845-62849	1531	_	
266-223	62853-62861	Midbrain	_	
266-224	62861-62862	/	_	
266-225	62862-62868	limbic	_	
266-226	62869-62870	c	_	
266-227	62877-62881	8895	_	
266-228	62886-62894	Thalamus	_	
266-229	62895-62899	Left	_	
266-230	62900-62901	−	_	
266-231	62901-62902	7	_	
266-232	62903-62904	−	_	
266-233	62904-62906	23	_	
266-234	62907-62908	6	_	
266-235	62909-62913	7.98	_	
266-236	62914-62915	<	_	
266-237	62916-62925	.00000001	_	
266-238	62931-62941	Substantia	_	
266-239	62942-62947	Nigra	_	
266-240	62948-62953	Right	_	
266-241	62954-62955	4	_	
266-242	62956-62957	−	_	
266-243	62957-62959	26	_	
266-244	62960-62961	−	_	
266-245	62961-62962	9	_	
266-246	62963-62967	7.26	_	
266-247	62968-62977	.00000002	_	
266-248	62983-62991	Thalamus	_	
266-249	62992-62997	Right	_	
266-250	62998-62999	2	_	
266-251	63000-63001	−	_	
266-252	63001-63003	14	_	
266-253	63004-63005	8	_	
266-254	63006-63010	7.01	_	
266-255	63011-63020	.00000004	_	
266-256	63026-63033	Ventral	_	
266-257	63034-63043	Tegmental	_	
266-258	63044-63048	Area	_	
266-259	63049-63054	Right	_	
266-260	63054-63055	/	_	
266-261	63055-63059	Left	_	
266-262	63060-63061	−	_	
266-263	63061-63062	1	_	
266-264	63063-63064	−	_	
266-265	63064-63066	16	_	
266-266	63067-63068	−	_	
266-267	63068-63069	9	_	
266-268	63070-63074	6.90	_	
266-269	63075-63084	.00000005	_	
266-270	63090-63101	Hippocampus	_	
266-271	63102-63107	Right	_	
266-272	63108-63110	23	_	
266-273	63111-63112	−	_	
266-274	63112-63114	23	_	
266-275	63115-63116	−	_	
266-276	63116-63117	6	_	
266-277	63118-63122	6.75	_	
266-278	63123-63132	.00000008	_	
266-279	63138-63148	Substantia	_	
266-280	63149-63154	Nigra	_	
266-281	63155-63159	Left	_	
266-282	63160-63161	−	_	
266-283	63161-63162	4	_	
266-284	63163-63164	−	_	
266-285	63164-63166	17	_	
266-286	63167-63168	−	_	
266-287	63168-63169	9	_	
266-288	63170-63174	6.48	_	
266-289	63175-63184	.00000018	_	
266-290	63189-63195	Globus	_	
266-291	63196-63204	Pallidus	_	
266-292	63205-63210	Right	_	
266-293	63211-63213	17	_	
266-294	63214-63215	−	_	
266-295	63215-63216	5	_	
266-296	63217-63218	−	_	
266-297	63218-63219	6	_	
266-298	63220-63224	6.59	_	
266-299	63225-63234	.00000013	_	
266-300	63235-63238	324	_	
266-301	63242-63251	Posterior	_	
266-302	63252-63261	Cingulate	_	
266-303	63262-63267	Gyrus	_	
266-304	63268-63272	Left	_	
266-305	63273-63274	−	_	
266-306	63274-63275	4	_	
266-307	63276-63277	−	_	
266-308	63277-63279	53	_	
266-309	63280-63281	9	_	
266-310	63282-63286	6.36	_	
266-311	63287-63296	.00000026	_	
266-312	63297-63300	720	_	
266-313	63303-63313	Cerebellum	_	
266-314	63317-63325	Anterior	_	
266-315	63326-63330	Lobe	_	
266-316	63330-63331	,	_	
266-317	63332-63338	Culmen	_	
266-318	63339-63344	Right	_	
266-319	63345-63347	29	_	
266-320	63348-63349	−	_	
266-321	63349-63351	50	_	
266-322	63352-63353	−	_	
266-323	63353-63355	21	_	
266-324	63356-63360	9.38	_	
266-325	63361-63362	<	_	
266-326	63363-63372	.00000001	_	
266-327	63373-63377	4395	_	
266-328	63381-63389	Anterior	_	
266-329	63390-63394	Lobe	_	
266-330	63394-63395	,	_	
266-331	63396-63406	Cerebellar	_	
266-332	63407-63414	Lingual	_	
266-333	63415-63419	Left	_	
266-334	63420-63421	−	_	
266-335	63421-63422	4	_	
266-336	63423-63424	−	_	
266-337	63424-63426	44	_	
266-338	63427-63428	−	_	
266-339	63428-63429	9	_	
266-340	63430-63434	7.76	_	
266-341	63435-63436	<	_	
266-342	63437-63446	.00000001	_	
266-343	63447-63450	345	_	
266-344	63454-63462	Anterior	_	
266-345	63463-63467	Lobe	_	
266-346	63467-63468	,	_	
266-347	63469-63475	Culmen	_	
266-348	63476-63481	Right	_	
266-349	63482-63484	14	_	
266-350	63485-63486	−	_	
266-351	63486-63488	59	_	
266-352	63489-63490	−	_	
266-353	63490-63492	18	_	
266-354	63493-63497	6.25	_	
266-355	63498-63507	.00000036	_	
266-356	63508-63511	602	_	
266-357	63515-63524	Posterior	_	
266-358	63525-63529	Lobe	_	
266-359	63529-63530	,	_	
266-360	63531-63541	Cerebellar	_	
266-361	63542-63548	Tonsil	_	
266-362	63549-63553	Left	_	
266-363	63554-63555	−	_	
266-364	63555-63556	7	_	
266-365	63557-63558	−	_	
266-366	63558-63560	50	_	
266-367	63561-63562	−	_	
266-368	63562-63564	30	_	
266-369	63565-63569	6.21	_	
266-370	63570-63579	.00000041	_	
266-371	63580-63583	494	_	
266-372	63587-63591	Note	_	
266-373	63591-63592	.	_	

#Text=Data shown are from the activation map for the OH > UH contrast, thresholded at FDR-corrected q < .001 and a minimum cluster size of 300 mm3.
267-1	63593-63597	Data	_	
267-2	63598-63603	shown	_	
267-3	63604-63607	are	_	
267-4	63608-63612	from	_	
267-5	63613-63616	the	_	
267-6	63617-63627	activation	_	
267-7	63628-63631	map	_	
267-8	63632-63635	for	_	
267-9	63636-63639	the	_	
267-10	63640-63642	OH	_	
267-11	63643-63644	>	_	
267-12	63645-63647	UH	_	
267-13	63648-63656	contrast	_	
267-14	63656-63657	,	_	
267-15	63658-63669	thresholded	_	
267-16	63670-63672	at	_	
267-17	63673-63686	FDR-corrected	_	
267-18	63687-63688	q	_	
267-19	63689-63690	<	_	
267-20	63691-63695	.001	_	
267-21	63696-63699	and	_	
267-22	63700-63701	a	_	
267-23	63702-63709	minimum	_	
267-24	63710-63717	cluster	_	
267-25	63718-63722	size	_	
267-26	63723-63725	of	_	
267-27	63726-63729	300	_	
267-28	63730-63733	mm3	_	
267-29	63733-63734	.	_	

#Text=Results are presented at a more stringent threshold of q < .001 to better delineate specific neuroanatomical locations of activated clusters.
268-1	63735-63742	Results	_	
268-2	63743-63746	are	_	
268-3	63747-63756	presented	_	
268-4	63757-63759	at	_	
268-5	63760-63761	a	_	
268-6	63762-63766	more	_	
268-7	63767-63776	stringent	_	
268-8	63777-63786	threshold	_	
268-9	63787-63789	of	_	
268-10	63790-63791	q	_	
268-11	63792-63793	<	_	
268-12	63794-63798	.001	_	
268-13	63799-63801	to	_	
268-14	63802-63808	better	_	
268-15	63809-63818	delineate	_	
268-16	63819-63827	specific	_	
268-17	63828-63843	neuroanatomical	_	
268-18	63844-63853	locations	_	
268-19	63854-63856	of	_	
268-20	63857-63866	activated	_	
268-21	63867-63875	clusters	_	
268-22	63875-63876	.	_	

#Text=Within each lobe, clusters are ordered by decreasing level of significance.
269-1	63877-63883	Within	_	
269-2	63884-63888	each	_	
269-3	63889-63893	lobe	_	
269-4	63893-63894	,	_	
269-5	63895-63903	clusters	_	
269-6	63904-63907	are	_	
269-7	63908-63915	ordered	_	
269-8	63916-63918	by	_	
269-9	63919-63929	decreasing	_	
269-10	63930-63935	level	_	
269-11	63936-63938	of	_	
269-12	63939-63951	significance	_	
269-13	63951-63952	.	_	

#Text=Talairach coordinates in millimeters with origin at the anterior commissure, representing peak voxels in each cluster. x, y, z coordinates refer to right (+) to left (−), anterior (+) to posterior(−), and superior (+) to inferior(−), respectively.
270-1	63953-63962	Talairach	_	
270-2	63963-63974	coordinates	_	
270-3	63975-63977	in	_	
270-4	63978-63989	millimeters	_	
270-5	63990-63994	with	_	
270-6	63995-64001	origin	_	
270-7	64002-64004	at	_	
270-8	64005-64008	the	_	
270-9	64009-64017	anterior	_	
270-10	64018-64028	commissure	_	
270-11	64028-64029	,	_	
270-12	64030-64042	representing	_	
270-13	64043-64047	peak	_	
270-14	64048-64054	voxels	_	
270-15	64055-64057	in	_	
270-16	64058-64062	each	_	
270-17	64063-64070	cluster	_	
270-18	64070-64071	.	_	
270-19	64072-64073	x	_	
270-20	64073-64074	,	_	
270-21	64075-64076	y	_	
270-22	64076-64077	,	_	
270-23	64078-64079	z	_	
270-24	64080-64091	coordinates	_	
270-25	64092-64097	refer	_	
270-26	64098-64100	to	_	
270-27	64101-64106	right	_	
270-28	64107-64108	(	_	
270-29	64108-64109	+	_	
270-30	64109-64110	)	_	
270-31	64111-64113	to	_	
270-32	64114-64118	left	_	
270-33	64119-64120	(	_	
270-34	64120-64121	−	_	
270-35	64121-64122	)	_	
270-36	64122-64123	,	_	
270-37	64124-64132	anterior	_	
270-38	64133-64134	(	_	
270-39	64134-64135	+	_	
270-40	64135-64136	)	_	
270-41	64137-64139	to	_	
270-42	64140-64149	posterior	_	
270-43	64149-64150	(	_	
270-44	64150-64151	−	_	
270-45	64151-64152	)	_	
270-46	64152-64153	,	_	
270-47	64154-64157	and	_	
270-48	64158-64166	superior	_	
270-49	64167-64168	(	_	
270-50	64168-64169	+	_	
270-51	64169-64170	)	_	
270-52	64171-64173	to	_	
270-53	64174-64182	inferior	_	
270-54	64182-64183	(	_	
270-55	64183-64184	−	_	
270-56	64184-64185	)	_	
270-57	64185-64186	,	_	
270-58	64187-64199	respectively	_	
270-59	64199-64200	.	_	

#Text=Number of contiguously activated voxels within a cluster.
271-1	64201-64207	Number	_	
271-2	64208-64210	of	_	
271-3	64211-64223	contiguously	_	
271-4	64224-64233	activated	_	
271-5	64234-64240	voxels	_	
271-6	64241-64247	within	_	
271-7	64248-64249	a	_	
271-8	64250-64257	cluster	_	
271-9	64257-64258	.	_	

#Text=Note that where no volume is given for an anatomical region, it forms part of a larger cluster that spans anatomically distinct regions.
272-1	64259-64263	Note	_	
272-2	64264-64268	that	_	
272-3	64269-64274	where	_	
272-4	64275-64277	no	_	
272-5	64278-64284	volume	_	
272-6	64285-64287	is	_	
272-7	64288-64293	given	_	
272-8	64294-64297	for	_	
272-9	64298-64300	an	_	
272-10	64301-64311	anatomical	_	
272-11	64312-64318	region	_	
272-12	64318-64319	,	_	
272-13	64320-64322	it	_	
272-14	64323-64328	forms	_	
272-15	64329-64333	part	_	
272-16	64334-64336	of	_	
272-17	64337-64338	a	_	
272-18	64339-64345	larger	_	
272-19	64346-64353	cluster	_	
272-20	64354-64358	that	_	
272-21	64359-64364	spans	_	
272-22	64365-64377	anatomically	_	
272-23	64378-64386	distinct	_	
272-24	64387-64394	regions	_	
272-25	64394-64395	.	_	

#Text=Brain deactivation in mothers with addictions to the contrast of own happy (OH) versus unknown happy (UH)
#Text=\tHemisphere\tTalairach coordinates a\tPeak t value\tp\tVolume b (mm3)\t \t\t \tx\ty\tz\t \tLimbic lobe/Sub-lobar regions\t\t\t\t\t\t\t6970\t \t Ventromedial PFC\tRight\t11\t34\t6\t−5.78\t0.000002\t\t \t Ventral Striatum\tLeft\t−13\t19\t3\t−5.41\t0.000005\t\t \t Ventromedial PFC\tLeft\t−16\t37\t3\t−4.60\t0.000054\t\t \t Ventral Striatum\tRight\t8\t10\t−3\t−4.38\t0.000104\t\t \t Hypothalamus\tRight/Left\t−2\t1\t−3\t−3.32\t0.002102\t\t \t
#Text=Note.
273-1	64396-64401	Brain	_	
273-2	64402-64414	deactivation	_	
273-3	64415-64417	in	_	
273-4	64418-64425	mothers	_	
273-5	64426-64430	with	_	
273-6	64431-64441	addictions	_	
273-7	64442-64444	to	_	
273-8	64445-64448	the	_	
273-9	64449-64457	contrast	_	
273-10	64458-64460	of	_	
273-11	64461-64464	own	_	
273-12	64465-64470	happy	_	
273-13	64471-64472	(	_	
273-14	64472-64474	OH	_	
273-15	64474-64475	)	_	
273-16	64476-64482	versus	_	
273-17	64483-64490	unknown	_	
273-18	64491-64496	happy	_	
273-19	64497-64498	(	_	
273-20	64498-64500	UH	_	
273-21	64500-64501	)	_	
273-22	64503-64513	Hemisphere	_	
273-23	64514-64523	Talairach	_	
273-24	64524-64535	coordinates	_	
273-25	64536-64537	a	_	
273-26	64538-64542	Peak	_	
273-27	64543-64544	t	_	
273-28	64545-64550	value	_	
273-29	64551-64552	p	_	
273-30	64553-64559	Volume	_	
273-31	64560-64561	b	_	
273-32	64562-64563	(	_	
273-33	64563-64566	mm3	_	
273-34	64566-64567	)	_	
273-35	64573-64574	x	_	
273-36	64575-64576	y	_	
273-37	64577-64578	z	_	
273-38	64581-64587	Limbic	_	
273-39	64588-64592	lobe	_	
273-40	64592-64593	/	_	
273-41	64593-64602	Sub-lobar	_	
273-42	64603-64610	regions	_	
273-43	64617-64621	6970	_	
273-44	64625-64637	Ventromedial	_	
273-45	64638-64641	PFC	_	
273-46	64642-64647	Right	_	
273-47	64648-64650	11	_	
273-48	64651-64653	34	_	
273-49	64654-64655	6	_	
273-50	64656-64657	−	_	
273-51	64657-64661	5.78	_	
273-52	64662-64670	0.000002	_	
273-53	64675-64682	Ventral	_	
273-54	64683-64691	Striatum	_	
273-55	64692-64696	Left	_	
273-56	64697-64698	−	_	
273-57	64698-64700	13	_	
273-58	64701-64703	19	_	
273-59	64704-64705	3	_	
273-60	64706-64707	−	_	
273-61	64707-64711	5.41	_	
273-62	64712-64720	0.000005	_	
273-63	64725-64737	Ventromedial	_	
273-64	64738-64741	PFC	_	
273-65	64742-64746	Left	_	
273-66	64747-64748	−	_	
273-67	64748-64750	16	_	
273-68	64751-64753	37	_	
273-69	64754-64755	3	_	
273-70	64756-64757	−	_	
273-71	64757-64761	4.60	_	
273-72	64762-64770	0.000054	_	
273-73	64775-64782	Ventral	_	
273-74	64783-64791	Striatum	_	
273-75	64792-64797	Right	_	
273-76	64798-64799	8	_	
273-77	64800-64802	10	_	
273-78	64803-64804	−	_	
273-79	64804-64805	3	_	
273-80	64806-64807	−	_	
273-81	64807-64811	4.38	_	
273-82	64812-64820	0.000104	_	
273-83	64825-64837	Hypothalamus	_	
273-84	64838-64843	Right	_	
273-85	64843-64844	/	_	
273-86	64844-64848	Left	_	
273-87	64849-64850	−	_	
273-88	64850-64851	2	_	
273-89	64852-64853	1	_	
273-90	64854-64855	−	_	
273-91	64855-64856	3	_	
273-92	64857-64858	−	_	
273-93	64858-64862	3.32	_	
273-94	64863-64871	0.002102	_	
273-95	64876-64880	Note	_	
273-96	64880-64881	.	_	

#Text=Data shown are from the activation map for the OH > UH contrast, thresholded at FDR-corrected q < .05 and a minimum cluster size of 300 mm3.
274-1	64882-64886	Data	_	
274-2	64887-64892	shown	_	
274-3	64893-64896	are	_	
274-4	64897-64901	from	_	
274-5	64902-64905	the	_	
274-6	64906-64916	activation	_	
274-7	64917-64920	map	_	
274-8	64921-64924	for	_	
274-9	64925-64928	the	_	
274-10	64929-64931	OH	_	
274-11	64932-64933	>	_	
274-12	64934-64936	UH	_	
274-13	64937-64945	contrast	_	
274-14	64945-64946	,	_	
274-15	64947-64958	thresholded	_	
274-16	64959-64961	at	_	
274-17	64962-64975	FDR-corrected	_	
274-18	64976-64977	q	_	
274-19	64978-64979	<	_	
274-20	64980-64983	.05	_	
274-21	64984-64987	and	_	
274-22	64988-64989	a	_	
274-23	64990-64997	minimum	_	
274-24	64998-65005	cluster	_	
274-25	65006-65010	size	_	
274-26	65011-65013	of	_	
274-27	65014-65017	300	_	
274-28	65018-65021	mm3	_	
274-29	65021-65022	.	_	

#Text=Talairach coordinates in millimeters with origin at the anterior commissure, representing peak voxels in each cluster. x, y, z coordinates refer to right (+) to left (−), anterior (+) to posterior(−), and superior (+) to inferior(−), respectively.
275-1	65023-65032	Talairach	_	
275-2	65033-65044	coordinates	_	
275-3	65045-65047	in	_	
275-4	65048-65059	millimeters	_	
275-5	65060-65064	with	_	
275-6	65065-65071	origin	_	
275-7	65072-65074	at	_	
275-8	65075-65078	the	_	
275-9	65079-65087	anterior	_	
275-10	65088-65098	commissure	_	
275-11	65098-65099	,	_	
275-12	65100-65112	representing	_	
275-13	65113-65117	peak	_	
275-14	65118-65124	voxels	_	
275-15	65125-65127	in	_	
275-16	65128-65132	each	_	
275-17	65133-65140	cluster	_	
275-18	65140-65141	.	_	
275-19	65142-65143	x	_	
275-20	65143-65144	,	_	
275-21	65145-65146	y	_	
275-22	65146-65147	,	_	
275-23	65148-65149	z	_	
275-24	65150-65161	coordinates	_	
275-25	65162-65167	refer	_	
275-26	65168-65170	to	_	
275-27	65171-65176	right	_	
275-28	65177-65178	(	_	
275-29	65178-65179	+	_	
275-30	65179-65180	)	_	
275-31	65181-65183	to	_	
275-32	65184-65188	left	_	
275-33	65189-65190	(	_	
275-34	65190-65191	−	_	
275-35	65191-65192	)	_	
275-36	65192-65193	,	_	
275-37	65194-65202	anterior	_	
275-38	65203-65204	(	_	
275-39	65204-65205	+	_	
275-40	65205-65206	)	_	
275-41	65207-65209	to	_	
275-42	65210-65219	posterior	_	
275-43	65219-65220	(	_	
275-44	65220-65221	−	_	
275-45	65221-65222	)	_	
275-46	65222-65223	,	_	
275-47	65224-65227	and	_	
275-48	65228-65236	superior	_	
275-49	65237-65238	(	_	
275-50	65238-65239	+	_	
275-51	65239-65240	)	_	
275-52	65241-65243	to	_	
275-53	65244-65252	inferior	_	
275-54	65252-65253	(	_	
275-55	65253-65254	−	_	
275-56	65254-65255	)	_	
275-57	65255-65256	,	_	
275-58	65257-65269	respectively	_	
275-59	65269-65270	.	_	

#Text=Number of contiguously activated voxels within a cluster.
276-1	65271-65277	Number	_	
276-2	65278-65280	of	_	
276-3	65281-65293	contiguously	_	
276-4	65294-65303	activated	_	
276-5	65304-65310	voxels	_	
276-6	65311-65317	within	_	
276-7	65318-65319	a	_	
276-8	65320-65327	cluster	_	
276-9	65327-65328	.	_	

#Text=Volume is not reported for each anatomical region, as each region forms part of a larger cluster that spans anatomically distinct regions.
277-1	65329-65335	Volume	_	
277-2	65336-65338	is	_	
277-3	65339-65342	not	_	
277-4	65343-65351	reported	_	
277-5	65352-65355	for	_	
277-6	65356-65360	each	_	
277-7	65361-65371	anatomical	_	
277-8	65372-65378	region	_	
277-9	65378-65379	,	_	
277-10	65380-65382	as	_	
277-11	65383-65387	each	_	
277-12	65388-65394	region	_	
277-13	65395-65400	forms	_	
277-14	65401-65405	part	_	
277-15	65406-65408	of	_	
277-16	65409-65410	a	_	
277-17	65411-65417	larger	_	
277-18	65418-65425	cluster	_	
277-19	65426-65430	that	_	
277-20	65431-65436	spans	_	
277-21	65437-65449	anatomically	_	
277-22	65450-65458	distinct	_	
277-23	65459-65466	regions	_	
277-24	65466-65467	.	_	

#Text=Brain activation in mothers with addictions to the contrast of own sad (OS) versus unknown sad (US)
#Text=\tHemisphere\tTalairach coordinates a\tPeak t value\tp\tVolume b (mm3)\t \t\t \tx\ty\tz\t \tFrontal lobe\t \t Precentral Gyrus\tRight\t50\t−17\t42\t9.22\t< .00000001\t3791\t \t Superior Frontal Gyrus\tRight/Left\t2\t−5\t60\t8.30\t< .00000001\t1525\t \t Precentral Gyrus/Postcentral Gyrus\tLeft\t−46\t−17\t39\t7.20\t.00000002\t899\t \t Inferior Frontal Gyrus\tRight\t53\t7\t30\t6.72\t.00000009\t1120\t \tParietal lobe\t \t Precuneus\tRight\t17\t−71\t33\t7.96\t< .00000001\t1018\t \tTemporal/Occipital lobe\t \t Fusiform Gyrus\tLeft\t−28\t−47\t−18\t8.43\t< .00000001\t595\t \t Inferior Temporal Gyrus/Middle Temporal Gyrus\tLeft\t−43\t−56\t−12\t7.62\t.00000001\t724\t \t Inferior Temporal Gyrus/Middle Temporal Gyrus\tRight\t41\t−47\t3\t7.26\t.00000002\t1895\t \t Occipital Gyri\tRight\t41\t−77\t−3\t7.24\t.00000002\t404\t \t Middle Temporal Gyrus/Occipital Gyri\tLeft\t−37\t−74\t18\t6.66\t.00000011\t1128\t \t Cuneus\tLeft\t−10\t−68\t12\t6.38\t.00000025\t479\t \tLimbic/Sub-lobar regions\t \t Substantia Nigra\tRight/Left\t−4\t−23\t−21\t8.36\t< .00000001\t823\t \t Parahippocampal Gyrus/Thalamus\tRight\t8\t−35\t3\t7.79\t< .00000001\t478\t \t Thalamus\tRight/Left\t−1\t−17\t6\t7.78\t< .00000001\t1017\t \t Posterior Cingulate Gyrus\tLeft\t−16\t−53\t12\t7.65\t.00000001\t570\t \t Middle Cingulate Gyrus\tRight/Left\t−4\t7\t33\t6.81\t.00000007\t701\t \t Parahippocampal Gyrus/Thalamus\tLeft\t−19\t−38\t−3\t6.68\t.00000010\t434\t \t Anterior Cingulate Gyrus\tLeft\t−4\t34\t27\t6.16\t.00000048\t504\t \tCerebellum\t \t Anterior Lobe, Culmen/Posterior Lobe, Declive\tRight\t32\t−50\t−21\t9.08\t< .00000001\t1844\t \t Anterior Lobe, Culmen/Posterior Lobe, Declive\tLeft\t−28\t−56\t−21\t7.96\t< .00000001\t1878\t \t Anterior Lobe, Cerebellar Lingual\tRight/Left\t−1\t−44\t−9\t7.32\t.00000002\t461\t \t Anterior Lobe, Fastigium\tLeft\t−7\t−56\t−18\t6.09\t.00000059\t322\t \t
#Text=Note.
278-1	65468-65473	Brain	_	
278-2	65474-65484	activation	_	
278-3	65485-65487	in	_	
278-4	65488-65495	mothers	_	
278-5	65496-65500	with	_	
278-6	65501-65511	addictions	_	
278-7	65512-65514	to	_	
278-8	65515-65518	the	_	
278-9	65519-65527	contrast	_	
278-10	65528-65530	of	_	
278-11	65531-65534	own	_	
278-12	65535-65538	sad	_	
278-13	65539-65540	(	_	
278-14	65540-65542	OS	_	
278-15	65542-65543	)	_	
278-16	65544-65550	versus	_	
278-17	65551-65558	unknown	_	
278-18	65559-65562	sad	_	
278-19	65563-65564	(	_	
278-20	65564-65566	US	_	
278-21	65566-65567	)	_	
278-22	65569-65579	Hemisphere	_	
278-23	65580-65589	Talairach	_	
278-24	65590-65601	coordinates	_	
278-25	65602-65603	a	_	
278-26	65604-65608	Peak	_	
278-27	65609-65610	t	_	
278-28	65611-65616	value	_	
278-29	65617-65618	p	_	
278-30	65619-65625	Volume	_	
278-31	65626-65627	b	_	
278-32	65628-65629	(	_	
278-33	65629-65632	mm3	_	
278-34	65632-65633	)	_	
278-35	65639-65640	x	_	
278-36	65641-65642	y	_	
278-37	65643-65644	z	_	
278-38	65647-65654	Frontal	_	
278-39	65655-65659	lobe	_	
278-40	65663-65673	Precentral	_	
278-41	65674-65679	Gyrus	_	
278-42	65680-65685	Right	_	
278-43	65686-65688	50	_	
278-44	65689-65690	−	_	
278-45	65690-65692	17	_	
278-46	65693-65695	42	_	
278-47	65696-65700	9.22	_	
278-48	65701-65702	<	_	
278-49	65703-65712	.00000001	_	
278-50	65713-65717	3791	_	
278-51	65721-65729	Superior	_	
278-52	65730-65737	Frontal	_	
278-53	65738-65743	Gyrus	_	
278-54	65744-65749	Right	_	
278-55	65749-65750	/	_	
278-56	65750-65754	Left	_	
278-57	65755-65756	2	_	
278-58	65757-65758	−	_	
278-59	65758-65759	5	_	
278-60	65760-65762	60	_	
278-61	65763-65767	8.30	_	
278-62	65768-65769	<	_	
278-63	65770-65779	.00000001	_	
278-64	65780-65784	1525	_	
278-65	65788-65798	Precentral	_	
278-66	65799-65804	Gyrus	_	
278-67	65804-65805	/	_	
278-68	65805-65816	Postcentral	_	
278-69	65817-65822	Gyrus	_	
278-70	65823-65827	Left	_	
278-71	65828-65829	−	_	
278-72	65829-65831	46	_	
278-73	65832-65833	−	_	
278-74	65833-65835	17	_	
278-75	65836-65838	39	_	
278-76	65839-65843	7.20	_	
278-77	65844-65853	.00000002	_	
278-78	65854-65857	899	_	
278-79	65861-65869	Inferior	_	
278-80	65870-65877	Frontal	_	
278-81	65878-65883	Gyrus	_	
278-82	65884-65889	Right	_	
278-83	65890-65892	53	_	
278-84	65893-65894	7	_	
278-85	65895-65897	30	_	
278-86	65898-65902	6.72	_	
278-87	65903-65912	.00000009	_	
278-88	65913-65917	1120	_	
278-89	65920-65928	Parietal	_	
278-90	65929-65933	lobe	_	
278-91	65937-65946	Precuneus	_	
278-92	65947-65952	Right	_	
278-93	65953-65955	17	_	
278-94	65956-65957	−	_	
278-95	65957-65959	71	_	
278-96	65960-65962	33	_	
278-97	65963-65967	7.96	_	
278-98	65968-65969	<	_	
278-99	65970-65979	.00000001	_	
278-100	65980-65984	1018	_	
278-101	65987-65995	Temporal	_	
278-102	65995-65996	/	_	
278-103	65996-66005	Occipital	_	
278-104	66006-66010	lobe	_	
278-105	66014-66022	Fusiform	_	
278-106	66023-66028	Gyrus	_	
278-107	66029-66033	Left	_	
278-108	66034-66035	−	_	
278-109	66035-66037	28	_	
278-110	66038-66039	−	_	
278-111	66039-66041	47	_	
278-112	66042-66043	−	_	
278-113	66043-66045	18	_	
278-114	66046-66050	8.43	_	
278-115	66051-66052	<	_	
278-116	66053-66062	.00000001	_	
278-117	66063-66066	595	_	
278-118	66070-66078	Inferior	_	
278-119	66079-66087	Temporal	_	
278-120	66088-66093	Gyrus	_	
278-121	66093-66094	/	_	
278-122	66094-66100	Middle	_	
278-123	66101-66109	Temporal	_	
278-124	66110-66115	Gyrus	_	
278-125	66116-66120	Left	_	
278-126	66121-66122	−	_	
278-127	66122-66124	43	_	
278-128	66125-66126	−	_	
278-129	66126-66128	56	_	
278-130	66129-66130	−	_	
278-131	66130-66132	12	_	
278-132	66133-66137	7.62	_	
278-133	66138-66147	.00000001	_	
278-134	66148-66151	724	_	
278-135	66155-66163	Inferior	_	
278-136	66164-66172	Temporal	_	
278-137	66173-66178	Gyrus	_	
278-138	66178-66179	/	_	
278-139	66179-66185	Middle	_	
278-140	66186-66194	Temporal	_	
278-141	66195-66200	Gyrus	_	
278-142	66201-66206	Right	_	
278-143	66207-66209	41	_	
278-144	66210-66211	−	_	
278-145	66211-66213	47	_	
278-146	66214-66215	3	_	
278-147	66216-66220	7.26	_	
278-148	66221-66230	.00000002	_	
278-149	66231-66235	1895	_	
278-150	66239-66248	Occipital	_	
278-151	66249-66253	Gyri	_	
278-152	66254-66259	Right	_	
278-153	66260-66262	41	_	
278-154	66263-66264	−	_	
278-155	66264-66266	77	_	
278-156	66267-66268	−	_	
278-157	66268-66269	3	_	
278-158	66270-66274	7.24	_	
278-159	66275-66284	.00000002	_	
278-160	66285-66288	404	_	
278-161	66292-66298	Middle	_	
278-162	66299-66307	Temporal	_	
278-163	66308-66313	Gyrus	_	
278-164	66313-66314	/	_	
278-165	66314-66323	Occipital	_	
278-166	66324-66328	Gyri	_	
278-167	66329-66333	Left	_	
278-168	66334-66335	−	_	
278-169	66335-66337	37	_	
278-170	66338-66339	−	_	
278-171	66339-66341	74	_	
278-172	66342-66344	18	_	
278-173	66345-66349	6.66	_	
278-174	66350-66359	.00000011	_	
278-175	66360-66364	1128	_	
278-176	66368-66374	Cuneus	_	
278-177	66375-66379	Left	_	
278-178	66380-66381	−	_	
278-179	66381-66383	10	_	
278-180	66384-66385	−	_	
278-181	66385-66387	68	_	
278-182	66388-66390	12	_	
278-183	66391-66395	6.38	_	
278-184	66396-66405	.00000025	_	
278-185	66406-66409	479	_	
278-186	66412-66418	Limbic	_	
278-187	66418-66419	/	_	
278-188	66419-66428	Sub-lobar	_	
278-189	66429-66436	regions	_	
278-190	66440-66450	Substantia	_	
278-191	66451-66456	Nigra	_	
278-192	66457-66462	Right	_	
278-193	66462-66463	/	_	
278-194	66463-66467	Left	_	
278-195	66468-66469	−	_	
278-196	66469-66470	4	_	
278-197	66471-66472	−	_	
278-198	66472-66474	23	_	
278-199	66475-66476	−	_	
278-200	66476-66478	21	_	
278-201	66479-66483	8.36	_	
278-202	66484-66485	<	_	
278-203	66486-66495	.00000001	_	
278-204	66496-66499	823	_	
278-205	66503-66518	Parahippocampal	_	
278-206	66519-66524	Gyrus	_	
278-207	66524-66525	/	_	
278-208	66525-66533	Thalamus	_	
278-209	66534-66539	Right	_	
278-210	66540-66541	8	_	
278-211	66542-66543	−	_	
278-212	66543-66545	35	_	
278-213	66546-66547	3	_	
278-214	66548-66552	7.79	_	
278-215	66553-66554	<	_	
278-216	66555-66564	.00000001	_	
278-217	66565-66568	478	_	
278-218	66572-66580	Thalamus	_	
278-219	66581-66586	Right	_	
278-220	66586-66587	/	_	
278-221	66587-66591	Left	_	
278-222	66592-66593	−	_	
278-223	66593-66594	1	_	
278-224	66595-66596	−	_	
278-225	66596-66598	17	_	
278-226	66599-66600	6	_	
278-227	66601-66605	7.78	_	
278-228	66606-66607	<	_	
278-229	66608-66617	.00000001	_	
278-230	66618-66622	1017	_	
278-231	66626-66635	Posterior	_	
278-232	66636-66645	Cingulate	_	
278-233	66646-66651	Gyrus	_	
278-234	66652-66656	Left	_	
278-235	66657-66658	−	_	
278-236	66658-66660	16	_	
278-237	66661-66662	−	_	
278-238	66662-66664	53	_	
278-239	66665-66667	12	_	
278-240	66668-66672	7.65	_	
278-241	66673-66682	.00000001	_	
278-242	66683-66686	570	_	
278-243	66690-66696	Middle	_	
278-244	66697-66706	Cingulate	_	
278-245	66707-66712	Gyrus	_	
278-246	66713-66718	Right	_	
278-247	66718-66719	/	_	
278-248	66719-66723	Left	_	
278-249	66724-66725	−	_	
278-250	66725-66726	4	_	
278-251	66727-66728	7	_	
278-252	66729-66731	33	_	
278-253	66732-66736	6.81	_	
278-254	66737-66746	.00000007	_	
278-255	66747-66750	701	_	
278-256	66754-66769	Parahippocampal	_	
278-257	66770-66775	Gyrus	_	
278-258	66775-66776	/	_	
278-259	66776-66784	Thalamus	_	
278-260	66785-66789	Left	_	
278-261	66790-66791	−	_	
278-262	66791-66793	19	_	
278-263	66794-66795	−	_	
278-264	66795-66797	38	_	
278-265	66798-66799	−	_	
278-266	66799-66800	3	_	
278-267	66801-66805	6.68	_	
278-268	66806-66815	.00000010	_	
278-269	66816-66819	434	_	
278-270	66823-66831	Anterior	_	
278-271	66832-66841	Cingulate	_	
278-272	66842-66847	Gyrus	_	
278-273	66848-66852	Left	_	
278-274	66853-66854	−	_	
278-275	66854-66855	4	_	
278-276	66856-66858	34	_	
278-277	66859-66861	27	_	
278-278	66862-66866	6.16	_	
278-279	66867-66876	.00000048	_	
278-280	66877-66880	504	_	
278-281	66883-66893	Cerebellum	_	
278-282	66897-66905	Anterior	_	
278-283	66906-66910	Lobe	_	
278-284	66910-66911	,	_	
278-285	66912-66918	Culmen	_	
278-286	66918-66919	/	_	
278-287	66919-66928	Posterior	_	
278-288	66929-66933	Lobe	_	
278-289	66933-66934	,	_	
278-290	66935-66942	Declive	_	
278-291	66943-66948	Right	_	
278-292	66949-66951	32	_	
278-293	66952-66953	−	_	
278-294	66953-66955	50	_	
278-295	66956-66957	−	_	
278-296	66957-66959	21	_	
278-297	66960-66964	9.08	_	
278-298	66965-66966	<	_	
278-299	66967-66976	.00000001	_	
278-300	66977-66981	1844	_	
278-301	66985-66993	Anterior	_	
278-302	66994-66998	Lobe	_	
278-303	66998-66999	,	_	
278-304	67000-67006	Culmen	_	
278-305	67006-67007	/	_	
278-306	67007-67016	Posterior	_	
278-307	67017-67021	Lobe	_	
278-308	67021-67022	,	_	
278-309	67023-67030	Declive	_	
278-310	67031-67035	Left	_	
278-311	67036-67037	−	_	
278-312	67037-67039	28	_	
278-313	67040-67041	−	_	
278-314	67041-67043	56	_	
278-315	67044-67045	−	_	
278-316	67045-67047	21	_	
278-317	67048-67052	7.96	_	
278-318	67053-67054	<	_	
278-319	67055-67064	.00000001	_	
278-320	67065-67069	1878	_	
278-321	67073-67081	Anterior	_	
278-322	67082-67086	Lobe	_	
278-323	67086-67087	,	_	
278-324	67088-67098	Cerebellar	_	
278-325	67099-67106	Lingual	_	
278-326	67107-67112	Right	_	
278-327	67112-67113	/	_	
278-328	67113-67117	Left	_	
278-329	67118-67119	−	_	
278-330	67119-67120	1	_	
278-331	67121-67122	−	_	
278-332	67122-67124	44	_	
278-333	67125-67126	−	_	
278-334	67126-67127	9	_	
278-335	67128-67132	7.32	_	
278-336	67133-67142	.00000002	_	
278-337	67143-67146	461	_	
278-338	67150-67158	Anterior	_	
278-339	67159-67163	Lobe	_	
278-340	67163-67164	,	_	
278-341	67165-67174	Fastigium	_	
278-342	67175-67179	Left	_	
278-343	67180-67181	−	_	
278-344	67181-67182	7	_	
278-345	67183-67184	−	_	
278-346	67184-67186	56	_	
278-347	67187-67188	−	_	
278-348	67188-67190	18	_	
278-349	67191-67195	6.09	_	
278-350	67196-67205	.00000059	_	
278-351	67206-67209	322	_	
278-352	67213-67217	Note	_	
278-353	67217-67218	.	_	

#Text=Data shown are from the activation map for the OS > US contrast, thresholded at FDR-corrected q < .001 and a minimum cluster size of 300 mm3.
279-1	67219-67223	Data	_	
279-2	67224-67229	shown	_	
279-3	67230-67233	are	_	
279-4	67234-67238	from	_	
279-5	67239-67242	the	_	
279-6	67243-67253	activation	_	
279-7	67254-67257	map	_	
279-8	67258-67261	for	_	
279-9	67262-67265	the	_	
279-10	67266-67268	OS	_	
279-11	67269-67270	>	_	
279-12	67271-67273	US	_	
279-13	67274-67282	contrast	_	
279-14	67282-67283	,	_	
279-15	67284-67295	thresholded	_	
279-16	67296-67298	at	_	
279-17	67299-67312	FDR-corrected	_	
279-18	67313-67314	q	_	
279-19	67315-67316	<	_	
279-20	67317-67321	.001	_	
279-21	67322-67325	and	_	
279-22	67326-67327	a	_	
279-23	67328-67335	minimum	_	
279-24	67336-67343	cluster	_	
279-25	67344-67348	size	_	
279-26	67349-67351	of	_	
279-27	67352-67355	300	_	
279-28	67356-67359	mm3	_	
279-29	67359-67360	.	_	

#Text=Results are presented at a more stringent threshold of q < .001 to better delineate specific neuroanatomical locations of activated clusters.
280-1	67361-67368	Results	_	
280-2	67369-67372	are	_	
280-3	67373-67382	presented	_	
280-4	67383-67385	at	_	
280-5	67386-67387	a	_	
280-6	67388-67392	more	_	
280-7	67393-67402	stringent	_	
280-8	67403-67412	threshold	_	
280-9	67413-67415	of	_	
280-10	67416-67417	q	_	
280-11	67418-67419	<	_	
280-12	67420-67424	.001	_	
280-13	67425-67427	to	_	
280-14	67428-67434	better	_	
280-15	67435-67444	delineate	_	
280-16	67445-67453	specific	_	
280-17	67454-67469	neuroanatomical	_	
280-18	67470-67479	locations	_	
280-19	67480-67482	of	_	
280-20	67483-67492	activated	_	
280-21	67493-67501	clusters	_	
280-22	67501-67502	.	_	

#Text=Within each lobe, clusters are ordered by decreasing level of significance.
281-1	67503-67509	Within	_	
281-2	67510-67514	each	_	
281-3	67515-67519	lobe	_	
281-4	67519-67520	,	_	
281-5	67521-67529	clusters	_	
281-6	67530-67533	are	_	
281-7	67534-67541	ordered	_	
281-8	67542-67544	by	_	
281-9	67545-67555	decreasing	_	
281-10	67556-67561	level	_	
281-11	67562-67564	of	_	
281-12	67565-67577	significance	_	
281-13	67577-67578	.	_	

#Text=Talairach coordinates in millimeters with origin at the anterior commissure, representing peak voxels in each cluster. x, y, z coordinates refer to right (+) to left (−), anterior (+) to posterior(−), and superior (+) to inferior(−), respectively.
282-1	67579-67588	Talairach	_	
282-2	67589-67600	coordinates	_	
282-3	67601-67603	in	_	
282-4	67604-67615	millimeters	_	
282-5	67616-67620	with	_	
282-6	67621-67627	origin	_	
282-7	67628-67630	at	_	
282-8	67631-67634	the	_	
282-9	67635-67643	anterior	_	
282-10	67644-67654	commissure	_	
282-11	67654-67655	,	_	
282-12	67656-67668	representing	_	
282-13	67669-67673	peak	_	
282-14	67674-67680	voxels	_	
282-15	67681-67683	in	_	
282-16	67684-67688	each	_	
282-17	67689-67696	cluster	_	
282-18	67696-67697	.	_	
282-19	67698-67699	x	_	
282-20	67699-67700	,	_	
282-21	67701-67702	y	_	
282-22	67702-67703	,	_	
282-23	67704-67705	z	_	
282-24	67706-67717	coordinates	_	
282-25	67718-67723	refer	_	
282-26	67724-67726	to	_	
282-27	67727-67732	right	_	
282-28	67733-67734	(	_	
282-29	67734-67735	+	_	
282-30	67735-67736	)	_	
282-31	67737-67739	to	_	
282-32	67740-67744	left	_	
282-33	67745-67746	(	_	
282-34	67746-67747	−	_	
282-35	67747-67748	)	_	
282-36	67748-67749	,	_	
282-37	67750-67758	anterior	_	
282-38	67759-67760	(	_	
282-39	67760-67761	+	_	
282-40	67761-67762	)	_	
282-41	67763-67765	to	_	
282-42	67766-67775	posterior	_	
282-43	67775-67776	(	_	
282-44	67776-67777	−	_	
282-45	67777-67778	)	_	
282-46	67778-67779	,	_	
282-47	67780-67783	and	_	
282-48	67784-67792	superior	_	
282-49	67793-67794	(	_	
282-50	67794-67795	+	_	
282-51	67795-67796	)	_	
282-52	67797-67799	to	_	
282-53	67800-67808	inferior	_	
282-54	67808-67809	(	_	
282-55	67809-67810	−	_	
282-56	67810-67811	)	_	
282-57	67811-67812	,	_	
282-58	67813-67825	respectively	_	
282-59	67825-67826	.	_	

#Text=Number of contiguously activated voxels within a cluster.
283-1	67827-67833	Number	_	
283-2	67834-67836	of	_	
283-3	67837-67849	contiguously	_	
283-4	67850-67859	activated	_	
283-5	67860-67866	voxels	_	
283-6	67867-67873	within	_	
283-7	67874-67875	a	_	
283-8	67876-67883	cluster	_	
283-9	67883-67884	.	_	

#Text=Mothers’ post-scan affect ratings of own and unknown infant face images
#Text=\tOwn infant\tUnknown infant\tDifference (z)c\t \tMothers’ perceived ratings of infants’ affect a\t \t  Happy affect\t8.22 ± 0.12\t7.39 ± 0.21\t7.39**\t \t  Sad affect\t7.31 ± 0.24\t6.70 ± 0.24\t4.72**\t \t  Distressed affect\t7.13 ± 0.25\t6.53 ± 0.28\t4.26**\t \t\t \tMothers’ own affective responses to infants’ affect b\t \t  Happy affect\t8.54 ± 0.11\t6.07 ± 0.36\t19.69**\t \t  Sad affect\t6.97 ± 0.28\t4.69 ± 0.32\t13.95**\t \t  Distressed affect\t6.56 ± 0.35\t4.51 ± 0.31\t12.59**\t \t
#Text=Note.
284-1	67885-67892	Mothers	_	
284-2	67892-67893	’	_	
284-3	67894-67903	post-scan	_	
284-4	67904-67910	affect	_	
284-5	67911-67918	ratings	_	
284-6	67919-67921	of	_	
284-7	67922-67925	own	_	
284-8	67926-67929	and	_	
284-9	67930-67937	unknown	_	
284-10	67938-67944	infant	_	
284-11	67945-67949	face	_	
284-12	67950-67956	images	_	
284-13	67958-67961	Own	_	
284-14	67962-67968	infant	_	
284-15	67969-67976	Unknown	_	
284-16	67977-67983	infant	_	
284-17	67984-67994	Difference	_	
284-18	67995-67996	(	_	
284-19	67996-67997	z	_	
284-20	67997-67998	)	_	
284-21	67998-67999	c	_	
284-22	68002-68009	Mothers	_	
284-23	68009-68010	’	_	
284-24	68011-68020	perceived	_	
284-25	68021-68028	ratings	_	
284-26	68029-68031	of	_	
284-27	68032-68039	infants	_	
284-28	68039-68040	’	_	
284-29	68041-68047	affect	_	
284-30	68048-68049	a	_	
284-31	68054-68059	Happy	_	
284-32	68060-68066	affect	_	
284-33	68067-68071	8.22	_	
284-34	68072-68073	±	_	
284-35	68074-68078	0.12	_	
284-36	68079-68083	7.39	_	
284-37	68084-68085	±	_	
284-38	68086-68090	0.21	_	
284-39	68091-68095	7.39	_	
284-40	68095-68096	*	_	
284-41	68096-68097	*	_	
284-42	68102-68105	Sad	_	
284-43	68106-68112	affect	_	
284-44	68113-68117	7.31	_	
284-45	68118-68119	±	_	
284-46	68120-68124	0.24	_	
284-47	68125-68129	6.70	_	
284-48	68130-68131	±	_	
284-49	68132-68136	0.24	_	
284-50	68137-68141	4.72	_	
284-51	68141-68142	*	_	
284-52	68142-68143	*	_	
284-53	68148-68158	Distressed	_	
284-54	68159-68165	affect	_	
284-55	68166-68170	7.13	_	
284-56	68171-68172	±	_	
284-57	68173-68177	0.25	_	
284-58	68178-68182	6.53	_	
284-59	68183-68184	±	_	
284-60	68185-68189	0.28	_	
284-61	68190-68194	4.26	_	
284-62	68194-68195	*	_	
284-63	68195-68196	*	_	
284-64	68202-68209	Mothers	_	
284-65	68209-68210	’	_	
284-66	68211-68214	own	_	
284-67	68215-68224	affective	_	
284-68	68225-68234	responses	_	
284-69	68235-68237	to	_	
284-70	68238-68245	infants	_	
284-71	68245-68246	’	_	
284-72	68247-68253	affect	_	
284-73	68254-68255	b	_	
284-74	68260-68265	Happy	_	
284-75	68266-68272	affect	_	
284-76	68273-68277	8.54	_	
284-77	68278-68279	±	_	
284-78	68280-68284	0.11	_	
284-79	68285-68289	6.07	_	
284-80	68290-68291	±	_	
284-81	68292-68296	0.36	_	
284-82	68297-68302	19.69	_	
284-83	68302-68303	*	_	
284-84	68303-68304	*	_	
284-85	68309-68312	Sad	_	
284-86	68313-68319	affect	_	
284-87	68320-68324	6.97	_	
284-88	68325-68326	±	_	
284-89	68327-68331	0.28	_	
284-90	68332-68336	4.69	_	
284-91	68337-68338	±	_	
284-92	68339-68343	0.32	_	
284-93	68344-68349	13.95	_	
284-94	68349-68350	*	_	
284-95	68350-68351	*	_	
284-96	68356-68366	Distressed	_	
284-97	68367-68373	affect	_	
284-98	68374-68378	6.56	_	
284-99	68379-68380	±	_	
284-100	68381-68385	0.35	_	
284-101	68386-68390	4.51	_	
284-102	68391-68392	±	_	
284-103	68393-68397	0.31	_	
284-104	68398-68403	12.59	_	
284-105	68403-68404	*	_	
284-106	68404-68405	*	_	
284-107	68409-68413	Note	_	
284-108	68413-68414	.	_	

#Text=Numbers shown (M ± SE) are mothers’ self-reported ratings of affect provided on a Likert scale of 1 to 9.
285-1	68415-68422	Numbers	_	
285-2	68423-68428	shown	_	
285-3	68429-68430	(	_	
285-4	68430-68431	M	_	
285-5	68432-68433	±	_	
285-6	68434-68436	SE	_	
285-7	68436-68437	)	_	
285-8	68438-68441	are	_	
285-9	68442-68449	mothers	_	
285-10	68449-68450	’	_	
285-11	68451-68464	self-reported	_	
285-12	68465-68472	ratings	_	
285-13	68473-68475	of	_	
285-14	68476-68482	affect	_	
285-15	68483-68491	provided	_	
285-16	68492-68494	on	_	
285-17	68495-68496	a	_	
285-18	68497-68503	Likert	_	
285-19	68504-68509	scale	_	
285-20	68510-68512	of	_	
285-21	68513-68514	1	_	
285-22	68515-68517	to	_	
285-23	68518-68519	9	_	
285-24	68519-68520	.	_	

#Text=For each given affect, 1 represented “not at all,” 5 represented “somewhat,” and 9 represented “very.”
286-1	68521-68524	For	_	
286-2	68525-68529	each	_	
286-3	68530-68535	given	_	
286-4	68536-68542	affect	_	
286-5	68542-68543	,	_	
286-6	68544-68545	1	_	
286-7	68546-68557	represented	_	
286-8	68558-68559	“	_	
286-9	68559-68562	not	_	
286-10	68563-68565	at	_	
286-11	68566-68569	all	_	
286-12	68569-68570	,	_	
286-13	68570-68571	”	_	
286-14	68572-68573	5	_	
286-15	68574-68585	represented	_	
286-16	68586-68587	“	_	
286-17	68587-68595	somewhat	_	
286-18	68595-68596	,	_	
286-19	68596-68597	”	_	
286-20	68598-68601	and	_	
286-21	68602-68603	9	_	
286-22	68604-68615	represented	_	
286-23	68616-68617	“	_	
286-24	68617-68621	very	_	
286-25	68621-68622	.	_	
286-26	68622-68623	”	_	

#Text=Mothers’ ratings of how they perceived the infant to be feeling in the image.
287-1	68624-68631	Mothers	_	
287-2	68631-68632	’	_	
287-3	68633-68640	ratings	_	
287-4	68641-68643	of	_	
287-5	68644-68647	how	_	
287-6	68648-68652	they	_	
287-7	68653-68662	perceived	_	
287-8	68663-68666	the	_	
287-9	68667-68673	infant	_	
287-10	68674-68676	to	_	
287-11	68677-68679	be	_	
287-12	68680-68687	feeling	_	
287-13	68688-68690	in	_	
287-14	68691-68694	the	_	
287-15	68695-68700	image	_	
287-16	68700-68701	.	_	

#Text=For happy faces, mothers were asked, “how happy do you think the baby was feeling?”
288-1	68702-68705	For	_	
288-2	68706-68711	happy	_	
288-3	68712-68717	faces	_	
288-4	68717-68718	,	_	
288-5	68719-68726	mothers	_	
288-6	68727-68731	were	_	
288-7	68732-68737	asked	_	
288-8	68737-68738	,	_	
288-9	68739-68740	“	_	
288-10	68740-68743	how	_	
288-11	68744-68749	happy	_	
288-12	68750-68752	do	_	
288-13	68753-68756	you	_	
288-14	68757-68762	think	_	
288-15	68763-68766	the	_	
288-16	68767-68771	baby	_	
288-17	68772-68775	was	_	
288-18	68776-68783	feeling	_	
288-19	68783-68784	?	_	
288-20	68784-68785	”	_	

#Text=For sad faces, mothers were asked to respond to both, “how sad do you think the baby was feeling?”
289-1	68786-68789	For	_	
289-2	68790-68793	sad	_	
289-3	68794-68799	faces	_	
289-4	68799-68800	,	_	
289-5	68801-68808	mothers	_	
289-6	68809-68813	were	_	
289-7	68814-68819	asked	_	
289-8	68820-68822	to	_	
289-9	68823-68830	respond	_	
289-10	68831-68833	to	_	
289-11	68834-68838	both	_	
289-12	68838-68839	,	_	
289-13	68840-68841	“	_	
289-14	68841-68844	how	_	
289-15	68845-68848	sad	_	
289-16	68849-68851	do	_	
289-17	68852-68855	you	_	
289-18	68856-68861	think	_	
289-19	68862-68865	the	_	
289-20	68866-68870	baby	_	
289-21	68871-68874	was	_	
289-22	68875-68882	feeling	_	
289-23	68882-68883	?	_	
289-24	68883-68884	”	_	

#Text=and, “how distressed do you think the baby was feeling?”
290-1	68885-68888	and	_	
290-2	68888-68889	,	_	
290-3	68890-68891	“	_	
290-4	68891-68894	how	_	
290-5	68895-68905	distressed	_	
290-6	68906-68908	do	_	
290-7	68909-68912	you	_	
290-8	68913-68918	think	_	
290-9	68919-68922	the	_	
290-10	68923-68927	baby	_	
290-11	68928-68931	was	_	
290-12	68932-68939	feeling	_	
290-13	68939-68940	?	_	
290-14	68940-68941	”	_	

#Text=Mothers’ ratings of their own affective responses to viewing the infant face image.
291-1	68942-68949	Mothers	_	
291-2	68949-68950	’	_	
291-3	68951-68958	ratings	_	
291-4	68959-68961	of	_	
291-5	68962-68967	their	_	
291-6	68968-68971	own	_	
291-7	68972-68981	affective	_	
291-8	68982-68991	responses	_	
291-9	68992-68994	to	_	
291-10	68995-69002	viewing	_	
291-11	69003-69006	the	_	
291-12	69007-69013	infant	_	
291-13	69014-69018	face	_	
291-14	69019-69024	image	_	
291-15	69024-69025	.	_	

#Text=For happy faces, mothers were asked, “how happy did this picture make you feel?”
292-1	69026-69029	For	_	
292-2	69030-69035	happy	_	
292-3	69036-69041	faces	_	
292-4	69041-69042	,	_	
292-5	69043-69050	mothers	_	
292-6	69051-69055	were	_	
292-7	69056-69061	asked	_	
292-8	69061-69062	,	_	
292-9	69063-69064	“	_	
292-10	69064-69067	how	_	
292-11	69068-69073	happy	_	
292-12	69074-69077	did	_	
292-13	69078-69082	this	_	
292-14	69083-69090	picture	_	
292-15	69091-69095	make	_	
292-16	69096-69099	you	_	
292-17	69100-69104	feel	_	
292-18	69104-69105	?	_	
292-19	69105-69106	”	_	

#Text=For sad faces, mothers were asked both, “how sad did this picture make you feel?”
293-1	69107-69110	For	_	
293-2	69111-69114	sad	_	
293-3	69115-69120	faces	_	
293-4	69120-69121	,	_	
293-5	69122-69129	mothers	_	
293-6	69130-69134	were	_	
293-7	69135-69140	asked	_	
293-8	69141-69145	both	_	
293-9	69145-69146	,	_	
293-10	69147-69148	“	_	
293-11	69148-69151	how	_	
293-12	69152-69155	sad	_	
293-13	69156-69159	did	_	
293-14	69160-69164	this	_	
293-15	69165-69172	picture	_	
293-16	69173-69177	make	_	
293-17	69178-69181	you	_	
293-18	69182-69186	feel	_	
293-19	69186-69187	?	_	
293-20	69187-69188	”	_	

#Text=and, “how distressed did this picture make you feel?”
294-1	69189-69192	and	_	
294-2	69192-69193	,	_	
294-3	69194-69195	“	_	
294-4	69195-69198	how	_	
294-5	69199-69209	distressed	_	
294-6	69210-69213	did	_	
294-7	69214-69218	this	_	
294-8	69219-69226	picture	_	
294-9	69227-69231	make	_	
294-10	69232-69235	you	_	
294-11	69236-69240	feel	_	
294-12	69240-69241	?	_	
294-13	69241-69242	”	_	

#Text=z-Statistic comparing own and unknown infant faces for each given affect within the final mixed-effects linear regression model including a subject-level random intercept.
#Text=p < .001.
295-1	69243-69254	z-Statistic	_	
295-2	69255-69264	comparing	_	
295-3	69265-69268	own	_	
295-4	69269-69272	and	_	
295-5	69273-69280	unknown	_	
295-6	69281-69287	infant	_	
295-7	69288-69293	faces	_	
295-8	69294-69297	for	_	
295-9	69298-69302	each	_	
295-10	69303-69308	given	_	
295-11	69309-69315	affect	_	
295-12	69316-69322	within	_	
295-13	69323-69326	the	_	
295-14	69327-69332	final	_	
295-15	69333-69346	mixed-effects	_	
295-16	69347-69353	linear	_	
295-17	69354-69364	regression	_	
295-18	69365-69370	model	_	
295-19	69371-69380	including	_	
295-20	69381-69382	a	_	
295-21	69383-69396	subject-level	_	
295-22	69397-69403	random	_	
295-23	69404-69413	intercept	_	
295-24	69413-69414	.	_	
295-25	69415-69416	p	_	
295-26	69417-69418	<	_	
295-27	69419-69423	.001	_	
295-28	69423-69424	.	_	

#Text=Mixed-effects regression models for mothers’ post-scan affect ratings
#Text=Mothers’ affective responses to infants’ affect a\tWald b\tInfant affect effect c\tIdentity effect\tInfant affect c x Identity\t \t\t\t\t\t \tχ2 (df = 3)\tCoefficient d (95% CI)\tCoefficient d (95% CI)\tCoefficient d, e (95% CI)\tSimple slope own infant\tSimple slope unknown infant\t \t  Happy affect\t664.63**\t.61** (.51 to .70)\t4.64** (3.25 to 6.03)\t−.33** (−.50 to −.16)\t.28** (.13 to .42)\t.61** (.51 to .70)\t \t  Sad affect\t664.53**\t.62** (.52 to .71)\t.10 (−.87 to 1.08)\t.23** (.10 to .37)\t.85** (.74 to .96)\t.62** (.52 to .71)\t \t  Distressed affect\t596.22**\t.56** (.47 to .65)\t−.27 (−1.18 to .64)\t.27** (.14 to .39)\t.82** (.72 to .93)\t.56** (.47 to .65)\t \t
#Text=Mothers’ own affective response to infant face images.
296-1	69425-69438	Mixed-effects	_	
296-2	69439-69449	regression	_	
296-3	69450-69456	models	_	
296-4	69457-69460	for	_	
296-5	69461-69468	mothers	_	
296-6	69468-69469	’	_	
296-7	69470-69479	post-scan	_	
296-8	69480-69486	affect	_	
296-9	69487-69494	ratings	_	
296-10	69495-69502	Mothers	_	
296-11	69502-69503	’	_	
296-12	69504-69513	affective	_	
296-13	69514-69523	responses	_	
296-14	69524-69526	to	_	
296-15	69527-69534	infants	_	
296-16	69534-69535	’	_	
296-17	69536-69542	affect	_	
296-18	69543-69544	a	_	
296-19	69545-69549	Wald	_	
296-20	69550-69551	b	_	
296-21	69552-69558	Infant	_	
296-22	69559-69565	affect	_	
296-23	69566-69572	effect	_	
296-24	69573-69574	c	_	
296-25	69575-69583	Identity	_	
296-26	69584-69590	effect	_	
296-27	69591-69597	Infant	_	
296-28	69598-69604	affect	_	
296-29	69605-69606	c	_	
296-30	69607-69608	x	_	
296-31	69609-69617	Identity	_	
296-32	69626-69628	χ2	_	
296-33	69629-69630	(	_	
296-34	69630-69632	df	_	
296-35	69633-69634	=	_	
296-36	69635-69636	3	_	
296-37	69636-69637	)	_	
296-38	69638-69649	Coefficient	_	
296-39	69650-69651	d	_	
296-40	69652-69653	(	_	
296-41	69653-69656	95%	_	
296-42	69657-69659	CI	_	
296-43	69659-69660	)	_	
296-44	69661-69672	Coefficient	_	
296-45	69673-69674	d	_	
296-46	69675-69676	(	_	
296-47	69676-69679	95%	_	
296-48	69680-69682	CI	_	
296-49	69682-69683	)	_	
296-50	69684-69695	Coefficient	_	
296-51	69696-69697	d	_	
296-52	69697-69698	,	_	
296-53	69699-69700	e	_	
296-54	69701-69702	(	_	
296-55	69702-69705	95%	_	
296-56	69706-69708	CI	_	
296-57	69708-69709	)	_	
296-58	69710-69716	Simple	_	
296-59	69717-69722	slope	_	
296-60	69723-69726	own	_	
296-61	69727-69733	infant	_	
296-62	69734-69740	Simple	_	
296-63	69741-69746	slope	_	
296-64	69747-69754	unknown	_	
296-65	69755-69761	infant	_	
296-66	69766-69771	Happy	_	
296-67	69772-69778	affect	_	
296-68	69779-69785	664.63	_	
296-69	69785-69786	*	_	
296-70	69786-69787	*	_	
296-71	69788-69791	.61	_	
296-72	69791-69792	*	_	
296-73	69792-69793	*	_	
296-74	69794-69795	(	_	
296-75	69795-69798	.51	_	
296-76	69799-69801	to	_	
296-77	69802-69805	.70	_	
296-78	69805-69806	)	_	
296-79	69807-69811	4.64	_	
296-80	69811-69812	*	_	
296-81	69812-69813	*	_	
296-82	69814-69815	(	_	
296-83	69815-69819	3.25	_	
296-84	69820-69822	to	_	
296-85	69823-69827	6.03	_	
296-86	69827-69828	)	_	
296-87	69829-69830	−	_	
296-88	69830-69833	.33	_	
296-89	69833-69834	*	_	
296-90	69834-69835	*	_	
296-91	69836-69837	(	_	
296-92	69837-69838	−	_	
296-93	69838-69841	.50	_	
296-94	69842-69844	to	_	
296-95	69845-69846	−	_	
296-96	69846-69849	.16	_	
296-97	69849-69850	)	_	
296-98	69851-69854	.28	_	
296-99	69854-69855	*	_	
296-100	69855-69856	*	_	
296-101	69857-69858	(	_	
296-102	69858-69861	.13	_	
296-103	69862-69864	to	_	
296-104	69865-69868	.42	_	
296-105	69868-69869	)	_	
296-106	69870-69873	.61	_	
296-107	69873-69874	*	_	
296-108	69874-69875	*	_	
296-109	69876-69877	(	_	
296-110	69877-69880	.51	_	
296-111	69881-69883	to	_	
296-112	69884-69887	.70	_	
296-113	69887-69888	)	_	
296-114	69893-69896	Sad	_	
296-115	69897-69903	affect	_	
296-116	69904-69910	664.53	_	
296-117	69910-69911	*	_	
296-118	69911-69912	*	_	
296-119	69913-69916	.62	_	
296-120	69916-69917	*	_	
296-121	69917-69918	*	_	
296-122	69919-69920	(	_	
296-123	69920-69923	.52	_	
296-124	69924-69926	to	_	
296-125	69927-69930	.71	_	
296-126	69930-69931	)	_	
296-127	69932-69935	.10	_	
296-128	69936-69937	(	_	
296-129	69937-69938	−	_	
296-130	69938-69941	.87	_	
296-131	69942-69944	to	_	
296-132	69945-69949	1.08	_	
296-133	69949-69950	)	_	
296-134	69951-69954	.23	_	
296-135	69954-69955	*	_	
296-136	69955-69956	*	_	
296-137	69957-69958	(	_	
296-138	69958-69961	.10	_	
296-139	69962-69964	to	_	
296-140	69965-69968	.37	_	
296-141	69968-69969	)	_	
296-142	69970-69973	.85	_	
296-143	69973-69974	*	_	
296-144	69974-69975	*	_	
296-145	69976-69977	(	_	
296-146	69977-69980	.74	_	
296-147	69981-69983	to	_	
296-148	69984-69987	.96	_	
296-149	69987-69988	)	_	
296-150	69989-69992	.62	_	
296-151	69992-69993	*	_	
296-152	69993-69994	*	_	
296-153	69995-69996	(	_	
296-154	69996-69999	.52	_	
296-155	70000-70002	to	_	
296-156	70003-70006	.71	_	
296-157	70006-70007	)	_	
296-158	70012-70022	Distressed	_	
296-159	70023-70029	affect	_	
296-160	70030-70036	596.22	_	
296-161	70036-70037	*	_	
296-162	70037-70038	*	_	
296-163	70039-70042	.56	_	
296-164	70042-70043	*	_	
296-165	70043-70044	*	_	
296-166	70045-70046	(	_	
296-167	70046-70049	.47	_	
296-168	70050-70052	to	_	
296-169	70053-70056	.65	_	
296-170	70056-70057	)	_	
296-171	70058-70059	−	_	
296-172	70059-70062	.27	_	
296-173	70063-70064	(	_	
296-174	70064-70065	−	_	
296-175	70065-70069	1.18	_	
296-176	70070-70072	to	_	
296-177	70073-70076	.64	_	
296-178	70076-70077	)	_	
296-179	70078-70081	.27	_	
296-180	70081-70082	*	_	
296-181	70082-70083	*	_	
296-182	70084-70085	(	_	
296-183	70085-70088	.14	_	
296-184	70089-70091	to	_	
296-185	70092-70095	.39	_	
296-186	70095-70096	)	_	
296-187	70097-70100	.82	_	
296-188	70100-70101	*	_	
296-189	70101-70102	*	_	
296-190	70103-70104	(	_	
296-191	70104-70107	.72	_	
296-192	70108-70110	to	_	
296-193	70111-70114	.93	_	
296-194	70114-70115	)	_	
296-195	70116-70119	.56	_	
296-196	70119-70120	*	_	
296-197	70120-70121	*	_	
296-198	70122-70123	(	_	
296-199	70123-70126	.47	_	
296-200	70127-70129	to	_	
296-201	70130-70133	.65	_	
296-202	70133-70134	)	_	
296-203	70138-70145	Mothers	_	
296-204	70145-70146	’	_	
296-205	70147-70150	own	_	
296-206	70151-70160	affective	_	
296-207	70161-70169	response	_	
296-208	70170-70172	to	_	
296-209	70173-70179	infant	_	
296-210	70180-70184	face	_	
296-211	70185-70191	images	_	
296-212	70191-70192	.	_	

#Text=For happy faces, ratings were obtained from mothers’ responses to the question, “how happy did this picture make you feel?”
297-1	70193-70196	For	_	
297-2	70197-70202	happy	_	
297-3	70203-70208	faces	_	
297-4	70208-70209	,	_	
297-5	70210-70217	ratings	_	
297-6	70218-70222	were	_	
297-7	70223-70231	obtained	_	
297-8	70232-70236	from	_	
297-9	70237-70244	mothers	_	
297-10	70244-70245	’	_	
297-11	70246-70255	responses	_	
297-12	70256-70258	to	_	
297-13	70259-70262	the	_	
297-14	70263-70271	question	_	
297-15	70271-70272	,	_	
297-16	70273-70274	“	_	
297-17	70274-70277	how	_	
297-18	70278-70283	happy	_	
297-19	70284-70287	did	_	
297-20	70288-70292	this	_	
297-21	70293-70300	picture	_	
297-22	70301-70305	make	_	
297-23	70306-70309	you	_	
297-24	70310-70314	feel	_	
297-25	70314-70315	?	_	
297-26	70315-70316	”	_	

#Text=For sad faces, ratings were obtained from the questions, “how sad did this picture make you feel?”
298-1	70317-70320	For	_	
298-2	70321-70324	sad	_	
298-3	70325-70330	faces	_	
298-4	70330-70331	,	_	
298-5	70332-70339	ratings	_	
298-6	70340-70344	were	_	
298-7	70345-70353	obtained	_	
298-8	70354-70358	from	_	
298-9	70359-70362	the	_	
298-10	70363-70372	questions	_	
298-11	70372-70373	,	_	
298-12	70374-70375	“	_	
298-13	70375-70378	how	_	
298-14	70379-70382	sad	_	
298-15	70383-70386	did	_	
298-16	70387-70391	this	_	
298-17	70392-70399	picture	_	
298-18	70400-70404	make	_	
298-19	70405-70408	you	_	
298-20	70409-70413	feel	_	
298-21	70413-70414	?	_	
298-22	70414-70415	”	_	

#Text=and, “how distressed did this picture make you feel?”
299-1	70416-70419	and	_	
299-2	70419-70420	,	_	
299-3	70421-70422	“	_	
299-4	70422-70425	how	_	
299-5	70426-70436	distressed	_	
299-6	70437-70440	did	_	
299-7	70441-70445	this	_	
299-8	70446-70453	picture	_	
299-9	70454-70458	make	_	
299-10	70459-70462	you	_	
299-11	70463-70467	feel	_	
299-12	70467-70468	?	_	
299-13	70468-70469	”	_	

#Text=Wald χ2 values are those obtained for the best-fitting mixed-effects models for the respective outcome variables.
300-1	70470-70474	Wald	_	
300-2	70475-70477	χ2	_	
300-3	70478-70484	values	_	
300-4	70485-70488	are	_	
300-5	70489-70494	those	_	
300-6	70495-70503	obtained	_	
300-7	70504-70507	for	_	
300-8	70508-70511	the	_	
300-9	70512-70524	best-fitting	_	
300-10	70525-70538	mixed-effects	_	
300-11	70539-70545	models	_	
300-12	70546-70549	for	_	
300-13	70550-70553	the	_	
300-14	70554-70564	respective	_	
300-15	70565-70572	outcome	_	
300-16	70573-70582	variables	_	
300-17	70582-70583	.	_	

#Text=Mothers’ perceived ratings of infants’ affect.
301-1	70584-70591	Mothers	_	
301-2	70591-70592	’	_	
301-3	70593-70602	perceived	_	
301-4	70603-70610	ratings	_	
301-5	70611-70613	of	_	
301-6	70614-70621	infants	_	
301-7	70621-70622	’	_	
301-8	70623-70629	affect	_	
301-9	70629-70630	.	_	

#Text=For happy faces, ratings were obtained from mothers’ responses to the question, “how happy do you think the baby was feeling?”
302-1	70631-70634	For	_	
302-2	70635-70640	happy	_	
302-3	70641-70646	faces	_	
302-4	70646-70647	,	_	
302-5	70648-70655	ratings	_	
302-6	70656-70660	were	_	
302-7	70661-70669	obtained	_	
302-8	70670-70674	from	_	
302-9	70675-70682	mothers	_	
302-10	70682-70683	’	_	
302-11	70684-70693	responses	_	
302-12	70694-70696	to	_	
302-13	70697-70700	the	_	
302-14	70701-70709	question	_	
302-15	70709-70710	,	_	
302-16	70711-70712	“	_	
302-17	70712-70715	how	_	
302-18	70716-70721	happy	_	
302-19	70722-70724	do	_	
302-20	70725-70728	you	_	
302-21	70729-70734	think	_	
302-22	70735-70738	the	_	
302-23	70739-70743	baby	_	
302-24	70744-70747	was	_	
302-25	70748-70755	feeling	_	
302-26	70755-70756	?	_	
302-27	70756-70757	”	_	

#Text=For sad faces, ratings were obtained from the questions, “how sad do you think the baby was feeling?”
303-1	70758-70761	For	_	
303-2	70762-70765	sad	_	
303-3	70766-70771	faces	_	
303-4	70771-70772	,	_	
303-5	70773-70780	ratings	_	
303-6	70781-70785	were	_	
303-7	70786-70794	obtained	_	
303-8	70795-70799	from	_	
303-9	70800-70803	the	_	
303-10	70804-70813	questions	_	
303-11	70813-70814	,	_	
303-12	70815-70816	“	_	
303-13	70816-70819	how	_	
303-14	70820-70823	sad	_	
303-15	70824-70826	do	_	
303-16	70827-70830	you	_	
303-17	70831-70836	think	_	
303-18	70837-70840	the	_	
303-19	70841-70845	baby	_	
303-20	70846-70849	was	_	
303-21	70850-70857	feeling	_	
303-22	70857-70858	?	_	
303-23	70858-70859	”	_	

#Text=and, “how distressed do you think the baby was feeling?”
304-1	70860-70863	and	_	
304-2	70863-70864	,	_	
304-3	70865-70866	“	_	
304-4	70866-70869	how	_	
304-5	70870-70880	distressed	_	
304-6	70881-70883	do	_	
304-7	70884-70887	you	_	
304-8	70888-70893	think	_	
304-9	70894-70897	the	_	
304-10	70898-70902	baby	_	
304-11	70903-70906	was	_	
304-12	70907-70914	feeling	_	
304-13	70914-70915	?	_	
304-14	70915-70916	”	_	

#Text=Coefficients shown are beta weights (i.e., slopes) for the main and interaction effects of infant affect and identity derived from the best-fitting multilevel mixed-effects regression models.
305-1	70917-70929	Coefficients	_	
305-2	70930-70935	shown	_	
305-3	70936-70939	are	_	
305-4	70940-70944	beta	_	
305-5	70945-70952	weights	_	
305-6	70953-70954	(	_	
305-7	70954-70957	i.e	_	
305-8	70957-70958	.	_	
305-9	70958-70959	,	_	
305-10	70960-70966	slopes	_	
305-11	70966-70967	)	_	
305-12	70968-70971	for	_	
305-13	70972-70975	the	_	
305-14	70976-70980	main	_	
305-15	70981-70984	and	_	
305-16	70985-70996	interaction	_	
305-17	70997-71004	effects	_	
305-18	71005-71007	of	_	
305-19	71008-71014	infant	_	
305-20	71015-71021	affect	_	
305-21	71022-71025	and	_	
305-22	71026-71034	identity	_	
305-23	71035-71042	derived	_	
305-24	71043-71047	from	_	
305-25	71048-71051	the	_	
305-26	71052-71064	best-fitting	_	
305-27	71065-71075	multilevel	_	
305-28	71076-71089	mixed-effects	_	
305-29	71090-71100	regression	_	
305-30	71101-71107	models	_	
305-31	71107-71108	.	_	

#Text=Significance reflects differences in the strengths of associations between infant affect and maternal affective response as a function of infant identity.
#Text=p < .001.
306-1	71109-71121	Significance	_	
306-2	71122-71130	reflects	_	
306-3	71131-71142	differences	_	
306-4	71143-71145	in	_	
306-5	71146-71149	the	_	
306-6	71150-71159	strengths	_	
306-7	71160-71162	of	_	
306-8	71163-71175	associations	_	
306-9	71176-71183	between	_	
306-10	71184-71190	infant	_	
306-11	71191-71197	affect	_	
306-12	71198-71201	and	_	
306-13	71202-71210	maternal	_	
306-14	71211-71220	affective	_	
306-15	71221-71229	response	_	
306-16	71230-71232	as	_	
306-17	71233-71234	a	_	
306-18	71235-71243	function	_	
306-19	71244-71246	of	_	
306-20	71247-71253	infant	_	
306-21	71254-71262	identity	_	
306-22	71262-71263	.	_	
306-23	71264-71265	p	_	
306-24	71266-71267	<	_	
306-25	71268-71272	.001	_	
306-26	71272-71273	.	_	
